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v 
Diazepam is an effective pharmaceutical used for both medicinal and illicit 
purposes and its popularity has led to the sale of both diverted 
pharmaceutical tablets and illicitly manufactured products.  The aim of this 
project was to characterise 65 different cases of illicit tablets seized from the 
Tayside area. Physical and chemical analysis was compared with known 
pharmaceutical tablets and resulting data was statistically evaluated, to reveal 
potential links between illicit cases and distinguish pharmaceutically 
manufactured diverted products. 
Physical differences between cases revealed many of the tablets were not 
pharmaceutically manufactured for the UK market. This was supported by 
chemical analysis using GC-MS and HPLC, which indicated that only 39 of 
the 63 cases analysed contained diazepam as the main active ingredient, 
with diazepam levels varying between 8 – 48 mg and more potent substances 
found in many tablets.  An innovative use of DSC demonstrated great 
sensitivity in distinguishing between cases, based largely on excipients.  A 
novel approach for forensic analysis was taken both through visual 
comparison of thermograms and by statistical analysis of resulting data.  
The statistical clustering techniques of AHC and k-means were used to 
explore combined results and potential links between a subset of cases were 
visualised in a heat map.  DSC data points were then explored by PCA and 
LDA to further distinguish between the pharmaceutical tablets and seized 
cases.  
Overall, a combination of physical characteristics, chemical properties and 
statistical analysis were able to distinguish between the small number of 
pharmaceutically manufactured diverted cases and the majority revealed to 
be illicitly produced. This is important new research into street drugs, which 
reveals an insight into the illicit market and the dangerous nature of blue 
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1.1 Aims of the Research 
Benzodiazepines have been implicated in an increasing number of drug related 
deaths in Scotland in recent years.  The threat posed is elevated by the existence of 
illicitly manufactured tablets, which are in circulation within the illegal supply chain 
(Police Scotland, 2016; McGivern, 2016), with 10 mg tablets believed to be the most 
abused of the diazepam (1) tablets (Doward, 2012; McGivern, 2018). 
The aim of this project was to characterise sixty-five different cases of illicit blue 
tablets, believed to have been sold as 10 mg diazepam (1) tablets, which had been 
seized in the Tayside area by Police Scotland.  By measuring a range of physical 
and chemical characteristics, it was intended to generate data which could be tested 
using statistical clustering methods to determine whether these characteristics could 
be used to link separate cases. Principal component analysis and linear discriminant 
analysis of the dataset would then be used with the purpose of distinguishing known 
pharmaceutical tablets from pharmaceutically plausible tablets. 
1.2 Objectives of the Research 
The objectives of this thesis were to analyse the physical and chemical properties of 
seized cases of blue tablets, in order to characterise them.  This included recording 
the weight, diameter and depth of the 1989 tablets contained within the sixty-five 
seized cases being assessed and the five batches of pharmaceutical tablets used for 
comparative purposes.  Chemical analysis was performed using gas 
chromatography-mass spectrometry (GC-MS) to identify the main active drug 
substances and high performance liquid chromatography (HPLC) for quantification of 
diazepam (1) content.  Information about the excipients was determined by 
differential scanning calorimetry (DSC). 
All data on the physical and chemical properties of the tablets was stored in an MS 
Access database which could be searched and subsets extracted.   
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The first objective of the statistical analysis was to determine whether illicit cases 
could be linked by identifying clusters within the data derived from illicit tablets.   
Clustering was carried out using visual methods, agglomerative hierarchical 
clustering and k-means clustering.  
The second objective of the statistical analysis was to use the physical and chemical 
data to develop a series of methods that could distinguish illicitly made tablets from 
possible pharmaceutical tablets that had been diverted into the illegal supply chain. 
Principal component analysis and linear discriminant analysis was used for further 
analysis of cases that most resembled the pharmaceutically manufactured tablets. 
1.3 Chapter Overview 
The work undertaken for this project will be described in detail in the following 
Chapters:- 
Chapter 2 – Introduction 
This chapter provides a background to this project and describes the diazepam (1) 
drug substance in context of the discovery and use of benzodiazepines.  The 
increase in diazepam (1) use and abuse is explained with data showing the numbers 
of deaths related to its misuse and the UK legislation concerning benzodiazepines is 
also described. 
Factors influencing the effectiveness of the drugs, including tablet manufacturing 
processes are explored.  This chapter also exposes how illicit tablets can pose 
hidden dangers with their highly variable composition and how differences can be 
identified between tablets produced by different manufacturers. 
Chapter 3 – Physical Characteristics 
The techniques used to measure the physical weights and measurements of seized 
illicit tablets and those of pharmaceutical origin are described.  The weight, diameter 
and depth of all tablets were recorded on a Microsoft access database, enabling 
comparisons to be performed. Data was analysed and visualised in graphical form 
and by using box plots. 
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The colour of the tablets was recorded by photography using a purpose built 
lightbox. 
Chapter 4 – Gas Chromatography - Mass Spectrometry 
Tablets from each of the cases were analysed by GC-MS in order to confirm the 
active drug substance present.  Although the street samples were believed to be 
sold as 10 mg diazepam (1) tablets and were blue in colour, the origin of the tablets 
was unknown and therefore the actual content was also uncertain.  However, tablets 
containing diazepam (1) were not necessarily of pharmaceutical origin. 
Chapter 5 – High Performance Liquid Chromatography 
HPLC was used to quantify the diazepam (1) content of three tablets taken from 
each case.  All of the illicit cases analysed were blue in colour, which is consistent 
with the colour of 10 mg diazepam (1) tablets manufactured for the UK market.  
However, the presence of the correct amount of active drug substance does not 
guarantee the tablets have been pharmaceutically manufactured. 
Chapter 6 – Differential Scanning Calorimetry 
The thermal technique of differential scanning calorimetry was tested as a way to 
explore differences in the excipient content of the tablets.  A large proportion of a 
pharmaceutical diazepam (1) tablet is comprised of excipients, with an anticipated 
amount of about 10 mg of active drug substance being present.  Therefore, 
information gained on the excipient content was explored as a way to differentiate 
between different tablets. 
Chapter 7 – Statistical Cluster Analysis 
The information gained from the physical and chemical tests was used to provide 
data for statistical and chemometric analysis.  Agglomerative hierarchical clustering 
and k-means clustering were used to explore patterns in the data and identify 
potential groupings.  The results of all of the experiments were then added to a heat 
map under the premise that the more individual cases cluster with other individual 
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cases, as an indication of the probability of there being a potential link between 
them. 
Chapter 8 – Linear Discriminant Analysis 
In order to further examine the seized cases which contained approximately 10 mg 
of diazepam (1), a smaller test sample was chosen.  As the tablets could not be 
differentiated from the pharmaceutical tablets based on physical characteristics or 
type and quantity of active drug substance, the data generated by DSC was 
analysed using chemometric methods.  DSC was chosen because the thermograms 
generated were largely influenced by the excipient content of the tablets.  The data 
points were explored by principal component analysis and linear discriminant 
analysis to determine if any differences could be found between the 
pharmaceutically manufactured tablets and the street diazepam (1) cases.   
Chapter 9 – Conclusion and recommendations for Future Work 
The conclusion describes the context in which this study was based and briefly 
summarises the work performed and results obtained.   
Innovative methods of analysis such as the forensic use of the DSC performed 
during this project, are described along with its potential benefits. Ideas for future 
work are also discussed, in order to build upon the analysis performed during this 
project. The research carried out in this study has provided an important step on 
which to base future work and suggestions are described with a view to obtaining 
further information that would help in the characterisation of illicit tablets. 
Appendices 
The appendices contain “hand-worked” examples of the statistical techniques of 
principal component analysis, agglomerative hierarchical clustering and k-means 
clustering and the script used for principal component analysis using the ‘R’ 




2.1 Chapter Summary 
This chapter provides a background to the project and describes the diazepam (1) 
drug substance in context of the discovery and use of benzodiazepines.  The 
increase in diazepam (1) use and abuse is explained with data showing the numbers 
of deaths related to its misuse and the UK legislation concerning benzodiazepines is 
also described. 
Factors influencing the effectiveness of the drugs, including tablet manufacturing 
processes are explored and exposes how illicit tablets can pose hidden dangers with 
their highly variable composition and how differences can be identified between 
tablets produced by different manufacturers. 
 
2.2 Diazepam 
2.2.1 Description and Structure 
Diazepam (1), or 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one  is a 
benzodiazepine type drug with the chemical formula C16H13ClN2O (Figure 2.1).  In its 
pure pharmaceutical form, diazepam (1) is odourless and has the appearance of an 
off-white crystalline powder (British Pharmacopoeia Commission, 2017a). The 
chemical structure includes a heterocyclic ring containing nitrogen, making it an 





Figure 2.1.  The structure of diazepam (1), with carbon numbering. 
Medically, diazepam (1) is used to treat anxiety, sleep disorders, muscle spasms and 
alcohol withdrawal.  However, over time there may be an increased tolerance to 
many of the sedative effects and both physical and psychological dependence can 
develop.  Sudden withdrawal from diazepam (1) can cause adverse reactions 
including nausea, restlessness, anxiety, nervousness, tremors, dysphoria, insomnia, 
stiffening muscles, abdominal pain and headaches.  In more extreme cases 
hallucination, hyperthermia, panic attacks, disorientation and delirium can set in, 
leading to tachycardia, hypertension and seizures (Ashton, 2013).  These risks are 
aggravated by the use of other drugs including opiates, barbiturates, alcohol and 
other central nervous system depressants. Benzodiazepines are sedatives and 
taken with other sedatives, such as barbiturates, have an accumulative effect.  
Therefore dangerous doses of other substances could lead to fatality when 
consumed in conjunction with benzodiazepines   (Medicines and Healthcare 
Products Regulatory Agency, 2015b; Ashton, 2013). 
2.2.2  Discovery of Diazepam 
Sedatives have long been used for medical purposes to aid physiological and mental 
depression, producing a more sedate state. Anxiolytic drugs are designed to reduce 
anxiety without affecting physical functions but many have sedative properties, 
leading to a degree of overlap between treatments (Rang, 2016).  Previous 
sedatives have included alcohol, chloral hydrate and bromides but all of these have 
been shown to have serious side effects.  Bromides for example, are toxic, with a 
half-life of approximately twelve days and accumulation in tissues, leads to delirium, 
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hallucinations, gastrointestinal problems and irritability (López-Muñoz, Álamo and 
García-García, 2011). 
The synthesis of barbituric acid in 1864 gave rise to the introduction of the first 
barbiturates in 1904. Almost immediately problems with tolerance, dependence, 
ease of overdose and hazards of withdrawal were recorded.   However, over 2500 
barbiturates were synthesised by the early 1950s with around 50 introduced into 
clinical use (López-Muñoz, Ucha-Udabe and Alamo, 2005; Dundee and Mcilroy, 
1982; Maxwell, 2012). 
An alternative to the barbiturates, meprobamate was introduced as an anxiolytic in 
the 1950s but had limited effects, while dangers posed by tolerance, dependence, 
potential for abuse and overdose meant it was withdrawn in North America during 
the 1960s (López-Muñoz, Ucha-Udabe and Alamo, 2005).  Interestingly, the last 
licence for meprobamate production in the United Kingdom was only withdrawn after 
a review across the European Union in 2016 (Medicines and Healthcare Products 
Regulatory Agency, 2016a).   
During the 1950’s the dangers posed by prescribed sedatives created an impetus for 
the development of new safer drugs. The intention to patent a new product inspired 
Hoffmann-La Roche to research compounds previously unused by the 
pharmaceutical industry (Weatherall, 1990). Leo Sternbach investigated what were 
thought to be benzheptoxdiazines but were later classified as quinazoline 3-oxides 
(Sternbach, 1979).  Previous post-doctoral research into dyes had demonstrated that 
these compounds were easy to synthesize, crystallize, isolate and purify.   The 
marketing of the antipsychotic drug chlorpromazine, with a chain attached to the 
tricyclic compound, encouraged Sternbach to investigate the effects of different side 
chains.  Chlorpromazine is a phenothiazine derivative, comprising of a tricyclic 
compound substituted with chlorine at position 2 and tertiary alkylamine at position 




Figure 2.2.  Structure of chlorpromazine. 
Phenothiazines are biologically active and Sternbach decided to investigate whether 
altering the side chains could affect their biological influence (López-Muñoz, Álamo 
and García-García, 2011).  Amino ketones with different benzene ring substituents 
were acylated and further treatment with secondary amines was performed to 
produce a variety of side chains. Hydrogenation and removal of the oxygen from the 
N-oxide were both attempted, however, laboratory research indicated that the 
compounds produced no pharmacological effect (Sternbach, 1979).  Further work at 
Hoffmann-La Roche meant that the investigation into the compounds had to be 
postponed but eighteen months later, during a laboratory clean-up operation, a 
crystalline substance resulting from the earlier work was discovered and sent for 
biological assessment (Maxwell, 2012).  The results indicated that the substance 
relaxed muscles and calmed mice by preventing convulsions caused by electrical 
stimuli; and monkeys were found to be less aggressive without apparent tiredness, 
after being treated with the drug.  Toxicologically it was discovered that large 
quantities could be consumed without fatal consequences.  The benefit being that in 
cases of overdose, the patient may become unconscious but would not manifest 
symptoms of asphyxiation or respiratory failure, which could occur with barbiturates, 
and it did not affect the heart (Weatherall, 1990; Maxwell, 2012).  Another benefit 
was the greater difference in human dosage levels required between anxiolytic and 
sedative effects, when compared to barbiturate or meprobamate concentrations 
(Maxwell, 2012).  The substance was marketed as Librium in 1960 and was given 




Figure 2.3.  Structure of chlordiazepoxide (3). 
Sternbach performed further research into chlordiazepoxide (3) in order to determine 
why this had been the only one of the synthesized substances to demonstrate 
physiological properties.  The results indicated that a primary amine had been used 
instead of a secondary amine, during the final treatment, causing a ring enlargement 
reaction to occur (López-Muñoz, Álamo and García-García, 2011).  
Chlordiazepoxide hydrochloride was found to be bitter, hygroscopic and unstable but 
examination of the main metabolite, demoxepam (5) revealed that simplification of 
the compound by removal of the N-oxide functionality resulted in a more potent 
product.  This became the new parent compound and exploration began into the 
addition of chains in positions 1 and 3, as shown in Figure 2.4.  The 1-methyl 
derivative proved to be more effective than chlordiazepoxide (3) and it was marketed 
as Valium (1) in 1963 (Sternbach, 1979; López-Muñoz, Álamo and García-García, 
2011).  When the patent expired in 1985, production was opened to generic forms of 




Figure 2.4.  The chemical structure of the parent compound used in Sternbach’s research.  
Positions 1 and 3, which are indicated in red, identify the locations where different groups 
were substituted. (Sternbach, 1979) 
2.2.3 Benzodiazepine Family 
Benzodiazepines are characterised by a benzene ring, which is fused to a seven-
membered diazepine ring containing nitrogen at positions 1 and 4 (Sultan and El-
Mubarak, 1996).  Research by Sternbach revealed that the pharmacological effects 
increased when electron withdrawing groups, such as chlorine or nitro were attached 
to position 7 of Ring A, (Figure 2.5).  Electron donating groups, such as a methyl, 
caused a reduction in pharmacological properties.  Sternbach also discovered that 
groups located in any other position on Ring A, diminished pharmacological activity.   
 
Figure 2.5.  Structure used by Sternbach as a basis for studying the pharmacological effects of 
different substituents and their positions. (Sternbach, 1979) 
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The addition of a methyl group on position 1 of Ring B also produces an increase in 
pharmacological activity but larger groups can diminish the effect. The addition of a 
phenyl in position 5 also demonstrated greater biological effects. Pharmacological 
properties increase with a halogen in position 2 of Ring C, as demonstrated in 
phenazepam (16) (Figure 2.6) with a potency around five times that of diazepam (1) 
(World Health Organisation, 2015c).  However, the pharmacological properties 
decrease when a group is added to position 4.  During his studies on diazepam (1) 
compounds Sternbach synthesised over 3000 related compounds (Sternbach, 
1979). 
 
Figure 2.6.  Structure of phenazepam (16). 
After the launch of chlordiazepoxide (3) in 1960 and diazepam (1) in 1963 by 
Hoffmann-La Roche, the first benzodiazepine marketed by a different company was 
oxazepam (15), sold under the brand name Serax, by Wyeth laboratories in 1965.  
Research had indicated that the N-oxides could easily be synthesized and after 
acetic acid or acetic anhydride or treatment, a 3-acetoxy derivative is formed. The 3-









Figure 2.7.  The synthesis of Oxazepam (15). (Sternbach, 1979) 
 
Oxazepam (15) is an active metabolite of diazepam (1) and undergoes 
glucuronidation to aid excretion from the body. A potential disadvantage of being 
prescribed diazepam (1), is that the demethylation process results in the production 
of nordiazepam (14) (Figure 2.8), which has a much longer half-life of between 36-
200 hours.  This poses particular problems for the elderly as the oxidative reaction 
slows during the ageing process, thus increasing the time before converting to 
oxazepam (15) and then exiting the body (Ashton, 2013; Rang, 2016).
 
Figure 2.8.  The metabolism of diazepam (1), showing the active metabolites nordiazepam (14) 
and oxazepam (15). 
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The degrees of pharmacological activity produced by the benzodiazepines vary with 
the drug substance, therefore a number of them are used for different clinical 
purposes. For example, diazepam (1), oxazepam (15) and chlordiazepoxide (3) are 
marketed as anxiolytics; clonazepam (4) as an anti-convulsant; and nitrazepam (13) 
as a hypnotic, to aid sleep. However, there may be some cross-over depending on 
the symptoms and the patient, so clonazepam (4) may also be used as an anxiolytic, 
for example and oxazepam (15) is prescribed for treating insomnia. The 
benzodiazepines also vary in absorption rate, active metabolites and length of 
duration (Ashton, 2013; Maxwell, 2012) 
Potency varies between the different benzodiazepines.  For example, a 10 mg dose 
of diazepam (1) would be equivalent to 25 mg of chlordiazepoxide (3), 20 mg of 
oxazepam (15), 2 mg of phenazepam (16) or 0.5 mg of alprazolam (2) (Ashton, 
2013; World Health Organisation, 2015c). Each of these are prescribed as 
anxiolytics, however, it is the speed of onset, the properties of active metabolites, 
half-life and patient characteristics that would decide which drug is prescribed 
(Maxwell, 2012). 
Phenazepam (16) (7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-
one) (Figure 2.6) with a potency around five times that of diazepam (1), was 
developed in Russia and although not prescribed in the UK, it is medically used in 
some other countries, where it is prescribed for anxiety and insomnia (World Health 
Organisation, 2015c).  Phenazepam (16) use became more widespread through 
internet sales, leading to it becoming a controlled substance in the UK in 2012 
(United Kingdom Government, 2012).  
A new designer drug, pyrazolam (17), appeared on the market in 2012 under the 
description of ‘research chemical’, opening the door to a variety of substances that 
were not used medically anywhere in the world (Moosmann et al., 2013).  This 
includes flubromazepam (8) and diclazepam (6), which unlike phenazepam (16) are 
manufactured entirely for the recreational market.  Flubromazepam (8) is similar in 
structure to phenazepam (16) with the bromine substituted for a fluorine atom 
(Figure 2.9).  Diclazepam (6) is more structurally similar to diazepam (1), with an 
extra chloride (O'Connor, Torrance and McKeown, 2016) (Figure 2.9). Other 
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substances which were legally sold at the time include meclonazepam, nifoxipam, 
nitrazolam and the thienodiazepines such as deschloroetizolam and metizolam 
(Manchester et al., 2018). The introduction of the Psychoactive Substances Act of 
2016 brought an end to the legal sale of such substances by preventing the 
production, supply, import and export of any psychoactive substance.  Interestingly, 
the potential for benzodiazepine abuse was realised soon after their introduction and 
thirty-five different benzodiazepine type drugs were controlled under the UN 
Convention on Psychotropic Substances 1971 (United Nations Office on Drugs and 
Crime, 1971). 
In addition to the designer drugs, potent drug substances that were prescribed in 
other countries, such as etizolam (7), continued to enter the UK.  Etizolam (Figure 
2.9) is a thienotriazolodiazepine developed in Japan with a potency ten times higher 
than diazepam (1) and became a controlled substance listed in the Misuse of Drugs 
Act 1971 (Amendment Order) 2017 (Figure 2.9) (United Kingdom Government, 







Flubromazepam Diclazepam  
 
 
Figure 2.9.  Structure of four of the substances that were legally sold in the UK until the 
Psychoactive Substances Act of 2016 and the Misuse of Drugs Act 1971. (Amendment Order) 




2.2.4 The Rise in Popularity of Diazepam 
Due to the relative safety of the benzodiazepines compared to previously available 
anxiolytics, there was a 110% rise in benzodiazepine prescriptions between 1965-
1970 and they became the most prescribed tablets across the world within ten years 
of their introduction (López-Muñoz, Álamo and García-García, 2011).  By 1977, 
diazepam (1) was estimated as being taken by one in ten adults in the USA and it 
has been suggested that this was because of a rise in social stress leading to 
diazepam (1) being prescribed for non-medical problems (Waldron, 1977). 
The benefit of diazepam (1) over other benzodiazepines is the speed of absorption 
and the duration of the drug substance, which limits potential fluctuations in blood 
concentration.  Active substances with higher potency, such as alprazolam (2), are 
expelled more quickly, causing a drop in levels and leading to anxiety between 
doses. Less potent prescriptions such as chlordiazepoxide (3), with a maximum daily 
dose of 100 mg for anxiety, may not be the most suited for the symptoms presented 
(Ashton, 1994), though the dose of chlordiazepoxide (3) can be repeated after 2 
hours in the treatment of severe alcohol withdrawal (Dr Reddy's Laboratories (UK) 
Ltd, 2015) 
Data supplied by the National Health Service in Scotland (Figure 2.10) indicates that 
the number of diazepam (1) prescriptions had been on a steady rise over the last 
decade, reaching a peak of 893,146 in 2011/12 (Information Services Division, 
National Health Services Scotland, 2016).  Over the last few years there has been a 
slight downward trend in the number of prescriptions, possibly due to concerns over 





Figure 2.10.  The number of diazepam (1) prescriptions dispensed in Scotland since 2005/6. 
(Information Services Division, National Health Services Scotland, 2016)  
 
2.2.5 Illicit Benzodiazepine Use 
Benzodiazepines were originally marketed as a safer option to barbiturates, with 
cases of benzodiazepine overdose leading to unconsciousness as opposed to the 
fatalities caused by high concentrations of barbiturate (López-Muñoz, Álamo and 
García-García, 2011; Cappell, 1986).  However, there is a greater risk posed to 
those with a history of substance abuse, the elderly and patients with respiratory or 
renal disease or when ingested in conjunction with other active substances or 
alcohol (Palmaro, Dupouy and Lapeyre-Mestre, 2015).  For example, the arrhythmic 
effects experienced by more vulnerable subjects when diazepam (1) is ingested at 
pharmaceutical levels, are heightened when the amount is increased.  It has been 
reported that substance abusers often consume up to ten times the prescribed dose 
(Johnson, Barnsdale and McAuley, 2016). 
Studies have indicated that a control group of subjects who have never used 
benzodiazepines, do not tend to favour benzodiazepines but they have more appeal 
to patients who had previously been prescribed for medical reasons and/or those 
with a history of drug or alcohol abuse (Cappell, 1986).  Screening interviews of 
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produce a mild feeling of euphoria and therefore they would preferentially choose 
more potent substances such as cocaine or MDMA.  However, it was noted that 
benzodiazepines were taken to boost the effects of other active substances including 
methadone. Trials revealed that diazepam (1) was the most popular benzodiazepine 
and in high doses was sometimes believed to be a barbiturate (J. O. Cole and 
Chiarello, 1990).  In 2016, records in the United Kingdom indicate that three times 
more people listed benzodiazepines as their secondary substance when referred to 
treatment centres, than their primary drug of abuse.  Over two thirds of these cases 
identified heroin as the main active drug substance used (United Kingdom 
Government Focal Point on Drugs, 2017).  However, it has been suggested that 
secondary drug substances are frequently under-reported (Johnson, Barnsdale and 
McAuley, 2016). Therefore, the rise of diazepam (1) abuse is not isolated but is 
reflected in the abuse of other depressant type substances. 
Interestingly, in surveys, subjects taking part in trials and recognising the effects of 
diazepam (1), ascribed a higher monetary street value to diazepam (1) than other 
benzodiazepines, such as oxazepam (15) (Griffiths et al., 1984), which introduces a 
motive for clandestine laboratories and illicit traders. 
2.2.5.1 Polydrug Use 
Benzodiazepines are commonly ingested at high levels, in conjunction with alcohol 
to speed up and intensify the intoxification; with cocaine to alleviate agitation and 
irritability; and opioids to enhance the euphoric effect (Stevens and King, 2013).  
Polydrug use exacerbates respiratory depression through synergistic effects, which 
is especially dangerous with opioids, antidepressants, and antipsychotics (Dear and 
Bateman, 2016). In addition, competition for metabolic pathways leads to an 
increase in drug concentration levels within the body and is exacerbated when the 
active substances are ingested in larger quantities (Johnson, Barnsdale and 
McAuley, 2016). 
The combined use of benzodiazepines and opioids can trigger physical and 
psychological problems.  Drug interactions can cause selective serotonin reuptake 
inhibitors to raise diazepam (1) levels in the blood and during metabolism, 
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interactions exacerbated by hepatic dysfunction can raise the concentration of opioid 
serum in the body, thus increasing sedation and the likelihood of overdose (Stevens 
and King,2013; Stein et al., 2017; Johnson, Barnsdale and McAuley, 2016). A patient 
survey performed in a drug treatment centre in America, revealed that almost a third 
of the subjects admitted to having overdosed during the previous year.  However, 
their continued use of benzodiazepines indicates a potential dependency (Stein et 
al., 2017).  In addition, some overlap exists in the withdrawal symptoms of 
benzodiazepines and opioids, emphasising the potential connection in 
neurochemical pathways.  Benzodiazepines influence the impact of the GABA 
system on the locus coeruleus, aggravating opiate withdrawal symptoms (de Wet et 
al., 2004).  
2.2.5.2 Drug Related Deaths 
Dangers posed by drug addiction and possible overdose are dependent on the types 
of drugs consumed.  However, the problem is heightened by polydrug use and one 
of the most common drugs used in conjunction with other drugs and/or alcohol is 
diazepam (1), which is often taken   to enhance euphoric effects, or for the alleviation 
of agitation and anxiety (J. O. Cole and Chiarello, 1990). This polydrug use is 
dangerous and has the potential of resulting in coma or death.  In 2002, it was noted 
that the majority of people who died in amphetamine, cocaine or MDMA related 
incidents were also found to have consumed benzodiazepines and / or opiates, 
usually in conjunction with alcohol.  It was even recorded that the most common 
combination was morphine, alcohol and benzodiazepines (EMCDDA.Europa.EU, 
2002). 
Problems related to polydrug use have been highlighted by the National Institute on 
Drug Abuse in the USA.  Data released in 2017 year reveals a dramatic difference in 
the number of deaths related to benzodiazepines when taken with opioids, compared 
to benzodiazepines alone. The figures show that between 2002 - 2015, 
benzodiazepine deaths involving opioids increased twice as much as those that did 




Figure 2.11.  Comparison of benzodiazepine related deaths in the USA, when taken with and 
without opioids. (National Institute on Drug Abuse, 2017) 
 
Records in England and Wales during 2016, indicated that the number of drug 
related deaths had increased by 2% over the previous year, reaching a record high 
of 3,744.  Around 69% of the drug related deaths were listed as being the result of 
drug misuse.  The number of deaths identifying specific substances indicate that 
benzodiazepines were implicated in 406 deaths during 2016.  This is a rise of 10.9% 
over the previous year (Office for National Statistics, 2017).  Proportionately the 
number of deaths involving benzodiazepines is much lower in England and Wales 
than recorded in Scotland. 
In Scotland, there were 867 drug-related deaths recorded during 2016, an increase 
of 23% compared to 2015.  Of these, benzodiazepines “were implicated in, or 
potentially contributed to” 49% (426 deaths) (National Records of Scotland, 2017).  
In 2015, benzodiazepines were implicated in only 27% (191) of drug related deaths, 
indicating that there was a massive increase of 123% over the previous year.  
 
21 
The statistical reports on drug related deaths in England and Wales, as well as the 
report for Scotland, both use records of all registered deaths in conjunction with 
International Statistical Classification of Diseases and Related Health Problems 
(ICD) codes.  The ICD codes identify the cause of death based on the registration of 
death certificates.   In Scotland, further information is gained from certifying doctors, 
pathologists and Procurators Fiscal.  This information is obtained through a 
questionnaire, which requests details of any drugs or solvents found.  The 
questionnaire was updated in 2014, allowing greater detail and differentiation 
between the identified substances (Office for National Statistics, 2017; National 
Records of Scotland, 2017). 
A comparison showing the numbers of drug related deaths with those linked to 
benzodiazepines can be seen in Figure 2.12. The report on drug related deaths in 
Scotland released in 2017, indicates that the majority of cases involved the 
consumption of more than one active drug substance, thus emphasising the dangers 
posed by polydrug use (National Records of Scotland, 2017). 
 
Figure 2.12.   Comparison of the number of drug related deaths in Scotland, to those where 















































According to the National Records of Scotland report on drug related deaths during 
2016, benzodiazepines were identified in 277 out of 286 incidents, where New 
Psychoactive Substances (NPS) had potentially contributed to or been implicated in 
a death.  Although a variety of substances were identified, the most common NPS 
found was etizolam (7). The number of incidents relating to etizolam (7) and 
diclazepam (6) rose at a much faster rate than for diazepam (1) (Figure 2.13).  Until 
recently, diazepam (1) had been the most commonly identified benzodiazepine in 
drug related deaths (National Records of Scotland, 2017). However, whether the 
consumers had chosen to change active ingredients or were taking tablets 
unwittingly believing them to contain diazepam (1), cannot be determined.  
Potentially, illicit manufacturers could have swapped drug substance in order to stay 
within the law because etizolam (7) for example, was not controlled until the 
Psychoactive Substances Act of May 2016. However, it is now controlled as a class 
C drug under the Misuse of Drugs Act of 1971, due to an amendment in May 2017 
and has been listed as Schedule 1 (United Kingdom Government, 2017b).  As 
described in section ‘2.1.3 – Benzodiazepine Family’, diclazepam (6), which was 
recorded as being on the rise, has no medical use but was produced exclusively for 





Figure 2.13.  Comparison of the total number of benzodiazepine related deaths in Scotland, to 
those where diazepam (1) was identified, since 2008.  (National Records of Scotland, 2017) 
 
Although the number of drug related deaths in Scotland has been reported as being 
the highest in the European Union, differences in reporting and areas covered make 








































2.3.1 Formulation of Tablets 
Tablet formulation is vitally important in the manufacture of pharmaceutical products.  
Ethical pharmaceutical tablets are designed to ensure a consistent medicinal dosage 
is provided, while ensuring stability and the correct bioavailability over the term of 
their shelf-life (Narang, Desai and Badawy, 2012). The bioavailability is the level of 
the administered drug substance that enters the systemic circulation enabling it to 
have an effect (Aulton, 2007b). However, there are many influencing factors, 
including particle size, dissolution properties, ease of handling, and the flow and 
compression properties.  This means that a variety of constituents (excipients) have 
to be added along with the drug substance, to ensure the viability of the tablet.  In 
addition, interactions between the different substances have to be monitored to 
safeguard the integrity of the product. 
Formulations vary between manufacturing companies and therefore not all the 
excipients will be the same or create the same interactions within a tablet.  However, 
the final product is registered with the Medicines and Healthcare products 
Regulatory Agency (MHRA), who monitor the quality and specifications of each 
product. 
2.3.2  Impact of Particle Size 
Particle size has a significant impact on tablets and their properties as it affects 
content uniformity, particularly in low-dosage tablets.  Pharmaceutical blue diazepam 
(1) tablets produced for the UK market and analysed for this project (chapter 3 – 
Physical Characteristics), ranged in weight between approximately 148 – 180 mg, of 
which 10 mg is diazepam (1) and the remaining weight relates to a variety of 
excipients.  By incorporating the active ingredient as a larger quantity of smaller 
particles, a more consistent batch can be produced. Small particles also provide a 





2.3.3 Crystal Properties of Molecules 
Solid components used to manufacture tablets exist in crystalline, amorphous and 
polymorphic forms. Loosely packed molecules are more likely to fragment, dissolve 
or melt, which impacts on tablet compaction, storage and use.  Although some 
substances are enantiotropic, meaning they can change between different equally 
stable polymorphic forms under certain conditions, many are not. Substances used 
in pharmaceutical formulations are often monotropic, meaning that one of the 
polymorphs is more stable and the less stable forms will convert over time.  
Consequently, the crystalline structure of some tablets changes over time, reducing 
the bioavailability of the active ingredient but the rate of conversion fluctuates 
according to storage conditions.  (Aulton, 2007b).  In order to limit these problems, 
analytical tests are often performed to check for the presence of polymorphic forms 
(European Medicines Agency, 2000). 
The level of amorphous content also influences the crystal state and is affected by 
the glass transition temperature.  Samples kept below this temperature will be hard 
and brittle with no mobility.  However, above the glass transition temperature the 
molecules become more fluid, enabling them to recrystallize in a more regular 
structure.  
The absorption of moisture by amorphous substances can act as an effective 
plasticizer by lowering the glass transition temperature.  The added water can either 
form hydrogen bonds with the polar molecules in the structure, which binds the water 
within the network; or if the substance is more hydrophobic, the molecules will create 
distance by breaking the secondary bonds that already exist within the molecule.  
Both of these effects allow movement of the molecules, enabling them to find a more 
stable form (Smith et al., 2009).  Unbound water content may be expelled through 
the crystallisation process.  However, some substances including lactose, which is a 





2.3.4 Tablet Excipients 
The term ‘excipient’ relates to all the constituents added to a tablet, other than the 
active drug substance. Excipients are “inert substances” with no biological effects 
however, they significantly influence the absorption rates of active drug substances 
(Aulton, 2007b). Each excipient has its own function and some compounds have 
multiple roles.    The purpose of many of the excipients is described below. 
Formulations vary between different manufacturing companies but each factor 
requires consideration and is tested to assess the interactions taking place between 
the various constituents. 
2.3.4.1 Diluents Used In Tablet Manufacture 
The use of a diluent or bulking agent is important for giving volume to tablets 
containing a small amount of active drug substance. Bulk is required for tablet 
compression and manageability (Lachman, Lieberman and Kanig, 1970).  A tablet 
containing only 10 mg of diazepam (1) on its own would not be practical.  Ideal 
diluents should be biocompatible, chemically inert and non-hygroscopic with good 
solubility and compaction properties (Aulton, 2007b). The most common bulking 
agent used in diazepam (1) tablets produced for the UK market is lactose (Medicines 
and Healthcare Products Regulatory Agency, 2014; Medicines and Healthcare 
Products Regulatory Agency, 2016b; Medicines and Healthcare Products Regulatory 
Agency, 2015b; Medicines and Healthcare Products Regulatory Agency, 2015c; 
Actavis UK Ltd, 2014) 
Lactose exists as both crystalline and amorphous structures. Either the -
monohydrate or the anhydrous β-lactose are produced depending on the 
crystallisation conditions.  Amorphous lactose is easier to dissolve and compact but 
is hygroscopic and unstable. High relative humidity and a rise in temperature can 




2.3.4.2 Disintegrants Used In Tablet Manufacture 
Disintegrants are added to the formula in order to facilitate the breakdown of the 
tablet thus creating a larger surface area for dissolution. Disintegrants work in two 
ways:  firstly, some disintegrants promote the uptake of water by increasing 
hydrophilicity and the interfacial tension is reduced and the tablet disintegrates when 
it becomes wet.  Secondly, the disintegrant particles swell during sorption of water, 
causing the tablet to rupture.  The most prevalent disintegrant used in tableting is 
starch, which works by the latter method (Aulton, 2007b).  Maize starch is commonly 
used in the diazepam (1) pharmaceutical tablets produced for the UK market 
(Medicines and Healthcare Products Regulatory Agency, 2014; Medicines and 
Healthcare Products Regulatory Agency, 2016b; Medicines and Healthcare Products 
Regulatory Agency, 2015b; Medicines and Healthcare Products Regulatory Agency, 
2015c; Actavis UK Ltd, 2014) 
2.3.4.3 Binders Used In Tablet Manufacture 
The use of binders helps to hold a tablet together and gives the required mechanical 
strength.  Binders can be added as a dry powder or as a solution depending on the 
tableting method.   The binder used for diazepam (1) tablets by MA Pharmachem 
and Wockhardt, is polyvinyl pyrrolidone (PVP), otherwise known as Povidone 
(Medicines and Healthcare Products Regulatory Agency, 2015c; MA Pharmachem 
Ltd, 2011). Povidone is a synthetic polymer, which has increased adhesive 
properties.  Due to its hydrophilic nature, Povidone can also act as a disintegrant and 
can reduce the speed of polymorphic conversion of crystals by working as a 
viscosity-inducing agent (Panakanti and Narang, 2012). 
2.3.4.4 Glidants Used In Tablet Manufacture 
Glidants are used to improve the smooth flowing of powders through the tableting 
machine. This restricts blockages and helps to promote correct filling of the dies. 
Ensuring consistency within tablets and between batches in the pharmaceutical 
industry is of the utmost importance. Consistency is affected by particle shape and 
size, the effectiveness of the mix and the ease of flow through the tableting machine.   
Irregular flow leads to uneven filling of the die wells on the tableting machine, 
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potentially producing fragile tablets due to incorrect compression, which, could result 
in tablets containing an incorrect blend and uneven dosage.   
Spherical particles flow more easily than irregular crystals, which are more likely to 
interlock.  This results in the rough crystals clumping together creating an uneven, 
more heterogeneous blend. There are a variety of measures which can be taken to 
limit these problems.  For example, certain additives can be introduced which are 
designed to encourage crystal growth on particular faces during the production 
process.  In terms of tableting, glidants such as talc, colloidal silicon dioxide or 
magnesium stearate can be added to help reduce the bulk density.  Diazepam (1) 
tablets in the UK contain magnesium stearate, which has a dual purpose as both a 
glidant and a lubricant (Medicines and Healthcare Products Regulatory Agency, 
2014; Medicines and Healthcare Products Regulatory Agency, 2016b; Medicines 
and Healthcare Products Regulatory Agency, 2015b; Medicines and Healthcare 
Products Regulatory Agency, 2015c; Actavis UK Ltd, 2014; Aulton, 2007b). 
2.3.4.5 Lubricants Used In Tablet Manufacture 
Lubricants are used to enable compressed tablets to slide out of the die wells 
(Lachman, Lieberman and Kanig, 1970).   They are generally fine powders which 
create a thin barrier between the tablet and die to reduce friction. 
However, there are a number of problems associated with lubricants.  For example, 
agglomeration of particles can increase through static charge of the fine powder.  
Also, as lubricants are often lipophilic, they can slow down the dissolution rate of the 
tablet by increasing hydrophobicity.  Magnesium stearate used in the manufacture of 
some pharmaceutical diazepam (1) tablets (MA Pharmachem Ltd, 2011), is 
hydrophobic and although it is useful as both a lubricant and anti-adherent, it can 
hinder the dissolution of tablets by adhering to the surface of the tablet creating a 
film (Ariyasu, Hattori and Otsuka, 2016).  Quantities of magnesium stearate are 
therefore kept to a minimum.  Alternatively, a water-soluble surfactant and 
hydrophilic diluent can be added.  Surfactants can aid dissolution by decreasing the 
interfacial tension between solid and liquids thus allowing the solid particles to 
become wet.  They also have the ability to disrupt membranes in the gastro-intestinal 
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tract, increasing absorption.  This requires careful monitoring however, as an 
increase in absorption and bioavailability could have potentially toxic consequences 
(Aulton, 2007b).  
The choice of excipient is important because some substances interact to the 
detriment of bioavailability or by increasing toxicity.  The presence of magnesium 
stearate for example, can increase the alkalinity and encourage hydrolysis of some 
active ingredients. The effects may be further influenced by the presence of 
magnesium oxide which is an impurity produced during the manufacture of 
magnesium stearate, thus increasing the level of alkalinity.  Alternatively, stearic acid 
being used as the lubricant can help to protect some active drug substances from 
degradation.  Further interactions with magnesium stearate can occur through 
oxidation, interactions with primary amines and the magnesium metal ions leading to 
metal chelation (Li and Wu, 2014). The pharmaceutical company Actavis list both 
magnesium stearate and stearic acid in their list of ingredients in their 10 mg 
diazepam (1) tablets (Actavis UK Ltd, 2014).   
2.3.4.6 Anti-adherents Used In Tablet Manufacture 
Anti-adherents, including magnesium stearate, prevent tablets from sticking to the 
punch or die wall (Lachman, Lieberman and Kanig, 1970). Sticking is related to the 
moisture content of the tablet and is a common problem, which is particularly 
prevalent with patterned punches. Accumulation of powder on the dies can create 
uneven tablets with indistinct logos. 
The tableting of illicit preparations can be performed in a variety of ways.  Firstly, a 
paste can be made containing the active ingredient, excipients and dyes, which are 
placed into a mould and allowed to dry.  This forms a more rough and uneven tablet, 
without logo and bearing little resemblance to pharmaceutical tablets and therefore 
creating tablets less affected by the anti-adherent.  This is an older method that is 
rarely used industrially but may still be used in some illicit circles.  
A much more common process is the use of tablet presses (Humphries, 1984).  The 
use of a single punch press means that dies containing pharmaceutical logos can 
allow distinguishing between illicit and legitimate tablets more difficult, especially as 
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the clandestine manufacturers perfect their formula to prevent sticking.  However, 
incorrect alignment or mishandling of the equipment can lead to punch marks which 
can link tablets back to the press.  The more sophisticated multi-station press makes 
the linking of tablets less likely as many more tablets are manufactured at the same 
time and not necessarily bearing the same logo (Humphries, 1984). 
2.3.4.7 Colourants Added in Tablet Manufacture 
Colourants are added to tablets for a number of reasons, including as a complement 
to the flavour, to mask a less appealing colour or to hide a colour change.  For 
example, primary amines can interact with amorphous lactose in a Maillard Reaction, 
resulting in a brown discolouration of tablets (Rowe, Sheskey and Weller, 2003).  
This reaction has also been reported with secondary amines but not with nitrogen 
present in heterocyclic rings (Narang, Desai and Badawy, 2012). 
Dyes may be added as a coating or as an integral part of the tablet but blue 
diazepam (1) tablets produced for the UK market have the colourant blended 
throughout.  Colour also enables standardisation and helps with tablet identification.  
The colourant helps to identify the strength of the different tablets, so for diazepam 
(1) produced for the UK market, 10 mg tablets are blue, 5 mg yellow and 2 mg are 
white.  This colour coding therefore assists in tablet differentiation and housekeeping 
for pharmacists, but although all 10 mg diazepam (1) tablets from UK manufacturers 
are blue, the type of dye used may vary.  
The dyes used can be oil or water soluble but may also be in lake form.  Aluminium 
lake complexes are insoluble in water or oil and demonstrate an increased stability to 
light and pH compared to the dye alone (Aulton, 2007b).  In the UK, the most 
common dye used in 10 mg pharmaceutical diazepam (1) tablets is indigo carmine 
(E132).  However, Actavis list the indigo carmine lake as their colourant (Actavis UK 
Ltd, 2014) and Bristol laboratories use dispersed blue 12726 (Medicines and 
Healthcare Products Regulatory Agency, 2015a), which is an alumina lake (Harvey 




2.3.4.8 Pharmaceutical Excipients 
Each company produces an information leaflet to inform consumers of the 
constituents of their tablets.  MA Pharmachem for example, list their ingredients as: 
lactose for the diluent, making up the majority of the bulk; maize starch is used as 
the disintegrant, Povidone or PVP as the binder and magnesium stearate as the 
glidant, lubricant and anti-adherent.  The colourant used by MA Pharmachem is 
indigo carmine dye (E132). 
2.3.4.9 Interactions between Excipients  
Excipients are “inert substances” but they do interact with each other and the active 
ingredients, impacting on the bioavailability of the active drug substance.  Excipients 
are intended to help the absorption process by ensuring the active drug substance is 
dissolved so that it rapidly reaches its absorption site.  However, poorly chosen 
excipients could form complexes that have lower solubility or increased molecular 
size rendering them incapable of diffusing through cell membranes.  Extensive tests 
are performed by the manufacturing companies to ensure interactions are beneficial 
and do not hinder the bioavailability (Panakanti and Narang, 2012). 
In terms of diazepam (1) tablets, an investigation into incompatibilities between the 
active ingredient and excipients has been performed by Matos et al. (2017)  This 
research entailed using Differential Scanning Calorimetry (DSC) and 
thermogravimetric analysis (TA), in conjunction with infrared spectroscopy (IR).  The 
excipients tested were lactose monohydrate (diluent), microcrystalline cellulose 
(emulsifier and bulking agent), pregelatinized starch (binder), sodium starch 
glycoloate (disintegrant and gelling agent), croscarmellose sodium (super 
disintegrant), colloidal silicon dioxide (glidant, adsorbent, disintegrant and anti-caking 
agent) and magnesium stearate (lubricant).  The study showed that an interaction 
took place between the diazepam (1) and colloidal silicon dioxide, however this was 
not significant enough to cause incompatibility.  This interaction was detected using 
DSC but not by TA or IR and it was suggested that DSC was more sensitive for this 
type of analysis (Matos et al., 2017).  
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2.3.5 Tableting Methods 
There are two methods used for tablet manufacture by the pharmaceutical industry, 
granulation, which binds powders together to form granules before compaction; or 
direct compression, which uses pressure to force the powder to stick together as a 
cohesive unit (Aulton, 2007b).  Granulation is the method used by MA Pharmachem 
(Wesley, 2014). 
2.3.5.1 Granulation Method 
The aim of granulation is to promote the even distribution of active drug substance 
and excipient content within pharmaceutical tablets.  Granulation is an intermediary 
step which is usually performed after all of the tablet constituents have been mixed 
together, whereby the mixed powders adhere together to form granules, usually of 
around 0.2 - 0.5mm.  Once the granulation has taken place, further excipients may 
be added before the tablets are compacted.  Excipients added prior to granulation 
include diluents for bulking, disintegrants for granule fragmentation and adhesives 
that are predominantly added as a dry powder for this process.  Lubricants are 
added after granulation and sometimes additional disintegrant or all of the 
disintegrant can be incorporated at this time (Aulton, 2007b).   
Granulation is advantageous in pharmaceutical manufacturing for a variety of 
reasons. Firstly, as a mixture of components are combined in the granule, they are 
kept together during the tableting process (Aulton, 2007b).  Through movement, 
powders segregate according to size and density, with the small and more dense 
particles accumulating at the bottom.  Granules therefore help to maintain a uniform 
blend of constituents throughout a batch, providing a more uniform drug dosage. 
Granules help to improve the flow of the blend as they tend to be more spherical in 
shape than powders (Figure 2.14). The flow is also aided by the larger size of the 
granules because they are often more able to absorb moisture in the system without 
affecting the flow.  Powders which are more hygroscopic and those with an irregular 
shape and increased friction, can flow more slowly. Compaction is improved in 
granular methods, due to even dispersion of the adhesive within the structure, which 
results in more cohesive tablets.  Compactability relates to the ability to form a robust 
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and viable tablet, which is resilient to fractures, capping and lamination (Aulton, 
2007b). 
 
Figure 2.14.  Sketch of a granule, showing a variety of components of different sizes combined 
into a coherent unit. 
 
Granulation can be performed using either a dry or a wet granulation process.  Dry 
granulation is preferred for more hygroscopic substances. The dry granulation 
technique uses pressure to aggregate the powder and this can be done in a heavy 
duty press to produce slugs, or by using two rollers resulting in a sheet.  The 
products are then granulated by milling and granules of the required size are 
separated through sieves (Aulton, 2007b). 
Wet granulation combines the powders with a granulating fluid, causing them to bind 
together. The fluid contains a volatile, non-toxic solvent such as water, ethanol or 
isopropanol, which is removed in a drying step.  The solvent can be combined with 
binding agents such as Povidone, which maintain adhesion after drying.  Wet 
granulation can either be performed on a fluidized-bed, where the powder is 
‘fluidized’ by being blown with a stream of heated air, while being sprayed with the 
granulating fluid and then dried; or in a high-speed mixer. The high-speed mixer 
technique agitates the particles while fluid is progressively added to give an even 
coating, which helps to form and shape spherical granules (Saleh, Vialatte and 
Guigon, 2005). Low-shear wet granulation and high-shear wet granulation 
techniques both use a high-speed mixer but the low-shear method uses a separate 
granulator, whereas it is an integral part of the high-shear system.   
 
34 
The method of granulation used impacts on the pore structure both within and 
between granules by influencing the level of packing between the granules, for 
example, granules produced by the fluid-bed are not as tightly packed as those that 
had been sprayed (Aulton, 2007b).  The inclusion of an adhesive in wet granulation 
techniques increases the strength of the tablets.  A study comparing granulation by 
fluidized-bed to low and high-shear methods, to create a low dose soluble active 
tablet was performed by researchers at Procter & Gamble (Hausman, 2004).  The 
experiment combined an unnamed active drug substance with lactose monohydrate, 
microcrystalline cellulose, Povidone, Crospovidone (polyvinyl polypyrrolidone, which 
is a cross-linked version of povidone) and magnesium stearate.  Many of the 
excipients used in the experiment are formulated into pharmaceutical diazepam (1) 
tablets in the UK.  The test concluded that in terms of producing a viable cohesive 
product, the fluidized-bed method was effective as low and high-shear granulation 
methods. 
2.3.5.2 Direct Compression Method 
In direct compression the active drug substance and excipients are mixed and 
tableted. Although this can prove a speedier and less expensive option, the specially 
formulated binders and other excipients can increase the cost. Disadvantages 
include the increased likelihood of particle segregation and a reduced level of 
compactability (Aulton, 2007b).   
Direct compression is preferred for soluble or potent drug substances, where they 
can be combined with course excipient particles, to improve flow and even 
distribution of active drug substance.  Other benefits of direct compression include 
an improvement in tablet stability because water and heat are not required in the 
manufacturing process and disintegration rates can increase due to particles being 
held together with weaker bonds. Dry granulation and direct compression use Van 
der Waals forces which increase in magnitude as the particles are forced together at 
pressure.   
In contrast, wet granulation distributes a liquid film around the particles, which forms 
liquid bridges.  As the granule dries, the added adhesive hardens creating a solid 
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bridge between the particles. Adhesives which bind in this way include PVP, which is 
present in the 10 mg diazepam (1) tablets produced by Wockhardt.  Partial 
dissolution of powdered components through wet granulation, can result in 
crystallisation binding the particles as they dry. Lactose crystallises in this way, using 
water as the solvent in the wet granulation process. Bonds created during 
crystallisation produce stronger, more robust tablets (Aulton, 2007b). 
Clandestine laboratories tend to use the direct compaction method of tableting, by 
compressing the free flowing powders (Humphries, 1984) which avoids the added 
expense of purchasing granulation equipment.  However, research into the 
manufacture of ecstasy tablets revealed that another method of tableting involved a 
combination of the moulded method of dye filling, whereby the mixture is fed into a 
moulded plate, pressed with a steel punch to even it and then compressed by hitting 
it with a hammer (Baer, 2007). 
2.3.6  Tablet Manufacture 
The blend of granules and/or powders is poured into the tableting machine through a 
hopper, or funnel.  From there it flows by gravitational force towards the die table and 
into the die.  The die is a well in the die table, which has the lower punch positioned 
at the bottom. The location of the lower punch determines the amount of powder that 
will be compressed into the tablet, thus affecting tablet depth.  The lower punch may 
be stationary or could move upwards during compression. 
Once the die has been filled, the upper punch enters the die well from above and 
compresses the powder into a tablet.  The upper punch withdraws and the lower 
punch moves up the die, allowing the tablet to be ejected. 
2.3.6.1 Tablet Presses 
Two main types of press are used for manufacturing tablets: - the single-punch press 
or the rotary press.  Hydraulic presses are often used for development stages or 
research but are not usual for product manufacture (Aulton, 2007b).   
A single-punch press can produce around 200 tablets per minute and is mainly used 
for small batches of tablets, such as in clinical trials.  Single- punch presses have 
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one die and set of punches (Figure 2.15). The powder flows from the hopper into a 
hopper shoe above the die table. The hopper shoe moves across until positioned 
over the die, allowing the powder to fall in to the well and then returns to allow the 
upper punch to descend. The lower punch in a single-punch press is stationary and 
does not push upwards during compression. The pressure is therefore applied from 
above by the upper punch.  The new tablet is then ejected and pushed away by the 
hopper shoe as it returns to refill the die well (Aulton, 2007b). 
 
Figure 2.15.   Diagram of a single- punch tablet press. (Aulton, 2007b) 
  
The rotary press is a multi-station press, which can produce over 10,000 tablets per 
minute. The number of die and punch sets can vary from three to over 60 for large 
scale operations. The dies are positioned in a circle around the die table and the 
table rotates with the punches so that the same punch is always used for each die 
(Figure 2.16). Compression is completed by the vertical motion of both the upper and 




Figure 2.16.  Diagram of rotary press mechanism. (Sajib, 2011) 
 
Machine maintenance and cleaning to keep the surfaces smooth helps to limit 
technical problems.  Most tableting problems result from powder content, such as 
variability in dosage or weight, uneven flow, sticking to the punch, low mechanical 
strength and capping or laminating. Capping is where the top of the tablet separates 
from the bulk of the tablet and lamination is a horizontal split across the tablet. 
The availability of tableting machines on the internet allows clandestine 
manufacturers easy access to more sophisticated equipment.  Research into ecstasy 
tablets noted that although older or second hand machines may be used by illicit 
manufacturers, the investigation had identified that newer and more powerful 
tableting machines were also used in clandestine laboratories (Baer, 2007).  This 
can provide a more professional appearance for the illicit tablets and allows them to 




2.3.6.2 Compression of Powders 
Compression of powder takes place over several stages: 
1. Rearrangement of the powder within the die. 
2. Once a certain pressure is exerted, the particles no longer move due to the 
finite space and an increase in inter-particulate friction. 
3. Particles undergo elastic deformation, plastic deformation or brittle deformation.  
Viscoelastic recovery means that powders that undergo elastic deformation can 
revert on decompression, or may reverse more slowly.  Plastic deformation is 
a permanent alteration and brittle deformation results in fragmentation into 
smaller particles.  The type and level of deformation is dependent on the 
formulated powders and the pressure exerted (Roopwani and Buckner, 2011).     
4. The smaller particles then repeat the compression process beginning with 
rearrangement, as further force is exerted. 
5. As the particles are forced together, agglomerations form. 
6. On decompression, powders which underwent elastic deformation begin to 
revert back, breaking some of the newly formed bonds (Buckner, Friedman and 
Wurster, 2010).  
The stages were confirmed in a study by Roopwani, who investigated the 
compaction behaviour of some common pharmaceutical excipients, including 
lactose, varying grades of corn starch and microcrystalline cellulose.  It was found 
that at lower pressure, there was rearrangement of the powder and some 
fragmentation.  Plastic deformation increased with the pressure, until available pore 
space was filled leaving nowhere for the particles to flow.  At higher pressure, there 
was an increase in elastic deformation.  These results were supported by the 
statistical principal component analysis used to examine the generated data.  The 
statistical analysis also identified differences in the change of decompression density 
of pre-gelatinized corn starch, which was believed to relate to its unique viscoelastic 
properties (Roopwani and Buckner, 2011). 
Compression of granules is different to powder compression and can result in 
deformation of the granules and/or the powders within the granules. At low pressure, 
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granules rearrange within the die but due to the course nature of granules and better 
flow properties, this stage is less significant than for powders.  As the pressure 
increases, granules undergo elastic and plastic deformation.  In addition, 
intragranular porosity reduces, resulting in an increased density of the granules.  
Limited fragmentation does occur but to a lesser extent than deformation.   Minimal 
attrition can also occur through friction with the die walls (Aulton, 2007b). 
2.3.7 Tablet Properties 
Properties of pharmaceutical tablets produced for the UK market are specified in the 
British and European Pharmacopeia, the MHRA and by the individual manufacturing 
companies.  The manufactured tablets are required to meet a variety of quality 
control measures, which include: 
1. Correct dosage and uniformity of dosage.  Uniformity of the dose is tested by 
analysing a sample of tablets and calculating whether their contents lie within 
the stipulated limit of standard deviation from the mean.   
2. Consistency of tablet appearance, weight and size. Uniformity of weight is batch 
tested by weighing a sample of tablets and calculating the mean. 
3. Consistent release and bioavailability of active drug content. 
4. Safety of content, with no harmful substance or microorganisms present 
5. Mechanical strength to ensure the tablet will remain intact under reasonable 
conditions, for the duration of its lifetime. 
6. Crystalline stability for the duration of its lifetime so that changes in amorphous 
content do not affect bioavailability of the active drug substance. 
7. Appropriate packaging to ensure the integrity of the tablets.  (Aulton, 2007b) 
A study was performed into the relationship between mechanical strength and 
dissolution rates of diazepam (1) tablets. The experiment compared varying 
quantities of excipients including microcrystalline cellulose, lactose and magnesium 
stearate, with different mixing times and compression pressures.  Results indicated 
that although the mechanical strength of the tablets was affected, this did not directly 
correlate with the dissolution rates of the tablets (Pesonen et al., 1997). 
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A study using a computer-generated hologram, investigated the homogeneity of the 
surface of tablets containing the common pharmaceutical excipient, EmcompressTM 
(Dicalcium phosphate dihydrate) compared to those containing starch.  The tablet 
surface is important because it impacts on dissolution, surface wetting and contact 
angles.  The technique used the diffuse reflection of incident laser light from the 
surface of a tablet to create the hologram.  The results indicated that the surface of 
the tablets containing starch were more homogenous than those containing 
EmcompressTM.  It was suggested that during the compression process starch was 
more likely to break and form new bonds than EmcompressTM (Ketolainen et al., 
1997). 
Tablet manufacture is therefore a complex process.  Some of the considerations are 
purely to help with the production of tablets, such as the inclusion of glidants, 
whereas others are concerned with bioavailability and safety of use.  Illicit 
manufacturers may want to make tablets easily but are not necessarily as aware or 
even concerned about the impact of their formula.  Therefore, irrespective of the 
active drug substance, the excipients used by illicit producers may cause harmful 
effects. 
Little is known about excipients used in illicit diazepam (1) tablets but they are likely 
to differ between the illicit manufacturers based on their own experience and 
according to the substances that are readily available.  It has been suggested that 
due to the complications posed by the tableting process, once an illicit manufacturer 
finds a formula that works, they are likely to stick to it (Baer, 2007). 
In 2010, an investigation into excipients used as cutting agents in a variety of illicit 
preparations, performed by the Centre for Public Health, based at John Moores 
University, reported that amphetamine tablets were found to contain glucose, 
bicarbonate of soda and paracetamol. They also noted that previous interviews with 
drug dealers had revealed that they regularly added caffeine, ephedrine, 
paracetamol and sugars, although dimethyl sulphone had recently been found.  This 
had also been discovered in methamphetamine tablets in Australia, along with 
caffeine and a variety of sugars.  In addition, ecstasy tablets were reported to 
regularly contain lactose as the main sugar, accompanied by cellulose, calcium 
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phosphate, and calcium and magnesium stearate.  However, these tablets were also 
found to contain additional active ingredients such as paracetamol, caffeine, 
ephedrine, procaine, amphetamine and 1- phenylethylamine.  Interestingly the 
investigation also claimed that heroin samples were sometimes cut with diazepam 
(1) (C. Cole et al., 2010). 
The rise of internet sales has also impacted on excipient availability and the 
European Monitoring Centre for Drugs and Drug Addiction (2016) reported that not 
only could relatively cheap tableting equipment and die stamps be bought from 
China, the vendors could also provide pre-mixed coloured excipients, which 
therefore makes accessing the ingredients easier and negates the problems of 
finding a viable formula.   
The differences between illicit cases of tablets therefore result from a number of 
factors from the formula and excipients used, to the tableting and compaction 
methods and the dies used.  Each of the choices made by the illicit manufacturer 
impact on the final characteristics of the tablet and can provide useful information for 
linking together the illicit tablets.  Therefore, this project aimed to investigate a 
variety of physical and chemical characteristics of the illicit tablets in order to detect 
any similarities that could identify links between the different cases.   This was done 
by comparing the results of the different forms of analysis and the data obtained and 
by employing statistical clustering techniques and linear discriminant analysis to 
group cases with similar characteristics.  This is a novel type of research that has 
never previously been performed on illicit blue tablets seized in Scotland which 




2.4  Drugs and the Law 
The growth of the opium trade in Asia alerted trading countries, particularly America, 
to problems created by drugs, which became recognised as an international 
problem.  After the establishment of the League of Nations, drug production, levels 
and usage were monitored internationally.  The list of controlled drugs increased, 
with the inclusion of cannabis by the 1925 Geneva Convention.  However, the 
emergence of new drugs meant that further legislation was required and this was 
finally brought together in 1961, with the United Nations Single Convention on 
Narcotic Drugs. This described an order for drugs based on the level of perceived 
danger and the amount of restriction required.  Concern over the increasing abuse of 
stimulants and hallucinogenic drug substances lead to The Convention on 
Psychotropic Substances, 1971. This legislation listed substances such as psilocybin 
and lysergide under schedule 1 and named diazepam (1) and other benzodiazepines 
in schedule 4 (United Nations Office on Drugs and Crime, 1971).  
The Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 
1988 was implemented due to a rise in recreational drug use, which had sparked an 
increase in clandestine laboratories and international drug trafficking during the 
1970s-80s. The legislation was aimed at targeting the drug traffickers and had 
provisions for money laundering, as well as restricting the availability of many drug 
precursors (United Nations Office on Drugs and Crime, 1971). 
The international policies were embedded into drug legislation in each of the 
participating countries.  In the United Kingdom, the Dangerous Drugs Act, 1951 
supported the policies set out in the Geneva Convention and focussed on restriction 
of production, import and export of cannabis, opium and morphine (United Nations 
Office on Drugs and Crime, 1951).  The Dangerous Drugs Act of 1964 addressed 
concerns about cannabis cultivation and use, while the Drugs (Prevention of Misuse) 
Act of the same year concentrated on criminalising the possession of amphetamines, 
which were believed to be related to juvenile crime (Reuter and Stevens, 2007).  In 
1965 a new Dangerous Drugs Act was drafted to consolidate the previous laws. 
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The 1968 Medicines Act, classified drugs into prescription only; (those which could 
only be sold by pharmacies) and medicines (which could be sold in any shop); and 
then further detailed in the Misuse of Drugs Act of 1971, which brought in the new 
classification system.  The 1971 Act aimed to classify around 250 named drug 
substances along with salts, stereoisomers which have the same molecular structure 
but in a different spatial arrangement and other preparations, into three main 
classes, A, B and C, where substances which were believed to present the most 
potential danger, such as cocaine, heroin and morphine were classified as group A. 
Group B included substances such as amphetamine and codeine and, Group C, 
which were considered to pose a lesser threat, contained the benzodiazepines 
(United Kingdom Government, 1971).   Offences and penalties related to each of the 
classification levels, were also listed and are shown in Table 2.1.   
Table 2.1.  The penalties for certain drug offences according to the Misuse of Drugs Act, 1971.   
(United Kingdom Government, 1971) 
Classification Production or Supply Possession 
Class A Life imprisonment, 
unlimited fine, or both. 
7 years imprisonment, 
unlimited fine, or both. 
Class B 14 years imprisonment, 
unlimited fine, or both. 
5 years imprisonment, 
unlimited fine, or both. 
Class C 14 years imprisonment, 
unlimited fine, or both. 
2 years imprisonment, 
unlimited fine, or both. 
 
Exemptions were permitted for doctors, dentists, pharmacists and veterinarians 
acting in their professional capacity and allowances were also made for scientific 
research (United Kingdom Government, 1971).  An Advisory Council on the Misuse 
of Drugs (ACMD) was established in order to classify any future drugs (The British 
Medical Association, 2017).  Various modifications have been made to the Misuse of 
Drugs Act, 1971, with the last one in 2017, which added the synthetic opioid known 
as U47,700 to the list of Class A drugs; twelve substances (some of which were 
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previously listed in the ‘temporary’ category) were classified as Class B; and sixteen 
”‘designer’ benzodiazepines” were added to Class C.  These sixteen include: 
Etizolam (7) (4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-
a] [1,4]diazepine ), Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f] 
[1,2,4]triazolo[4,3-a][1,4]  diazepine) and Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-
[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) (United Kingdom Government, 2017b). 
The 1971 Misuse of Drugs Regulations were introduced to clarify the 1971 Act. The 
regulations helped to outline the circumstances permitting controlled substances to 
be lawfully supplied, such as through prescription and pharmaceutical dispensation, 
for use by a named patient only and covered everything from prescription, to 
storage, disposal and record keeping.   
The regulations have been updated over the years with the most recent version 
being the Misuse of Drugs Regulations of 2001. (United Kingdom Government, 
2001). In addition to the classifications outlined in the Misuse of Drugs Act, 1971, the 
drug regulations group the specified drug substances into schedules which specify 
how each of the controlled substances must be handled to ensure safe usage.  Drug 
substances listed under Schedule 1 such as cannabis, cathinone, LSD and now 
etizolam (7) are illegal and are prohibited for use. Schedule 2 drugs, which include 
diamorphine and cocaine, must be stored in a locked safe with a handwritten register 
of all additions and withdrawals.   These drug substances may be prescribed with 
details of the form and dosage level to be taken.  Schedule 3 drugs such as 
temazepam (19), flunitrazepam and phenazepam (16) require the same security as 
Schedule 2 without the handwritten register.  The majority of benzodiazepines, 
including diazepam (1) itself are listed as Schedule 4 part 1.  These drug substances 
do not require such a high level of security as those above but are only legal by 
prescription and are illegal if supplied otherwise, where Schedule 4 part 2 drugs do 
not require a prescription but must be for personal use.  The only requirement for 
Schedule 5 substances such as is that invoices must be retained for two years.  
Schedule 5 drugs include preparations of some controlled substances such as 
codeine and morphine in a prepared and low strength form. 
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The Psychoactive Substances Act of 2016 was introduced in order to prevent the 
production, supply, import and export of any psychoactive substances, with the 
exceptions of caffeine, tobacco and alcohol, not already regulated by the Misuse of 
Drugs Act (Home Office, 2016). 
In the United Kingdom, the manufacturing, distribution, supply and storage of all 
medicines is monitored by the Medicines and Healthcare products Regulatory 
Agency (MHRA). In order to manufacture medicinal products, pharmaceutical 
companies are required to have a Home Office Licence in addition to any MHRA 
registration documents.  Pharmaceutical companies register with the MHRA, stating 
the product they intend to manufacture along with a list of ingredients, the intended 
purpose of the medicinal product and potential side-effects.  Tablet specifications 
particular to that company, such as tablet weight and size are also provided.  Tablet 
weight and size may be variable between companies but each company has to 
register the details of their own product.  Each licensed company is then legally 
obliged to ensure that the tablets meet the stipulated criteria for the entirety of their 
shelf life. The MHRA ensure that the specifications for the tablets, including dosage 
level are met, in accordance with the British Pharmacopeia monographs by 
undertaking regular inspections. (Medicines and Healthcare Products Regulatory 
Agency, 2012).  This means that not only do the MHRA perform inspections and 
quality checks but pharmaceutical companies also monitor their own products.  
Therefore, preformulation studies are performed ensuring tablets are stable and 
have the correct bioavailability; and random samples are regularly analysed to 




2.5 Illicit Drugs  
2.5.1 Substandard and Counterfeit Products 
One of the problems within the drugs sector is the rise in the sale of inferior and/or 
counterfeit medicines.  According to the World Health Organisation (WHO) 
‘Substandard’ medicines are authorised products, which do not fulfil the standard of 
quality expected nationally and/or internationally.  Counterfeit or ‘falsified’ medicine is 
defined as misrepresenting the true origin or content of the product by deliberate or 
fraudulent means (World Health Organisation, 2015b). This is a particular problem 
for people trying to buy medicinal products without a prescription and in countries 
such as the USA, where medical treatment needs to be paid for.  The possibility of 
buying products over the internet at a cheaper price is very appealing.  However, the 
purchasing of medicinal products is problematic because unless the supplier is 
known, there is no certainty that the tablets have been pharmaceutically 
manufactured or are of sufficient quality.  This dilemma was discussed by Liang and 
Mackey (2009), who called for more regulation and accountability for internet sales.  
They identified the real victims as being the more vulnerable patients including the 
elderly who may be naïve or less well-off.  As a consequence they may receive 
tablets that are not effective, suitable nor safe and take the tablets with no medical 
supervision and consequently suffer further financial loss as well as potential harm.  
It has been suggested that although counterfeit products do exist, the majority of 
sub-standard drugs on the market are pharmaceutical medications that were not 
made with adequate quality control (Johnston and Holt, 2014).  The problem is 
exacerbated when the products are bought to treat severe medical conditions or 
disease.  In the UK, the collection of information relating to counterfeit medication, as 
well as quality control, falls within the remit of the MHRA (Medicines and Healthcare 
Products Regulatory Agency, 2012).  
In 2016, the WHO noted that 920 types of medical product had so far been identified 
as ‘substandard, spurious, falsely labelled, falsified and counterfeit’ (SSFFC) (World 
Health Organisation, 2016).  In addition, they warned of the dangers posed by these 
products, which had been found to contain varying levels of active drug substance, 
no active ingredient or different drug substances altogether. It was commented that 
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the falsified products were often unhygienically produced by untrained operators, 
thus resulting in toxic levels of impurities, or chemicals and possibly having bacteria 
encapsulated within (World Health Organisation, 2015b).   
Although clandestine laboratories are known to produce tablets containing illegal 
substances such as methylenedioxymethylamphetamine (MDMA), with varying 
contents (Sherlock et al., 1999), knowledge on which medicinal products have 
counterfeit counterparts is slower to emerge.  In 2014, it was noted that 
approximately 10% of all drugs on the market were counterfeit (Dégardin, Roggo and 
Margot, 2014). A great deal of analysis has been performed and recorded about 
illicitly manufactured anti-malarial tablets (Ricci et al., 2007; Nyadong et al., 2007), 
as well as the erectile dysfunction drugs Viagra and Cialis (Jung et al., 2012; Bate 
and Hess, 2010; Kwok and Taylor, 2012; Goldstein et al., 2015).  Interest in 
diazepam (1) has grown over recent years, with reports claiming that the majority of 
the illicit tablets originate in Scotland (Birch, 2012); however, there has been little 
analytical work performed on these tablets. 
2.5.2 The Rise of Illicit Drug Usage in the United Kingdom 
During the 1960s, a new generation of heroin addicts emerged.  The Brain 
Committee reported this had resulted from over-prescribing by a small number of 
doctors.  It was believed that the unused prescription drugs had been diverted into 
the illicit market.   The drug problem continued to worsen and from 1975 - 2000, 
there was an estimated increase in the number of heroin addicts in England, from 
approximately 5,000 to 281,000.  In Scotland there were estimated to be over 50,000 
addicts by the year 2000 (Reuter and Stevens, 2007). 
Along with the increase in the reported number of heroin addicts came an increase in 
reported seizures. An interdepartmental government document on tackling drug 
misuse, along with guidelines for doctors was produced in1998 and updated in 2000 
(United Kingdom Cabinet Office, 2000).  Although concerns were raised over the 
social and economic problems associated with drug use, medical issues such as the 




By the end of the 20th century, a number of new drugs such as amphetamine, LSD, 
barbiturates and ‘party’ drugs such as ecstasy (3,4-
methylenedioxymethamphetamine) had emerged.  These became linked to crime, 
with a heavy socio-economic impact.  Surveys in England and Wales indicated that a 
third of men in prison and one quarter of those on community service admitted to 
problematic drug issues in the years 2000 and 2002. It has been estimated that in 
2005-6 approximately £508 million was spent on treatment; with an increase in the 
number of people being treated from approximately 67,000 in 1994 to around 
195,400 in 2006-7 (The British Medical Association, 2017).  
A government report into the impact of the drug market in Scotland estimated that 
over £51million was spent on benzodiazepines alone in 2006 (Casey et al., 2009).  
By 2007, it was estimated that the illicit drug market in the UK was worth over £5 
billion but the economic and social costs resulting from drug related crime in England 
and Wales was estimated to be over £13 billion (Reuter and Stevens, 2007).   
An advisory council report in 2016 noted an increase in individuals seeking treatment 
for addiction to prescription drugs and warned of an increase in diversion of 
pharmaceutical tablets.  However concern and urgent action was requested on the 
purchase of wholesale powders allowing illicit tablets to be illegally manufactured in 
the UK (Advisory Council on the Misuse of Drugs, 2016) 
2.5.3 Sourcing of Illicit Drugs 
A study carried out in the USA in 2014 reported that deceiving doctors was more 
prevalent than previously realised. Out of 2349 young adults surveyed 4% admitted 
misleading doctors to obtain prescription drugs, mainly for personal use, though 
around half also indicated that the ability to sell on the products provided an added 
incentive (Stogner, Sanders and Miller, 2014).  Surveys of patients in America have 
indicated that the majority of benzodiazepine users purchased their tablets on the 
street (Jaffe et al., 2004; Stein et al., 2017). 
In the United Kingdom, the diversion of pharmaceutical tablets into the illegal supply 
chain was described by the Advisory Council on the Misuse of Drugs in 2016.  The 
prescription medicines which were most frequently diverted were identified as 
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benzodiazepines and prescribed opioids.  It was also reported that the MHRA had 
investigated reports on diverted diazepam (1) tablets, along with other substances, 
leading to arrests.  (Advisory Council on the Misuse of Drugs, 2016).  However, a 
reduction in benzodiazepine prescriptions may be making the diversion of 
pharmaceutically manufactured diazepam (1) tablets less viable (Johnson, 
Barnsdale and McAuley, 2016). Data recorded by the Pharmaceutical Security 
Institute in America indicated that between 2005-10 there was a 66% rise in the 
number of incidents involving the theft or diversion of pharmaceutical tablets, 
whereas instances related to counterfeiting increased by 122% (Mackey et al., 
2015). 
A prevalence of bulk supply purchases over the internet has also been reported 
(Advisory Council on the Misuse of Drugs, 2016). The accessibility of the internet 
has provided an easy means for consumers to buy products from their own home 
without even visiting a doctor.  Apart from regular internet sales, the availability of the 
Darknet allows access to a variety of both illegal and prescription drugs including 
benzodiazepines.  The Global Drug Survey reported that there has been a 
continuing rise of sales through the Darknet over the last three years (Winstock et 
al., 2016). It has been noted that many customers believe this to be a safer way of 
buying illegal drugs with around a quarter of drug sales reported to take place over 
the internet; a trend that is likely to rise (United Nations Office on Drugs and Crime, 
2016; Van Buskirk et al., 2017).  Of those surveyed in 2015, 30% claimed to have 
ingested a wider variety of active substances because of the ability to purchase 
substances on the Darknet, rather than buying products elsewhere (United Nations 
Office on Drugs and Crime, 2016). 
An investigation into drug trafficking over the Darknet reported that the USA was 
listed as the country most ‘shipped from’, with 24.9% (11,996) of the 48,026 listings 
found on the Evolution marketplace.  The United Kingdom was listed as the second 
most ‘shipped from’ country at 12.4% (5972) of all listings.  Along with Agora, 
Evolution traded from January 2014 – March 2015 and was one of the two main 
Darknet marketplaces at the time the study was being performed.  It was also 
discovered that cannabis accounted for over 25% of the listings, opioids over 15% 
and benzodiazepines at under 10% of the listings (Rhumorbarbe et al., 2016).   
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The Darknet investigation was based at the University of Lausanne in Switzerland 
and part of their research involved making four purchases over Evolution.  Prices 
were believed to be higher than street samples but offered safety and anonymity of 
online purchases by avoiding physical contact with sellers.  The purchases were 
made from sellers who specified shipment from Switzerland.  The results of the 
investigation reported that the packages arrived by the Swiss postal system in a 
normal envelope.  However, inside the envelope the goods were packaged in heat 
sealed static shielding bags, to avoid detection (Rhumorbarbe et al., 2016). 
Chemical analysis on the samples of cocaine purchased in the Darknet study, 
showed that one of the samples had the same chemical profile and cutting agents as 
two cases previously seized by Swiss police.  It was therefore implied that the online 
sample and seized cases originated from the same distribution network 
(Rhumorbarbe et al., 2016). 
2.5.4 Drug Seizures 
A study in 2007, commented that law enforcement is focussed on tackling drug 
supply, by discouraging dealers and making the trade of illicit drugs more difficult.  It 
is hoped that this would lead to rising drug prices and lower illicit drug use.  
However, it reported that the drug markets in the USA were resilient and despite 
increasing conviction rates and lengthier jail sentences being put in place, the illicit 
drug market was thriving.  This was partly due to the expendability of those working 
in the supply chain and the ease of finding replacements, combined with stability in 
the prices of illicit market drugs (Bouchard, 2007). 
The trading of illicit drugs on the street poses problems for vendors.  They need to 
perform their transactions unseen, with customers they can trust.  There is also the 
dilemma of wanting to increase the customer numbers while avoiding becoming 
recognised as a drug dealer.  It was reported that sales would take place in areas 
with good visibility allowing look-out guards to be posted, or quick street transactions 
in commercial areas during daylight hours to avoid attracting attention, until mobile 
phones permitted the arrangement of private meetings.  This meant that new 
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customers were usually only accepted on recommendation (Aldridge and Askew, 
2017).  However, this remains problematic with police targeting the drug market. 
Over the period 2016/17, there were a total of 138,955 drug seizures made in 
England and Wales by the police force, the transport police and the Border Force.   
The majority of seizures were Class B drugs, with almost 75% involving cannabis 
(Broadfield and Marshall, 2017). 
Although the total number of seizures was recorded as a 6% decrease on the 
previous year, it does not account for changes in police activity or records.  It also 
does not reflect the prevalence of the illicit drug trade (Broadfield and Marshall, 
2017). 
In line with this, there was a 2% decrease in the seizure of Class C drugs, although 
this was only a fall of 1% in the case of benzodiazepines. The majority of Class C 
seizures (39%) comprised of benzodiazepines, with a total of 1,945 seizures during 
the 2016/17 time period.  The number of benzodiazepine tablets seized (567,438) 
was more than double the previous year but was heavily influenced by four different 
seizures, in South Wales, containing over 30,000 tablets.  It was noted however, that 
seizures made by the Border Force tended to contain far larger quantities than those 
made by the police.  This included 53% of the seizures of anabolic steroids and 47% 
of seizures containing other Class C drugs, which included the benzodiazepines 
(Broadfield and Marshall, 2017).  
The statistics on seizures in Scotland separate data according to 85-92% of supply 
cases and estimated figures relating to possession.  The data indicates that the 
majority of seizures in the period 2015/16, involved cannabis.   However, the Class C 
drug seizures were dominated by benzodiazepines, with diazepam (1) being 
reported as the most commonly found.  In crimes related to possession, 90% of all 
cases involved herbal cannabis, cannabis resin, cocaine, heroin or diazepam (1).  
For supply related crimes, 382 out of 393 seizures on Class C drugs, were listed as 
benzodiazepines and totalled 1,276,100 tablets (Scottish Government, 2017). 
Internet sales present different issues.  Purchasers and suppliers may be 
anonymous, making identification of the culprit difficult but they are faced with 
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problems relating to inconspicuous shipment and delivery.  Also there is no 
protection against misconduct.  Trading on the Darknet leaves customers open to 
exit scams, such as the closure of Evolution in March 2015, when the moderators 
stole around $12million of buyers money, stored in the system (Van Buskirk et al., 
2017). 
By using information on forums, the first Silk Road was closed down in 2013. In 
November 2014, Operation Onymous succeeded in closing down a number of 
cryptomarkets and several arrests were made (Rhumorbarbe et al., 2016; Aldridge 
and Askew, 2017).  Confronting cryptomarkets has become an essential part of 
dealing with the illicit drug market (Broséus et al., 2017).  
2.6 Analysis of Illicit Diazepam (1) Tablets 
According to British law, the possession and use of certain active substances are 
prohibited and prescription drugs, such as diazepam (1) are controlled.  The terms of 
use are detailed under the Misuse of Drugs Act 1971 and the Misuse of Drugs 
Regulations which are updated as the need arises.  Breaking these laws can lead to 
prosecution, however proof is required to confirm the active drug substance present 
along with the number of tablets involved in order to substantiate the crime that has 
been committed.  Tablet numbers could help support a supply charge but the 
circumstances of the case and the fact there is a controlled drug present determine 
the offence (United Kingdom Government, 1971; M. D. Cole, 2003).   
In addition, to providing forensic evidence for prosecutions, analysis of seized drug 
samples can provide useful intelligence for both police and medical staff. Medically, 
analysis can help alert doctors to problems that may arise in emergency cases, 
especially if drugs ingested are not those which the consumer believed them to be. 
Problem batches of tablets in circulation that have a specific visual appearance and 
which have been previously analysed, can therefore provide valuable information. 
Police intelligence can be gained from discovering potential links between cases, 
which could provide information regarding the origins of illicit substances or help to 
uncover a drug network (Esseiva et al., 2007).  
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In the past, it was suggested that if seized tablets appeared to be pharmaceutical 
products, then literature could be used to support the tablet identity but when the 
markings were not recognised, full chemical analysis was required.  This included 
presumptive and confirmatory chemical testing (United Nations Office on Drugs and 
Crime, 2012). However, it is no longer feasible to assume that an official logo is 
representative of tablets being pharmaceutically manufactured, as many of these 
markings are now reproduced in clandestine laboratories (Police Scotland, 2016)  
When an unknown substance is seized, presumptive tests may be used to give an 
indication of the active drug substance present and to inform decisions on the type of 
confirmatory test to be performed (Philp and Fu, 2017). 
Although the Zimmerman test has been used as a spot test for benzodiazepines, 
through the creation of a Meisenheimer complex (El-Hawary, Issa and Talat, 2007; 
Philp and Fu, 2017), colour tests are not ideal presumptive tests because the results 
are not specific.   
Thin Layer Chromatography (TLC) has also been used as a test for 
benzodiazepines.  Although there is not a development reagent that is specific for 
benzodiazepines, it can be performed using a sprayed solution of 1M sulphuric acid, 
which is visualised under UV at 366nm.  This is followed by spraying with acidified 
potassium iodoplatinate, which produces purple spots in the presence of alkaloids by 
reacting with tertiary and quarternary nitrogen atoms (United Nations Office on Drugs 
and Crime, 2012; Baerheim Svendsen and Verpoorte, 1983; M. D. Cole, 2003).  The 
method was compared to an Enzyme-Linked Immunosorbent Assay (ELISA) assay 
for detection of morphine in urine samples of drug abusers.  False positives were 
detected in the assay and it was therefore suggested that the TLC method be used 
in conjunction with assays as a relatively cheap method of checking for potential 
errors (Alireza Timcheh-Hariri et al., 2016). 
Due to lack of specificity, it is more common to analyse several tablets from one 
case using GC-MS and comparing the fragmentation pattern and retention time to 
identify the main drug substance (United Nations Office on Drugs and Crime, 2012). 
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An investigation into nimetazepam tablets in Malaysia used GC-MS to compare 
pharmaceutical batches to illicit cases.  The results revealed that 11 out of the 64 
illicit batches tested (17.2%), were found to contain diazepam (1) instead of 
nimetazepam (Abdullah et al., 2012).  Nimetazepam is a benzodiazepine used to 
treat severe insomnia and was commonly prescribed in Southeast Asia (Manchester 
et al., 2018). In the UK, nimetazepam is controlled under the Misuse of Drugs Act 
1971 as a class C substance under schedule 4 part 1 and was listed as one of the 
most commonly encountered controlled drugs in 2017 (United Kingdom 
Government). 
A comparison of techniques between a quadrupole mass spectrometer (QMS) and 
an ion-trap mass spectrometer (ITMS) was performed using diazepam (1). This 
showed that although the ITMS demonstrated greater sensitivity, the ion-mass ratio 
proved more precise than with the QMS. Full scan analysis was considered more 
beneficial than examining a smaller range but filtering out the unwanted ions meant 
that some accuracy was lost (Fitzgerald et al., 1997).  
As benzodiazepines are thermally labile, quantification of the active substance is 
better achieved by High Performance Liquid Chromatography (HPLC) (M. D. Cole, 
2003).  Until recently, the majority of benzodiazepine tablets in the illicit market were 
believed to have been pharmaceutically manufactured (United Nations Office on 
Drugs and Crime, 2012) therefore, much of the literature on HPLC analysis of the 
tablets has been aimed towards pharmaceutical batch analysis.  For example, the 
HPLC quantification of diazepam (1) by Sruthi et al. (2013) was performed by 
crushing twenty tablets together, mixing the powder and then removing 25 mg for 
analysis.  Similarly, an investigation into alprazolam (2) tablets, involved crushing ten 
tablets together for analysis (Pérez-Lozano et al., 2004).  This batch analysis is not 
suitable for illicit tablets as variability between concentrations of the active substance 
may occur through uneven blending and only an average value for the batch will be 
achieved.  
Further analytical techniques have been recommended by the UNODC, including 
infrared spectroscopy, although difficulties in extracting the pure drug substance and 
solubility of derivatives were noted. Although the current UNODC is dated 2012 
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some of the techniques listed are nonspecific and do not particularly reflect current 
laboratory best practise.  
It is also indicated in the report by UNODC, that any techniques used should always 
be repeated for comparative purposes, with a known pharmaceutical tablet alongside 
the unknown sample (United Nations Office on Drugs and Crime, 2012).  
The World Health Organisation (WHO) stress the importance of ensuring the quality 
of pharmaceutical products (Ratanawijitrasin and Wondemagegnehu, 2002), which 
supports the MHRA in their inspection and regulation of manufacturing processes.  
Quantification of diazepam (1) within tablets is regularly performed for quality control 
purposes in the pharmaceutical industry, leading to studies which are aimed at 
enhancing the techniques used (Ferreyra and Ortiz, 2001; Moros, Garrigues and 
Guardia, 2007).  However, even for industrial quantification of active ingredient, 
tablets tend to be batch tested, with the tablets being ground together. While this 
technique may be suitable as a quality control check during pharmaceutical 
manufacturing processes it is not suitable for the analysis of illicit tablets, where each 
item could be different. 
In 2015 the WHO sent out a Medical Product alert relating to falsified diazepam (1) 
tablets which had emerged in Central Africa.  The yellow tablets bearing the imprint 
AGOG were sold in containers labelled as diazepam (1) but were found to contain 
haloperidol (World Health Organisation, 2015b).  Instances of fake diazepam (1) 
tablets have also been recorded in Scotland (McGivern, 2016; BBC News, 2017).  
However, although it has been recorded that ‘diazepam’ (1) tablets produced in 
clandestine laboratories have entered the illegal supply chain little work has been 
done to identify active ingredients or quantify the level of drug substance present.    
2.7 The Use of Statistical Analysis  
Physical and chemical analysis of illicit tablets provides a variety of information 
regarding the content and manufacturing procedure.  Due to the different options 
regarding formulation and tableting methods, there is likely to be significant variation 
between the physical and chemical characteristics of tablets produced by different 
illicit manufacturers and more similarity between tablets made in the same 
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clandestine laboratory. Therefore, knowledge of these differences and similarities 
can be used to separate illicit cases into different groups.  Similarities between 
chemical profiles can therefore highlight potential links between illicit cases, 
indicating that they are not isolated incidents (Morelato et al., 2013).   
The use of a database allows information to be stored and compared to other cases, 
maybe from a wider area.  This means that whereas a single case of illicit tablets 
may require investigation for a particular prosecution, similarities to other cases may 
provide useful intelligence for investigating a bigger problem (Morelato et al., 2013). 
Potential links between cases are based on similarities demonstrated by a 
combination of physical, chemical and statistical characteristics rather than by a 
single factor (NicDaéid and Waddell, 2005). The characteristics chosen must be 
clearly defined and be able to distinguish between different batches.  Visual analysis 
of colour is often subjective (Dams et al., 2001) and therefore not ideal for this 
analysis.  Whereas, tablet weight and thickness are definable measurements and 
provide variable results based on differences in die pressure and the amount of 
powder added to the die, therefore allowing variation between cases to be observed 
(Marquis et al., 2008). 
Chemical analysis can include GC-MS to explore impurities created during the 
synthesis of the active drug substance if it makes up a large percentage of the tablet 
weight (Weyermann et al., 2008; Morelato et al., 2015).  A study into processing 
impurities of diazepam (1) led to six impurities being identified and characterised by 
Kalas et al. (2015). Identification of the active drug substances present, given the 
many types of drug available on the illicit market, along with identification of 
excipients, can also help to characterise the tablets, particularly if the illicit 
manufacturer continually uses the same formula (Baer, 2007).  Each of these 
characteristics help to distinguish between different cases of illicit tablets and 
similarities may therefore be significant. 
Comparison and interpretation of results can prove difficult and may be subjective, 
especially when large quantities of data are generated by a variety of analytical 
techniques being used to analyse a number of samples. Although statistics may not 
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provide a definitive solution, it does remove any bias in interpretation of results and 
is a good way of comparing large datasets. 
A variety of statistical methods are available for interpreting the data.  In terms of 
profiling illicit tablets in this study, the aim was to find ways of investigating potential 
links between cases.  Therefore, statistical clustering techniques such as 
agglomerative hierarchical clustering (AHC) and k-means clustering were an 
effective method of exploring patterns within the data (NicDaéid and Waddell, 2005).  
A review by Dams et al. (2001) described the benefits of using the chemometric 
methods of principal component analysis (PCA), AHC and k-means for investigating 
links between heroin samples.  Klemenc (2001) used these techniques and recorded 
results of between 95-100% accuracy.  K-means clustering was also used to 
characterise two clusters of ecstasy tablets seized in nine different cities in the Sao 
Paulo district of Brazil, thus identifying links based on the chemical profiles (Maione 
et al., 2017). 
Chemometric techniques can be used to enable prediction of group membership.  
Once different groupings can be separated, the data can be used to build a training 
set used to inform on the group membership of future samples.  These supervised 
techniques include linear discriminant analysis, which was used by Johnston and 
King (1998) to predict the country of origin of seized heroin, based on the 
concentrations of alkaloids and adulterants within the samples.   However, it was 
recorded that the content of heroin samples changed over time and therefore 
comparing data from future samples to information stored on a database generated 
by previous seized samples, may be flawed.   
The benefits of creating a database to store information can provide more than local 
intelligence (NicDaéid and Waddell, 2005).  Establishment of a common method of 
analysis, enabling a means to share intelligence through a common database has 
been discussed and tried (Weyermann et al., 2008; Lociciro et al., 2008).  The illicit 
drug market has no borders and it has been suggested that cross-border intelligence 




2.8 Assumptions and Strategies used in this Study 
Although it has been recognised that counterfeit versions of medicinal products are 
produced in clandestine laboratories, there appears to be little documentation or 
research on illicit diazepam (1) tablets.  A great deal of the work performed on 
diazepam (1) tablets appears to be based on the assumption that they are 
pharmaceutically manufactured and is concerned about ensuring standards are met 
or comparing the varying levels of active substance in tablets produced by different 
companies.  Batch testing is often applied to pharmaceutically manufactured tablets 
however, illicit tablets may show more variability between tablets and therefore need 
to be analysed individually. 
This project focussed on analysing individual tablets taken from 65 different cases of 
illicit tablets, which were seized in the Tayside area by Police Scotland. These 
tablets were compared to known pharmaceutical tablets. Data produced from 
physical and chemical tests was compiled on a database and a variety of statistical 
tests were performed to create models with the potential to identify similarities and 
differences which could highlight links between the different cases.  In order to carry 
out the research, certain assumptions and strategies were employed:   
1. The Tablets 
During this project 1989 tablets, which belonged to 65 different illicit cases and 5 
batches of known pharmaceutical tablets were analysed.  The illicit and the 
pharmaceutical tablets were treated in exactly the same way. 
2. Assumptions 
The assumption was made that the illicit tablets submitted from each case would be 
similar to each other in terms of physical and chemical properties.  This allowed a 
variety of analytical techniques to be performed using multiple tablets where 





3. Sampling Strategy 
On arrival at the University, each batch of illicit tablets were contained in separate 
plastic bags.  Within each bag, all of the tablets from the batch were loose and able 
to mix.  However, to ensure random samples would be selected for analysis, as the 
tablets were photographed separately, individual bags were labelled, providing a 
sample number for each tablet.  After photographing the tablets, a random number 
generator was used, in order to determine which number bag each sample would be 
placed in.  This meant that when tablets were taken for analysis, they were already 
randomly selected. The use of a random number generator was in line with 
recommendations in the ‘Guidelines on Representative Drug Sampling’ produced by 





3.1 Chapter Summary 
The physical weights and measurements of seized illicit tablets and those of 
pharmaceutical origin were recorded and compared.  The aim was to explore 
differences and similarities, with consideration to acceptable variability as outlined in 
the British Pharmacopeia.  The weight, diameter and depth of all tablets were 
recorded on a Microsoft access database, enabling the comparisons to be performed 
and the information used to differentiate between the different tablets. 
The colour of the tablets was recorded by photography using a purpose built 
lightbox. 
 
3.2 Introduction  
3.2.1 The Manufacture of Pharmaceutical Tablets 
A large variety of prescription tablets are manufactured for the United Kingdom 
market.  New branded products are initially patented, preventing other companies 
from manufacturing similar formulations until the patent expires.  This allows the 
developing company time to recoup the expense of discovering and introducing the 
new medication (National Health Service, 2014).  Once the patent period is 
completed, other manufacturers are permitted to produce their own formula for the 
manufacture of the same generic drug.  This may result in variations of colour, 
weight and dimensions, due to differences in colourants and excipients used.  
However, each company must license their product, specifying details of tablet 
content, weight and general appearance (European Medicines Agency, 2000; 
Medicines and Healthcare Products Regulatory Agency, 2012).  At present, twelve 
marketing authorisation licenses exist for the manufacture and sale of 10 mg 
diazepam (1) tablets in the UK (Goddard, 2018). 
 
61 
Colour and logos on the pharmaceutically made tablets are useful for identifying the 
manufacturer and drug substance present and are described on accompanying 
patient information leaflets.  However, the type of font and size are not registered 
characteristics.  This means that for 10 mg diazepam (1) tablets produced by MA 
Pharmachem for example, there could legitimately be a variety of fonts and sizes on 
their tablets (Wesley, 2014).  In the United States of America, the Department of 
Health and Human Services issue guidelines to promote coded imprints on the 
tablets or capsules themselves, to aid identification (Department of Health and 
Human Services USA, 2017).   
In the United Kingdom, the TICTAC database can be used to identify pharmaceutical 
tablets and is regularly updated with photographs and information regarding illicit 
tablets and capsules. The information provided includes the legal standing of the 
active substance present and details the formula and chemical structure, along with 
physical characteristics of the product, in order to separate it from other tablets or 
capsules of a similar appearance. It is estimated that TICTAC is used by over 60,000 
professionals from both healthcare and law enforcement sectors (TICTAC 
Communications Ltd., 2015). 
3.2.2 Tablet Quality 
Details of drug specifications and regulations determining the quality and 
consistency of manufactured products are defined in the British and European 
Pharmacopoeias and are upheld in the United Kingdom, by the Medicines and 
Healthcare Products Regulatory Agency (MHRA).  This ensures the safe 
manufacture and storage of pharmaceutical drug products. 
Consistency in dosage is affected by even distribution of drug substance in the tablet 
blend and by variation in tablet thickness, which results from over or under-filling dies 
on the tablet press and the pressure applied to the press.  Tablet circumference and 
diameter are determined by the die measurements and are therefore more 
consistent. Checks for confirming tablet consistency are described in the 
pharmacopoeia.  The test for uniformity of weight is defined in Appendix XII C of the 
British Pharmacopoeia.  It states that 20 tablets should be randomly analysed and 
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that from those tablets, no more than two are allowed to deviate from the average 
weight by more than a set percentage.  In addition, none of the tablets are permitted 
to deviate by more than twice the set percentage.  The percentage variation allowed 
differs according to the average mass of the tablet.  The diazepam (1) tablets 
analysed for this project all fell into the category of weight between 80 – 250 mg.  
Thus allowing a variation percentage of 7.5% (British Pharmacopoeia, 2008; British 
Pharmacopoeia Commission, 2017b).  This means that two of the tablets could go 
over or under the average weight by 7.5% but not beyond 15%.   
An investigation into identification of counterfeit capsules found that the weight of the 
legitimate pharmaceutical capsules within the study, fell within the range of 315 – 
321 mg, with a corresponding relative standard deviation (RSD) of 1%.  In contrast, 
the counterfeit capsules had a much larger weight range of between 224 – 384 mg 
and an RSD varying from 2 – 40% (Dégardin, Roggo and Margot, 2015). 
A study by Zaid, investigating the content of lorazepam (11) half-tablets discussed 
how the correlation between weight and drug uniformity was important because 
pharmacies are not equipped to check the uniformity of the drug substance.  Half 
tablets are also taken as lower dosage units, with the tablets split on the score line, 
therefore emphasising the importance of ensuring even distribution of the active 
ingredient (Zaid et al., 2013).  
 
3.2.3 Physical Appearance of Illicit Tablets 
3.2.3.1 Comparison of the Physical Characteristics 
Similarities in the physical appearance of tablets can identify potential links between 
illicit cases.  For example, Camargo explored the possibility of using different digital 
capabilities of photographs to compare colour, shape and texture of tablets.  The 
resulting information was then used to investigate potential links between tablets 
(Camargo et al., 2012).   
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3.2.3.2 Manufacturer Logos  
Logos could be a useful way to differentiate between batches of tablets.  However, it 
is possible that an illicit manufacturer may have a number of presses or a multi-
station press using a variety of dies, which could produce tablets with an appearance 
similar to one or more legitimate pharmaceutical manufacturer.   Potential links 
between tablets therefore require identification through chemical analysis as well.  
Alternatively, chemical differences may become apparent between tablets of a 
similar physical appearance, potentially indicating that different manufacturers are 
using similar dies.  
3.2.3.3 Tool Marks 
Another approach to investigating potential links would be to compare tool marks on 
the tablets.  If the same damage mark kept reoccurring within and between cases, it 
could indicate that the same die had been used.  However, it was decided for three 
reasons that this would not form part of this current research project.  The first being 
the difficulty in recognising a true damage mark from accidental damage and wear 
that has occurred over the tablet lifespan as well as any differences in the 
formulation leading to inconsistencies in visual appearance of the tablets.  As 
discussed in Chapter 2 - Introduction (Section 2.2.6.1 Tablet Presses), differences in 
blend or formula can result in powders sticking to the punch, produce differences in 
mechanical strength or result in capping or lamination causing a split in the tablet, 
making consistent damage marks difficult to identify.  Thirdly, with increasing 
complexity of modern illicit tableting operations, it is more likely that a multi-station 
tablet press could be used. 
3.2.3.4 Granularity of Tablets 
The granularity of tablets results from formulation, blend and manufacturing 
procedure employed (Lopatka and Vallat, 2011).  Similarities in granularity may 
therefore help to identify potential links.  A study performed in 2011 explored surface 
granularity though digital photography, which used the grey scale to differentiate 
shades of colour that represented various granules, facilitating comparison (Lopatka 
and Vallat, 2011).  This technique therefore required consistent digital photographs 
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of a good quality.  Although granularity was considered for this project, it was not 
pursued because the appearance of granules does not only result from the tablet 
constituents and manufacturing processes but also from the effects of storage and 
the consistent blend of the tablet mix, meaning that even tablets from the same 
batch could appear different.   
3.2.3.5 Colour of Tablets 
The colour of tablets vary according to the type and amount of colourant used, as 
well as how well mixed in the colourant is.  Consistency of colour gives the 
appearance of tablets being more evenly blended and therefore, well made.   In the 
United Kingdom, the colourant most often used in pharmaceutical 10 mg diazepam 
(1) tablets is indigo carmine (E132).  However, this may be present in powder or lake 
form, as discussed in Chapter 2 – Introduction (Section 2.2.4.7 Colourants)  (Actavis 
UK Ltd, 2014; Medicines and Healthcare Products Regulatory Agency, 2016b; 
Medicines and Healthcare Products Regulatory Agency, 2015b; Medicines and 
Healthcare Products Regulatory Agency, 2014; Medicines and Healthcare Products 
Regulatory Agency, 2015c). Alternatives, such as the lake dispersed blue 12726 are 
also used (Medicines and Healthcare Products Regulatory Agency, 2015a). 
Colourants may therefore aid in distinguishing between illicit batches of diazepam (1) 
tablets, however this was not pursued for the project as it was believed greater 
information may be obtained using other analytical techniques, particularly if only a 
limited number of colourants were used. 
 
3.3 Overview of the Analysis of the Physical Characteristics 
The physical characteristics of each tablet were recorded in as much detail as 
possible and added to a database built with Microsoft Access.  The use of a 
database for storing information related to the analysis of capsules and tablets is 
becoming more widespread.  It provides a structured method of storing detailed 
information which can be constantly updated, while allowing comparisons of relevant 
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characteristics to be performed.  Databases can even be set up to flag notifications 
of similarity as new entries are added (Dégardin, Roggo and Margot, 2015). 
The intention for creating a database for this project was twofold.  Firstly, the 
information was detailed in order that a selection of characteristics could be 
extracted from the database, as required.  Thus allowing a variety of differentiation 
criteria to be utilised.  Secondly, as many of the tablets were to be destroyed through 
chemical analysis, it was important to maintain a record containing as much detail as 
possible for future work.   
Many of the physical characteristics, such as colour, font and surface 
inconsistencies, were best captured with photography. In case of visual comparison 
of the tablets at a later date, as much consistency as possible was maintained 
between the photographs (the details of which are described in section 3.3.1.4 
Camera Set-Up). Photographs were then linked to the database. 
Tablet weights and measurements were recorded and where possible, compared to 
data supplied by the MA Pharmachem and Wockhardt, in order to differentiate 
between the pharmaceutical and illicitly manufactured tablets.  This was done by 
adding the recorded information into the database, which allowed a direct 
comparison of the information relating to tablet markings, weights and 
measurements. 
3.4 Experimental 
3.4.1 Photography of Tablets 
In order to keep an accurate visual record of each tablet before its destruction, 
photographs were taken of every tablet received.  The diazepam (1) tablets were all 
circular in shape, usually with a flat surface on both sides.  However, some of the 
cases had bevelled edges and a few were convex in shape.  In order to record as 
much variation as possible, photographs were taken of the front, the reverse and 
from the side. 
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Initially photographs were taken using an Olympus DSX100 optical microscope, with 
a 3.6x objective lens and 1.3x zoom, creating a photograph of 1194 x 1194 pixels at 
96 dpi.  Later intakes of tablets were photographed with a Nikon D5100 camera, 
using a 36mm extension tube and a 5000K lightbox producing pictures 3696 x 2448 
pixels at 300 dpi.  
In order to keep the photographs consistent, a 5000K lightbox was constructed.  This 
was then configured on the white balance settings of the camera.  The use of a 
lightbox meant that the light source could be kept even and shadow avoided.  It also 
prevented any influence from external light sources affecting the colour temperature 
and ensuring consistency over multiple use.  The construction was based on the 
lightbox used in the study on illicit tablet distribution networks by image collection 
performed by Camargo et al. (2012). 
3.4.1.1 Light Intensity 
The intensity of the light was important for the photographs.  As the tablets were 
photographed alongside a measure, the depth of field needed to keep both in focus.  
An increase in light helped to keep the image sharp. 
While Digital Single Lens Reflex (DSLR) cameras can boost the brightness of a 
picture this is usually done at the expense of the quality. In order to reduce any grain 
and to retain the detail of the surface photographed, the lowest International 
Standards Organisation (ISO) setting of the camera was used (Brady, 2017). 
The other benefit with using greater light was that a higher shutter speed could be 
used.  This helped to reduce the impact of external vibration or “camera shake”, 
which is more noticeable in highly magnified subjects. 
3.4.1.2 Materials for the Light Box 
Black Plastic Box (MB7 177 x 120 x 83 mm), 2 x PCB Mounting 4 AA Battery Boxes 
with mounting screws, 16/0.2 mm Stranded Copper AWG 16/32 3 Amp Equipment 
Wire 10 mm (black and red) and a Snap-in Miniature Round Rocker Switch (Black) 
were obtained from Maplin, Edinburgh. 8 x 48 LED 5000K Panels, Size 39 x 48 mm 
(Part No. SKU014825 – 25210 EVU) and a dual flash bracket holder for studio light 
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stand tripod camera DSLR 1/4" Screw were purchased from ebay. A plastic cat litter 
tray (1 mm thick black) was bought from Asda, Dundee and cut to size to mount the 
LED panels on. Roof bolts (2 x M6 25 mm), dome nuts (2 x M6), spring and flat 
washers (2 x M6) and 8 x AA Alkaline Batteries were purchased from Homebase, 
Dundee. 
3.4.1.3 Construction of the Light Box 
A circle was drawn around the camera lens, in the centre of the top of the black box. 
A hole was cut which was approximately ¾ inches larger diameter than the drawn 
circle maintaining a 5 mm distance from the edge of where the camera bracket was 
to be mounted.  The 5 mm clearance allowed for the box and LED panel thickness. 
The camera bracket was fastened onto the long face of the box with the M6 roof 
bolts.  The 1mm black tray was cut to size and the LED panels were mounted with 
the electrical connections towards the lens aperture to allow the assembly to be 
withdrawn for periodic battery changes. 
The four AA battery boxes were screwed to each short end on the inside of the box, 
allowing a 3 mm clearance from the base lid to allow the box to fully close.  Then a 
20 mm hole was drilled to position the rocker switch away the components. The two 
AA battery boxes were soldered in series to create a 12V source and the LED panels 
in parallel via the rocker switch to the battery boxes (i.e. all positive terminals 
combined and similarly the negative terminals).  Finally, the eight AA batteries were 
fitted and the panels were replaced ensuring the wires remained away from the lens 
aperture. 
A sheet of photographic paper was printed black, with a 2.5 mm square left white.  
The sheet was cut to size, locating the white square towards one corner.  This was 
fixed onto the inside of the lid of the black box, which was used as the base.  
Alongside this, a corner scale was fixed alongside it, to allow measurements to be 




   
    
Figure 3.1.  The purpose built light-box.  Showing the light box turned off, allowing the LED 
lights inside to be seen; switched on, to show brightness; from underneath to show 
construction; showing the scale and background mounted on the lid; and as seen by the lens; 
how the camera is fixed to the lightbox and the lens from underneath. 
 
3.4.1.4 Camera set-up 
A Nikon D5100 camera with a standard lens was set to 55mm and the filter was 
removed to prevent reflection.  A 36mm extension tube was attached.   
The camera was set to manual, with an aperture of F36 and a shutter speed of 0.5 
seconds.  The ISO was 100 and whitebalance of 5, for the 5000K colour 
temperature.  The quality used was Raw-F (large) for high resolution and spot 
metering was chosen to focus on a mark or edge of the tablet. 
Once the settings had been adjusted, the camera was mounted on the bracket. 
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3.4.2 Tablet Markings 
Before analysis each tablet was physically examined and a brief description of the 
colour was recorded, along with the tablet markings.  Although a note was made of 
the colour of the tablets, it was acknowledged that this was subjective. However, 
descriptions such as mid blue or bright blue could be used to give an indication of 
colour.  Differences in colour were best recorded through keeping methods of 
photography as consistent as possible.  The photographs taken in the light box were 
taken against a black background with a small white box measuring 2.5 mm in one 
corner.  This was to ensure that the white balance was kept constant. This 
methodology was based on a study by Camargo et al. (2012). 
Each tablet was checked for surface irregularities, such as chipping or double strikes 
and any noticeable detail was recorded. Noticeable differences in font size and style 
between some cases bearing the same marking, were apparent.  Initially, it was 
believed this may be an area worth investigating.  However, after discussions with 
MA Pharmachem, it was discovered that no specification was listed on the 
manufacturing licence from the Medicines and Healthcare products Regulatory 
Agency (MHRA) (as described in section 3.1.1 The Manufacture of Pharmaceutical 
Tablets). 
3.4.3 Tablet Measurements 
3.4.3.1 Weight of the Tablets 
Due to the stringent rules regarding tablet weight that are laid down in the British and 
European Pharmacopoeias, weights were recorded and assessed in comparison to 
the prescribed criteria (British Pharmacopoeia, 2008).   
The tablets were each weighed three times on a calibrated Mettler Toledo analytical 
balance.  The mean weight of each tablet was recorded, in order to reduce variation.  
The weights were noted and the mean, standard deviation (SD) and relative 
standard deviation (RSD) were calculated for each case.  This was compared to the 
±7.5% difference permitted and an allowance for any errors of measurement.  The 
error of measurement of the independently calibrated Mettler Toledo was estimated 
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at ±0.1 mg. Ten weights were recorded of the same tablet, giving a standard 
deviation of 9.48 x 10-4 mg. 
As tablet weight was originally determined by each pharmaceutical company and 
registered for their own product, it varied between manufacturers.  For example, MA 
Pharmachem manufacture tablets within the weight range 165-175 mg (Wesley, 
2014), whereas tablets produced by Wockhardt are noticeably lighter, with the 
average weight of Wockhardt pharmaceutical tablets analysed for this project being 
around 153 mg.  The variation in weight results from differences in excipient content 
because although the amount of active drug substance would have been the same, 
the exact formulations could vary.  Therefore, the allowances in weight described for 
this project were linked to the measured tablet weight and compared to the 
pharmaceutical criteria. 
3.4.3.2 Dimensions of the Tablets 
The diameter and the depth of each individual tablet were measured using digital 
callipers. The callipers with an estimated error of measurement of ±0.02 mm, were 
calibrated against a series of metric ‘Matrix’ steel slip gauges by the Coventry Gauge 
& Tool Company Ltd.  The diameter and depth of the tablets were measured across 
the centre, in line with any markings.  Each measurement was taken three times and 
the mean was calculated, to minimise any variance. The mean, standard deviation 
and relative standard deviation were then calculated for each case. 
The tablet diameter was taken across the centre of the tablets, in line with any 
markings, where appropriate.  However, although lifted from a flat surface, the 
callipers did not always touch the tablets in the same place on both sides, meaning 
that instead of being taken directly across the tablet, measurements may have been 
taken at a slight angle, as demonstrated in Figure 3.2.  Any inaccurate 
measurements were avoided as much as possible and all measurements were taken 








Figure 3.2.  Diagram showing position that the callipers could have measured the diameter of 
tablets. 
 
Despite the potential inconsistency in measurement, due to human errors of 
measurement, little difference was demonstrated between the diameters within each 
case, with a relative standard deviation not exceeding 0.56%.  Combined with the 
error of measurement allowance of 0.02 mm, variations in diameter within each case 
were of little significance. However, because manufacturers re-use their dyes for 
producing multiple tablets, this was not unexpected.  Therefore, the analysis of 
measurement focuses more on the differences in the depth of the tablets. 
Tablet depth was measured around the centre of the tablet and may have suffered 
from the same problems of measurement as the diameter but this was less of an 
issue because it was easier to ensure the tablet was held evenly in the callipers. 
There was more variation in the depth of the tablets because this was affected by the 
flow rate and consistency of the tablet blend and the pressure of the tablet press. As 
there is little deviation in the diameter, it is predominantly differences in formula, 




3.5 Results and Discussion 
3.5.1 Photography of the Tablets 
The photographs taken managed to capture much of the detail on the tablets, as 
shown in Figure 3.3.   
Case 2 Case 76 
  
Figure 3.3.  Photographs taken by different cameras.  Case 2 was taken on the Olympus 
DSX100 and Case 76 was taken using the Nikon D5100.  Difference in colour is genuine. 
The main difficulty with the photographs was related to inconsistency with the 
lightbox.  As the lightbox had been designed to be portable and easy to use 
anywhere, batteries were fitted.  However, it soon became apparent that consistency 
of colour was dependent on the battery life and the tablets became more blue in 
colour as the battery life reduced.   Therefore the photography had to be closely 
monitored.   In hindsight, to avoid battery degradation, an external regulated 12v 
mains power supply should have been fitted to maintain the power level. 
3.5.2 Tablet Markings  
3.5.2.1 Imprint Details on the Tablets 
The illicit tablets all bore the same logo within each case.  Altogether, 15 types of 
logo were represented by the different cases.  The markings related each case are 




Table 3.1.  Table identifying the number of cases and the case numbers which bear each logo. 
The markings on the front and reverse of each tablet are separated by the | symbol. 
Logo Number of Cases with the 
Logo 
Case Numbers 
MA | D/10 24 2, 4, 5, 13, 14, 16, 24, 25, 26, 
29, 30, 31, 73, 74, 75, 76, 79, 
82, 83, 86, 130, 132, 135, 159 
Half Score 1 3 
Cox | DC 7 6, 7, 8, 27, 71, 72, 150 
STADA | D/10 4 9, 12, 28, 129 
CP | D/10 2 10, 81 
ROCHE 10 | half score 1 11 
MSJ | half score 3 23, 78, 90 
1|0 | plain reverse 10 77, 84, 85, 87, 88, 89, 131,134, 
137, 152  
TENSIUM | half score 1 80 
MSJ | plain reverse 4 127, 128, 153, 154 
C/DC | plain reverse 1 133 
Half score | plain reverse 1 136 
EZ/1.0 | plain reverse 4 151, 155, 157, 160 
10 | half score 1 156 
NTZ/1.0 | plain reverse 1 158 
 
The tablet markings MA | D/10 and Tensium are known to relate to pharmaceutical 
companies who produced tablets for the UK market.  Although MA 10 mg diazepam 
(1) tablets have not been in production since November 2012 (Wesley, 2014), they 
may have still been legitimately available at the time of seizure due to the length of 
shelf life.  However, the imprint CP | D10 relates to products manufactured by 
Wockhardt UK, who are still licensed to manufacture diazepam (1) products. 
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Cox | DC is not a recognised imprint for diazepam (1) tablets licensed for the UK 
market, nor are those marked with EZ or NTZ. STADA is a German pharmaceutical 
company and MSJ are based in Sri Lanka, neither of these companies manufacture 
tablets for the UK and neither do the Swiss company Roche.  Therefore tablets 
bearing logos from these companies are not licensed for the UK market.  Similarly, 
Case 3, which bears a half score and is convex in shape was identified as containing 
10 mg of diazepam (1) by HPLC analysis (Chapter 5) but does not correspond to any 
products licensed for the UK. It may be a pharmaceutical product licensed in another 
country but the lack of detail imprinted on the tablets makes them difficult to identify. 
Tablets marked 1/0 were found to contain phenazepam (16) by GC-MS analysis 
(Chapter 4) which is not a licensed product in the UK and therefore these tablets are 
clearly illicit. 
3.5.2.2 Damage Marks on the Tablets  
Damage marks including small areas of damage to the circumference on each of the 
tablets were noted when appropriate. Chips were recorded in conjunction with tablet 
weight to ensure that ‘partial tablets’ were not included in the analysis of 
measurements.  In addition, possible damage marks and double strikes were noted, 
as can been seen in Figure 3.4. Multiple tablets were found to have double strikes in 
cases 13, 25, 26, 31 and 159. However, further investigation as to the significance of 
these physical marks were not carried out. 
 
Figure 3.4.  Tablet from Case 159, showing a double strike. 
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3.5.3 Measurements of the Tablets 
The results of the measurements are shown in Table 3.2 and are summarised as a 
bar chart in Figure 3.5 and as scatter graphs and box plots in Figures 3.6 and 3.7.  
Table 3.2 lists the mean diameter, depth and weight of every illicit case and batch of 
pharmaceutical tablets, although allowance needs to be made for the ±0.02mm error 
of measurement for diameter and depth and the ±0.1mg error of measurement for 
weight. In addition, the relative standard deviations (RSD) are listed for the depth 
and weight of each case.   
Table 3.2 also lists Roche next to the Pharmaceutical tablets.  Although the Roche 
tablets were pharmaceutically manufactured, they were not produced for the UK 
market.  However, with similar work on pharmaceutical intelligence being performed 
in other countries, Roche tablets may be used for comparative work elsewhere and it 
has been noted that there is little variability between Roche products manufactured 
either on one site or in multiple locations and they remain consistently within 




Table 3.2. The mean measurements and weights of each case of tablets.  Relative Standard 
Deviation (RSD) is also given for the Depth and the weights of each case. However, there was a 
large variation in case size.  Where there is a blank, not enough tablets were available in the 
case to calculate the data. An RSD of zero indicates there were multiple tablets but no deviation. 














2 8.08 2.64 2.64 0 170.2 167.6 – 172.6 1.21 
3 7.99 3.55 3.51 – 3.57 0.91 206.6 198.1 – 212.1 3.00 
4 8.07  2.65 2.63 – 2.66 0.80 220.5 215.0 – 225.9 3.50 
5 8.13 3.11 3.07 – 3.15 1.82 216.3 213.6 – 218.8 1.20 
6 8.08 2.90 2.83 – 2.97 3.41 189.5 187.6 – 193.2 1.70 
7 8.15 3.10 3.10 – 3.47 6.23 181.4 181.4  
8 8.09 3.13 2.79 – 3.46 15.16  181.7 171.5 – 188.5 4.95 
9 8.13 3.14 2.82 – 3.45 14.21 195.7 179.1 – 226.0 13.50 
10 8.06 2.88 2.88  160.2 158.5 – 161.9 1.50 
11 8.03 2.65 2.64 – 2.66 0.53 172.2 172.2  
12 8.08 2.85 2.82 – 2.88 1.49 177.6 175.3 – 179.4 1.20 
13 8.08 2.78 2.74 – 2.83 1.65 173.6 171.5 – 176.6 1.30 
14 8.16 2.64 2.61 – 2.66 0.96 213.3 185.6 – 228.9 11.3 
16 8.07 2.58 2.57 – 2.60 0.59 168.9 168.3 – 171.6 0.46 
23 5.53 2.80 2.52 – 2.96 8.61 74.6 71.7 – 77.6 0.1 
24 8.09 2.59 2.58 – 2.61 0.67 169.7 169.7 – 170.3 0 
25 8.13 3.08 3.07 – 3.09 0.46 214.2 214.2  
26 8.07 3.45 3.44 – 3.45 0.17 181.5 174.1 – 186.9 1.64 
27 8.06 3.23 3.12 – 3.45 5.90 194.2 192.6 – 197.4 1.39 
28 8.05 2.79 2.74 – 2.84 2.53 178.6 173.8 – 181.7 1.90 
29 8.09 2.58 2.57 – 2.59 0.39 174.3 169.3 – 178.4 3.29 
30 8.13 2.61 2.60 – 2.62 0.44 170.4 169.9 – 170.8 0.17 
31 8.14 3.17 3.03 – 3.46 7.82 181.0 176.7 – 185.4 1.90 
71 8.12 2.88 2.77 – 3.03 3.34 171.6 153.7 – 182.1 4.29 
72 8.12 3.04 2.96 – 3.18 1.91 185.6 159.7 – 197.7 2.89 
73 8.11 2.85 2.81 – 3.00 1.90 181.1 172.9 – 194.2 1.78 
74 8.10 2.64 2.59 – 2.72 1.28 169.6 149.7 – 173.3 2.85 
75 8.13 2.90 2.76 – 2.97 2.13 181.8 169.0 – 223.5 7.89 
76 8.13 2.89 2.82 – 2.99 1.92 180.7 173.5 – 186.5 1.80 
77 8.08 2.68 2.64 – 2.75 1.12 193.9 185.4 – 197.5 1.87 
78 5.59 2.42 2.37 – 2.54 1.59 73.8 70.2 – 76.3 2.13 
79 8.09 2.68 2.63 – 2.78 1.87 170.1 167.3 – 172.6 0.90 
80 8.04 2.67 2.59 – 2.77 1.95 170.1 162.6 – 180.1 2.32 
81 8.06 2.29 2.23 – 2.71 2.02 153.7 150.5 – 158.9  2.50 
82 8.11 2.61 2.58 – 2.65 0.73 170.1 168.4 – 172.1 0.76 
83 8.08 2.67 2.61 – 2.71 1.04 169.4 166.1 – 173.4 1.10 
84 8.08 2.81 2.69 – 3.01 2.83 244.2 222.6 – 268.1 4.41 
85 8.09 2.80 2.74 – 2.89 2.44 242.5 234.7 – 255.3 3.21 
86 8.09 2.66 2.60 – 2.73 1.45 169.2 165.3 – 172.7 1.23 
87 8.06 2.66 2.64 – 2.68 1.55 194.0 185.0 – 204.3 3.34 
88 8.10 2.66 2.65 – 2.69 0.75 198.4 293.6 – 203.5 2.50 
89 8.07 2.65 2.63 – 2.66 0.42 197.0 188.8 – 200.1 1.70 
90 5.56 2.38 2.32 – 2.43 1.50 73.4 70.3-75.5 2.50 
127 7.12 3.33 3.30 – 3.37 0.81 141.7 139.8 – 142.9 0.64 
128 7.12 3.31 3.07 – 3.36 2.07 140.6 138.2 – 142.1  0.75 
129 8.11 2.89 2.76 – 3.01 2.97 168.9 157.4 – 173.6 2.56 
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130 8.10 2.92 2.86 – 3.06 1.89 179.8 172.9 -  196.0 3.32 
131 8.08 2.78 2.66 – 2.89 2.42 240.4 231.0 – 259.0 3.21 
132 8.12 3.07 2.98 – 3.17 1.80 195.0 178.7 – 208.5 3.46 
133 8.22 2.85 2.74 – 3.24 4.98 170.5 159.1 – 175.8 2.94 
134 8.08 2.61 2.41 – 2.82 4.05 223.3 201.5 – 247.2 5.74 
135 8.15 2.89 2.81 – 2.98 1.61 179.1 173.5 – 18.36 1.65 
136 8.12 2.94 2.82 – 3.06 1.97 197.0 186.1 – 212.9 3.39 
137 8.06 2.81 2.69 – 3.06 4.09 234.8 227.8 – 253.4 3.85 
150 8.10 2.87 2.74 – 3.06 2.90 174.1 160.6 – 191.5 4.99 
151 8.09 2.83 2.78 – 2.87 0.95 178.7 165.1 – 186.0 4.57 
152 8.15 2.70 2.60 – 3.03 3.23 234.7 225.1 – 262.1 3.40 
153 7.11 3.31 3.17 – 3.38 1.65 141.5 138.6 – 143.8 0.88 
154 7.11 3.32 3.26 – 3.37  0.94 141.2 139.0 – 143.7 1.27 
155 8.11 2.88 2.78 – 3.09 2.80 185.3 174.0 – 191.1 2.25 
156 8.07 2.52 2.48 – 2.54 0.83 174.2 171.2 – 176.1 0.88 
157 8.10 2.89 2.76 – 2.96 2.30 181.9 177.5 – 186.0 1.84 
158 8.10 2.81 2.59 – 3.00 2.87 176.5 152.9 – 187.6 5.66 
159 8.16 2.90 2.78 – 3.07 2.50 174.4 162.8 – 185.5 3.65 
160 8.11 2.83 2.73 – 2.88 1.47 181.6 177.1 – 185.8 1.52 
Roche 8.11 2.58 2.57 – 2.60 0.51 169.7 168.3 – 171.2 0.62 
MA 061 8.08 2.59 2.55 – 2.63 0.62 170.7 168.1 – 173.0 0.66 
MA 064 8.07 2.65 2.61 – 2.70 0.78 170.3 166.9 – 173.6 0.93 
Actavis 8.10 2.71 2.66 – 2.78 0.92 173.6 168.6 – 178.6 1.66 
Teva 8.10 2.59 2.52 – 2.67 1.17 175.7 167.1 – 179.0 1.14 










Figure 3.5b  Bar chart showing the range of diameters measured from pharmaceutical batches of 
diazepam (1) tablets. 
















































Figure 3.6a The RSD of depth and weight within cases of illicit tablets. 
 
Figure 3.6b The RSD of depth and weight within cases of illicit tablets. 
Figure 3.6 Scatter graphs comparing the Relative Standard Deviation (%) in depth and weight 





Figure 3.7a Box plot comparing RSD of tablet depth between illicit and pharmaceutical batches of 
diazepam (1) tablets.  
 
Figure 3.7b Box plot comparing RSD of tablet weight between illicit and pharmaceutical batches of 
diazepam (1) tablets.  
Figure 3.7 Box Plots showing the range of Relative Standard Deviation (%) in depth and weight 


































































3.5.3.1 Tablet Diameter 
As shown in Table 3.2 and Figure 3.5 all of the pharmaceutical tablets had a 
diameter measuring between approximately 8.05 - 8.12 mm, with little variation due 
to the fixed size of the dyes used and allowing for errors of measurement.   
In comparison, there was much more variation between the measurements 
generated by the illicit tablets.  Cases 23, 78, 90 had a much smaller diameter at 
around 5.5 mm.  These tablets were all marked MSJ, with a half score on the 
reverse and were found to contain approximately 9 – 10 mg diazepam (1). 
Cases 127, 128, 153 and 154, also bore the MSJ marking but with a plain reverse, 
all had a diameter measuring around 7.11 – 7.12 mm, a depth of between 3.31 - 
3.33 mm and mean weight of 141 mg.  The highest RSD for these four cases was 
1.74% for the weight of Case 128 and 2.07% for the depth of the same case 
however, it is worth noting that this is still within the ±7.5% range permitted within the 
pharmaceutical industry.  Notably, these tablets were also marked MSJ but were 
coated, convex shaped tablets that were very different in appearance to Cases 23, 
78 and 90.  However, analysis by gas chromatography – mass spectrometry (GC-
MS) later revealed that these tablets contained promethazine as the active drug 
substance.  
Visually the two groups of tablets with the MSJ marking were well made.  It was the 
markings on the tablets and difference in shape and size that identified these tablets 
as being illicit for the UK market.  However, they do have the potential of being 
pharmaceutically manufactured for use in other countries, since it is not possible to 
check the markings of all legitimate tablets produced for the rest of the world 
markets.  However, research has shown that MSJ Industries is a subsidiary 
company of  J.L. Morison Son & Jones (Ceylon) plc., which is a legitimate 
pharmaceutical company producing tablets in Asia and Scandinavia 
(Substance.org.uk, 2017).  However, information regarding the types of tablets 




All of the remaining illicit cases appear to be much closer in diameter to the known 
pharmaceutical tablets. Case 3 was the smallest, with a diameter of approximately 
7.99 mm and Case 133 was the largest with a diameter of about 8.22 mm (Figure 
3.8). In comparison, the pharmaceutical tablets measured in the range of around 
8.07 - 8.10 mm.  In total 76.9% (50 cases) of all seized cases (including those 
marked MSJ), fell within the range of the measured pharmaceutical tablets.  This 
number includes all cases within ±0.04 mm of the recorded diameter to allow for 
errors in measurement of both the pharmaceutical and illicit tablets (therefore in the 
range 8.03 – 8.13 mm). 
 
 
Figure 3.8.  Diagram illustrating variation in mean diameter of the cases analysed (excluding the 
cases marked MSJ which had a mean diameter of around 5.5 mm).   All of the pharmaceutical 
batches were recorded between 8.07 - 8.10 mm which is shown in red.  The outer and inner 
measurements of 8.22 mm and 7.99 mm represent the cases with largest and smallest diameters 




3.5.3.2 Tablet Depth 
The difference in range of tablet depth is visualised in Figures 3.6 and 3.7a.  The 
whiskers of the box plot (Figure 3.7a) highlight the large difference in RSD range, 
while the lower median and smaller variability recorded from the pharmaceutical 
tablets is also demonstrated.   
The depth of the pharmaceutical tablets varied in range from approximately 2.59 - 
2.71 mm, with the exception of the tablets manufactured by Wockhardt which had a 
mean depth of about 2.28 mm. The Wockhardt tablets were the thinnest of all cases, 
with Case 81 measuring a similar size given the potential error of measurement of 
±0.04 mm and showing a recorded mean thickness of approximately 2.29 mm.  
Interestingly the marking of CP | D10 present on the tablets in Case 81 is consistent 
with the logo used by the pharmaceutical company Wockhardt UK. 
The MSJ marked cases 90 and 78 were the next smallest tablets measuring 
approximately 2.38 mm and 2.42 mm respectively.  These cases were discussed 
above in section 3.4.3.1 (tablet diameter) regarding their potential to be 
pharmaceutically manufactured outside the UK for a foreign market.  However, in 
this instance, Case 23, which had a comparable diameter to cases 90 and 78, was 
recorded as having a greater mean depth of around 2.8 mm, which presents a 
potentially significant variation. 
The pharmaceutical batch with the largest mean depth were manufactured by 
Actavis and had a mean thickness of approximately 2.71 mm.  41 illicit cases had a 
recorded mean depth above this, with only 36.9% (24 cases) falling within the range 
2.24 – 2.75 mm and allowing for the ±0.04mm error of measurement (Figure 3.9).  






Figure 3.9.   Diagram illustrating variation in mean depth of the cases analysed.  All 
pharmaceutical tablets fell between the two red lines marked by the Actavis and Wockhardt 
batches.  Twenty-four of the illicit cases also fell within this range but the majority (41 cases) 
appeared to be deeper tablets than the pharmaceutical products made for the UK market, that 




3.5.3.3 Tablet Weight 
The difference in range of tablet weight is visualised in Figures 3.6 and 3.7b.  The 
whiskers of the box plot (Figure 3.7b) demonstrate that greater variability was 
measured between the illicit tablets, while the lower median of the pharmaceutical 
tablets is also shown.   
The known pharmaceutical tablets all weighed between approximately 153 – 176 
mg. The heaviest were the tablets produced by Teva with a mean weight of 
approximately 175.7 mg and the lightest were the tablets manufactured by 
Wockhardt, which were considerably thinner and had a mean weight of about 153.6 
mg.  Based on the mean weight of pharmaceutical tablets manufactured by 
Wockhardt and Teva to provide a boundary and calculated with the permitted ±7.5% 
deviation, it was found that 66.1% (43 cases) of the sixty-five illicit cases fell within 
the acceptable range of 140 - 190 mg, allowing for errors of measurement of ±0.1 
mg.   
The lightest tablets were cases 90, 78 and 23, which were marked MSJ and had a 
mean weight between 73 – 75 mg.  This corresponds with them having the smallest 
diameter and thickness.  These tablets are not licensed for the UK market and it is 
unknown whether these tablets are pharmaceutically manufactured outside the UK.  
No legitimate tablets are available for comparison. 
The lightest pharmaceutical tablets, which were manufactured by Wockhardt, had a 
mean weight of approximately 153.6 mg.  The only illicit cases that bore the CP logo 
used by Wockhardt were cases 10 and 81.  Case 10 contained tablets with a range 
from 158.5 – 161.9 mg, and a mean weight of 160.2 mg and Case 81 had a mean 
weight of 153.7 mg, with a range of 150.5 – 158.9 mg.  Both of these cases were 
within the permitted ±7.5% range of deviation for weight.   Case 81 had only a 0.01 
mm difference in both diameter and depth from the pharmaceutical tablets and Case 
10 was slightly deeper giving it a heavier weight but both tablets fell within the 
pharmaceutical criteria, making them consistent with the Wockhardt products in 
terms of physical characteristics.  This suggests both cases 10 and 81 have the 
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potential to be pharmaceutically manufactured but diverted into the illegal supply 
chain.    
Cases 4, 5, 14, 25, 84, 85, 131, 134, 137, 152 each had a mean weight of over 210 
mg and were too heavy to be pharmaceutical tablets produced for the UK market, 
when compared to the data produced by the legitimate tablets tested.  Interestingly, 
the later six cases, which had mean weights in the range of 223 – 245 mg were all 
marked 1/0 and were found to contain phenazepam (16) (Chapter 4 – GCMS).  
Cases 4 and 14 with the MA & D/10 markings also contained phenazepam (16) but 
had a slightly lower mean weight of approximately 220.5 mg and 213.3 mg 
respectively. 
The only ‘heavy’ tablets which contained diazepam (1) were cases 5 and 25, which 
each had a mean weight between 214 – 216 mg and were both marked MA |D/10.  
Correspondence with MA Pharmachem indicated that their tablets should weigh 
between 165 - 175 mg.  In total, twelve of the illicit cases with the corresponding MA 
| D/10 marking were found to weigh within this range (Figure 3.10).  These were 
cases 2, 13, 16, 24, 29, 30, 74, 79, 82, 83, 86 and 159.  The remaining twelve cases 





Figure 3.10.  Diagram illustrating variation in mean weight of the cases marked MA | D/10 
compared to the manufacturers designed range.  The mean weight of the two pharmaceutical 
batches MA061 and MA064 were very close to each other in the centre of the weight range used 
by MA Pharmachem.  The diagram shows that half of the twenty-four seized cases marked with 
the MA logo fell within the permitted range of 165 – 175 mg but twelve cases had a mean weight 
above the maximum 175 mg limit, even with the allowance of ±0.2 mg for errors of measurement.  
The diagram is not to scale. 
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Any comparison becomes more complicated however, due to the regulations laid 
down in the pharmacopoeia.  The criteria states that in testing twenty units, up to two 
tablets can deviate in mass by up to 15% for tablets that weigh between 80 – 250 mg 
(British Pharmacopoeia, 2008).  This would allow two of the tablets produced by MA 
Pharmachem, for example, to weigh between 144.5 - 195.5 mg. In reality however, 
manufacturers tend to be more precise than this, with the samples tested having a 
RSD of less than 1%. 
Case 9 contained tablets with an approximate weight in the range of 179.1 – 226 mg 
and the largest RSD of 13.5%. As this case is imprinted with the STADA logo, it is 
not manufactured for the UK market. However, the high level of variation indicates 
little consistency in the tablet manufacture and therefore suggests that this case is 
unlikely to be pharmaceutically manufactured.   
3.5.4 Comparison of Results 
By comparing the physical data generated by the illicit cases against those of the 
pharmaceutical batches, the indications are that some of the cases could have the 
potential to have been manufactured by pharmaceutical companies and diverted into 
the illegal supply chain.  The results of the comparison of physical data is shown in 
Figure 3.11 and demonstrates that only fourteen of the of the 65 seized cases 
demonstrated similarity to the pharmaceutical tablets in all three measurements.  







Figure 3.11.   Venn diagram comparing the physical characteristics of cases against the criteria 
demonstrated by the known pharmaceutical tablets.  Each bubble represents a different physical 
measurement and lists the cases which matched the pharmaceutical batch for that 
characteristic.  Cases 3 and 23 did not comply with any of the measurements recorded for the 
pharmaceutical tablets. 
 
By analysing the physical data in conjunction with the markings, it is revealed that 
some of the tablets have not been legitimately manufactured for the UK market.  For 
example, Case 160 is marked EZ / 1.0 which is also not a legitimate marking for 
diazepam (1) tablets in this country and Case 12 bears the logo STADA, which is a 
German pharmaceutical company and does not produce diazepam (1) for the UK 
market either.  Case 11 is marked Roche and the tablets seized were contained in 
packaging labelled as Roche, Pakistan.  Roche is a Swiss pharmaceutical company 
that produces diazepam (1) tablets in other countries and notably in Asia.  This case 
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was consistent with all of the physical characteristics demonstrated by the UK 
pharmaceutical tablets but is not a licensed product for the UK market. 
Cases need to be compared to the pharmaceutical tablets bearing the same logo.  
Case 81 only weighs 153.7 mg, however it bears the logo of Wockhardt and is 
consistent with their pharmaceutical tablets. Case 10 also bears the Wockhardt logo 
but recorded a greater depth when measured, at 2.88 mm.  Although this tablet fell 
outwith the range of depths recorded for the entire batch of Wockhardt tablets, in this 
study, it may be that differences between batches, or tablets produced in different 
factories have slight inconsistencies, such as a variation in pressure which could 
affect tablet depth.  In addition, they may be pharmaceutically manufactured tablets 
that were rejected, as they met the criteria of diameter and weight.  Another 
possibility is that tablets in Case 10 were affected by storage conditions.  Therefore 
variation in one measurement may not entirely discount the case from being of 
pharmaceutical origin.    
Likewise, allowing for errors of measurement, Case 133 could be described as 
consistent with tablets produced by Actavis. The small differences in weight and 
diameter of 0.07 mg and 0.12 mm respectively, above the largest and deepest tablet 
in the pharmaceutical batch, may be due to errors of measurement.  However, it was 
recorded that the relative standard deviations in both depth and weight between all 
of the tablets in the seized case were greater, at 4.98% and 2.94%, than the 
pharmaceutical batch which recorded levels below 1% for each measurement.   
Case 156 bearing markings consistent with tablets manufactured by Teva, was also 
consistent with tablets from the pharmaceutical batch.  Case 80, marked Tensium, 
which produces legitimate diazepam (1) tablets for the UK market, recorded 
measurements consistent with all of the pharmaceutical criteria used in this study.  
Ten cases appeared to be consistent with MA Pharmachem tablets according to 





The results of the physical analysis of the tablets was found to be an important part 
of the project.    The tablet markings were an integral part of the analysis and were 
assessed in conjunction with the physical measurements. Data generated was 
shown to be valuable for determining whether tablets may have been 
pharmaceutically manufactured, emphasising the benefits of this new research. 
The analysis of physical measurements and comparison to known pharmaceutical 
tablets has not previously been explored with illicit blue tablets.  This new research 
revealed both similarities and variances between different cases in the illegal supply 
chain and also to those of pharmaceutical origin. By comparing the tablets to 
pharmaceutical diazepam (1) tablets and exploring the data statistically, using box 
plots, the level of variation in measurements was highlighted giving insight into 
differences in consistency between pharmaceutical and illicit tablets and increasing 
our understanding of illicit manufacturing processes. 
The findings of the physical investigation proved that some of the tablets could be 
identified as being of illicit origin because they were too heavy or of the wrong size.  
Measurements can therefore be used to differentiate between legitimate and 
illegitimate tablets in some of the cases.  The use of box plots further revealed the 
amount of variation within the illicit and pharmaceutical batches and clearly indicated 
that many of the illicit cases contained tablets which had greater inconsistency in 
weight and depth.  Thus indicating that a simple test into levels of variation may 
provide an important initial step into the origins of seized cases. 
Similarities in physical characteristics, such as imprint details and diameter could 
also reveal potential similarities between cases, or even to pharmaceutical 
manufacturers.  The similarities indicated that some of the seized cases may have 
been diverted into the illegal supply chain. Chemical analysis of the tablets, through 
HPLC, GC-MS and DSC later revealed that some of the potential pharmaceutical 
tablets contained varying levels of diazepam (1) or different active drug substances 




The comparison of the physical information brought to light potential similarities or 
links between some of the cases providing an important first step in differentiation 
between groups of tablets.  The next step was therefore to ascertain chemical 
information regarding the illicit cases which could then be explored in conjunction 
with the knowledge gained by analysis of the physical characteristics. The combined 
results of physical and chemical tests were then analysed in further statistical tests 





4.1 Chapter Summary 
Where sufficient tablet numbers allowed, Gas Chromatography-Mass Spectrometry 
(GC-MS) analysis was performed on at least one tablet from each of the cases in 
order to determine the main active drug substance present.  Although the street 
samples were believed to be sold as 10 mg diazepam (1) tablets and were blue in 
colour, the origin of the tablets was unknown and therefore the actual content was 
also uncertain.  In addition, any tablets containing diazepam (1) were not necessarily 
going to be of pharmaceutical origin. 
The total ion chromatograms of all case samples were compared to retention time 
(Rt) and mass ions produced from purchased certified standards analysed using the 
same method conditions.  Following this process allowed likely identification of the 
main drug substance to be made in each analysed tablet.  Known pharmaceutical 
diazepam (1) standards were also run as part of the sequence, to determine any day 
to day drift present in Rt and on-going accuracy of the mass spectrometry detector. 
Standards were run both at the beginning and end of each run sequence. 
 
4.2 Introduction  
Gas Chromatography (GC) is an effective analytical technique used for separating a 
mixture of volatile organic compounds in a sample and when coupled with Mass 
Spectrometry (MS), structural information about many of the components present 
can be gained from the mass ions present.  This technique was therefore used to 
provide valuable information regarding the main organic components present in the 
illicit blue tablets under examination.  While the sensitivity of the method is 
determined by the limit of detection for each compound in question, in this instance, 
provided an active drug substance was detected in each tablet then limit of detection 
determination was not carried out.  HPLC analysis was performed (Chapter 5) to 




The work performed in this project is important because no reports have previously 
been published on GC-MS analysis of illicit blue tablets with markings consistent with 
diazepam (1) tablets. This may be partly because of the large numbers of 
pharmaceutical tablets that were being diverted into the illegal supply chain, as 
described by the Advisory Council on the Misuse of Drugs (2016).  However, 
previous work using GC-MS to confirm the identity of benzodiazepines has been 
performed on unknown powders and body fluids or wastewater, to investigate drug 
consumption (Papoutsis et al., 2012; Boumba et al., 2016; Fatta-Kassinos, Meric and 
Nikolaou, 2011). 
4.2.1 Analysis of Benzodiazepines 
4.2.1.1 Analysis of Impurities 
GC-MS has been used widely in the pharmaceutical industry to analyse impurities 
(Hiriyanna and Basavaiah, 2008).  The impurities in a formulated tablet include 
everything that is not the active drug substance, and can include precursors of 
synthesized substances, degradation products, reaction specific impurities and 
excipients (Stawny, Piekarski and Marciniec,2016).  
In forensic science, impurities are analysed to identify the by-products of drug 
synthesis (Power et al., 2013).  For example, GC-MS is often used to investigate 
impurities found in tablets such as MDMA, because identification can give an 
indication of the method of synthesis, thus providing information that can potentially 
link cases. However, GC-MS can also identify other active drug substances present 
in the illicit tablets. An investigation into both the impurities and active drug content of 
ecstasy tablets in Hong Kong (Cheng et al., 2006) revealed that although many 
tablets had varying quantities of MDMA, others also contained a mixture of MDMA 
with MDA (3,4-methylenedioxyamphetamine) and methamphetamine (MA) and 
seven of the 89 tablets analysed were identified as containing ketamine in levels 
varying between 1 – 50 mg. Such information may help link the manufacture of 
different batches of tablets, as it relates to formulations and manufacturing 
processes used. It was therefore suggested that ketamine may have been present 
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due to cross contamination from the production of other illicit ketamine tablets, which 
is widely abused in Hong Kong. 
Similarly, although the primary purpose of GC-MS analysis in this project was to 
identify the main active drug substance present in the tablet, on occasion quantities 
of other active substances, such as paracetamol were identified in some of the 
tablets containing phenazepam (16).  This could therefore indicate that these 
phenazepam (16) tablets form a distinct group produced by an illicit manufacturer 
who included paracetamol in their formulation, or as a result of contamination from 
other products containing paracetamol which were manufactured within the same 
clandestine laboratory.  However, due to the low levels of active drug substance 
present in most benzodiazepine tablets, the levels of reaction specific impurities and 
degradants would be extremely low, making detection very difficult.  Therefore, 
linking synthetic benzodiazepines based on their impurities is less practical. 
4.2.1.2 Derivatisation of Benzodiazepines 
Analysis should be performed on the original substance when possible in order to 
prevent the appearance of additional impurities and to avoid complications through 
incomplete derivatisation, particularly if the technique is used quantitatively. Many 
benzodiazepines such as diazepam (1), chlordiazepoxide (3), nordiazepam (14), 
flurazepam (9) and alprazolam (2), are volatile and do not require derivatisation 
(Levine, 2003) and can be analysed by GC-MS directly after extraction in methanol 
(M. D. Cole, 2003).  One of the main excipients added to pharmaceutically produced 
diazepam (1) tablets for the UK market, is lactose (Chapter 2 Introduction, Section 
2.2.4 Excipients) which is ‘very slightly soluble in alcohol’ (National Center for 
Biotechnology Information, 2017).  Therefore, after extraction into methanol, the 
samples were filtered to remove any insolubles prior to filling the sample vials for 
analysis to prevent interference. 
Derivatisation of the more polar benzodiazepines and their metabolites by silylation 
of active hydrogens, acylation of the polar functional groups or alkylation with amine 
hydrogens and acidic hydroxyl groups can lower the Rt caused through adsorption 
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on the stationary phase in some columns and may prevent thermal degradation of 
polar compounds (Levine, 2003; Kyle, 2017; Blachut et al., 2004). 
A ZB-5MS column was used for the analysis in this project. The 5 % - phenyl-arylene 
phase incorporated into a polymer of 95% dimethylpolysiloxane creates a complex 
network making interaction with the stationary phase more difficult and allowing 
preferential access based on compound shape.  Therefore, the limited access 
causes stronger adsorption to the stationary phase, thus allowing greater resolution 
of structures such as multi-ring aromatic compounds, like benzodiazepines 
(Phenomenex, 2014). 
4.2.1.3 Thermal Degradation of Benzodiazepines 
A major consideration when carrying out GC-MS is the thermal stability of the 
compounds likely to be under investigation.  Instability of some substances can 
result in rearrangement of the molecules and degradation.  Functional groups 
containing active hydrogens, including the hydroxyl group (as in Oxazepam 15 which 
is an active metabolite of diazepam 1) and amine group (as in Chlordiazepoxide 3) 
can reduce volatility and are thermally unstable.  Peak broadening may also occur 
due to interactions with the stationary phase (Danielson, Gallagher and Bao,2000; 
Lin et al., 2008).  As the tablets analysed in this project were illicit, the active drug 
substance present and its thermal stability was therefore unknown.  However, 
chlordiazepoxide (3) was identified in one of the cases tested (case 136) and 
multiple peaks were produced due to thermal degradation. 
Some benzodiazepines may be thermally unstable during GC-MS analysis.  A study 
of sixteen benzodiazepines using capillary gas chromatography related thermal 
degradation directly to the chemical structure of the drugs (Joyce et al., 1984).  It 
was found that nine of the sixteen benzodiazepines tested were thermally unstable.  
This included ketazolam (10), which decomposed to diazepam (1) (Figure 4.1), 
making identification of ketazolam (10) and the presence of any diazepam (1) difficult 
by GC-MS alone.  Therefore, for this project, the tablets identified as containing 
diazepam (1) by GC-MS were also analysed by HPLC, along with both ketazolam 
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(10) and diazepam (1) standards, in order to gain additional information through 
comparison of Rt. 




Figure 4.1.  The structure of diazepam (1) and ketazolam (10). 
Chlordiazepoxide (3) and demoxepam (5) (which is an active metabolite of 
chlordiazepoxide (3) (Valentine, Middleton and Sparks, 1996)), both lose an oxygen 
radical due to thermal degradation in the injector port during GC (Joyce et al., 1984; 
Blachut et al., 2004).  This reduces demoxepam (5) to the active drug substance 
nordiazepam (14), causing identification difficulties for studies where both 
substances may be found (Figure 4.2).  Neither demoxepam (5) nor nordiazepam 
(14) were found in the cases analysed for this project.  
 




Figure 4.2.  The structure of chlordiazepoxide (3), demoxepam (5) and nordiazepam (14).  
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A report by the United Nations Office on Drugs and Crime (UNODC) (2012) noted 
that chlordiazepoxide (3), temazepam (19) and lormetazepam (12), produce multiple 
peaks in the GC chromatogram.  Although the report notes that three peaks were 
detected from the chlordiazepoxide (3) sample, no further information regarding the 
resulting spectra was provided.  
A study by Hida et al (1999), into thermal desorption gas chromatography (TDGC) of 
benzodiazepines investigated differences in thermal stability of the various drug 
substances.  The results indicated that benzodiazepines which demonstrated melting 
and decomposition temperatures that were considered closer together, such as 
chlordiazepoxide (3), tended to produce multiple peaks.  The results of the TDGC 
recorded a melting temperature for chlordiazepoxide (3) of 242.7 oC and a 
decomposition temperature of 284.2 oC, resulting in seven peaks being produced.  
This compares to diazepam (1) with a greater difference in melting and 
decomposition temperatures of 132.3 oC and 282.9 oC respectively, which resulted in 
just one peak.  Therefore it is important to find a balance whereby the temperature is 
high enough to vaporise the sample while sufficiently low to limit degradation.   
Previous GC-MS analysis of benzodiazepines by Joyce et al (1984) and Blachut et al 
(2004)  used different temperature programmes.  Joyce set an injection temperature 
of 270 oC and the oven temperature was ramped from 50 oC at a rate of 30 oC / min 
to 260 oC.  Blachut used an injector temperature of 250 oC and the initial oven 
temperature of 110 oC was maintained for 2 minutes before increasing by 15 oC / min 
up to 255 oC.  The ramp rate was then decreased to 8 oC / min up to 300 oC and 
maintained for 5 minutes. 
As Rt vary according to conditions and temperature, UNODC recommend that when 
GC-MS is used for the examination of benzodiazepines and barbiturates, all samples 
should be tested alongside certified standards on the same instrument and under the 
same conditions.  (United Nations Office on Drugs and Crime, 2012).   However, it is 
important to note that in some cases where new psychoactive drug substances have 
been used, certified standards may not always be available for purchase.  Although 
this was not the case in this project, it may impact on the certainty of the drug 
substance identification by GC-MS alone.  
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4.2.2 Application of GC-MS to the Analysis of Illicit Drug Samples 
A paper by Morelato et al. (2014)  discussing how illicit drugs were examined in 
Australia focussed on prioritising a simple, relatively quick method of analysing 
MDMA seizures for intelligence purposes. The aim was to determine which methods 
of analysis would provide the best intelligence on links between seizures in the 
shortest time.  The data came from 54 cases of seized tablets, divided into three 
groups: i) those known to be linked; ii) those suspected of being linked; and iii) those 
where no connection was evident.  The results indicated that greater discrimination 
between cases was achieved through GC-MS analysis and that although using a 
combination of techniques provided more information, GC-MS could be prioritised in 
order to provide information quickly for purely intelligence purposes.  However, the 
greater concentration of active drug substance which is often present in MDMA 
tablets, also results in an increase in the detection of process impurities.  
Consequently this is not suitable for “diazepam” (1) tablets, because the larger 
sample size required to pick up low levels of impurities may result in overloading the 
detector and obscuring the data actually being sought.  They also studied GC-MS 
peak areas of the active drug substance and compared impurities.  Although forty 
organic impurities were detected in the samples, an investigation was performed to 
determine whether analysis of a reduced number of the impurities could be as 
effective while reducing experimental time.  The results indicated that analysis of all 
impurities was significantly more effective thus reducing the numbers could not be 
scientifically justified. 
Due to GC-MS enabling identification of compounds in small samples, this technique 
was used to confirm the main active drug substance present in the illicit blue tablets 
analysed in this study.  On occasion, the main organic excipients, such as stearic 
and palmitic acid, which are often found in tablets, were also detected in some of the 
samples.  Due to the relatively small amount of active drug substance present 
though, the lower levels of organic impurities were likely to remain undetected. In 
addition, a limitation of this project is the possibility that low levels of other active 
drug substances have gone unrecorded. However, as the aim of the project was to 
compare data from a variety of chemical and physical techniques, in order to explore 
potential links between the illicit batches, it was believed that identification of the 
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main active drug substance was sufficient for this investigation.  The objective was 
not to provide a detailed analysis of each tablet but, that the results of the GC-MS 
would be supported by diazepam (1) quantification through HPLC and thermal 
analysis by DSC, to further explore the excipients to reveal similarities and 
differences between the illicit batches.  For example, although Case 137, produced a 
peak consistent with phenazepam (16), another peak with a Rt of 10.78 minutes was 
detected with a suggested similarity of 97.28% to caffeine, according to the National 
Institute of Standards and Technology (NIST) library (Number 14), however this was 
not verified by analysing a standard.  
4.2.2.1 Mass Spectrometry 
It has been noted that the presence of the halogen in benzodiazepines is particularly 
suited to analysis with an Electron Capture Detector (Levine, 2003; Pirnay et al., 
2002).  Fitzgerald et al. (1997) chose diazepam (1) as the model compound to 
compare an ion-trap and a quadrupole mass spectrometer, using the same column 
and heating program. Diazepam (1) was selected due to its ability to elute without 
derivatisation, producing a good chromatographic peak shape and because of the 
presence of an aromatic halogen.   The pure drug sample was injected in an 
unextracted state to avoid any interference from a matrix. The results revealed 
differences between the two methods which were explained by greater sensitivity of 
the ion-trap mass spectrometer and increased ion-ratio precision when the 
quadrupole mass spectrometer was in selected ion mode. 
For this project, a 5977E single quadrupole mass spectrometer was used for 
detection.  Pirnay et al. (2002) noted that the ion-trap detectors are not as reliable for 
detecting all benzodiazepines and as the active drug substance present in the illicit 
tablets was unknown, neither would the selected ion mode have been suitable.  
Therefore, the detector was used to scan the range of ions with a mass-to-charge 






The GC-MS analysis was performed on an Agilent 7820A gas chromatograph with a 
5977E mass spectrometer using a ZB-5MS column with 30 mm x 0.25 mm inner 
diameter and 0.25 µm film thickness (Phenomenex, Macclesfield, England). 
4.3.2 Method of Analysis 
A syringe and 4mm filter with 0.2 μm pore size was used to remove any undissolved 
material before transferring the solutions into vials for analysis.  The samples were 
injected in a split-less mode and the injection port was held at 250 oC. The carrier 
gas was helium, which was set at a constant flow rate of 1 mL / minute.   The oven 
programme was set at 50 oC for 2 minutes, then ramped at 15 oC / minute to 280 oC, 
with the final temperature being held for 11 minutes. The ion source was maintained 
at 230 oC and the detector was set to acquire spectra in the range of 40 - 600 amu.  
The mass spectra were compared to certified drug standards, run at the beginning 
and end of the same run sequence and with the NIST 14 mass spectral library 
(NIST, Maryland, USA).   
 
The above method for GC-MS benzodiazepine analysis method was taken from 
Clarke’s Analysis of Drugs and Poisons and adapted for use in this project, based on 
information described by the Home Office Forensic Science Service based at 
Aldermaston (Joyce et al., 1984) and on research into the application of GC-MS to 
the analysis of benzodiazepines (Blachut et al., 2004).  
 
The method was amended three times (Methods 2, 3 and 4) for separating etizolam 
(7) and triazolam (18), which were found to have similar retention times of 17.52 





Method 2 used an initial oven temperature of 50 oC, held for 2 minutes, ramped at 15 
oC / minutes to 260 oC, held for 5 minutes, then ramped at 10 oC / minutes to 280 oC 
and held for 10 minutes.   
 
Method 3 had the initial oven temperature of 50 oC which was held for 2 minutes 
The initial ramp rate was reduced by 5 oC /minute, to 10 oC / minutes to 260 oC, 
which was held for 5 minutes and ramped at 10 oC / minutes to 280 oC.  The 
temperature was held for 10 minutes.   
 
Method 4 set the initial oven temperature at 50 oC, held for 2 minutes and ramped at 
10 oC / minutes to 230 oC.  The temperature was held for 30 minutes, then ramped at 
10 oC / minutes to 280 oC and held for 10 minutes.   
4.3.3 Materials used in this Project 
HPLC grade acetonitrile, diethyl ether and HPLC grade methanol were supplied by 
Fisher Scientific (Loughborough, England).  Chlordiazepoxide (3) (certified standard 
1 mg / mL in methanol), diazepam (1) (certified standard 1 mg / mL in methanol), 
etizolam (7) (certified standard 1 mg  / mL in methanol), triazolam (18) (certified 
standard 1 mg / mL in methanol), paracetamol (acetaminophen; 1 g analytical 
standard), aspirin, (1 g analytical standard)  and bupivacaine (1 g analytical 
standard) were obtained from Sigma Aldrich (Gillingham, England).  Ketazolam (10) 
(certified standard 1 mg / mL in methanol) and phenazepam (16) (certified standard 
1 mg / mL in methanol) were purchased from LGC (Middlesex, England).  MA tablets 
were supplied by MA Pharmachem Ltd (Bolton, UK); Wockhardt tablets were 
supplied by Wockhardt UK Ltd (Wrexham, UK); Teva tablets were supplied by Teva 
UK Ltd (Runcorn, UK); Actavis Tablets were supplied by Actavis Ltd (Barnstaple, 




4.3.4 Preparation of Standards 
Standards of diazepam (1), ketazolam (10), phenazepam (16), etizolam (7), 
triazolam (18), chlordiazepoxide (3), promethazine, aspirin and paracetamol were 
prepared separately, from certified drug standards diluted with methanol to produce 
a working stock solution of 0.1 mg / mL.  
 
4ml of each 0.1mg / mL drug standard was pipetted into a separate 5ml flask.  1mL 
of an internal standard of 0.1mg /mL bupivicaine solution used to make up to the 
mark. Resulting in a flask containing 0.08 mg / mL drug standard and 0.02 mg / mL 
bupivacaine. 
 
Standards were analysed both individually and in combination with other drug 
standards.  Vials were prepared for analysis containing an equal combination of 
diazepam (1), phenazepam (16), etizolam (7), triazolam (18) and bupivacaine all 
taken from working stock solutions with the concentration of 0.1 mg / mL.  Resulting 
in a solution containing 0.02 mg / mL of each drug substance.  
 
Additional vials were prepared with a combination of triazolam (18), etizolam (7) and 
the bupivacaine internal standard by adding equal amounts of each 0.1 mg / mL 
working stock solution resulting in 0.033 mg / mL of each drug in the final solution.  
 
Vials were also prepared containing equal amounts of the 0.1 mg / mL phenazepam 
(16), aspirin, paracetamol and bupivacaine standards, resulting in a solution 
containing 0.025 mg / mL of each drug in the final solution. 
 




4.3.5 Preparation of Samples 
4.3.5.1 Preparation of Samples using Diethyl Ether 
A single tablet from each case was quartered and one quarter of the tablet was 
taken for analysis (or one eighth for cases indicated as containing over 20 mg of 
diazepam (1) by HPLC analysis).  The remaining three-quarters of the tablet was 
retained for future experimentation. 
The one quarter tablet was crushed in a folded piece of filter paper.  The powdered 
sample was added to a test tube containing dilute ammonia (2 M; 1 mL) and the test 
tube was gently agitated to dissolve the tablet.  Diethyl ether (2 mL) was added to 
the test tube and it was gently agitated to facilitate the extraction of the sample into 
the diethyl ether.  A sample was taken from the upper diethyl ether layer and 
transferred to a GC-MS vial using a Pasteur pipette prior to analysis. 
4.3.5.2 Preparation of Samples using Methanol 
A quarter (or eighth for cases containing over 20 mg of diazepam (1) by HPLC 
analysis) of a tablet was crushed in a folded piece of filter paper.  The powdered 
sample was added to methanol (1 mL) a test tube.  The test tube was gently agitated 
to dissolve the drug substance.  A syringe and 4mm filter with 0.2 μm pore size was 
then used to filter any undissolved material before transferring the solutions into vials 
for analysis. 
4.3.5.3 Preparation of whole tablets using Methanol 
A whole tablet from cases where no chromatographic peaks were found from smaller 
samples (quarter tablets, using both methanol and diethyl ether extraction, then half 
tablets), was individually crushed in a piece of folded filter paper and added to a test 
tube.  Methanol (2 mL) was added and the solution was agitated to dissolve the drug 




4.3.6 Overview of the GC-MS analysis performed 
4.3.6.1 Benzodiazepines in Salt and Freebase Form 
According to a report by the United Nations Office on Drugs and Crime (2012), the 
majority of benzodiazepines encountered are in the free base form and likely to be 
soluble in methanol alone, or on occasion, they may be in the form of a 
hydrochloride salt or mesylate.  For qualitative analysis, the report states that most 
benzodiazepines are soluble in methanol, whether in free base / acid or salt form 
and this was the recommended method for qualitative analysis (United Nations 
Office on Drugs and Crime, 2012). 
The tablets analysed in this study were illicit and therefore neither the active drug 
substance present, nor their form, was known.   Therefore, the drug substances 
present in the illicit tablets were converted to their freebase form by adding dilute 
ammonia and then extracted into diethyl ether.  In addition, the illicit tablets were 
also subjected to GC-MS after only being dissolved in methanol.    
4.3.6.2 Sample size used for GC-MS Analysis 
GC-MS is a sensitive technique and therefore a quarter or an eighth of a tablet was 
initially used for analysis. This was to allow multiple experiments to be performed, 
including initial drug identification by GC-MS, followed by a further run for 
comparison alongside the certified standard; thus leaving the remaining portion for 
DSC. Additional tablets from cases containing diazepam (1) were further analysed 
by HPLC and these Rt compared with that of certified diazepam (1) and ketazolam 
(10) standards as an additional consistency check. However, cases containing 
etizolam (7) or phenazepam (16), such as cases 76 and 77, did not produce an 
identifiable chromatographic peak on the GC-MS, when analysing a quarter tablet, 
therefore the sample size was increased to a half tablet and then a whole tablet, as 
required.   
With the exception of the early cases, where only one or two tablets were available 
for analysis. For cases where the active substance was not detected, the analysis 
was repeated another two times, in case of inhomogeneity. When the active 
 
106 
substance remained undetected, a half tablet was analysed and then, when 
unsuccessful, a whole tablet, when tablets numbers allowed.  As little difference was 
found in the results but more identifiable peaks were produced using methanol, this 
was the method used for the whole tablet preparations.  
4.3.6.3 Run sequence of Samples 
Each run sequence of cases began with a blank to ensure there was no carry over 
from previous runs.  The blank was a vial of methanol when the tablet preparation 
used methanol and a blank of diethyl ether when the preparation method used dilute 
ammonia and diethyl ether. 
The second vial in a sequence was a diazepam (1) standard in order to provide a 
comparison and Rt for the sequence.  This was followed by a blank in order to pick 
up any carry over.  In cases of carry over, which occurred on the initial analysis of 
case 136 and the certified chlordiazepoxide (3) standard, the run time of the 
sequence was lengthened.  
Samples prepared from the illicit cases were then run, alternating with blanks until 
the end of the sequence.  Finally, a second diazepam (1) standard was run followed 
by a blank to complete the sequence.  The second standard ensured consistency of 
the results and monitored drift.  The Rt and spectra were compared between the 
standards and the case samples to corroborate initial results suggested from the 
mass spectral libraries to determine whether the certified standard did indeed 
produce the same mass ions and Rt as the case samples. Only then, was the 
identification accepted. 
Diazepam (1) standards were run at the beginning and end of every sequence. 
However, when samples did not have Rt or mass spectra which corresponded to the 
diazepam (1) standard, a comparison was made to the NIST 14 library, to give a 
tentative identification.  The sample was then rerun with a vial of mixed standards 
and a separate standard of the active substance suggested by the NIST 14 library, in 




This method of analysis allowed a direct comparison of Rt and the mass ions to be 
performed, for each of the illicit cases.  The aim of the analysis was to provide an 
identification of the main active drug substance present within each of the cases by 
comparing results of the samples to certified standards and the NIST 14 library.  As 
drug substances were identified in all case samples and no quantification was 
attempted using GC-MS, then, the limit of detection (LOD) and limit of quantification 
(LOQ) for the GC-MS methodology were not carried out during this project.  
4.3.6.4 Small Case Size 
Some of the illicit cases analysed for this project contained only a small quantity of 
tablets.   The aim of the project was to characterise cases of illicit blue tablets and 
build statistical models with the potential to differentiate between different groupings. 
Since police seizures vary in size having valid statistical models that are appropriate 
for small case numbers may be beneficial.  However, this does mean at times that 
the analysis performed has to be prioritised in order to gain the most useful 
information.  Initial screening results carried out by the Robert Gordon University 
suggested that cases 7 and 10 contained diazepam (1).   Although not enough 
tablets were available for GC-MS analysis, samples from these two cases were 
however, run alongside a diazepam (1) standard on the HPLC for quantification 
purposes and remaining fragments were thermally analysed using differential 
scanning calorimetry (DSC) in order to gain information about excipients..  In both of 
these cases, the single chromatographic peak produced by the HPLC analysis 
corresponded with the Rt of the diazepam (1) standard.  The thermograms resulting 
from DSC indicated that their thermal profiles were consistent with the presence of 
diazepam (1).  Therefore, an assumption has been made that both cases 7 and 10 
contained diazepam (1).  
Similarly, cases 4 and 14 were found to contain phenazepam (16) in screening tests 
performed at Robert Gordon University.  Again, HPLC analysis indicated that the 
single chromatographic peak produced by samples from each of the two cases 
corresponded to the Rt produced by the certified phenazepam (16) standard and 
DSC thermograms were also consistent with phenazepam (16).  Therefore, the 
assumption was made that both cases 4 and 14 contained phenazepam (16).  
 
108 
4.4 Results and Discussion 
The method used was intended to be a balance between those used in two previous 
studies. The research by Blachut (2004) and Joyce (1984) both revealed thermal 
degradation of the benzodiazepines, including complete degradation of ketazolam 
(10) to diazepam (1) and decomposition of chlordiazepoxide (3) (See section 4.2.1.3. 
Thermal Degradation).  This may have been due to the higher injection temperature 
set by Joyce and high oven temperature used by Blachut. The similarity of melting 
and degradation temperatures as suggested by Hida (1999) indicated that lower 
temperatures may limit some of the degradation.  Therefore, for this project, an 
injection temperature of 250 oC was used, the same as in Blachut’s research (2004) 
but the lower oven temperature (from Joyce (1984)) was selected.  It was ramped at 
15 oC / min (the same as in Blachut’s study) but to 280 oC, a temperature between 
the intermediate and higher levels previously used by Blachut.  Both research 
studies had used a split-less injection for the samples.  Both split and split-less 
injections were tested in this project, with no significant difference in the results, 
other than the smaller peaks becoming more difficult to detect.   
Analysis of individual standards was carried out in order to determine the relative Rt, 
resolution and mass ions of the different active drug substances using the 
methodology in this study and an internal standard of bupivacaine was used to 
monitor relative Rt for drug substances.  Additional vials containing a combination of 
triazolam (18), etizolam (7) and the bupivacaine certified standards were also 
analysed as part of the run sequence comprising of the unknown samples with Rt of 
around 17 minutes. This was performed as an added comparison because of the 
similarity in Rt between the triazolam (18) and etizolam (7) standards and because 
etizolam (7) was not identified using the NIST 14 library.  Identification was facilitated 







Vials were also prepared containing equal amounts of phenazepam (16), aspirin, 
paracetamol and bupivacaine standards as a comparison to samples which 
produced peaks with a match of over 90% to phenazepam (16), paracetamol and 
aspirin according to the NIST 14 library.   
 
The certified standards were run at the start and end of each sample sequence to 
demonstrate that there had been no significant drift in Rt during the run.  The 
standards produced distinct chromatographic peaks with mass ion fragmentation 
patterns that corresponded well with the instrument mass spectral libraries.  This 
gave confidence that the method was capable identifying the active drug substances. 
The results produced by the combined standards can be seen in Figure 4.3.   
 
Differentiation between ketazolam (10) and diazepam (1) was supported by HPLC 
analysis as the certified standards were found to produce peaks with different Rt, 
whereas GC-MS alone, may result in ketazolam (10) undergoing thermal 
degradation to diazepam (1) as detailed in paragraph 4.2.1.3 ‘Thermal degradation’ 





Figure 4.3.  Chromatogram of the diazepam (1) standard compared to a sample of mixed 
standards.  The upper image is the diazepam (1) standard, and shows the two peaks produced 
by the bupivacaine enantiomers at 13.17 and 13.72 minutes.  The bottom image shows the 
chromatogram produced by the mixed standards.  The small broad peak at about 6.5 minutes 
was not identified.  The remaining peaks are from left to right, bupivacaine (Rt 13.72 minutes), 
diazepam (1) (Rt 14.61 minutes), phenazepam (16) (Rt 15.95 minutes) and the unresolved peak 
of etizolam (7) and triazolam (18) (17.52 and 17.59 minutes).   
 
4.4.1 Diazepam and Ketazolam  
Using the instrumentation and methodology stated above, analysis of the certified 
diazepam (1) standard, demonstrated a 97.78% similarity to the NIST 14 library. 
Comparison of the spectra produced by the standard revealed that the eight ions 
with greatest abundance (m/z 256, 283, 221,165, 110, 77, 89, 177) were consistent 
with the diazepam (1) spectrum recorded on the NIST 14 library.  However, there 
was a difference in the order of abundance between m/z 165 and 110. The certified 
standard also demonstrated similar abundance between mass ions at 177 and 241, 
therefore contributing to the slight discrepancy in similarity.  These discrepancies 
were likely to be a result of having different MS conditions on different machines. 
The diazepam (1) spectra produced by the pharmaceutical tablets was consistent 
with the certified standard, applying the methodology and equipment used in this 
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analysis. The exceptions were the similar abundance of the mass ions 165 and 110 
and that the analysis of the pharmaceutical tablet identified a greater abundance of 
m/z 241 than 177, thus resulting in a similarity of 97.46%.  The differences in 
abundance of the first nine mass ions are shown in Table 4.1. 
Table 4.1 Comparison of mass ion abundance between the NIST 14 library, a certified 
diazepam (1) standard and a known pharmaceutical tablet produced by MA Pharmachem. 
Diazepam 
Mass Ion 








256 29.24  31.75 32.89 
283 28.07 30.16 31.25 
221 11.11 9.52 9.87 
165 5.85 5.40 5.26 
110 5.56 6.03 5.26 
89 5.56 4.76 3.95 
77 5.56 4.76 3.95 
177 5.26 3.81 3.62 
241 3.80 3.81 3.95 
 
Using the methodology described above, the certified diazepam (1) standard 
recorded a Rt of 14.57 minutes on the first analysis.  However, there was a slight 
drift over the course of the analysis between 14.55 – 14.62 minutes.  Analysis of the 
pharmaceutical tablet manufactured by MA Pharmachem demonstrated a Rt and 
mass ions similar to the certified standard, therefore demonstrating consistency with 
the certified drug substance using this methodology. 
4.4.1.1 Detection of Ketazolam (10) 
During the initial runs of the illicit tablets, the suggested identification from the mass 
ion fragmentation pattern and the NIST 14 library for three of the illicit cases (Cases 
150, 156 and 159) was ketazolam (10).  Therefore, a certified standard of ketazolam 
(10) was obtained and run alongside the diazepam (1) standard and the relevant 
cases for comparative purposes.  The ketazolam (10) standard was found to 
produce a chromatographic peak at the same Rt as diazepam (1) at 14.61 minutes 
(Figure 4.4) along with matching spectra (Figure 4.5).  In addition, no molecular ion 
was produced by the certified ketazolam (10) standard, during this analysis, 
supporting the complete degradation to diazepam (1) recorded by Joyce et al. 
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(1984). This indicated that the ketazolam (10) molecule fragmented to form the same 
ions as the diazepam (1) standard, thus making a definitive identification by GC-MS 
very problematic.  The chromatographic peaks at 13.17 and 13.72 minutes relate to 








Figure 4.4.  Comparison of GC-MS chromatogram of the certified ketazolam (10) and diazepam (1) standards. The peaks at 13.17 and 




Figure 4.5.  Comparison of GC-MS spectra of the certified ketazolam (10) and diazepam (1) standards.  
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As discussed in Section ‘4.2.1.3. Thermal Degradation’, it is likely that due to its 
thermal instability, ketazolam (10) degrades by losing C4H4O2. This thermal 
degradation to diazepam (1) is indicated below in Figure 4.6.   
 
Figure 4.6.  The structure of ketazolam (10).  Thermal instability causes ketazolam (10) to 
degrade to diazepam (1) during gas chromatography unless the sample has been derivatised 
(Joyce et al., 1984) 
 
While the difference between the two drug substances could not be easily 
distinguished by GC-MS alone without carrying out a derivatisation process, it was 
possible to separate both the standards and illicit tablets successfully by high 
performance liquid chromatography (HPLC) as discussed in Chapter 5, where both 
diazepam (1) and ketazolam (10) were found to have good chromatographic 
separation, with Rt of 8.8 minutes and 11.4 minutes respectively. 
Using the methods described above, the certified diazepam (1) standard generated a 
peak with the Rt of 14.61 minutes and ions with mass to charge ratio (m/z) of (in 
order of abundance) 256, 283, 221, 165, 110, 77, 241, 205, 51, 151 and 177 (Table 
4.2).  This was supported by the identification indicated by the NIST 14 mass 
spectral library which listed the mass ions in the following order of abundance 256, 




The certified diazepam (1) standard was run at the beginning and end of every 
sequence in order to provide confidence in the results. Peaks with the same Rt and 









NIST m/z abundance (%) Retention 
Time 
m/z  
(In order of abundance %) 
Diazepam (1) 







14.61 256(31.8%), 283(30.2%), 
221(9.5%), 110(6.0%), 
165(5.4%), 77(4.8%), 
89(4.8%), 241(3.8%)  
Phenazepam (16) 











Etizolam (7)  17.52 342(44.0%), 313(15.0%), 
266(13.2%), 224(10.6%), 
137(6.2%), 75(4.4%), 






203(8.0%), 102(7.4%)  
17.59 313(25.4%), 342(23.9%), 
238(16.0%), 75(8.1%), 
137(7.4%), 203(6.6%), 























14.83 270(49.7%), 219(11.9%), 
313(9.4%), 77(8.5%), 
239(7.0%), 44(6.0%), 
207(4.0%), 165(3.5%)  




(NIST 96.63%)  16.67 282(54.5%), 220(8.5%), 
247(6.8%), 77(6.8%), 
163(6.2%), 123(5.6%), 














A tablet taken from the batch manufactured by MA Pharmachem was analysed by 
GC-MS in order to provide a comparison for illicit cases marked MA / D10 containing 
diazepam (1).  The MA / D10 logo was the most common marking found on the 
seized tablets, with twenty-four out of the sixty-five illicit cases bearing these 
markings.  
The known MA pharmaceutical tablet produced a chromatographic peak which 
corresponded with diazepam (1) and two further peaks with Rt of 11.66 and 12.89 
minutes, which were identified as palmitic acid (n-hexadecanoic), with a match of 
97.76% in the NIST 14 library and stearic acid (octadecanoic) with a match in the 
NIST 14 library of 95.97%, respectively.  However, no further analysis was carried 
out in attempt to confirm the identity of the palmitic and stearic acid in this project but 
the importance of these compounds is further discussed in section 4.4.5 ‘Lubricants’. 
Analysis of the twenty-four illicit cases marked MA, indicated that six contained 
active ingredients other than diazepam (1).  Eight of the cases were later shown by 
HPLC analysis to contain levels of diazepam (1) which varied significantly from the 
anticipated 10 mg amount present in pharmaceutical tablets.   Interestingly, the 
remaining ten illicit cases produced a GC-MS chromatogram which visually matched 
that generated by the MA pharmaceutical tablets, with the three peaks assigned to 
diazepam (1), palmitic and stearic acid and similarity in the mass spectra.  These ten 
cases (2, 16, 24, 29, 30, 74, 79, 82, 83 and 86) were also found by HPLC analysis, 
to contain 10 mg of diazepam (1).  Thus when information on physical characteristics 
was examined in conjunction with both chromatographic and mass spectrum data, 
tablets from each of these ten cases were found to be consistent with 
pharmaceutical tablets diverted into the illegal supply chain. 
4.4.2 Identification of Phenazepam  
Using the methods described above, the certified phenazepam (16) standard 
generated a peak with the Rt of 15.95 minutes and the ions as shown in Table 4.2.  
This was supported by the identification indicated by the NIST 14 mass spectral 




All cases which had an initial indication of phenazepam (16) according to the NIST 
14 library, were re-tested with a certified phenazepam (16) standard run at the 
beginning and end of all sequences. All of the cases with the initial indication of 
phenazepam (16) produced peaks with the same Rt and ions as the phenazepam 
(16) standard.  Table 4.3 gives a brief summary of the main active drug substances 
found within the illicit cases.   
Table 4.3.  Table identifying the active ingredients detected in the illicit cases by GC-MS.   
Substances Detected Case Number 
Diazepam (1) 2, 3, 5, 6, 8, 9, 11, 12, 13, 16, 23, 24, 25, 26, 27, 28, 29, 30, 
31, 71, 72, 74, 75, 78, 79, 80, 81, 82, 83, 86, 90, 129, 130, 
133, 150, 156, 159 
Phenazepam (16) 
+ Paracetamol and aspirin 
+ Caffeine 






76, 132, 135, 158 
73   
151, 155, 157, 160 
Chlordiazepoxide (3) 
(+ Diazepam – maybe a product of degradation) 
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Promethazine 127, 128, 153, 154  
 
In addition to a peak resembling phenazepam (16) with a Rt of 15.95 mins and 
similar mass ions produced, Cases 134 and 152 were also found to contain both a 
large peak consistent in Rt and mass ions with the paracetamol standard and 
another with the aspirin standard (Figures 4.7 and 4.8).  These were first identified in 
the initial GC-MS run and then confirmed by rerunning the illicit tablets alongside 
standards both by GC-MS and HPLC.   
Similarly, case 137 produced a peak consistent with phenazepam (16) but a peak 
with the Rt of 10.78 minutes was also detected.  This had a suggested match of 
97.28% to caffeine, according to the NIST 14 library but it was not verified by 
analysing a certified standard.  The presence of caffeine was not detected in other 
cases containing phenazepam (16), therefore distinguishing it apart from the other 
illicit cases.  This was supported by DSC analysis, which produced a thermal profile 
which was distinct from other cases identified as containing phenazepam (16).  This 
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is likely to have been because phenazepam (16) and caffeine have similar melting 
points of 225-230 oC and 235oC respectively and because caffeine sublimes at 178 
oC, which would have had an impact on thermal analysis (See Chapter 6 – 
Differential Scanning Calorimetry). 
 
 
Figure 4.7.  Spectra of Case 134.  The peaks at 6.28 and 6.97 minutes were identified as aspirin 
and the broad peak from 10-12 minutes was identified as paracetamol and metacetamol.  The 
peaks at 13.00 minutes and 15.95 minutes indicated stearic acid and phenazepam (16) 
respectively.  The peak at about 15.95 minutes corresponds to the phenazepam (16) of the 
mixed standard (bottom image).
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Figure 4.8.  Structures of aspirin, paracetamol and metacetamol. 
 
4.4.3 Chromatographic Separation of Etizolam and Triazolam  
GC-MS results revealed that etizolam (7) and triazolam (18) had a very similar Rt at 
less than 30 seconds apart (Figure 4.9) at 17.52 and 17.59 minutes respectively.  
Although the peaks were distinct, the resolution was not satisfactory.  In order to 
further resolve the chromatographic peaks, adjustments were made to the oven 
temperature and ramp rate, as follows: 
The original method had an initial oven temperature at 50 oC, hold for 2 minutes, 
ramp at 15 oC / minutes to 280 oC, hold for 11 minutes.  The amended method 2 
introduced an intermediate step by separating the ramp in temperature into two 
stages, with the oven held 260 oC for 5 minutes, before ramping at 10 oC / minutes to 
280 oC and holding for 10 minutes.  The results indicated that slowing the ramp rate 
by adding an intermediate stage did not resolve the peaks but delayed them from the 
original Rt of 17.52 minutes for etizolam (7) and triazolam (18) at 17.59 minutes to 
18.18 minutes and 18.32 minutes respectively.  Maintaining temperature can help 
with the separation of substances with similar Rt (Agilent Technologies, 2007) 
however, despite the temperature being held for 5 minutes before the final ramp, the 
separation was not significant enough to resolve the peaks. 
 
Method 3 was used in order to benefit from differences in vaporisation temperature 
between etizolam (7) and triazolam (18), by reducing the ramp rate to 10 oC /minute. 
However, the change in temperature resulted in delaying the elution, with etizolam 
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(7) having a Rt of 24.22 minutes and triazolam (18) eluting at 24.57 minutes with no 
further significant resolution.   
 
By holding the temperature for 5 minutes, as an intermediate stage, in method 2, a 
small increase in the separation between the two peaks had been produced but had 
not achieved complete resolution.  Therefore, method 4 was introduced to hold the 
temperature for 30 minutes, to test whether the separation could be enhanced. 
Complete resolution was still not achieved but broader peaks were produced with a 
Rt of 29.50 minutes for etizolam (7) and 29.93 minutes for triazolam (18). 
 
The change in methodology did not result in the complete resolution of etizolam (7) 
and triazolam (18) but increased the run time to 65 minutes.  This new methodology 
also increased the Rt of other benzodiazepines included in the mixed standards run 
along with the illicit cases, while also producing broader peaks. 
 
In addition, etizolam (7) was not listed in the NIST 14 library and was therefore 
labelled as ‘not identified’.  In order to resolve these issues, both etizolam (7) and 
triazolam (18) standards were analysed before and after tablets suspected of 
containing either drug in order to directly compare Rt as well as the mass spectra.  It 
was noted that while the Rt were similar, the spectra produced for each drug 
standard were notably different (Figure 4.10) thereby making identification possible, 
based on the certified standard used for the analysis. The Rt of the remaining 
standards used in the analysis were distinct and fully resolved isolated peaks were 
produced.  Comparison of the Rt and spectra therefore enabled identification to be 
made. 
 








Figure 4.9. Chromatograms showing the closeness of the chromatographic peaks produced by certified standards of etizolam (7) with a Rt of 17.52 





Figure 4.10. Comparison of GC-MS Rt and spectra of the etizolam (7) and triazolam (18) standards.   
The upper image shows the etizolam mass spectrum and the lower shows the triazolam (18).  
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Using the original method described above, the pharmaceutical etizolam (7) 
standard generated a peak with the Rt of 17.52 minutes and the ions (with 
abundance) 342(44.0%), 313(15.0%), 266(13.2%), 224(10.6%), 137(6.2%), 
75(4.4%), 102(3.5%), 45(3.1%), as listed in Table 4.2.  The etizolam (7) standard 
was not recognised by the NIST 14 mass spectral library (Number 14), however 
consistent results were achieved using the certified standard during the analysis 
performed for this work.  The standard was analysed at the beginning and end of 
each sequence containing illicit tablet samples for comparative purposes and to 
ensure that consistent results were obtained. 
Peaks with the same Rt and ions as the etizolam (7) standard were identified in the 
illicit cases listed in Table 4.3. 
Using the original method described, the certified triazolam (18) standard generated 
a peak with the Rt of 17.59 minutes, which was very close to that produced by the 
etizolam (7) standard.  However, the fragmentation of triazolam (18) produced the 
ions (with abundances) 313(25.4%), 342(23.9%), 238(16.0%), 75(8.1%), 137(7.4%), 
203(6.6%), 102(6.3%), 279(6.3%)   which were distinct from etizolam (7) allowing 
differentiation between the two active substances.  The spectra produced by the 
triazolam (18) standard was supported by the identification indicated by the NIST 14 
mass spectral library (Number 14) with a suggested similarity of 93.14%.  
No peaks with the same Rt and ions as the triazolam (18) standard were identified in 
the illicit cases and none are therefore listed in Table 4.2. 
4.4.3.1 Identification of Etizolam (7) 
All of the illicit cases with Rt at 17.52 – 17.55 minutes (cases 73, 76, 132, 135, 151, 
155, 157, 158 and 160) were run with the mixed standard of etizolam (7) and 
triazolam (18).  In each instance, the Rt was similar (+/- 0.03 minutes) to that of 
etizolam (7) with a corresponding match to the mass ions found in the etizolam (7) 
standard. This therefore indicated that each of these illicit cases contained etizolam 




The illicit tablets and certified standards were also analysed by HPLC to quantify the 
amount of active drug substance present in the illicit cases as well as build up a 
knowledge of the Rt of known standards using HPLC methodology.  The Rt values 
generated by HPLC for the illicit cases was able to corroborate the original 
identification by GC-MS.  Interestingly, the elution of the certified triazolam (18) 
standard occurred approximately 1 minute before the certified etizolam (7) standard 
and could therefore support the GC-MS distinction between the two substances (see 
Chapter 5 – High Performance Liquid Chromatography).  A comparison of the data 
produced as a combination of both the HPLC and GS-MS therefore helped to give 
strength to the original identification of the active drug substance present in the illicit 
cases 
In addition to etizolam (7), the GC-MS results indicated the presence of 
chlorphenamine in cases 151, 155, 157, 160, with a match in the NIST 14 library of 
94% but this was not verified by further analysis. Interestingly, the remaining cases 
which were identified as containing etizolam (7) did not contain the chlorphenamine 
peak. The presence of chlorphenamine in the four cases, could indicate that these 
cases form a distinct group, with an increased likelihood of being linked, possibly by 
being manufactured in the same clandestine laboratory.  The tablet markings of 
EZ/10 on the front and with a plain reverse are also only evident on these four cases 
and therefore supports the theory of a potential link.   
The difference between these four cases and the remaining cases identified as 
containing etizolam (7) can be seen through the comparison of cases 158 and 160 
(Figure 4.11).  The peak at 12.1 minutes in case 160 was potentially identified as 
chlorphenamine with 95.27% similarity.  Peaks at 11.82 and 12.98 minutes were 
identified as palmitic acid and stearic acid respectively.  The peak at 17.6 minutes 
was ‘not identified’ in the NIST 14 library but matched the Rt and spectra produced 









Although a chlorphenamine standard was not run in conjunction with case 160, to 
confirm the result, the spectra did correspond with that identified in the NIST 14 
library (Figure 4.12). 
 
Figure 4.12.  The mass spectrum of chlorphenamine shown in the NIST 14 library. (National 
Institute of Standards and Technology, 2017) 
The physical differences in the tablet markings of EZ/1.0 on one side with a plain 
reverse, separated cases 151, 155, 157, 160 from the other illicit cases.  The 
remainder of the cases containing etizolam (7) (cases 73, 76, 132 and 135) were 
marked MA and D/10 and a single case (158) marked NTZ/1.0 with a plain reverse 
was found to contain etizolam (7) as well.  Interestingly, the results revealed that 
each of the tablet markings on all of the illicit cases, varied with the drug substance 
content identified through GC-MS. 
GC-MS analysis also identified a small chromatographic peak in case 73, which 
produced the same ions (120, 92, 152, 65, 53, 81, 137, 167 in order of abundance) 
and had the same Rt of 6.27 minutes as the aspirin standard.   This peak was not 
detected in the other cases containing etizolam (7). Although, tablets in this case had 
a similar appearance to those in cases 76, 132 and 135, there are several 
explanations for the difference.  Firstly, the cases may not be related and may be 
manufactured completely independently of each other; secondly, inconsistent 
blending could result in larger quantities of constituents such as aspirin, being 
present in some tablets within a batch, while being of lower concentration in others 
even if the tablets were produced together; or thirdly, if the tablets were produced by 
the same manufacturer, it may be that different batches of tablets were made with 
varying levels of active drug substances and the cases were made at different times. 
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As the chromatographic peak was very small however, and given that it was only 
detected in the sample which was prepared using the whole tablet, it is possible that 
inconsistent blending leading to differences within tablets meant that the aspirin was 
not detected elsewhere.   
4.4.4 Identification of Chlordiazepoxide (3) 
In this project, the temperature of the injection port was set higher than the melting 
temperature of chlordiazepoxide (3) at 250 oC to allow vaporisation. The oven was 
set at 50 oC for 2 minutes before being ramped up at a rate of 15 oC / minute to 280 
oC. It would therefore, have taken 17 minutes to reach the higher temperature.  The 
chlordiazepoxide (3) peaks had Rt of 14.83, 15.02 and 16.67 minutes, relating to 
temperatures of approximately 230 oC, 245 oC and 260 oC respectively, making them 
lower than the degradation temperature recorded by Hida.    
However, the chlordiazepoxide (3) certified standard produced multiple peaks when 
analysed by GC-MS, as indicated by the UNODC (section 4.1.2.3 ‘Thermal 
Degradation’ (Division of Narcotic Drugs, 1988)) with Rt of 14.83 minutes, 15.02 
minutes and 16.67 minutes (Figure 4.13).   
The ions of the three peaks are listed in Table 4.2.  The spectra show that the peak 
at 16.67 mins contains an ion consistent with the molecular ion at m/z 299. The ion 
at m/z 299 was not visible in the peak at 15.02 mins (Figure 4.14). It has been 
suggested by both Joyce (1984) and Blachut (2004), that thermal degradation is a 
result of the N-4 oxide in the 4-position of the 1,4-azepine ring, losing the oxygen 
atom in the injection port.  The molecular ion of chlordiazepoxide (3) appears with an 
m/z at 298.  The loss of the oxygen therefore creates an ion at m/z 282.  The 
generation of a base peak at 282 was consistent with the analysis performed in this 
study and were found in the two peaks with the Rt of 15.02 and 16.67 minutes. 
The mass spectrum of the chromatographic peak at 14.83 minutes shows an ion at 
m/z 313 which is larger than the molecular mass of chlordiazepoxide (3).  The origin 
of this ion is unclear.  Different preparations of the chlordiazepoxide (3) standard 
were prepared and each were found to contain this peak and blanks run between 





Figure 4.13.  Chromatogram and mass spectrum produced by the chlordiazepoxide (3) 
standard.  The upper image shows the peaks at 13.18 and 13.72 minutes, which relate to the 
bupivacaine standard isomers.  The final three peaks were generated by the chlordiazepoxide 






Figure 4.14.  Spectra of two of the peaks produced by the chlordiazepoxide (3) standard.  The 
upper image shows the mass spectrum of the smaller peak at 14.83 minutes and the lower 
image shows the spectrum of the peak at 15.02 minutes.  
The origin of the chromatographic peak at 14.83 minutes with the ion at m/z 313, 
larger than the molecular mass of chlordiazepoxide (3) is uncertain and does not 
appear to relate to chlordiazepoxide (3). It could be a result of contamination, or 
perhaps from a rearrangement but it appeared in both the analysis of the certified 
standard and in samples taken from case 36.  This chromatographic peak is not 
recorded by either Joyce or Blachut.  Interestingly, the report by the United Nations 
Office on Drugs and Crime (UNODC) noted that chlordiazepoxide (3), produces 
multiple peaks.  Although no specific details of the GC-MS results are given, the 
UNODC note that three peaks were detected using GC with a flame ionization 
detector (United Nations Office on Drugs and Crime, 2012) 
4.4.4.1 Analysis of Case 136 
The results produced by the gas chromatograph of Case 136, showed results 
consistent with a tablet containing chlordiazepoxide (3) (Figure 4.15), with peaks at 
14.83 minutes, 15.02 minutes and 16.67 minutes, as produced by the 
chlordiazepoxide (3) standard.  Interestingly, the mass spectrum for the 
chromatographic peak at 14.83 minutes is consistent with that from the 
chlordiazepoxide (3) standard, including the ion at an m/z of 313 (Figure 4.16).  The 





Figure 4.15.  Chromatogram produced by Case 136 compared to the chlordiazepoxide (3) standard.  The peaks at 13.18 and 13.72 as shown on the 









Figure 4.16. Chromatograms and spectra of case 136. The three images at the top show the Rt of the chromatographic peaks produced by Case 
136 in comparison to the chlordiazepoxide (3) standard.  The two lower images show the spectra produced by the peaks at 14.82 and 15.16 









In addition to the chlordiazepoxide (3), other peaks were present, which would be 
expected due to excipients in a tablet preparation.  The smaller peaks at 9.43 and 
11.32 minutes were not identified but the spectrum produced at 12.57 minutes was 
indicated to be methyl stearate by the NIST 14 library, with a similarity of 95.94%.  
Although no further work was performed to confirm this suggested identification, it 
would be consistent with tablet excipients.   
A very small peak, barely visible above the baseline, was produced at 14.61 minutes 
by the chlordiazepoxide (3) standard, however, a much larger peak was visible on 
the chromatogram produced by Case 136.  The spectra indicated that this was 
diazepam (1) (Figure 4.18) and was consistent with the diazepam (1) standard 
analysed by the same instrument in the same run sequence (Figure 4.19). 
 
 







Figure 4.19.  Comparison of the chromatographic peak at 14.61 minutes in Case 136 to the 
diazepam (1) standard.  The peaks at 13.17 and 13.72 minutes shown with the diazepam (1) 
standard relate to the bupivacaine internal standard. 
 
As diazepam (1) is closely related to chlordiazepoxide (3) the chromatographic peak 
produced by Case 136 may be a product of degradation, as seen by the very small 
peak generated by the chlordiazepoxide (3) standard.  In addition, the HPLC 
analysis of two different tablets taken from Case 136 indicated that the tablets did 
not contain diazepam (1).  However, it may be that additional diazepam (1) was 
present and due to the illicit origin of the case, it is possible that the presence and 




4.4.5 Detection of Lubricants 
Although no additional work was performed to identify excipients within the tablets, 
as the focus of the analysis was to identify the main active drug substance, the GC-
MS analysis detected stearic and palmitic acid in 32 of the illicit cases and all of the 
pharmaceutical tablets sampled (Figure 4.20).  These are ingredients commonly 
used as lubricants within the pharmaceutical industry, to reduce friction between the 
tablet and the tabletting machine during production (see section 2.2.4.5 lubricants, in 
Chapter 2 – Introduction).  Although stearic and palmitic acid are not listed 
individually as components of the tablets on the product information leaflet for MA 
pharmaceutical diazepam (1) tablets, for example (MA Pharmachem Ltd, 2011), 
magnesium stearate is listed. Magnesium stearate consists of a variety of fatty acids, 




Figure 4.20.  The identification of stearic acid and palmitic acid in Case 160.  These are used as 
lubricants within the pharmaceutical industry. 
 
Magnesium stearate is added to the pharmaceutical formula in small quantities of 
around 3%, due to its propensity to hinder tablet dissolution (see section 2.2.4.5 
lubricants, in Chapter 2 – Introduction).  Research has shown that magnesium 
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stearate is also present in illicit tablets, including ecstasy (Baer, 2007) and the NIST 
14 library suggested similarity to chromatographic peaks detected in cases 71 and 
72 (etizolam 7) as well as 76 and 77 (phenazepam 16), in this study, although this 
was not confirmed.  As etizolam (7) and phenazepam (16) are not licensed for use in 
the UK, the identification confirms the use of lubricants in illicit tablets in this country.  
However, these tablets could have entered the illicit supply chain as diverted 
pharmaceutical preparations since they are licenced in other countries. 
The use of lubricants may suggest a more advanced illicit tableting operation with 
clandestine producers having a knowledge of tablet manufacturing procedures.  
Searches of the internet reveal many websites describing how to make ‘vitamin 
tablets and supplements’ with some suggesting a formula (Ecomdash, 2019; HTC 
Health, 2019) and one website by London Fashion Arts sells tableting machines and 
provides a link to receive a free ebook on ‘How to make your own tablets’  (LFA 
Machines, 2019).  London Fashion Arts also have videos on ‘You Tube’ to 
demonstrate the process (2010).  The formulae described online can be adapted to 
contain other illicit ingredients obtained on the dark net.  In addition, cheap and 
easily accessible pharmaceutical tablets, such as paracetamol, may be crushed and 
added as a bulking agent to the mix, thus providing some of the pharmaceutical 
constituents.  However, little is known about the illicit production of diazepam (1) 
tablets and results of this analysis would indicate that cases which contain stearic or 
palmitic acid are not necessarily diverted, pharmaceutically manufactured products. 
4.4.6 Summary of GC-MS Results 
Results of the GC-MS analysis identified that 39 of the 63 seized cases analysed 
were found to contain diazepam (1).  Therefore, the remaining 24 cases were 
presumed to be illicit.  Discrimination according to main active ingredient divides the 
seized cases into five groups, those containing diazepam (1), etizolam (7), 
phenazepam (16), chlordiazepoxide (3) or promethazine (Figure 4.21).  Each of the 
illicit cases was found to contain at least one active drug substance using the GC-
MS procedure adopted in this project and on occasion additional substances such as 





Figure 4.21. Groupings of Illicit Cases according to main Active Drug Substance. 
Identification of the active drug substance present in cases 7, 10, 4 and 14 was based on pre-screening tests performed at Robert Gordon 
University, corroborated by HPLC and DSC results carried out as part of this project. 
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4.4.7 Analysis of Results 
In order to assess the results of the GC-MS analysis, they were compared to the 
results produced from the physical examination of the tablets (Chapter 3).  
Knowledge gained on the main active drug substance present in the seized cases 
was used to give greater insight into the discrimination already performed and the 
results can be seen in Figure 4.22.  The Venn diagram, shows the groupings 
indicated by the physical analysis of the tablets and further groupings which were 
discerned through the GC-MS.  For example, the cases which had previously been 
identified as being similar to the pharmaceutical tablets in diameter could now be 
separated into groups containing diazepam (1), etizolam (7), phenazepam (16) and 
chlordiazepoxide (3).  However, the tablets containing promethazine were shown to 
differ in both diameter and depth to the pharmaceutical diazepam (1) tablets but 
were of a similar weight. 
Similarly, case 136, which was identified as containing chlordiazepoxide (3), only 
resembled pharmaceutical diazepam (1) tablets in diameter but not in depth nor 
weight. 
Interestingly, groupings of cases containing phenazepam (16), which had been 
separated during the physical analysis, were found to show similarities to 
pharmaceutical diazepam (1) tablets in depth, or diameter, or both.  However, this 
was shown to be distinct from tablets containing etizolam (7) which indicated 
similarities in diameter and weight but not depth. 
It could be interpreted that manufacturers of these tablets could produce tablets 
containing phenazepam (16) and others with etizolam (7), using dies of a similar 
diameter, based on the results of the physical analysis.  However, by examining the 
results of the GC-MS analysis in conjunction with physical characteristics, it could be 
interpreted that the manufacturer of phenazepam (16) tablets tend to produce tablets 
of similar size in diameter and depth to the pharmaceutical tablets, whereas those 
who manufacture the etizolam (7) tablets, using similar dies, are less concerned with 
depth but produce tablets of a similar weight.  As the tablets use dies of a similar 
diameter, it may be that the weight is affected by differences in excipient.  For 
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example, EmcompressTM (Dicalcium phosphate dihydrate), is a heavier excipient, 
which although present in some pharmaceutical preparations, is not used in 
pharmaceutical diazepam (1) tablets produced for the UK market.  A difference in 
formulation between the cases, may therefore suggest that the etizolam (7) and 







Figure 4.22. Venn Diagram of Illicit Cases according to Physical and GC-MS Analysis.  Cases listed in blue contain diazepam (1). Those in red/pink 
shapes contain phenazepam (16), green contain etizolam (7), brown promethazine and yellow chlordiazepoxide (3).  Identification of the active 
drug substance present in cases 7, 10, 4 and 14 was based on pre-screening tests performed at Robert Gordon University, corroborated by HPLC 




For the first time, results from GC-MS analysis of real street drugs as obtained by 
Police Scotland have shown that there was a variety of active drug substances 
present in the illicit cases examined in this study.  Of the 63 seized cases, which 
were initially presumed to contain diazepam (1) due to their markings and were 
investigated by GC-MS only 39 were actually found to contain diazepam (1).  It is 
very interesting to note that the remaining 24 cases contained a variety of psycho 
actives many of which are illegal in the UK such as phenazepam (16) and etizolam 
(7).  This study provides a novel snapshot of the illicit diazepam (1) market and 
provides invaluable intelligence regarding the variety of content of street drugs 
confiscated in Scotland.  Interestingly, such seized drugs are normally not analysed 
to the extent as discussed in the current work and the information provided herein 
requires to be distributed as widely as possible as such knowledge is currently 
unavailable to police Scotland. 
It is also worth noting that the seized cases marked MA, previously recorded as 
having physical measurements consistent with the known pharmaceutical tablets 
(Chapter 3) and subsequently found to contain approximately 10 mg of diazepam (1) 
when later analysed by HPLC, produced visually similar chromatograms to that of 
the known MA pharmaceutical tablets.  Therefore, based on the sample preparation 
used in this project, it has been noted that no obvious differences exist for these 
particular ten seized MA cases indicating a further interesting facet of the drug chain, 
namely, some of the illicit drugs are probably genuine diazepam (1) tablets which 
may have been stolen, diverted or obtained by removal of quality control failures 
destined for destruction. 
This study also presents results relating to the use and detection of lubricants in 
many of the illicit cases which reflects the sophistication of current illicit 
manufacturing methods, although some of these tablets will have been 
pharmaceutically manufactured tablets, which had been diverted.  Initial work on the 
use of tablet presses and dies, has helped to link illicit cases via their mode of 
manufacture and circumvents the lack of quality of such produced illicit tablets which 
can make them difficult to recognise without extensive scientific measurement.  Thus 
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difference in active drug substance were detected via GC-MS analysis and revealed 
the true nature of street drugs and gave considerable insight into the illicit market. 
GC-MS analysis provided vital information for this study and the results were used to 
corroborate other data such as HPLC analysis and DSC.  HPLC (Chapter 5) proved 
to be highly useful for confirming identification, for example to aid in distinguishing 
between diazepam (1) and ketazolam (10), where thermal degradation made 
absolute identification problematic.  It also helped to further separate the illicit cases 
based on quantification of diazepam (1) because pharmaceutically manufactured 
tablets would not be expected to contain more than the “stated” dose. 
DSC (Chapter 6) also provided information to support the GC-MS analysis, by 
generating thermal profiles with distinct differences and similarities according to the 
varying tablet constituents.  This therefore enabled further distinction to be made 
between the illicit cases. 
This study reports for the first time an innovative approach by utilising a variety of 
analytical and physical techniques to establish similarities and differences between 
street drugs.  The use of GC-MS was invaluable at identifying more unusual active 
ingredients and could lead to methodology which could be expanded to provide drug 






5.1 Chapter Summary 
High Performance Liquid Chromatography (HPLC) was used to quantify the 
diazepam (1) content of three tablets taken from each seized case and from each of 
the pharmaceutical batches, used for comparative purposes.  Although the seized 
cases contained tablets which were blue in colour, consistent with the colour of 10 
mg diazepam (1) tablets manufactured for the UK market, some of the cases were 
identified as containing other active drug substances through GC-MS analysis 
(Chapter 4).  HPLC analysis was therefore used to further distinguish between 
tablets by identifying the seized cases which contained a level of drug content 
consistent with 10 mg diazepam (1) tablets manufactured for the UK market.  
However, the presence of the correct amount of active drug substance does not 
necessarily mean the tablets have been pharmaceutically manufactured. 
5.2  Introduction  
5.2.1  Uses of HPLC 
5.2.1.1 HPLC in Pharmaceutical Studies 
High Performance Liquid Chromatography (HPLC) is an important method of drugs 
analysis.  It is used in pre-formulation studies within the pharmaceutical industry, as 
well as in the testing of illicit drugs. However, until now, no work has been performed 
by HPLC, to quantify the amount of active drug substance present in illicit blue 
tablets with markings consistent with pharmaceutical diazepam (1) tablets.  This was 
partly because of the large numbers of pharmaceutical tablets that were being 
diverted into the illegal supply chain, as described by the Advisory Council on the 
Misuse of Drugs (2016), leading to an assumption that many of the diazepam (1) 
products in circulation were diverted products of pharmaceutical origin (United 
Nations Office on Drugs and Crime, 2012). 
In pre-formulation studies HPLC is utilised for the identification and quantification of 
impurities and degradation products (Narang, Desai and Badawy, 2012).  
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Wyttenbach, at Hoffmann La Roche, used the level of impurity found through HPLC 
analysis, as a means of determining the amount of drug degradation that had taken 
place (Wyttenbach et al., 2005).    Information on degradation products and 
impurities can also be of interest forensically and could potentially help to link 
different cases. However, matching retention times alone, does not necessarily 
mean that the same unknown substances are present.  Whereas, the benefit of 
using this technique for pharmaceutical testing is more palpable since a specific set 
of known impurities is often studied to provide assurance that there has been no 
significant impact on the efficacy of the material. 
An interesting study in Nigeria compared a variety of pharmaceutical ibuprofen 
tablets to investigate their equivalence. This included ensuring that each of the 
manufacturers produced tablets that conformed to the regulations stipulated in the 
British Pharmacopoeia, regarding everything from tablet size, disintegration and 
dissolution rates to the level of active drug content. The results of the study revealed 
that although the level of active drug substance may be similar, differences in 
physicochemical characteristics such as dissolution rates, could greatly affect the 
bioavailability of the ibuprofen.  The differences were likely to originate from variation 
between excipients.  Quantification of the active ingredient for the study, was 
performed on HPLC in addition to UV assay. The results indicated that despite all of 
the tablets falling within the guidelines, there was some variation between the 
pharmaceutically manufactured tablets.  However, it was noted that although the 
results generated by the HPLC demonstrated that all of the tablets did satisfy the 
regulations, the results produced by the UV assay did not and suggested that two of 
the brands contained a lower level of ibuprofen, at 92.43% and 91.18% compared to 
the HPLC indications of 100.54% and 96.66% respectively.  The results of the UV 
assay were not consistently lower with 50% indicating a higher concentration of 
ibuprofen than by HPLC analysis. It was suggested that this was because the HPLC 
was a more consistent and sensitive technique (Eraga et al., 2015). 
5.2.1.2 Analysis of Illicit Tablets 
In terms of illicit drug analysis, HPLC can help to corroborate identification of the 
active drug substance by comparing the retention time to a known standard, once 
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the substance has been identified by gas chromatography – mass spectrometry 
(GC-MS), as well as providing a reliable method of quantification.  This therefore 
makes it an invaluable technique for the analysis of illicit tablets. 
A study in 2011 compared the use of reversed-phase HPLC with capillary zone 
electrophoresis (CZE) for the separation of benzodiazepines. In this experiment, a 
Zorbax Stable Bond C-18 column was compared to a C-8 column using a mobile 
phase of acetonitrile and deionised water with acetic acid, at a pH of 3.0.  It was 
discovered that using the C-18 column reduced the retention time as a higher 
proportion of acetonitrile could be incorporated into the mobile phase. In comparison 
to the CZE, HPLC was the preferred technique because the level of baseline noise 
was lower.  In addition, the increased noise in combination with the smaller sample 
size for the CZE resulted in a much higher Limit of Detection (LOD) and Limit of 
Quantification (LOQ) (Kalíková et al., 2011). 
Although, Kalíková described how retention times could be reduced by increasing 
the amount of acetonitrile in the mobile phase, the shorter chain length in C-8 
columns also gives a lower retention time (Agilent Technologies, 2005).  For this 
research a C-8 column was used as good separation was achieved with the lower 
retention time. 
5.2.2 Methodology 
5.2.2.1 Methodological Background 
It was noted by the United Nations Office on Drugs and Crime (UNODC) that a 
specific methodology for use with the HPLC would not be appropriate for the 
analysis of all benzodiazepines.  This was due to the range of chemical structures 
within the drug family.  However, it was suggested that the drug sample being tested 
should be prepared in methanol, which could dissolve the drug substance whether in 
free base or salt form.  The recommended method included the use of a mobile 
phase consisting of methanol, water and phosphate buffer.  The proposed injection 
size was 20 µl, using a UV detector set at 240 nm. (United Nations Office on Drugs 
and Crime, 2012). 
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The method described by the UNODC was designed for the general analysis of 
benzodiazepines.  As the aim of this project was to analyse illicit blue tablets believed 
to be sold as diazepam (1), the adopted HPLC method used was based on the 
European Pharmacopeia Monograph for the purity assessment of diazepam (1) drug 
substance.  To ensure that the recovery of drug substance was complete the 
preparation of tablets for UV assay (B.P. monograph) using acidified methanol to 
quantitatively extract the diazepam (1) from the formulation was followed, with a 
mobile phase of 22: 34: 44 acetonitrile: methanol: potassium dihydrogen phosphate 
solution. 
The eluent was run as an isocratic system with a flow rate of 1 mL / minute and a run 
time of 15 minutes. 
The report by UNODC also suggested that multiple tablets should be combined and 
analysed together for quantification purposes.  However, this was based on the 
assumption that the illicit tablets had been pharmaceutically manufactured and 
diverted into the illegal supply chain.  Quantification of multiple tablets was not 
believed to be appropriate for this project, because the differences in active drug 
substance as well as the varying levels present, indicated that the tablets had been 
illicitly manufactured and may not be uniform.   This therefore meant that different 
tablets within a case could potentially contain disparate active ingredients or be 
inconsistent according to the effectiveness of the blend (United Nations Office on 
Drugs and Crime, 2012).   
After reviewing a variety of detectors, Siddiqui commented that UV detection is often 
preferred as it provides the best specificity, reliability and repeatability with a short 
analysis time (Siddiqui, Alothman and Rahman, 2017).  However, process or 
degradation impurities may have a similar structure and absorb at the same 
wavelength as the drug substance (Ryan, 1998), therefore producing a bigger peak 
by UV. 
Single wavelength analysis can provide excellent results when the corresponding 
wavelength is known and the European pharmacopeia monograph advised using a 
UV detector set to a wavelength of 254nm.  The use of a diode array detector would 
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have given confidence in the peak purity of the HPLC diazepam (1) peak, indicating 
that the chromatographic peak was only due to diazepam (1) and no other 
substance.  However, as a UV detector was used for this study, GC-MS was used to 
confirm the drug substance and determine the likelihood of co-elution on the HPLC. 
In addition, comparison of retention times with the appropriate drug standard was 
constantly performed by HPLC analysis. 
5.2.2.2 Sample Sizes 
In the ‘Guidelines on Representative Drug Sampling’ produced by the United Nations 
Office on Drugs and Crime, several methods for determining a suitable number of 
samples were suggested, including batch analysis according to markings. For police 
seizures, it indicated that each situation should be case dependent (2009). Izenman 
wrote a detailed analysis of representative sampling in America and noted how an 
Illinois court supported the decision of a chemist to analyse three tablets in a batch 
of 100 for identification purposes (Izenman, 2003).  The tablets received for analysis 
in this study were themselves just a representative amount of each police production 
sampled. Entire cases of small productions were obtained but when larger cases 
were seized by the police, a selection of the visually similar tablets were provided for 
the project. 
The tablets analysed for this study were divided into separate seized cases.  Many of 
the seizures were small, with 29 of the seized cases containing fewer than ten 
tablets for analysis and the remaining 36 seized cases contained between 20 and 70 
tablets.  The hypergeometric distribution method, uses a frequentist approach to 
determine the number of variations in drug substance within a batch, depending on 
the number of tablets analysed and the number of samples containing a variation.  In 
order for a 95% confidence interval (making a correct assumption for about 95% of 
the entire batch), a sample size of three would need to be analysed in cases 
containing fewer than ten tablets.  For cases containing between 10-70 tablets, four 
tablets were suggested (United Nations Office on Drugs and Crime., 2009), For this 
project, three illicit tablets taken from each case were analysed by HPLC to ensure 
the peak produced by the active drug substance present in the illicit tablets matched 
the retention time of the diazepam (1) standard. The scientific assumption was made 
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that all tablets within a case would be similar in terms of quantification, unless 
analysis proved otherwise. This allowed an average result to be reported for each 
case, given that in most cases the results were very similar.  Reproducibility was 
determined by preparing three tablets from each case, with three vials made from 
each tablet solution and three readings taken from each vial, thus giving confidence 
in the individual results.  This was further supported by comparison of the GC-MS 




The HPLC analysis was performed on a Shimadzu 10 HPLC system with autosampler 
and ultra-violet detector set at 254nm. This was supported by Clarity software. 
The column used was a Zorbax XDB C8 Eclipse column of 4.6 x 150mm, with a 5µm 
particle size and double end-capped, purchased from Agilent Technologies.  This was 
maintained at 30 oC in the column oven. 
5.3.2 Materials used in the HPLC Analysis 
Hplc grade acetonitrile, ethyl acetate, hplc grade methanol and potassium 
dihydrogen phosphate were obtained from Fisher Scientific, Loughborough.  
Chlordiazepoxide (3) certified standard 1 mg / mL in methanol, diazepam (1) certified 
standard 1 mg / mL in methanol, etizolam (7) certified standard 1 mg / mL in 
methanol, triazolam (18)  certified standard 1 mg / mL in methanol, acetaminophen 1 
g analytical standard, aspirin 1 g analytical standard and bupivacaine 1 g analytical 
standard were purchased from Sigma Aldrich, Gillingham.  Ketazolam (10) certified 
standard 1 mg / mL in methanol and phenazepam (16) certified standard 1 mg / mL 
in methanol were provided by LGC, Middlesex.  MA tablets (supplied by MA 
Pharmachem Ltd., Bolton, UK), Wockhardt tablets (supplied by Wockhardt UK Ltd., 
Wrexham), Teva tablets (supplied by Teva UK Ltd., Runcorn), Actavis tablets 
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(supplied by Actavis UK Ltd., Barnstaple) and illicit blue tablets (supplied by Police 
Scotland).  
5.3.3 Preparation of Solutions 
The method used acidified methanol to quantitatively extract the diazepam (1) from 
the formulation, with a mobile phase of 22: 34: 44 acetonitrile: methanol: potassium 
dihydrogen phosphate solution.   
500 mL of a 3.4 g / L solution of potassium dihydrogen phosphate was prepared and 
adjusted to pH5 with a 0.1 M sodium hydroxide. The resulting solution was then 5 
times the strength of the buffer required for the final mobile phase but since the storage 
was better than for a more dilute buffer, this was then diluted appropriately with distilled 
water immediately before adding to the mobile phase.   
The mobile phase was prepared by adding the prepared diluted potassium dihydrogen 
phosphate to a conical flask, containing methanol and acetonitrile and the solution was 
de-gassed with a vacuum filter, before use. 
This eluent was used as the mobile phase, for the dilution of samples and for the 
blanks.  
5.3.4 Preparation of Standards 
Each standard was prepared separately.  1 mL of the certified 1 mg / mL diazepam 
(1) drug standard was pipetted into a 10 mL volumetric flask and made up to the 
mark with methanol. This was the working 0.1 mg / mL stock solution.  The 
standards were prepared for the calibration of 0.0025 mg / mL, 0.01 mg / mL, 0.02 
mg / mL, 0.03 mg / mL and 0.05 mg / mL dilutions. 
 
In addition, a further 0.02 mg / mL diazepam (1) standard was prepared and used at 
the beginning and end of each run sequence in order to monitor drift and were run 
before and after corresponding samples from the illicit cases which had been 
identified by Gas Chromatography - Mass Spectrometry.  A 0.02 mg / mL solution 
was also prepared from each of the certified standards of other active drug 
substances identified through GC-MS analysis to run at the beginning and end of 
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each run sequence containing the corresponding drug substances as a comparison 
for the seized tablets and to identify the Rt of the known standards on the HPLC. 
5.3.5 Preparation of Tablets 
Both pharmaceutical and illicit tablets were prepared in the same way.  This involved 
softening the tablet in 5 mL of distilled water and then dissolving the drug content in 
approximately 40 mL of 0.5% w/v solution of sulphuric acid in methanol. 
The solution was agitated with a flask shaker for 15 minutes before being made up to 
100 mL with additional acidified methanol.  The agitate solution was then filtered into 
a flask to remove any insoluble material and an aliquot (2 mL) of the filtered solution 
was pipetted into a 10 ml volumetric flask and made up to the mark with eluent, giving 
a further 1 in 5 dilution. This was passed through a syringe fitted with 4mm filter (0.2μm 
pore size) into an HPLC vial. The sample was introduced into the HPLC as a 20 µL 
injection. 
Some of the tablets from the illicit cases were still outwith the linear working range of 
the method and required a further 1 in 25 dilution, which was analysed with a 20 µL 
injection, resulting in a multiplication factor of 2500. 
5.3.6 Validation of the Method 
The linearity of the method was determined by making up five solutions with different 
concentrations across the range 0.0025 mg / mL to 0.05 mg / mL and provided a 
validation for up to 25 mg of diazepam (1). Each of the solution concentrations were 
prepared three times to determine the method precision.  The area response was 
plotted against concentration and least-square regression was used to determine 
slope, intercept and correlation coefficient.  The resulting calibration curve (Figure 
5.1) had a correlation coefficient of 0.9994 with an equation of the line determined by 
the calibration curve. The equation of the line was used to calculate the 








Figure 5.1.  HPLC calibration curve. 
Precision was determined on six runs of the 0.02 mg / mL standard using a 20 µL 
injection and the coefficient of variation at 0.02 mg / mL was found to be 0.31%, as 
shown in the Table 5.1: 
Table 5.1.  Results of the coefficient of variation, based on six runs of a 0.02 mg / mL standard. 







Mean 5963.74 mAUs 
Standard Deviation  18.71 mAUs 
Coefficient of variation =  































The recovery of the method was assessed by spiking 2 mL taken from a 0.05 mg / 
mL sample prepared from a known 5 mg pharmaceutical tablet with 0.5 mL of a 0.1 
mg / mL standard solution and making up to the mark in a 10 mL volumetric flask, to 
give a final concentration of 0.015 mg / mL. The milli-absorbance units (mAUs) 





A mean recovery of 0.0141 mg / mL was obtained from three 0.0150 mg / mL 
samples analysed. This calculated to a final recovery of 94%:   
Injection 1:  mAUs recovered = 4197.583 
Therefore:     𝑥 =
4197.583+71.836 
301833
 = 0.0141449 
 
Injection 2:  mAUs recovered = 4196.315 
Therefore:    𝑥 =
4196.315+ 71.836
301833
 = 0.0141408 
 
Injection 3:  mAUs recovered = 4198.145 
Therefore:   𝑥 =
4198.145+71.836
301833
 = 0.0141468 
Mean = 0.0141442 
Amount of diazepam (1) in sample = 0.015 mg / mL 
Therefore 0.0141442 / 0.015 = 0.9429 




Sample solution stability was studied at 24, 48 and 120 (due to a weekend) hour 
intervals, using samples both stored in the autosampler at room temperature and in 
the refrigerator set at 4 oC, with consistent results being achieved.  Finally, the 
accuracy of the process was demonstrated by analysis of known pharmaceutical 
grade tablets, which allowed the calculated experimental values to be compared with 
the anticipated amounts. 
Limit of detection (LOD) was determined by analysing a series of dilutions down to 
0.000005 mg / mL.  The smallest level detected was found to be 13 ng / mL.  This 
gave an LOD calculated using the equation (Swartz, 2006): 
3.3 x standard deviation
gradient of the line
 
The results of the three samples detected were: 












= 0.00001327 mg / mL 
= 13 ng / mL 
and a limit of quantification (LOQ) calculated using the equation (Swartz, 2006): 
10 x standard deviation







= 0.00004022 mg / mL 
= 40 ng / mL 
 
5.3.7 Precision of Quantification 
Due to the larger numbers involved, it was calculated that the highest standard 
deviation from three replicates was produced by the 0.05 mg / mL standard, with a 
standard deviation of 76.14 milli-absorbance units (mAUs). The 95% confidence 
interval level of two standard deviations was used for acceptance of the results and 
was calculated at 152.28 mAUs.  This value was put into the equation of the line as 
the y value and multiplied by the appropriate dilution factors, in order to determine 
what the +/- allowance values would be in terms of mg / mL.  After taking into 
account the dilutions used in the tablet preparation, this equated to an allowance of 
±0.37 mg per tablet.  
Given that the tablet preparations had an initial dissolution factor of 100 followed by 
a one in five dilution to bring the sample solution within the calibration range for a 20 
µl injection, then this also meant that any errors would be subject to a multiplication 
factor of 500.  Clearly, this does have an impact on the reported quantification results 
and all results were initially rounded to one decimal place but reported to the nearest 
whole number.   
In an attempt to monitor the variation of results for any one tablet, three vials were 
prepared from each tablet and three injections run from each vial.  In order to 
understand within case variation, three tablets were prepared from each case 
following the above process. However, an awareness of the possibility of error must 
be considered when accepting the results of quantification. 
Although potential errors and large multiplication factors may impact on the 
quantification of diazepam (1), it is believed that an adequate assessment of drug 
content was achieved for the purposes of this project.  The results ultimately showed 
a variation in diazepam (1) levels between around 8 – 48 mg in tablets that were 
anticipated as containing 10 mg.  Any greater precision and accuracy would have 
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required far greater input of time and use of standards and been largely unnecessary 
for what was being attempted in this project.  Differences in concentration of around 
0.5 mg would have added little further information given that the pharmaceutical 
diazepam (1) drug release specification states that the level of active drug substance 
should be 10 mg +/- 7.5%, equating to 9.25 mg to 10.75 mg (British Pharmacopoeia 
Commission, 2017b). In addition, the quantification of diazepam (1) was only one of 
the parameters being studied for this project and the aim was to combine scientific 
results to provide a greater understanding of the illicit seized tablets. 
5.3.8 Run sequence  
Samples were run with blanks of eluent between vials, in order to avoid carry over 
between samples and to detect long retention times.  Standards were run at the 
beginning and end of each sequence to monitor drift and ensure daily accuracy.  In 
addition to the suitability check at the start and end of the run additional checks were 
made between tablets of the same case.  In total three tablets from each case were 
normally analysed by HPLC.  Three vials were prepared of each tablet solution and 
three different analyses were made from each vial, giving nine results for each tablet 
analysed and 27 results for each case.  
5.3.9 Overview of the HPLC Analysis 
5.3.9.1 Drift in Retention Times 
The retention times were found to drift on occasion.  This appeared to be caused by 
the age of the mobile phase, the fluctuating temperatures in the laboratory and by 
moving the location of the instrumentation.  The mobile phase was therefore 
changed weekly and was kept as consistent as possible for comparative purposes.  
In addition, a diazepam (1) drug standard was run at the beginning and end of each 
sequence to monitor any small drift that occurred each day.  
5.3.9.2 Difference in Colourants 
As each tablet was softened in water and acidified methanol, it was noted that there 
were a variety of differences in the solutions produced.  This was not only true of the 
illicit cases but also the different manufacturer’s pharmaceutical preparations.  For 
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example, the Actavis and Teva tablets produced a clear solution with insoluble blue 
particulates in the bottom of the flask, whereas the MA tablets produced a pale blue 
solution with a few fine residual white particulates.  This would suggest a difference 
in the colourant used.  MA Pharmachem use the water soluble indigo carmine dye 
(E132) in their manufacturing process (MA Pharmachem Ltd, 2011).  Whereas, 
Actavis 10 mg diazepam (1) tablets contain the HT lake (E132) version of the same 
colour.  The aluminium lake is a more stable dye, which is not water soluble and is 
often used in the food industry (Actavis UK Ltd, 2014).   Lakes are formed by the 
precipitation of a food dye with an aluminium salt, making them virtually insoluble in 
water and they therefore colour by dispersion (Pharmorgana GmbH, 2018).    
Although the Teva tablets dissolved to produce a clear solution with insoluble blue 
particulates, very similar to Actavis, the patient information leaflet only identifies the 
dye E132 without detailing whether this is in lake form (Medicines and Healthcare 
Products Regulatory Agency, 2015b).   
Results indicated there was more fluctuation in the level of diazepam (1) content 
found within the Actavis and Teva tablets during the initial analysis in this study.  The 
problem may have been due to incomplete dissolution of the diazepam (1) with some 
active drug substance becoming trapped in the larger particulate material which was 
removed during filtration.  Replacing the filtration step by centrifuging the samples at 
3000 RPM for 10 minutes, a more consistent level of diazepam (1) at around 10 mg 
was then recovered from the pharmaceutical tablets. As a result, the centrifuge was 
then used on all cases, in order to alleviate any discrepancies. 
5.3.9.3 Tablet Availability 
Given the small number of tablets within many of the batches, three tablets were 
normally used for HPLC analysis.   However, due to limited numbers of tablets, only 
one tablet was analysed by HPLC from Cases 2 – 31 as the few remaining tablets 
were required for other forms of analysis.  Limited availability of later cases meant 
the cases that were found not to contain diazepam (1) in the initial HPLC analysis 
were identified by GC-MS and re-run on the HPLC along with a standard of the 
indicated drug substance.   
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Although certified drug standards were run before and after each run of 
pharmaceutical and illicit tablets to ensure retention times were correct for the 
suspected substance, on occasion, this was not possible.   For example, the limited 
number of tablets available for Cases 4 and 14 meant that the initial HPLC was 
performed to provide an indication of retention time.  However, once the certified 
standards had been obtained there were no tablets left to compare them to.  The 
active drug substance was then tentatively identified by matching retention times 
with other cases run at the same time and then later matching them with the certified 
standards. The recorded retention time for the visible peaks produced by the earlier 
run of Cases 4 and 14, were also compared to the later standards.  DSC 
thermograms were also compared to gain additional information.  This therefore may 
give an indication of the active drug substance present but is not conclusive. 
5.3.9.4 Consistency of Blend of the Illicit Tablets 
In order to investigate the uniformity of the active drug substance within one of the 
illicit tablets, a single tablet from Case 27 was quartered and analysed.  A content 
uniformity test was performed by Zaid et al. (2013)  on ½ scored pharmaceutical 
lorazepam (11) tablets.  Lorazepam (11) tablets were chosen because of the 
popularity of benzodiazepines and as there was a small amount of active ingredient 
within the tablet.  Essentially this would mean that if the tablets were inconsistent in 
the distribution of active drug substance when half tablets were the prescribed dose, 
which Zaid suggested was common practice, then incorrect amounts may be taken. 
The results indicated that the analysed pharmaceutical tablets were evenly blended 
with consistent levels of lorazepam (11) in each tablet half.   
The situation was very different for this project.  Case 27 had the highest recorded 
level of diazepam (1) found in this study, with 48 mg reported in a single tablet.  The 
test was performed to investigate whether each quarter of the tablet contained an 
equal amount of the diazepam (1) content.  
However, as this was an illicitly manufactured tablet, it may be that if this tablet had a 
high diazepam (1) content then others in the batch may have been low, depending 
on how well mixed the ingredients had been prior to tableting.  It is worth pointing out 
 
160 
however, that several of the tablets from this case had been analysed both during 
this study and for honours projects and the quantity of diazepam (1) present had 
been consistently high.  Also, the results of this case may not necessarily reflect on 
the effect of batch mixing for other illicit cases. 
Although recreational drug use often involves the consumption of large quantities of 
multiple drugs, the option of internet purchases for medicinal use in countries such 
as America, may mean that half tablets are consumed. It would therefore be possible 
that a person splitting what is believed to be a 10 mg diazepam (1) tablet to provide 
a 5 mg dose, could be taking 20 mg of an unequally blended illicit tablet, for 
example. 
 
5.4 Results and Discussion 
5.4.1 Content of Illicit Cases 
5.4.1.1 Active Drug Substances Detected 
The results of the HPLC analysis are shown in Table 5.2. Results were rounded to 
give a reported level for statistical analysis.  However, cases found to contain 
between 9 – 11 mg were all reported as containing the 10 mg pharmaceutical dose 
to allow for errors of measurement and the 7.5% tolerance permitted within the 
pharmaceutical industry. 
The results indicate that of the 65 cases of illicit tablets analysed 31% (20 cases) 
were found to contain the 10 mg stated pharmaceutical dose of diazepam (1) 
(approximately 9 – 11 mg); 3% (2 cases) contained a slightly lower amount 
(approximately 8 mg); 26% (17 cases) contained considerably higher than the 
expected dose (19 – 48 mg); and 40% (26 cases) were found to contain no 




Table 5.2.  Results of the HPLC analysis.      The tablet marked * was used to check the 
homogeneity of a quartered tablet.  
 Diazepam (1) content recorded 










Tablet 1 Tablet 2 Tablet 3     
2 9.5 - - 10 9.5   
3 8.9 - - 9 8.9   
4 0 - - 0 0   
5 7.8 - - 8 7.8   
6 27.7 - - 28 27.7   
7 22.3 21.0 - 22 21.65 0.9 4.3 
8 20.4 - - 20 20.4   
9 21.9 - - 22 21.9   
10 9.9 - - 10 9.9   
11 9.6 - - 10 9.6   
12 22.3 - - 22 22.3   
13 21.5 - - 22 21.5   
14 0 - - 0 0   
16 9.8 - - 10 9.8   
23 9.6 - - 10 9.6   
24 9.8 - - 10 9.8   
25 7.9 - - 8 7.9   
26 24.8 - - 25 24.8   
27 48.4 *  40.6 - 48 44.5   
28 20.3 - - 20 20.3   
29 10.0 - - 10 10.0   
30 10.2 - - 10 10.2   
31 22.1 - - 22 22.1   
71 19.8 19.0 19.5 19 19.4 0.4 2.1 
72 20.6 23.1 20.3 21 21.3 1.5 7.2 
73 0 0 0 0 0 0  
74 8.8 9.0 8.8 9 8.9 0.1 1.3 
75 21.3 19.6 17.9 20 19.6 1.7 8.7 
76 0 0 0 0 0 0  
77 0 0 0 0 0 0  
78 8.8 8.6 8.4 9 8.6 0.2 2.3 
79 8.7 8.6 8.8 9 8.7 0.1 1.2 
80 9.0 8.7 8.7 9 8.8 0.2 2.0 
81 8.6 8.5 8.4 9 8.5 0.1 1.2 
82 8.9 8.9 8.8 9 8.9 1.0 0.7 
83 8.7 8.8 8.6 9 8.7 0.1 1.2 
84 0 0 0 0 0 0  
85 0 0 0 0 0 0  
86 8.5 8.7 8.5 9 8.6 0.1 1.4 
87 0 0 0 0 0 0  
88 0 0 0 0 0 0  
89 0 0 0 0 0 0  
90 8.5 8.6 8.6 9 8.6 0.1 0.7 
127 0 0 - 0 0 0  
128 0 0 - 0 0 0  
129 18.3 19.4 18.7 19 18.8 0.6 3.0 
130 19.6 19.7 - 20 19.7 0.1 0.4 
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 Diazepam (1) content recorded 










Tablet 1 Tablet 2 Tablet 3     
131 0 0 - 0 0 0  
132 0 0 - 0 0 0  
133 8.4 8.9 - 9 8.7 0.4 4.1 
134 0 0 - 0 0 0  
135 0 0 - 0 0 0  
136 0 0 - 0 0 0  
137 0 0 - 0 0 0  
150 21.4 23.6 24.1 23 23.0 1.4 6.2 
151 0 0 - 0 0 0  
152 0 0 - 0 0 0  
153 0 0 - 0 0 0  
154 0 0 - 0 0 0  
155 0 0 - 0 0 0  
156 10.6 10.6 9.4 10 10.2 0.7 6.8 
157 0 0 - 0 0 0  
158 0 0 - 0 0 0  
159 24.4 23.2 22.1 23 23.2 1.2 5.0 
160 0 0 - 0 0 0  
Actavis 10.5 10.6 10.7 10 10.6 0.1 0.9 
Teva  10.6 10.5 10.6 10 10.6 0.1 0.6 
MA Batch 
061 




10.1 10.6 10.5 10 10.4 
0.3 2.5 
Wockhardt 9.8 10.1 10.3 10 10.1 0.3 2.5 
 
The diazepam (1) content within each illicit case was found to be fairly consistent, 
with the largest relative standard deviation of 8.7% calculated for Case 75, which 
had three tablets ranging from 17.9 mg – 21.3 mg of diazepam (1).  This case was 
reported as containing 20 mg of diazepam (1) for statistical purposes.  However, 
there were large differences between the cases, with diazepam (1) content ranging 
between 8 – 48 mg.  The cases which did not produce peaks corresponding to 
diazepam (1) did generate peaks analogous to other active drug substances as can 




Table 5.3.  Results of HPLC analysis of different active drug standards.  The case numbers 
listed alongside indicate cases which were analysed at the same time as the drug standard 
and which generated the same retention time. 
 
Drug standard Retention 
Time (mins) 
Case Numbers 
Diazepam (1) 8.8 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, 23, 
24, 25, 26, 27, 28, 29, 30, 31, 71, 72, 74, 
75, 78, 79, 80, 81, 82, 83, 86, 90, 129, 
130, 133, 150, 156, 159 
Phenazepam (16) 7.1 – 7.3 77, 84, 85, 87, 88, 89, 131, 134, 137, 152 
Etizolam (7)  6.2 73, 76, 132, 135, 151, 155, 157, 158, 160 
Chlordiazepoxide (3)           12.1-12.2 136  
Promethazine 6.6 – 6.7 127, 128, 153, 154 
Acetaminophen 1.5 – 1.6 134, 152 
Aspirin 1.38  73, 134, 152 
Triazolam (18) 5.2  
Ketazolam (10) 11.4  
 
5.4.1.2 Chromatographic Separation of Active Drug Substances 
Analysis of a certified ketazolam (10) standard by Gas Chromatography - Mass 
Spectrometry (GC-MS), produced a chromatographic peak with the same retention 
time and mass spectrum as diazepam (1), in this study (see Chapter 4).  This meant 
that seized tablets which produced a peak similar to the certified standard of 
ketazolam (10) or diazepam (1), could not be positively identified by GC-MS alone.    
However, HPLC analysis of the two substances produced different retention times, 
enabling separation to be made between the ketazolam (10) and diazepam (1) 
certified standards (United Nations Office on Drugs and Crime, 2012).    By running 
both certified standards at the beginning and end of each HPLC sequence 
containing samples from the seized cases, allowed comparison to be made to the 
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HPLC retention times.  This enabled all of the seized cases in this study, which had 
produced chromatographic peaks similar to diazepam (1) and ketazolam (10) by GC-
MS analysis, to be identified as diazepam (1).  Each of these seized cases produced 
peaks with a retention time of 8.8 minutes, matching the certified diazepam (1) 
standard, instead of 11.4 minutes produced by the ketazolam standard (10), as 
shown in Table 5.3. 
Similarly, distinction between triazolam (18) and etizolam (7) was clarified through 
HPLC analysis, thus indicating that the illicit cases tested for this project contained 
etizolam (7).  A chromatogram demonstrating the retention times of various active 
drug substances can be seen in Figure 5.2.  
 
Figure 5.2. Chromatogram showing the peaks produced by five of the active drug substances. 
The five large peaks were identified by individual analysis to confirm retention times and from 
left to right, are triazolam (18), etizolam (7), phenazepam (16), diazepam (1) and ketazolam (10). 
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5.4.1.3 Comparison of Case 136 to the Certified Chlordiazepoxide Standard 
The cases that were not identified as diazepam (1) were tested alongside the drug 
standards indicated from the GC-MS analysis.  This included Case 136, which was 
analysed with the certified chlordiazepoxide (3) standard.  This not only produced a 
peak at 12.2 minutes but was also discovered to carry over into the following blank 
where it generated a peak at 9.8 minutes as noted in Figure 5.3 for both illicit tablets 
and known standard.  The reason for the two peaks is unclear but it may be due to the 
onset of degradation with the standard and sample being analysed at the end of a run 
sequence, leaving the prepared samples in slightly acidic conditions (pH5) at room 
temperature in the autosampler.  Further investigation could have been performed on 
the chlordiazepoxide (3) standard and the samples taken from Case 136, using fresh 
samples just before the run and samples which had been refrigerated. The results of 
the further analysis would not have added more information for the aim of this study 
which was to separate out different potential groupings among the seized cases and 




Case 136 Blank after Case 136 
  




Figure 5.3. Case 136 and the following blank, along with the certified chlordiazepoxide (3) 






Interestingly, GC-MS analysis of case 136 (Chapter 4) had indicated that there may 
have been diazepam (1) present in these tablets.  However, this was not corroborated 
by HPLC analysis, with no peaks visible at around 8.8 minutes.  If diazepam (1) was 
present, it was a quantity below the LOD of 75 ng / mL. 
A similar situation was discovered with Cases 127, 128, 153 and 154.  These cases 
were analysed at the same time as the certified promethazine standard and were 
found to be consistent with the main peak appearing at approximately 6.6 minutes and 
a smaller peak carrying over into the next run at about 3.7 minutes.   
The results of the HPLC analysis were added to the Venn diagram (Figure 5.4), in 
order to compare the new information with the previous findings.  The diazepam (1) 
quantification is listed in more detail in Table 5.4.  The level of diazepam (1) shown 
has been rounded to the nearest milligram and colour coded in groups of around 10 
mg.  The exception to the groupings, were the tablets which were analysed as 
containing between 9.4 – 10.6 mg, which were all reported as containing the 10 mg 
pharmaceutical dose to allow for errors of measurement.  Anything identified as 
being below 8 mg was deemed too low to be classified along with the 
pharmaceutical tablets.  No tablets were found to contain between 10 – 19 mgs of 









Figure 5.4. Venn diagram showing the combined results of the physical analysis, active drug 
substance identification through GC-MS and diazepam (1) quantification determined by HPLC.  
The coloured shapes identify active drug substances and colour coded case numbers relate to 




Table 5.4.  Results of HPLC analysis showing the level of diazepam (1) present in the illicit 
cases.  The case numbers have been colour coded for comparison to the Venn diagram 
(Figure 5.4) 
Diazepam level (mg) Case numbers 
8 5, 25 
9–11 2, 3, 10, 11, 16, 23, 24, 29, 30, 74, 78, 79, 80, 81, 82, 83, 
86, 90, 133, 156 
19 71, 129,  
20 8, 28, 75, 130 
21 72 
22 7, 9, 12, 13, 31 




The Venn diagram identifies interesting clusters when combining the quantification of 
diazepam (1) with the comparison of physical measurements.  Firstly, the majority of 
cases, which were recorded as containing a pharmaceutical level of diazepam (1) of 
between 9-11 mg appear to be comparable to the known pharmaceutical tablets in 
diameter, depth and weight.  Indeed these cases, typed in blue, are the only ones 
which appear in the central area of the Venn diagram, relating to consistency with the 
pharmaceutical tablets.  This would indicate that the illicit tablets, which do not contain 
the expected level of diazepam (1) are also not consistent in physical measurement 
to known pharmaceutical tablets.  However, it may be that some of the seized cases, 
which were found to contain the reported level of 10 mg of diazepam (1) are also of 
illicit origin and further analysis is needed to further distinguish between these cases. 
Interestingly, only six cases which were reported as containing 10 mg diazepam (1) 
(Cases 3, 10, 23, 78, 90 and 133), were found to vary from the pharmaceutical tablets 
in at least one measurement.  Of the six, cases 23, 78 and 90 were imprinted with the 
logo MSJ and differed from the pharmaceutical tablets manufactured for the UK 
market in both diameter and weight (with case 23 differing in depth too). As described 
in Chapter 3 (Section 3.5.3.1-Tablet Diameter), MSJ markings may be consistent with 
the pharmaceutical company J.L. Morison Son & Jones (Ceylon) plc., which is a 
licensed manufacturer in other countries.  However, this is not a licensed product in 
the UK, therefore these cases are deemed illicit.  Case 3 was an isolated case marked 
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only with a half score on one side and is not a licensed product for the UK market.  
Case 133 was a single case with the marking C/DC on one side and with a plain 
reverse, relating to the UK licensed manufacturer Actavis. However, it measured a 
greater depth and diameter than the known pharmaceutical batch and had a greater 
relative standard deviation between the measurements recorded within the case (See 
Chapter 3, section 3.5.4 - Comparison of Results).   
Case 10, along with Case 81 were marked CP and D/10, which is related to the 
pharmaceutical company Wockhardt.  Although the tablets from Case 81 were 
consistent in measurement with the pharmaceutical tablet, Case 10 was found to vary 
in tablet depth 
It is also worth noting that although the six cases had a reported level of 10 mg, four 
of them (cases 3, 78, 90 and 133) had an analytical level of below 9 mg and were 
rounded up to allow for errors of measurement.  By rounding up the level of diazepam 
(1), these four cases reached the lower end of the pharmaceutical level. 
5.4.3 Quartered Tablet 
A single tablet from Case 27 was cut into quarters using a scalpel and then weighed 
as a whole tablet, at 192.4 mg.  Each individual portion of the tablet was then re-
weighed individually in order to determine the percentage of the tablet size. Every 
quarter of the tablet was analysed on the HPLC, as an individual sample and the 
results are shown in Table 5.5. 
Table 5.5.  The weight and diazepam (1) content found in each quarter of a single tablet taken 
from Case 27. 
Number of 
Quarter 













1 52.5 27.3 % 11.4 28.1% +2.93% 
2 51.8 26.9 % 11.3 27.8% +3.34% 
3 40.0 20.8%   8.2 20.2% -2.88% 
4 48.1 25.0%   9.7 23.9% -4.40% 
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The results indicate that the diazepam (1) appears to have been fairly evenly spread 
throughout the tablet, with the largest quantity of diazepam (1) being found in the 
largest portion of the tablet and the second highest in the second largest etc.  The 
difference in diazepam (1) content defines the variation in the amount of diazepam (1) 
found compared to the expected level in each quarter of the tablet and was calculated 
by using the equation ((% diazepam (1) content - % tablet weight) / % tablet 
weight)*100.  However, there was a slight discrepancy, with the first two quarters 
showing an increase in diazepam (1) content compared to the weight and the smaller 
two having a slight loss.  However, as these are illicit tablets the consistency of the 
batch is still unknown because consistency may vary according to its position in the 
hopper.  Also, even if this batch was consistently produced, it may not follow that all 
of the other illicit cases were as well mixed.  Inconsistency in mixing tablets leads to 
dangers of overdose, either because tablets taken are extremely high in active drug 
content meaning the consumer does not realise how much they have actually 
consumed, or because the tablets taken contain very little active drug substance, 
giving little pharmaceutical effect.  Consequently, the consumer may take a greater 
quantity of tablets on the following occasion. 
5.5 Conclusion 
The HPLC analysis of blue tablets performed in this study was of vital importance.  
As the majority of benzodiazepines in the illicit market had largely been presumed to 
be diverted products of pharmaceutical origin (United Nations Office on Drugs and 
Crime, 2012), no work has previously been published on the content of seized blue 
‘diazepam’ (1) tablets.   
The results of the HPLC analysis would indicate that there is a huge variety of 
content within the illicit blue “diazepam” (1) tablet population.  The tablets analysed 
were all believed to be being sold as 10 mg diazepam (1) tablets however, the level 
of diazepam (1) present within the analysed tablets was found to vary between 
approximately 8 mg – 48 mg in a single tablet. In terms of this project HPLC proved 
invaluable for distinguishing between groups of tablets containing different amounts 
of diazepam (1) content.  The HPLC was also able to identify that only 20 cases out 
of the 65 analysed contained the pharmaceutical dose of between 9 – 11 mg of 
 
172 
diazepam (1), therefore revealing that the majority of illicit cases seized and 
analysed for this project were illicit.  This means that only 31% of the cases had the 
potential to be pharmaceutically manufactured diazepam (1) tablets produced for the 
UK market, which had been diverted into the illegal supply chain. This may reflect a 
change in the illicit market from diverted pharmaceutical tablets (Advisory Council on 
the Misuse of Drugs, 2016)  to illicitly manufactured products, with greater access to 
knowledge and equipment for clandestine operations (See Chapter 4, section 4.4.5 – 
Lubricants). 
In addition, the variety of active substances found including phenazepam (16) with a 
potency five times greater than diazepam (1) and etizolam (7) with a potency ten 
times higher reflect the variation and dangers within the illicit market.  The situation 
would be magnified if multiple tablets are consumed within a short time span or in 
conjunction with other drugs and / or alcohol, which could have potentially serious 
consequences.  Therefore the results of this analysis are extremely important and 




6.1 Chapter Summary 
Differential scanning calorimetry was tested as a way to explore thermal differences 
between batches of tablets.  A large fraction of a pharmaceutical diazepam (1) tablet 
is comprised of excipients, with only 10 mg of active drug substance present in the 
samples tested for this project.  Therefore, thermal events detected by DSC have the 
potential of providing valuable information on the excipient content of the illicit tablets 
by comparison to thermograms produced by known pharmaceutical preparations.  
The technique was also explored as a way to differentiate between different batches 
of seized tablets. 
6.2  Introduction  
6.2.1 Types of Differential Scanning Calorimeter 
Differential Scanning Calorimetry (DSC) is a well-established analytical technique 
that enjoys widespread use in both polymer characterisation and pharmaceutical 
development.  However, it is not commonly used for the forensic examination of illicit 
tablets.   
There are two kinds of DSC, a power compensation system and a heat flux system. 
The former uses two heaters, one for the sample and the other for the reference pan.  
The heaters utilise exactly the same temperature programme and it is the difference 
in power used to keep the temperature the same, which is measured. The heat flux 
DSC, which was employed in this study, uses a furnace to heat the sample and 
reference together and uses a thermocouple to measure the difference in the heat 
flow between the two pans.  The heat flow is affected by the thermal changes 
occurring in the sample (Craig and Reading, 2006).   
Changes to the heat capacity of a sample during a heating or cooling cycle can be 
used as an indication of the chemical reactions or phase changes, both of which are 
characteristic of the sample being tested.  Phase changes that can be detected with 
DSC include dehydration, de-solvation, recrystallization, melting and degradation. 
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6.2.2  Pharmaceutical Use 
6.2.2.1 Polymorphism in Solid Substances 
DSC is used extensively in the pharmaceutical industry, to test for the presence of 
polymorphic drug forms by measurement of melting/recrystallization behaviour and it 
can also be used to quantify the degree of crystallinity in samples.   The 
physicochemical properties of drugs and excipients are affected by the occurrence of 
polymorphism and this can influence the dissolution and solubility of tablets and the 
bioavailability of the drug substance itself (Aulton, 2007a).  Tablet storage, shelf-life 
and drug stability are all governed by the precise crystalline nature of tablet 
components and DSC is used to determine these inherent properties. A study in 
2008 explored the importance of understanding the thermal behaviour of polymorphs 
in relation to using high speed DSC in order to prevent concurrent recrystallization. 
The benefit of this was that it could restrict kinetically controlled processes while 
allowing the thermally activated events to take place (Mcgregor and Bines, 2008).  In 
simple terms, fast heating does not give enough time for metastable polymorphs 
(upon melting) to recrystallize into more stable forms.  This simplifies the results 
produced by eliminating exothermic events caused by so-called ‘solid state 
transitions’, i.e. one solid polymorph changing to a more stable solid polymorph 
through a recrystallization process.   
Polymorphism can also complicate any quantification performed by DSC.  For 
example, if diazepam (1) is present in the tablets, an endothermic peak will be 
produced by the breaking of ionic interactions and/or secondary bonds such as 
hydrogen bonds and Van der Waals forces, as the drug substance melts.  However, 
when amorphous forms of the drug are present, the melting temperature of the 
diazepam (1) may vary.  In these terms, ‘amorphous’ equates with ‘non-crystalline’.  
Semi-crystalline materials have a mixture of crystalline and non-crystalline parts and 
a broader onset to the crystalline melt is commonly encountered.  A slight 
depression (lowering) of the peak maximum may also be apparent. 
A study by Bruni et al., (2012) explored methods of quantification of amorphous and 
crystalline fractions.  The paper notes that the crystalline structures are more stable 
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but sometimes the amorphous form of the active drug substance is preferred as it 
improves bioavailability.  A large proportion of the pharmaceutically manufactured 
tablets are comprised of lactose, which contains both crystalline and amorphous 
forms (Rowe, Sheskey and Weller, 2003).  As a result, an exothermic peak can be 
seen on the thermograms when the particles anneal.  
The 𝞪-lactose monohydrate present in pharmaceutical tablets, has water molecules 
within its structure along with additional water molecules that are adsorbed onto the 
surface.  Therefore, as the sample is gradually heated in the DSC, the initial falling 
line on the thermogram relates to desorption of the moisture.  This is followed by the 
𝞪-lactose monohydrate dehydration and then its melt. It has been recorded that the 
starting point for lactose to become anhydrous is 120 oC, producing an endothermic 
peak at 150 oC and it begins to melt at 201 oC. The resulting peak produced by the 
melt varies according to the size of the particles (Rowe, Sheskey and Weller, 2003). 
The β-lactose melt takes place after this at 224 oC (Figure 6.1).   
 
Figure 6.1.  DSC thermogram of lactose identifying the thermal events.  There was very little 
crystallisation of this sample, therefore the peak was drawn in for demonstration. 
The thermal history of a tablet can also have a significant impact on the shape of the 
thermogram produced.  This is particularly true of semi-crystalline substances which 
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are strongly affected by the length of time taken to heat or cool the sample.  
Basically, the more time taken to cool, the more likely it is to have settled into a more 
ordered crystalline structure (Craig and Reading, 2006).  
6.2.2.2  Compatibility Studies 
Results produced by DSC can be problematic to interpret if multiple components are 
present in the tablets.  When only one pure substance is present, such as diazepam 
(1), a clear single peak is shown (Figure 6.2).  However, compatibility studies are 
another important investigation performed by DSC within the pharmaceutical 
industry, aimed at ensuring the safe use and stability of the formulation. 
 
Figure 6.2.  DSC trace produced by Diazepam (1) 
Tablets usually contain a variety of excipients, each with a different function but 
which also provide bulk to the tablet.  All of these added components produce their 
own trace by DSC, as well as further reactions derived from the combined 
ingredients interacting with each other.  In addition, when low levels of constituents 
are present, including the active drug substance, it can be overwhelmed and hidden 
on the thermogram because of the large quantity of other excipients.  As illicit tablets 
contain an indefinite variety of unknown substances in unspecified quantities, the 
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A recent study investigated the compatibility of diazepam (1) with various tablet 
excipients using thermal analysis. No incompatibilities between the substances were 
found but DSC did indicate that an interaction had taken place between the 
diazepam (1) and colloidal silicon dioxide by demonstrating a lower enthalpy value 
(Matos et al., 2017). Colloidal silicon dioxide is present in tablets produced by 
Sovereign Medical (Medicines and Healthcare Products Regulatory Agency, 2016b) 
and consequently pharmaceutical tablets produced by this company may show 
slightly smaller thermal peaks compared to other pharmaceutical tablets. 
6.2.3 Forensic Use of DSC 
Forensic interest has recently been growing into the potential use of DSC.  A study in 
2015 used DSC to investigate amphetamine type stimulants without the potential 
interference caused by creating artefacts through pre-treatment of samples 
(Boumrah et al., 2015).  Research performed into illicit diazepam (1) tablets, 
suggests that DSC may be a powerful tool for identifying similarities and differences 
between cases (Bibi et al., 2015). 
One of the benefits of using DSC for forensic analysis is that the excipients within the 
tablets and their interactions can be investigated.  Many of the more widely used 
methods of analysing illicit tablets concentrate on determination of the active drug 
substance.  However, as the amount of diazepam (1) present in the tablets is so 
small, DSC is heavily influenced by the excipient content, thus it produces a 




6.3 Overview of DSC analysis 
A selection of known tablet excipients and a variety of different grades of lactose 
were analysed by DSC.   In addition, different brands of known pharmaceutical 
tablets were also analysed.  The resulting thermograms were visually compared to 
the illicit cases.  Statistical analysis was also performed on the data and the results 
can be found in Chapters 7 and 8. 
Multiple samples were tested from the same tablets to ensure repeatability and 
consistency within individual tablets.  Repetitions were also tested using multiple 
tablets from the same case.   
The aim of the analysis was to investigate if it would be possible to create a chemical 
profile of the illicit cases that could give an indication of the constituents present 
within the tablets, by comparison to thermographic peaks of common excipients.  In 
addition, by producing thermograms which were visually very similar this may 
highlight chemical similarities between cases that had not previously been realised.  
For example, if an illicit manufacturer sticks to a formula that produces successful 
tablets but just changes the active ingredient, then the thermogram is likely to be 
very similar, particularly if the active drug substance in only added in small 
quantities.    It was also intended that comparisons with the known pharmaceutical 
tablets should help to denote a potential origin of the illicit cases.  Likewise, seized 
cases which produced DSC thermograms similar to those of known pharmaceutical 
tablets could support the previous analysis regarding physical characteristics and 




Differential Scanning Calorimeter (DSC) thermograms were produced on a TA 
Instruments Q100 Differential Scanning Calorimeter with RCS90 cooling system, 
using Thermal Advantage software.  Samples were analysed in standard aluminium 
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pans set with a starting temperature of 20 oC.  The heating rate was ramped up at 10 
oC per minute to a final temperature of 250 oC. The temperature was calibrated 
against indium, with a melting point of 156.60 oC, as shown in Figure 6.3. 
 
Figure 6.3.  Calibration of DSC with Indium. 
 
6.4.2 Materials used in DSC Analysis 
Illicit blue tablets were provided by Police Scotland. 10 mg diazepam (1) 
pharmaceutical tablets were supplied by Actavis UK Ltd., Barnstaple; Teva 
Pharmaceutical Industries, UK; and Wockhardt UK Ltd., Wrexham.  Two different 
batches of 10 mg diazepam (1) pharmaceutical tablets were provided M&A 
Pharmachem Ltd., Bolton.  Certified standards of diazepam (1) were obtained from 
Sigma Aldrich and Cow and Gate Follow on Baby Milk was purchased from Asda, 
Aberdeen. Standard DSC pans (900779.901) and standard lids (900786.901) were 
supplied by TA Instruments Ltd, Crawley. 
6.4.3 Methodology used in DSC Analysis 
Samples for DSC were prepared by crushing a tablet with a clean mortar and pestle.  
A small quantity between 5 – 10 mg of the powdered sample was place in a sealed 
aluminium pan and heated alongside an empty reference pan, in the DSC at the 
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(Although the samples could range between 5 – 10 mg in weight, the initial analysis 
aimed at using a consistent sample size of 9 mg, in order to avoid unnecessary 
discrepancies).    
Samples were prepared from common tablet excipients including 
polyvinylpyrrolidone (PVP), also known as Povidone.  This is a synthetic polymer 
that is used as a binder and is present in tablets manufactured by MA (MA 
Pharmachem Ltd, 2011), and Wockhardt (Wockhardt UK, 2015).  Other excipients 
analysed were magnesium stearate, which is a lubricant present in most 
pharmaceutically manufactured diazepam (1) tablets and EmcompressTM. 
EmcompressTM is the trading name for calcium hydrogen phosphate dihydrate.  This 
is a commonly used filler and diluent used in the pharmaceutical industry (Rowe, 
Sheskey and Weller, 2003).  Interestingly, it is not normally used in diazepam (1) 
tablets that are produced for the UK market.  In addition, various grades of lactose 
were run using DSC, in order to assess if a difference in grade would affect the 
resulting thermogram.  Lactose is a tablet filler or diluent used in all pharmaceutically 
manufactured diazepam (1) tablets in the UK. 
Samples were also prepared and run from each of the batches of known 
pharmaceutical tablets for comparative purposes.  This included multiple runs of up 
to three samples produced from the same powdered tablet and up to eight samples 
prepared from different tablets within the same batch.   
One tablet was taken and prepared from each of the illicit cases.  Depending on the 
number of tablets available, more than one sample was occasionally analysed from 
the same tablet, or multiple tablets were investigated from the same batch.  The 
repeats were performed on random tablets and consistency of the results was 
evident. 
Repeats of some of the samples were performed between 9-10 months later and 
some of the pharmaceutical cases were repeated after 4 months.   
Whole tablets were placed in small plastic bags and powdered tablets were 
contained in vials for storage.  These were not kept in a humidity or temperature 
controlled environment. Storage of the tablets before seizure was also unknown. 
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6.4.4 Repeatability of the Analysis 
Eight separate pharmaceutical tablets from MA Pharmachem were prepared and 
analysed. Consistent results were demonstrated, as shown in Figure 6.4. 
 
 
Figure 6.4.   Comparison of thermograms produced by eight different pharmaceutical tablets 
supplied by MA Pharmachem.  Differences occurring after 220 oC were the result of sample 
degradation and provided no relevant information for this project.   
 
6.4.5 Temperature Range Analysed 
The temperatures analysed for samples ranged between 100 – 220 oC.  Although 
the thermograms were recorded from 22 oC, many of the profiles indicate a gentle 
slope reflecting a decrease in heat flow up to 100 oC.  This is likely to be a result of 
solvent and water loss according to storage rather than being directly characteristic 
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Similarly, many of the samples analysed began to degrade at 220 oC as 
demonstrated in Figure 6.4 and by the thermogram produced by the Actavis tablet 
shown in Figure 6.8.   This meant that although the β-lactose melt had been 
recorded at 224 oC (Figure 6.1), this was not always consistent due to falling within 
the area of degradation. 
It was therefore decided that these areas would not be included for the analysis or 
for the data collection used in later statistical analysis.  However, a great deal of data 
was gained from the thermograms and data produced within the 100 – 220 oC range. 
 
6.5 Results and Discussion 
6.5.1 Common Excipients used in Pharmaceutical Tablets 
No surprisingly, the thermograms produced by the excipients demonstrated 







   
 
Figure 6.5.   Thermograms of three tablet excipients (Povidone, Mg Stearate and 
EmcompressTM) at a heating rate of 10 C / min.  
 However, there was less of a difference between the different varieties of lactose 
(Figure 6.6).  Although they are different grades, they are effectively the same 
substance and therefore all lactose samples exhibited endothermic peaks at about 
the same temperature for the dehydration and melt of the 𝞪-lactose monohydrate.   
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150 micron lactose Lactose Bp  Spray dried lactose 
   
 
Figure 6.6.   Thermograms of different lactose grades showing similarity in endothermic peaks.   
 
6.5.2  Certified Drug Standards Tested for Comparative Purposes 
Most of the drug substances analysed produced different thermograms by DSC 
(Figure 6.7) although the melting points of the phenazepam (16) and nitrazepam (13) 
were similar. Clonazepam (4) also demonstrated a high melting point but it appeared 
closer to 240 oC, than the other two. Although the analytical grade of the drug 
substances produce thermograms with distinct melting points, it is important to be 
aware that polymorphic forms or impurities can affect the melting point.  Therefore 
the drug substance suggested by comparison is not conclusive for identification 
purposes.  Illicit tablets in particular, contain a variety of unknown substances which 
interact with the active drug substance.  Synthesis of drug substances involves the 
use of different organic solvents to recrystallize the drug during recovery and 
purification.  Many drugs can form solvates and these have their own specific 
thermal behaviour which normally involves the loss of solvent to form a metastable 
desolvate, followed by subsequent recrystallization into a more stable polymorphic 
form.  Also, the origin of the drug substance itself is unspecified therefore the level of 




















Figure 6.7.  Thermograms produced by a selection of benzodiazepines using a single heating 
cycle at 10 C / min from 20 to 200 – 250 C. Thermograms of nitrazepam (13), oxazepam (15), 
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6.5.3 Pharmaceutical Tablets Analysed by DSC 
The results of DSC traces on the known pharmaceutical tablets proved interesting.  
All of the thermograms appeared to be dominated by lactose, which was one of the 
known ingredients.  Therefore the expected dehydration and melt of the 𝞪-lactose 
monohydrate was present.  Occasionally a peak could be seen which could be 
indicative of the β-lactose melt at 224 oC however, this could be subjective as it was 
either close to or within the area of degradation which began at 220 oC.  
The majority of the pharmaceutical cases produced a very similar thermogram, as 
demonstrated by the MA trace shown in Figure 6.8.  The thermogram generated by 
the Actavis tablet exhibited some differences, however.  Firstly the endothermic peak 
produced by the diazepam (1) melt at 130 oC was barely visible.  Only the very tip 
can be seen on the trace shown in Figure 6.8. In this case, it is largely hidden by the 
𝞪-lactose dehydration.  Another endothermic peak is also visible at just above 58 oC.  
Earlier work performed at Robert Gordon University identified this peak as stearic 
acid (Bibi et al., 2015).  This is a lubricant which is listed by Actavis as being in their 




Figure 6.8.   Thermograms showing the differences between DSC profiles produced by the 
Actavis tablet compared to the MA tablet.  The pharmaceutical companies Teva and Wockhardt 
manufactured tablets generated thermograms that were almost identical to that of the MA tablet. 
Thermogram of Actavis tablet courtesy of Robert Gordon University.  
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The indication of diazepam (1) concentration within the tablets was also detected in 
the pharmaceutical tablets.  Although Roche do not produce diazepam (1) tablets for 
the UK market, the tablets were originally treated as being of pharmaceutical origin 
and the data produced was consistent with results from the other legitimate 
manufacturers.  By analysing two Roche tablets, one containing 2 mg and the other 
10 mg of diazepam (1), a difference in the height of the peak produced by the 
diazepam (1) melt emerged (Figure 6.9). 
 
Figure 6.9.   Thermogram showing the difference in peak size produced by melting tablets with 





6.5.4 Illicit Cases Analysed by DSC 
At least one tablet from each case was used for DSC analysis in order to assess any 
potential links between the cases.  It was discovered that the 65 illicit cases could be 
visually grouped into eleven potential sub-groups based on the thermograms 
produced.  The details of the groupings can be seen in Table 6.1.  This table lists all 
of the cases that generated similar thermograms, along with an example of the trace.  
This allowed for minor differences, such as in the area of degradation and 
crystallisation.   
Table 6.1.   Grouping of the thermograms produced by the various cases. 
Group Thermogram Case Numbers 
Group 1  
 
2, 6, 7, 8, 9, 10, 11, 
12,13, 16, 23, 24, 26, 
28,29, 30, 31, 71, 72, 
74,75, 78, 79, 80, 81, 
82,83, 86, 90, 129, 
130, 150, 156, 159 
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Group Thermogram Case Numbers 
Group 3  
 
3, 5, 25 
Group 4  
 
4, 14, 87, 88, 152 
Group 5  
 
73, 76, 132, 135, 151, 
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Group Thermogram Case Numbers 
Group 6  
 
77, 89, 134 
Group 7  
 





























The cases listed in Group 1 include, with a few notable exceptions, the majority of 
illicit cases which were found to contain diazepam (1).  The fact that these tablets 
have been linked together is somewhat subjective because they were found to 
contain varying amounts of diazepam (1), ranging from 9 mg in Case 74 to 28 mg in 
Case 6. The difference in concentration is not immediately noticeable in the 
thermograms, which are largely dominated by the lactose. 
Group 2 
Interestingly, Case 27, which has been listed as Group 2, also produced a fairly 
similar trace to Group 1.  The difference with this profile was the extra endothermic 
peak after the dehydration of the 𝞪-lactose monohydrate, at 160 oC.  Tablets in this 
case bore the same markings as Case 6, but were found to contain approximately 48 
mg of diazepam (1) by HPLC analysis.  Comparison of the ratio of diazepam (1) to 
lactose dehydration in Groups 1 and 2 indicates an increased level of diazepam (1) 
in Group 2. 
Group 3 
The cases in Group 3 were an interesting mix.  Cases 5 and 25 had been recorded 
in the visual clustering as being slightly chalky in appearance and were found to 
contain approximately 8 mg of diazepam (1) by HPLC analysis.  Ageing and storage 
of tablets may have promoted the degradation of the drug substance and 
appearance of these tablets and therefore they could not have been conclusively 
deemed as being illicitly manufactured.  However, DSC analysis indicated that the 
thermogram produced by Cases 5 and 25 were different to the pharmaceutically 
manufactured tablets.  
Case 3 appeared very different visually to Cases 5 and 25, having different markings 
on the tablets and being convex in shape. However, tablets in this case were also 
found to contain a slightly lower amount of diazepam (1) at approximately 9 mg.  
Whether theses tablets had suffered through storage or were produced from a 




The cases in Group 4 were all found to contain phenazepam (16).  Although the 
single endothermic peak is closer to the temperature indicated for the melt of 
diazepam (1), it may be that the form of the phenazepam (16) has altered its melting 
point.  However, using HPLC, it was discovered that the level of phenazepam (16) 
present in the tablets was very small so, it is unlikely that this would produce such a 
strong peak.  Considering the magnitude of the heat transfer (almost 20 W/g), the 
precise temperature at which it occurred and the very sharp nature of the event, a 
single substance which is most probably an excipient, is dominating this tablet 
sample.  Without extra corroborating data such as hot stage microscope or thermal 
gravimetric analysis it is not possible to state the nature of the event.  
Group 5 
The Group 5 tablets appear to have a very similar formulation to the pharmaceutical 
diazepam (1) tablets.  The only difference is that there is no melt for the diazepam 
(1).  GC-MS and HPLC revealed that these tablets contained etizolam (7) and in fact, 
every case that was found to contain etizolam (7) was in this group. It appears that 
the main constituent in them is lactose and the small amount of drug substance 
present was not obvious in the form of an endothermic event. The tablets had a 
variety of logos and there were differences in their shades of blue. Although well 
made in appearance, the fact that etizolam (7) is not present in tablets produced for 
the UK market identifies these cases as illicit. 
Group 6 
The three cases in Group 6 were found to contain phenazepam (16) and once more, 
the small amount of active drug substance present is not clearly visible and may be 
hidden behind the strong trace produced by the excipients.  In these cases, the 
endotherm with an onset of 175 oC is consistent with the dehydration generated by 






Further analysis of the cases in Group 7 indicated that these also contained 
phenazepam (16), though clearly with a different formulation to those in either Group 
4 or 6.  It appears that the thermogram is shaped by the excipients.  Although the 
endothermic event at 225 oC is in the area of degradation, shown in greater detail in 
Figure 6.10, this small peak appears clearly on all three thermograms.  It is also 
close to the melt of phenazepam (16) indicated in DSC analysis of the drug 
substance, as seen in Figure 6.7.   
 
Figure 6.10.  Closer detail of thermogram produced by Group 7 cases. 
Case 85 was the only one of the three Group 7 cases, which generated an additional 
small endothermic peak at 165 oC.  Whether this was hidden in the remaining cases 
by the steep slope produced by melting is uncertain.  It may also be that whatever 
this constituent was, could have been present in a slightly larger concentration in 
Case 85. 
Group 8 
The Group 8 tablets included all of the cases, which GC-MS identified as containing 
promethazine.  Unfortunately, there is too much sample degradation occurring to see 





The thermogram produced by Case 133, which is listed as Group 9 was consistent 
with that produced by the pharmaceutical tablets manufactured by Actavis.  There 
was only a small indication of the diazepam (1) melt at 130 oC, which was obscured 
by the dehydration of the 𝞪-lactose monohydrate.  The endothermic peak at 50 oC, 
relating to stearic acid was also visible.  In addition, the tablet markings were 
consistent with those used by Actavis. 
Groups 10 and 11 
The remaining two groups contained only one isolated case each. Group 10, which 
consisted of only Case 137 was found by GC-MS analysis, to contain phenazepam 
(16) and caffeine and Case 136 (Group 11) was the only case that was identified as 
containing chlordiazepoxide (3) by GC-MS.   As the level of phenazepam (16) in 
Case 137 was small and the melting point of caffeine and chlordiazepoxide (3) is 
well in excess of 200 C, the two thermograms appear to be dominated by the 




6.5.5 Effects of Excipients 
Although, it is not possible to identify excipients through this analysis because there 
are so many influencing factors and interactions that must be considered, some 
similarities do appear.  For example, the thermogram produced by Case 136 is 
similar to a trace produced by a large concentration of lactose.  As a result of this, it 
was decided to run a sample of ‘Cow & Gate Growing Up Milk, age 1-2 years’.  As it 
consists mainly of lactose, this produced a result that was similar in shape to Case 
136 (Figure 6.11). 
 
Figure 6.11.  Thermogram from Case 136 overlaid with Baby milk. 
Differences can be seen between the thermograms generated by the baby milk and 
Case 136, however there are a wide variety of baby milk brands and formulations.  
Also, Case 136 contained active drug substances and maybe other ingredients that 
would have interacted with the formulation, therefore creating differences in the 
trace.   
Interestingly, Case 136 was the only case identified as containing chlordiazepoxide 
(3), making it different to the other illicit cases.  GC-MS analysis also indicated that 
there may have been a small amount of diazepam (1) present in the tablets from this 
case but this was not confirmed by HPLC.  It is likely that any diazepam (1) present 
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in the sample used for DSC analysis would have been obscured by the large 
endotherms produced by the lactose. 
 
6.5.6 Baby Milk 
Baby milk was further analysed in an attempt to determine if it would be possible to 
uncover the hidden interactions behind the large endotherms produced by the 
lactose.  As the lactose produced such a large desorption curve at the beginning of 
the trace, which was likely to be hiding other thermal events, a sample was run using 
a hermetically sealed pan to prevent the water from leaving.  
6.5.6.1 Methodology 
Baby milk (10 mg) was analysed in a hermetically sealed pan using a thermal 
programme consisting of equilibration at 20 oC (1 minute) and then heat at 20 oC per 
minute to 220 oC. 
6.5.6.2 Results of DSC Analysis 
The sample of baby milk produced a complicated thermogram to 145 oC, followed by 
a sudden dip (Figure 6.12). A large exothermic peak was then produced before the 
sample degraded.  The complicated line at the beginning of the trace is likely to be a 
result of the fats, oils and proteins within the milk formula, as well as their 
interactions, which will include melts, crystallisations and changes in the 
conformation of proteins.  The dip at 145 oC is likely to be caused by the dehydration 
of the lactose monohydrate.  Lactose is listed as one of the main constituents on the 





Figure 6.12.  Thermogram produced by heating baby milk in a hermetically sealed pan. 
 
6.5.7 Effects of Ageing 
DSC analysis of the illicit cases continued over several months and it was noted that 
changes had occurred in the tablets.  Analysis was performed on both powdered 
remains of the same tablets originally analysed, which had been stored in sealed 
vials, as well as analysis of fresh tablets taken from the same case.  Very few of the 
cases that had originally shown amorphous lactose content, demonstrated the 
exothermic peak indicating the transition to crystallinity in the later samples.  In 
addition, the endotherm produced by the dehydration of the monohydrate appeared 
slightly larger.  It may be that over time the meta-stable tablets had become more 
crystalline and settled into this more stable form.  The changes are demonstrated by 
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Figure 6.13.  DSC thermograms produced by tablets from the same case generated 9 months 
apart showing the disappearance of the inflected transition relating to crystallisation, centred 
around 175 C.   
The difference in crystallinity was also demonstrated in the pharmaceutical tablets 
(Figure 6.14).  The initial run of the tablets from this batch took place only one month 
before the expiry date given on the packet.  Therefore, these tablets were already 
beginning to age, which may explain the slightly smaller crystal transition in the 
original trace.  However, within sixteen months this exothermic event was no longer 
visible. 
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Figure 6.14.  DSC profiles produced by tablets taken from the same batch of pharmaceutical 
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DSC analysis was also performed on the baby milk to identify any changes that 
might have taken place over time (Figure 6.15).  Interestingly, this trace has begun to 
show similarities to the thermograms produced by the Group 7 cases, (84, 85 and 
131) (Figure 6.10).  There are still noticeable differences however but further work 
into the ageing of baby milk and maybe analysis of other brands could prove 
interesting in the future to gain insight into the behaviour of this material compared to 
lactose which is a major excipient in pharmaceutical and illicit tablets. 
 
Figure 6.15.  Thermogram produced by the same tub of baby milk as analysed in Figure 6.8 but 
analysed 10 months later. 
 
 
6.5.8 Analysis of Results 
The results of DSC analysis of the pharmaceutical and illicit tablets indicated that 
further separation could be made between the batches. By combining the data 
gained through previous investigations into the physical characteristics and chemical 
analysis using GC-MS and HPLC, with the groupings identified through comparison 
of the thermal profiles, a more complicated scenario of potential links emerged.  This 
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Figure 6.16.  Venn diagram produced by combining the results of DSC analysis with the 
previous data obtained from physical analysis and the chemical techniques of GC-MS and 
HPLC. 
Some of the groupings previously found to contain diazepam (1) by GC-MS analysis, 
such as cases 7, 31 and 159, are supported by DSC thermograms.  This would 
indicate that no significant differences were detected in the excipients.  However, 
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although DSC grouped these cases with the pharmaceutical tablets, they have been 
identified as illicit due to a higher level of diazepam (1) (15 – 24 mg).  Differences in 
the level of diazepam (1) were not easily visible on the thermogram as the profile 
was largely dominated by lactose, indicating that these illicit tablets use a formula 
with some similarities to pharmaceutical tablets. 
Other groupings of cases confirm the results of previous tests, such as cases 127, 
128, 153 and 154, which were separated out from the remaining cases by all other 
techniques.  Cases 3 and 23, however, produced distinct thermograms indicating 
differences between these two cases of tablets.  Case 3 notably showed similarities 
to cases 5 and 25 which recorded a diameter similar to the pharmaceutical tablets 
but did not match with the pharmaceutical range in either depth or weight.  Cases 5 
and 25 also contained a level of diazepam (1) slightly lower than the pharmaceutical 
dose at 8 mg.  It may be that if there is a link between cases 3, 5 and 25, that these 
are illicit tablets with an inconsistent blend of constituents or that they may have 
been pharmaceutical tablets that did not meet the accepted standard and were 
rejected.  However, difference in measurements, lower diazepam (1) levels and a 
thermal profile distinct from the pharmaceutical tablets would suggest that these 
three cases were illicitly manufactured. 
Case 23 produced a thermogram consistent with pharmaceutical tablets, along with 
cases 78 and 90.  These three cases were found to contain a slightly lower level of 
diazepam (1) by HPLC analysis, which was rounded up to 9 mg to allow for errors of 
measurement.  This meant that the diazepam (1) level was at the lower end of the 
pharmaceutical range.  A difference in the physical measurements of the tablets had 
previously separated these cases from the known pharmaceutical batches, with 
cases 78 and 90 only showing consistency with the legitimate tablets in depth.  Case 
23 differed in all measurements. 
Interestingly the cases which GC-MS analysis identified as containing phenazepam 
(16) have been separated into smaller clusters according to DSC analysis, with 
distinct differences being highlighted in the thermograms.  This could indicate that 
the phenazepam (16) tablets were produced by multiple manufacturers or at different 
times, with a varying formula.  However, this may require further investigation.  As 
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the constituents of the phenazepam (16) tablets are unknown, it is not understood 
how differences in storage conditions over a period of time may affect the thermal 
profile of the illicit tablets.  The initial investigations in this project have detected 
changes in lactose over a short period of time.  It may therefore be the case that 
some of the phenazepam (16) tablets are linked but were manufactured at varying 
times or have experienced different storage conditions.  Alternatively, it may be that 
there were differences in blend either during manufacture, or due to the small 
amount of sample analysed, the portion tested may not have been fully 
representative. 
In contrast, the cases containing etizolam (7), two of which (cases 132 and 135) had 
been separated by measurements of diameter and weight, were grouped together by 
thermal analysis.  The similarity in thermograms would indicate that there was no 
detectable difference in their excipients by DSC analysis.  As filling of die wells and 
blend are more likely to be effected by human judgement and a difference in 
diameter of 0.01mm may be due to errors of measurement, it may be that there is a 
potential link between cases 73, 76, 132, 135, 151, 155, 157, 158 and 160. 
Interestingly the DSC thermogram separated Case 133 into group 9.  This case was 
noted during the investigation into physical characteristics as bearing markings 
consistent with tablets manufactured by the UK licensed pharmaceutical company 
Actavis.  The tablets in this case had slight discrepancies in both weight and 
diameter with the known Actavis pharmaceutical tablets and also demonstrated a 
greater variation in measurements within the batch.  However, the thermogram 
generated by DSC was consistent with those produced by the known pharmaceutical 
samples.  As mentioned in section ‘6.5.3 – Pharmaceutical Tablets’, the thermogram 
produced by the Actavis pharmaceutical tablets was distinct from all other known 
pharmaceutical samples tested in this project.  This would therefore support the 
theory that Case 133 may contain pharmaceutically manufactured tablets that have 
been diverted into the illicit market.  The thermogram produced by Case 133 also 
revealed only a small indication of the melt of diazepam (1) at 130 oC, which was 
concealed by the 𝞪-lactose monohydrate dehydration.  This supports the findings of 
the HPLC analysis which revealed that the tablets analysed from Case 133 had a 
lower level of diazepam (1), which was rounded up to 9 mg, to allow for errors of 
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measurement.  This adjustment permitted Case 133 to reach the lower level of 
diazepam (1) accepted within the pharmaceutical range.  The reason for the lower 
level of diazepam (1) being present may be due to degradation through age and / or 
storage conditions or the tablets may have originated from a rejected batch. 
The group of tablets consistent with the known pharmaceutical tablets in the 
previous physical and chemical analysis performed in this project (cases 2, 11, 16, 
24, 29, 30, 74, 79, 80, 81, 82, 83, 86 and 156), also produced DSC thermograms 
similar to the known pharmaceutical tablets.  This continued to support the theory 
that these cases may be of pharmaceutical origin but have been diverted into the 
illegal supply chain. 
 
6.6 Conclusion 
DSC analysis into illicit tablets is an innovative use of an established technique and 
no previous work on this type of analysis has previously been published.  It has 
proved to be an interesting and informative technique. It is a quick method of 
analysis requiring little preparation and unlike many of the other analytical methods 
used, which focus on the active drug substance, DSC provides a valuable insight 
into the excipients present within the tablets.  This is particularly important when 
there is only a small amount of drug substance present. 
Experiments have shown consistent results when multiple runs have been performed 
on the same tablet and for different tablets within a case.  The technique was found 
to be sensitive enough to identify different concentrations of diazepam (1) within 
tablets, as can be seen on thermograms produced by two different Roche tablets.  
DSC could identify the tablets that contained diazepam (1) and distinguish between 
those which contained other active substances, alongside those which contain 
lactose as opposed to other diluents such as EmcompressTM.  Thus, DSC has the 
potential to show clear differences between the seized cases as well as showing 
similarities.   
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One of the major benefits of the technique however, is that the thermograms are 
largely influenced by the main excipients present within the tablets.  It may be that 
illicit manufacturers include a variety of active drug substances as they become 
available but if they have a formulation of excipients that work, it is possible that the 
other constituents will remain the same.  This could therefore produce a chemical 
profile which may help to identify potential links between illicit cases.  This analysis 
has therefore proved valuable for distinguishing between batches of seized tablets in 
this project but has also provided an important insight into a technique that deserves 
further investigation for future studies. 
In addition, although this chapter concentrated on visual comparison of DSC 
thermograms, the technique generated a vast dataset, allowing further analysis 
using k-means clustering and Principal Component Analysis (PCA). The statistical 
investigation compared finer detail missed by visual comparison.  Both statistical 
techniques were performed for this project and discussed in Chapters 7 and 8 – 
‘Statistical Cluster Analysis’ and ‘Statistical Differentiation of Pharmaceutically 
Manufactured Tablets’.  This project therefore, presents the benefits of using DSC 
for both visual and statistical analysis, making it a novel and innovative technique 






7.1 Chapter Summary 
The information gained from the physical and chemical tests was used to provide 
data for statistical and chemometric analysis.  Agglomerative hierarchical clustering 
and k-means clustering were used to explore patterns in the data and identify 
potential groupings.  The results of all of the experiments were then added to a heat 
map under the premise that the more individual cases cluster with other individual 
cases, as an indication of the probability of there being a potential link between them 
7.2 Introduction 
Analytical scientific techniques provide vital information regarding the chemical 
content of tablets but simple comparison of drug and excipient content cannot 
necessarily provide information regarding the origin of illicit cases.  During this study, 
chemical and physical examination of illicit and pharmaceutical diazepam (1) tablets 
produced a rich dataset of measurements for each case on a range of variables. 
Within this dataset there are likely to be cases that are related because they were 
produced by the same manufacturer, illicit or otherwise. Cluster analysis uses the 
values in a multivariate dataset such as the one produced in this study to group 
similar observations (cases) based solely on their numerical values on a set of 
variables. 
Statistical techniques involve both supervised and unsupervised methods.  
Supervised methods are used to distinguish between known numbers of groupings 
within the data when examples of each can be provided to build a training set, 
against which future samples can be tested.  Examples of a supervised procedure 
include linear discriminant analysis, which is used in the following chapter to 
distinguish between known pharmaceutical tablets and those of unknown origin. 
Unsupervised techniques are used to investigate patterns within the data without 
prior knowledge of potential groups, allowing clusters to be determined according to 
similarities between the samples alone (Clarke, 2009). In this chapter, cluster 
analysis will be used to reveal groupings within the illicit cases that may suggest 
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relationships between the groups. These groups will be decided objectively using 
only the numerical data produced by the analysis of the tablets’ physical and 
chemical characteristics. 
The clustering techniques used will be agglomerative hierarchical clustering (AHC) 
and k-means clustering. These techniques are well documented for identifying 
batches of illicit drugs, for example hierarchical cluster analysis was used by Ortiz 
(2012) for identifying clusters between illicit viagra and cialis tablets based on 
physical measurements of weight, thickness and length.  In the study, the clustering 
technique clearly separated the cialis tablets into two groups, illicitly and 
pharmaceutically manufactured but, there proved less separation between the viagra 
tablets, where the authentic tablets were grouped with batches of illicit tablets.  
Principal component analysis and k-means clustering were used by Myors (1998) for 
‘heroin fingerprinting’ and hierarchical clustering was also applied using ‘manhattan’ 
distances instead of euclidean.  However, the findings of this study indicated that the 
results were comparable and supported each other. 
In terms of this project, ‘pharmaceutically manufactured’ refers to tablets that have 
been legitimately manufactured for the UK market.   Tablets originating from other 
sources may have entered the illicit market through the internet, making purchases 
from unknown suppliers across the world a viable option.  Therefore, tablets that did 
not bear the markings of a legitimate manufacturer, known to have produced tablets 
for UK consumption, or tablets failing to meet the specifications regarding type and 
quantity of active drug substance, were deemed as illicit for this project. 
7.3 Aim of Statistical Cluster Analysis 
The aim of this study was to find related groups of illicit drugs and potential links 
between illicit and pharmaceutical tablets produced for the UK market by applying 
cluster analysis to the dataset of physical and chemical properties.  Two objective 
clustering techniques were used, AHC and k-means and a subjective visual 




Each clustering technique was carried out twice; one on the physical and chemical 
data and once on DSC thermogram data and combined with the subjective clustering 
produced five grouping outcomes.  Each clustering attempt was carried out 
independently of the others and the results visualised in a heat map. 
7.4 Procedure 
7.4.1 Variables Used in the Analysis 
The method of clustering is an exploratory data analysis method for grouping similar 
observations in multivariate data sets.  In this case, the observations are the cases 
and there were three independent data sets used: 
1. Subjective - colour, markings, general appearance and texture. Chemical 
analysis performed by high performance liquid chromatography was used to 
inform on type and level of active drug substance. 
2. Physical – tablet diameter, thickness, weight and standard deviation of weight 
was also combined with information generated through chemical analysis 
regarding the type of active drug substance and amount of diazepam (1). 
3. Differential Scanning Calorimetry data – 7211 heat flow measurements that 
form a thermogram, supported by the visual appearance of the thermograms 
provided an independent dataset that was heavily influenced by excipient 
content.  
7.4.1.1 Subjective Comparison 
Subjective separation was carried out in order to discriminate between cases 
according to physical appearance.   Initially the seized cases were separated 
according to tablet markings, with thirteen different sets of embossed markings 
revealed. The largest group consisted of twenty-four out of the total sixty-five cases 
and had the overlaid logo MA on one side with D/10 on the reverse (Figure 7.1).  MA 
and D/10 are the markings used by MA Pharmachem, a known pharmaceutical 
manufacturer that has supplied 10 mg tablets for the United Kingdom.  Although 
these tablets are no longer produced by MA Pharmachem, the tablets may have 
been legitimately available at the time of seizure, due to the length of their shelf-life. 
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MA Pharmachem provided specification details of their diazepam (1) tablets along 
with two batches of pharmaceutically manufactured tablets for comparative purposes 
in this study.  Therefore, these tablets became the focus of the statistical analysis as 
a valuable test sample group.   
 
 
Figure 7.1.  Bar chart showing the number of cases marked MA and D/10 and the amount of 
tablets within the cases.  Cases with the MA and D/10 marking are shown in red and those with 
alternative marking are shown in blue.  The named cases on the right of the chart identify 
pharmaceutically manufactured batches analysed for comparative purposes. 
 
The illicit cases bearing the MA and D/10 mark were separated visually according to 
general appearance.  Initially the style and size of font were considered but this was 
soon disregarded after correspondence with MA Pharmachem indicated that the 
company had previously produced tablets with some variability in the character size 
and appearance.  Thus, this feature could legitimately vary between the known 
pharmaceutical tablets. Albeit, this allowance could be made, it was deemed 
unnecessary as the font remained constant within the groups that were identified 
through the visual clustering process.  Two of the cases (case numbers 5 and 25) 
had a chalky appearance and others were a deeper blue (case 73) or more green in 
colour (case 5).  The differences can be seen in Figure 7.2. 
  
Cases bearing the MA marking 
Cases bearing alternate marking 
 
209 
Case 2 Case 5 Case 159 
   
Case 4 Case 73 MA Pharmaceutical 
Tablet 
   
 
Figure 7.2.  Photographs of tablets from different cases taken with the Olympus DSX100 opto-
digital microscope.  The MA pharmaceutical tablet was photographed using a Nikon D5100 
camera with 36mm extension and 5000K lightbox. 
 
 
Data regarding the identification of active drug substance by gas chromatography-
mass spectroscopy (Chapter 4) and quantification of diazepam (1) using high 
performance liquid chromatography (Chapter 5) was analysed in combination with 
the visual differences to gain extra insight.  This allowed tablets containing the 
expected 10 mg of diazepam (1) to be grouped together and those with a higher or 
lower concentration to be placed with one another.  Likewise, the tablets containing 





Figure 7.3.  Bar chart showing the number of available tablets within each case marked MA and 
D10, including the two batches of pharmaceutically manufactured tablets, labelled at the end.  
The blue coloured lines indicate the cases that contained diazepam (1), the green identifies 
those that contained phenazepam (16) and the red represents those with etizolam (7).  
 
7.4.1.2 The Physical Characteristics 
The physical characteristics of the tablets (weight, diameter and thickness) were 
measured three times and the mean of each tablet was added to the database.   
Although, the diameter of the tablets was recorded, there was found to be very little 
variation between the illicit tablets and their known pharmaceutical counterparts.  
Therefore, this was not used in the statistical analysis.  However, data relating to 
tablet thickness and weight was extracted from the database and analysed in 
conjunction with the chemical information regarding drug content and quantification.   
Tablet weight was used in two ways.  Firstly, by comparing the mean weight of the 
tablets in each case and secondly by calculating the relative standard deviation of 
weight from the tablets in each case.  It is acknowledged that only a small sample 
size of four tablets from each case was used for the weight analysis and was found 
to be a limitation of this project.  Case sizes collected by the police are variable and 
the small sample size reflects the fact that many of the cases contained fewer than 
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five tablets (Figure 7.3). Therefore, four tablets were selected from each case in 
order to maximise the number of cases that were available for analysis.  
It was noted that having such a small sample size for weight was a limitation with this 
project.  In order to test the viability of using only 4 tablets from a case, the analysis 
was performed with five different sets of four tablets from each case, when the 
quantities in the case so permitted.  However, this did mean that the cases which 
contained only four tablets continued to use data from the same four tablets.  If the 
four randomly chosen tablets were a representative sample, then the clustering 
should essentially remain consistent. 
7.4.1.3 Differential Scanning Calorimeter  
Pharmaceutical diazepam (1) tablets contain only 10 mg of active drug substance, 
with excipients making up the bulk of the tablet.  The Differential Scanning 
Calorimeter (DSC) measured changes in heat flow against temperature as a sample 
was heated, creating a thermogram based on the data points.   Endothermic and 
exothermic peaks were created according to thermal events taking place in the 
heated sample and varied in location and height according to the substances and 
quantities present (Figure 7.4).  DSC analysis therefore demonstrated the capacity to 
identify differences between tablets based largely on their excipient content (Chapter 
6 - Differential Scanning Calorimetry).  The data points generated by DSC were 
converted to an excel spreadsheet and analysed as an independent dataset.  
Although DSC thermograms ranged from 22 – 240 oC, only the 7211 data points 
relating to the temperatures between 100 oC – 220 oC were used.  This was because 
the lower temperature was affected by evaporation of water and solvent content from 
the samples and degradation manifested at higher temperatures did not characterise 




Figure 7.4. DSC Thermogram of a 10 mg pharmaceutical tablet produced by MA Pharmachem.  
The main peaks are identified but vary in size and location according to the components present. 
 
7.4.2 The Clustering Techniques  
A variety of statistical techniques were applied to the data produced by the physical 
and chemical analyses.  The intention was to demonstrate that the more frequently 
two cases clustered together, the greater the likelihood of there being a potential link 
between the two cases. The clustering techniques used were agglomerative 
hierarchical clustering (AHC) and k-means clustering. AHC utilised the principle of 
single linkage clustering to identify the different groupings, whereby each sample is 
clustered with its nearest neighbour according to euclidean distance.  K-means 
clustering also uses euclidean distance but groupings were determined by 
comparing each object to the cluster mean.   Worked examples of both AHC and k-
means clustering are demonstrated in the Appendix III.   The results of these 
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techniques were combined on a heat map to visualise results and determine whether 
repeats of the same groupings could identify potential links between the cases. 
7.4.2.1 The use of Subjective Clustering 
The physical appearance of the tablets was examined and a subjective assessment 
was made regarding colour and texture of the tablets.  Although description of colour 
is very subjective, noticeable differences between the shades of blue was very 
apparent, allowing tablets to be separated.  Variations in texture was also visible, 
with cases 5 and 25 appearing more chalky.  Again, this was subjective because the 
cause of the powdery nature of the tablets within the cases was unknown and may 
have been due to constituents within the tablet or storage conditions.  
Differences in font were not used for separation because it was acknowledged that 
pharmaceutical companies may use a variety of fonts.  Interestingly, the cases did 
separate according to font when chemical information was added. The identification 
of active drug substance (by GC-MS) and quantification of diazepam (1) (by HPLC) 
allowed further separation to made between the seized cases and all of this 
information combined into five distinct groups. 
7.4.2.2 The use of Agglomerative Hierarchical Clustering (AHC) 
AHC uses a single-linkage technique to classify continuous data, whereby each 
observation (case) starts off as being separated from the rest.  For each step, 
Euclidean distance is used to locate its nearest neighbour(s) and the observations 
are grouped together.  The process continues until all observations are grouped into 
one large cluster (Kogan, 2006).  The number of groups is determined by common 
sense relating to background information relating to the data explored.  For this 
study, the number of clusters was informed by the subjective clustering, in order to 
provide comparable data for the heat map.  However, the dendrograms were studied 
for additional intelligence generated by the data.  
The data was standardized using SPSS to create a Z-score.  This was done to avoid 
the data being weighted towards the higher numbers and allow each variable to 
contribute equally to the result.  Standardization was performed by subtracting the 
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mean from each variable and then dividing the remainder by the standard deviation, 





                                                                                   (Geert van den Burg, R., 2017). 
AHC was performed using SPSS and a range of solutions from 2 - 10 clusters was 
requested, in order to explore any alternative groupings present.  The method of 
nearest neighbour was used and the results were visualised in form of a 
dendrogram. 
7.4.2.3 The use of K-means Clustering 
K-means is a clustering technique used to analyse continuous data through 
Euclidean distance in a similar way to AHC.  However, k-means uses a cluster 
centroid to locate the nearest neighbour.  As observations (or cases) are added to 
the cluster, the centroid is recalculated for the following iteration (Kogan, 2006). 
The number of clusters has to be stipulated by the user based on knowledge of the 
data and background information and no alternatives are provided by the analysis.  
This therefore has the potential of being affected by outliers.  Outliers may be forced 
into clusters with nearest neighbours that may be some distance away, instead of 
forming a new cluster. As the centroid is then recalculated, the nature of the cluster 
is altered and distorted (Liu and Lu, 2015).  This is demonstrated in Figure 7.5. 
 
Figure 7.5.  The effect of outliers on k-means clustering.  In the first diagram two clusters can 
be identified, leaving the outlier.  The cluster centre is marked in red.  In the second diagram, 




The problem of distortion is less of an issue for AHC.  Using AHC, as the clusters 
increase in size new members are connected to the nearest neighbour, not to a 
centroid and cluster distance can be visualised on a dendrogram. Therefore, in order 
to help alleviate the problem caused by outliers, the number of clusters requested for 
the k-means was based on the results of the AHC dendrograms.  K-means clustering 
was performed using SPSS with 20 iterations using running means. 
7.4.3 Heat Map Creation 
The results of each of the clustering techniques were combined in a heat map.  This 
allowed a comparison of results to be performed with the aim of highlighting cases 
that consistently grouped together, given the three independent sets of variables and 
three different clustering techniques applied. 
Two cases consistently clustering together suggests that the two have similar 
features and, in this study, given that the features relate to physical and chemical 
parameters, this implies the tablets have similar chemical and physical features.  It is 
therefore possible that the two cases may be related i.e. they may be produced by 
the same manufacturer or maybe from the same batch. 
 
7.5 Results and Discussion 
7.5.1 Results of Subjective Clustering 
Examination of the tablet appearance in conjunction with chemical data regarding 
active drug substance, allowed the seized cases to be separated into five groups.  
Ten cases clustered in Group 1.  Group 1 cases contained tablets similar in 
appearance to the batches of pharmaceutical tablets provided by MA Pharmachem 
and contained the anticipated 10 mg of diazepam (1). 
The six cases placed in Group 2 contained more than double the expected amount 
of diazepam (1) with over 20 mg and are almost certainly illicitly manufactured.   
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Group 3 contained the two tablets with a chalky appearance but also contained a 
slightly lower level of diazepam (1) (8 mg instead of the purported 10 mg).  Both the 
drug substance level and the tablet appearance may be due to tablet content and 
manufacturing procedure or they may have been affected by deterioration and 
degradation over time.   
Two cases were placed together in Group 4 and four cases in Group 5.  The cases 
in Groups 4 and 5 did not contain diazepam (1) but contained different active drug 
substances, phenazepam (16) and etizolam (7) respectively, which are not licensed 
in the UK and so by definition originate from an illicit manufacturer.  The results of 
the subjective groupings are listed in Table 7.1.   







GROUP 4 GROUP 
5 
DIAZEPAM LEVEL (mg) ~10 >20 ~8 0 0 
OTHER 
CHARACTERISTICS 
  Chalky Phenazepam Etizolam 
CASE NUMBERS 2 13 5 4 73 
 16 26 25 14 76 
 24 31   132 
 29 75   135 
 30 130    
 74 159    
 79     
 82     
 83     




7.5.2 Results of AHC 
7.5.2.1 Active Drug Substance and Physical Data 
Agglomerative Hierarchical Clustering (AHC) was used to define groupings in the 
illicit cases using the variables of the mean weight and relative standard deviation of 
weight from a random sample of four tablets taken from each case and the quantity 
of diazepam (1) measured by HPLC (Chapter 5).  The two batches of known MA 
pharmaceutical tablets MA 061 and MA 064 were analysed alongside the illicit 
tablets for comparative purposes.  
Three clusters were requested in the analysis based on the subjective clustering of 
the MA marked cases. Subjectively these tablets had been separated into five 
groups; however neither cases 4 and 14 nor cases 5 and 25 contained four tablets 
where weight measurements had been available.  Therefore, these cases were not 
included in the AHC or k-means clustering of the physical data combined with the 
diazepam (1) quantification.  As these four cases alone made up two of the groups 
identified by subjective clustering (Groups 3 and 4), it meant that three clusters 
would have been expected, with Group 1 visually grouping alongside the 
pharmaceutical tablets. 
Both standardised and non-standardised data was tested (see section 7.3.2.2. – 
AHC) and the results indicated that when the data was not standardised, the 
diazepam (1) quantification dominated the clusters and the groupings reflected the 
concentration levels.  However, when the data was standardised the majority of 
cases clustered together, with a few outliers. Although the outliers were shown as 
individual groups, clusters could still be identified to support the subjective clustering 
results. This was shown in the dendrograms produced by the AHC of the MA marked 
cases as demonstrated in Figures 7.6 and 7.7.  In Figure 7.6 three clusters can be 
identified at a distance measure of 20, which is shown as a red dotted line.  The 
three clusters represent cases that contained 10 mg of diazepam (1), those with no 
diazepam (1) but etizolam (7) as the active drug substance and cases that contained 
over 20 mg of diazepam (1).  Figure 7.7 shows the same three clusters at a distance 
measure of 4 (shown as a red dotted line) but also identifies two outliers. The 
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number of groups were determined by the euclidean distance chosen. This is an 
exploratory approach and there is no definitive answer about determining the 
distance used.  It is context dependent and is largely decided through logic.  In this 
case, the clusters seen in Figures 7.6 and 7.7 at a distance of about 20 and 4 
respectively are consistent and support the visual groupings; however, outliers 
appear dependent on the tablets chosen. 
 
 
Figure 7.6.  Dendrogram of MA marked tablets using non-standardised data.  The 3 clusters 
stipulated (which can be seen at a distance of about 20, shown by a red dotted line) identify low 
or no diazepam (1) content, the expected 10 mg of diazepam (1) and the cases with a high 
concentration of diazepam (1).   
 





Figure 7.7.  Dendrogram of MA marked tablets using standardised data.  Although groupings 
containing the different concentrations of diazepam (1) can be seen, the three clusters stipulated 
identify one main cluster and two outliers and can be seen at a distance of 10 (blue dotted line).  
However, at a distance of 4 (red dotted line), the identified clusters support the visual groupings 




7.5.2.2 Sample Size Test 
The clustering was repeated using a different random sample of four tablets to 
evaluate whether such a small sample was representative for the case from which it 
was extracted. In total, the test was run five times, with a different sample of four 
tablets taken from each case, every time. The results were similar to previous 
dendrograms (Figures 7.6 and 7.7), which indicated that when a tablet was identified 
in Cluster 1 at a distance measure of about 10, it appeared to support the visual 
groupings, whereas clusters 2 and 3 appeared to be outliers.  The cases identified 
as outliers changed each time, according to the four tablets chosen for the weight 
analysis.  Each case fell within the same grouping each time, unless it was identified 
as an outlier (Figure 7.7).    Table 7.2 shows how many times each of the cases 
clustered in a group other than the main Cluster 1.  Eight of these separations 
occurred during the third run of the test.  The group in which each case clustered is 





Table 7.2.  Cluster membership for each case using five different samples containing four 
tablets.  According to the dendrogram shown in Figure 7.7, groups 2 and 3 appear to be outliers.  
The cases separated from the main cluster changed each time according to the four tablets 
chosen for the weight analysis, indicating some variation within each case. 













No of times case separates from main 
cluster 
2 1 1 1 1 1 0 
13 1 1 1 1 1 0 
16 1 1 1 1 1 0 
24 1 1 1 1 1 0 
26 1 1 3 1 1 1 
29 1 1 3 1 1 1 
30 1 1 1 1 1 0 
31 1 1 1 1 1 0 
73 1 1 2 1 1 1 
74 1 1 1 1 1 0 
75 1 1 1 1 3 1 
76 1 1 2 3 1 2 
79 1 3 1 1 1 1 
82 2 1 3 1 1 2 
83 1 1 1 1 1 0 
86 3 1 1 1 1 1 
130 1 1 1 1 1 0 
132 1 2 2 2 2 4 
135 1 1 2 1 1 1 
159 1 1 3 1 1 1 
MA 061 1 1 1 1 1 0 
MA 064 1 1 1 1 1 0 
 
In effect, the different cases which kept falling as outliers were largely inconsistent, 
with only 3 of the cases being identified as belonging to a different cluster on more 
than one occasion.  Case 132 was the only case identified more than twice, with four 
separate samples being identified as inconsistent with the main group.  These 
findings would indicate that there was some variability in weight between the tablets 
in a single case and therefore a sample set of four would not be ideal for producing 
the most consistent results in this type of analysis.  However, as explained in section 
7.3.1.2 (Physical Characteristics), due to the small number of tablets in some cases, 
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there was little choice but to use a small sample and a compromise was made 
between maximizing number of cases and maximizing sample size. 
For comparative purposes the statistical analysis was also run using all of the 
available weight measurements for every tablet in each case, alongside the drug 
substance content.  This was performed on all MA marked cases containing two or 
more tablet weights.  As this method included cases 4, 14, 5 and 25, five clusters 
could be stipulated.  The results are listed in Table 7.3.   However, as the standard 
deviation of the tablet weight is affected by the number of cases included, this data 
was removed before analysis. 
Table 7.3.  AHC cluster membership for cases marked MA and D/10 using all tablets where a 
weight had been recorded.  The cases marked MA061 and MA064 are tablets from two different 
pharmaceutical batches. 
 Case Numbers 
Statistical 
Analysis 














13,26,31,130,159 75 25 
The results were produced using both standardised and non-standardised data and 
demonstrated some differentiation between cases.  Standardised data generated 
results where clusters 1 and 3 were identical to those formed by subjective analysis.  
Clusters 4 and 5 identified Cases 14 and 25 as being different from other cases and 
cluster 2 contained the cases comprising of etizolam (7) as the active drug 
substance.  However, it also misclassified cases 4 and 5 along with the etizolam (7) 
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cases. Potentially, if these cases were illicitly made, the same formula could have 
been used with different active drug substances, therefore giving a similar weight. 
Case 5, which contained diazepam (1), had been visually grouped with Case 25 due 
to its chalky appearance and Case 4 had been previously clustered with Case 14 as 
they both contained phenazepam (16).    However, the AHC cluster analysis 
categorised these cases as being different.  The difference between the clusters are 
recorded in Figure 7.8.   
The non-standardised data clustered cases 4 and 14, which contained phenazepam 
(16), in Group 2, with the cases containing etizolam (7) and separated case 75.  
 
Figure 7.8.  Dendrogram of all MA marked tablets using all available tablet weights and 
standardised data.  
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The dendrogram of all tablets does contain a variety of case sizes.  The mean of all 
tablets within a case provides a centroid, with the larger cases forming a larger 
population in the cluster and a more accurate centroid on which to base the analysis.  
However, AHC is an unsupervised method of clustering which relies only on 
similarities within the dataset to form clusters rather than previous knowledge of the 
tablet origins, so there can be no certainty that the tablets within the suggested 
groupings bear any relationship with each other, except for their similar properties.   
7.5.2.3 Analysis of Chemical Test Results Generated by DSC 
DSC thermograms show the data generated by heat flow against temperature at a 
given time.  The data related to temperatures lower than 100 oC and above 220 oC 
were removed from the dataset (see section 7.3.1.3 - Differential Scanning 
Calorimeter) and the remaining data was standardised and compared using both 
AHC and k-means clustering.   
Initially the MA marked tablets were tested by AHC and the results indicated that for 
five clusters, all cases tended to group together except for four cases, which formed 
their own individual clusters as shown in the dendrogram in Figure 7.9.  The five 
clusters can be seen at a distance measure of about 13 and is indicated with a red 
dotted line.  The cases clustered individually were numbers 4, 14, 5 and 25, which 
subjective analysis had anticipated as being different but clustered in pairs.  




Figure 7.9.  Dendrogram of the MA marked cases generated using data produced by DSC.  
 
The dendrogram based on DSC data was generated from DSC thermogram data 
alone and contains no further input, such as drug quantification. Each thermogram is 
composed of 7211 sample heat flow values at a temperature between 100 and 220 
oC. The thermogram is based on the reactions of the sample constituents, the 
majority of which are excipients rather than the active drug substance itself.  
Although the five clusters suggested by the subjective comparison are not entirely 
consistent with DSC results, the different clusters are still visible at the smaller 
distances with the subjective groups 1 and 2 being split into two clusters  
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each.  Interestingly, the tablets in Cluster 1, which were considered to be potential 
pharmaceutical tablets in the subjective cluster have been separated.  Due to 
potential errors of measurement and precision, during hplc analysis, all cases found 
to contain between 9-11 mg of diazepam (1) had a reported level of 10 mg for this 
project.  However, in terms of DSC results, the cases which had been found to 
contain around 10 mg of diazepam (1) in the HPLC analysis, clustered very closely 
with the pharmaceutical tablets in DSC clustering.  However, those with a recorded 
weight closer to 9 mg of diazepam (1) during HPLC analysis (cases 74,79,82,83 and 
86), clustered separately based on DSC results.  9 mg is slightly low for the drug 
concentration permitted within the pharmaceutical industry but the level is close 
enough that it may be a result of degradation through ageing of the tablet, or maybe 
due to mathematical or analytical errors e.g. rounding of figures, or experimental 
inconsistencies, therefore they were reported as 10 mg tablets with the potential to 
be pharmaceutical. It is therefore interesting that DSC data identified a variation in 
these cases based largely on the excipient content, when no extra information 
regarding drug substance or quantification was included in this analysis.  Cases 4, 
14, 5 and 25 were notably different to the other cases. 
The nine clusters (including outliers) at a distance of 5 were taken as the results of 
the AHC cluster analysis of DSC data, for the generation of the heat map in section 
7.4.4.  
7.5.3 Results of K-means Clustering 
7.5.3.1 Active Drug Substance and Physical Data 
K-means clustering of the physical data and chemical information regarding active 
drug substance was tested in both standardised and non-standardised form.  This 
was based on the mean weight and standard deviation of weight, along with quantity 
of diazepam (1) from four randomly chosen tablets within each case.   K-means 
produced the same results as the AHC analysis and indicated that non-standardised 
data was heavily influenced by diazepam (1) quantification, whereas standardised 
data produced one main cluster and isolated ungrouped cases.  
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7.5.3.2 Sample Size Test 
The results of the sample size test, where a different four tablets were randomly 
chosen from each case when the required data was available, revealed that the 
cases which clustered apart from the main group were not necessarily identical to 
those separated by AHC.  The results are shown in Table 7.4, which shows that 
fifteen more cases were separated from the main cluster using k-means clustering 
than with AHC.  In each of these fifteen instances, the cases were separated away 
from Group 1 which contained the known pharmaceutical batches.  Interestingly, with 
the exception of Case 29 in the fourth run of the experiment, all of the remaining 
separations were cases which had been subjectively differentiated from the 
pharmaceutical tablets based on the level of diazepam (1) present and the type of 
active drug substance. These cases were therefore likely to be illicitly manufactured 




Table 7.4.  Cluster membership for each case using five different samples of four tablets, 
indicated by AHC and k-means cluster analysis.  The cases separated from the main cluster 
changed each time according to the four tablets chosen for the weight analysis, indicating some 
variation within each case.  Cluster membership that differed between the groupings identified 
by AHC and k-means are highlighted in yellow.  The case numbers at the side are coloured 
according to the subjective clustering technique, whereby the dark blue represents Group 1 
which contain 10 mg of diazepam(1), pale blue represents Group 2 which contain over 20 mg of 
diazepam(1) and the pink represents Group 5 which contain etizolam (7). 





































2 1 1 1 1 1 0 1 1 1 1 1 0 
13 1 1 1 1 1 0 1 1 1 3 1 1 
16 1 1 1 1 1 0 1 1 1 1 1 0 
24 1 1 1 1 1 0 1 1 1 1 1 0 
26 1 1 3 1 1 1 1 1 3 3 1 2 
29 1 1 3 1 1 1 1 1 3 3 1 2 
30 1 1 1 1 1 0 1 1 1 1 1 0 
31 1 1 1 1 1 0 1 1 3 3 1 2 
73 1 1 2 1 1 1 1 2 2 1 2 3 
74 1 1 1 1 1 0 1 1 1 1 1 0 
75 1 1 1 1 3 1 1 1 3 3 3 3 
76 1 1 2 3 1 2 1 2 2 2 2 4 
79 1 3 1 1 1 1 1 3 1 1 1 1 
82 2 1 3 1 1 2 2 1 3 1 1 2 
83 1 1 1 1 1 0 1 1 1 1 1 0 
86 3 1 1 1 1 1 3 1 1 1 1 1 
130 1 1 1 1 1 0 1 1 1 3 1 1 
132 1 2 2 2 2 4 1 2 2 2 2 4 
135 1 1 2 1 1 1 1 2 2 1 2 3 
159 1 1 3 1 1 1 1 1 3 3 1 2 
MA 061 1 1 1 1 1 0 1 1 1 1 1 0 
MA 064 1 1 1 1 1 0 1 1 1 1 1 0 
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Cluster analysis of the weight measurements from every tablet in each case, along 
with data regarding the level of diazepam (1) present indicated that k-means 
clustering was not as discerning as the AHC.  The k-means analysis using 
standardised data misclassified three cases containing etizolam (7) with the 
pharmaceutical tablets (Table 7.5).   However, using the non-standardized data, the 
etizolam (7) cases are separated out, along with the phenazepam (16) tablets and 
the chalky Case 5.  Interestingly, this technique differentiated between the 
pharmaceutical tablets and cases 74, 82, 83, 86 which all contained 10 mg of 
diazepam (1) and had been subjectively comparable. 
Table 7.5.  Cluster membership for cases marked MA and D/10 analysed by k-means and using 
all tablets where a weight had been recorded.  The cases marked MA061 and MA064 are tablets 
from two different pharmaceutical batches. 
 Case Numbers 
Statistical 
Analysis 













13,26,31,75,130,159 74,82,83,86 25 
 
The possibility of Case 5 separating out based on weight was further investigated.  
As this was a seized case, storage conditions may have caused the case to 
deteriorate at a faster speed and resulted in the chalky appearance. The data was 
examined using the tablet measurements and standard deviations as shown in 
‘Chapter 3 - Physical Characteristics’.  The results indicated that the diameter and 
depth of the tablets within Case 5 were slightly larger than the tablets provided by 
MA Pharmachem (Table 7.6).  This resulted in a distinctively heavier weight.  In 
addition, the standard deviations and relative standard deviations of size and weight 
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indicate a greater variation within the case, compared to the pharmaceutical tablets.  
This would therefore suggest that the statistical methods were correct in separating 
out this case from the pharmaceutical tablets. 
 
Table 7.6.   Mean weight and size measurements of tablets within Case 5 in comparison to 
pharmaceutical batches.  Information taken from Chapter 3 – Physical Characteristics. 


















Case 5 8.13 3.11 0.057  1.82 216.3 2.60 1.20 
MA061 8.08 2.59 0.016 0.62 170.7 1.13 0.66 
MA064 8.07 2.65 0.021 0.78 170.3 1.58 0.93 
 
The results of the k-means clustering appeared to be slightly less discerning than the 
AHC.  This is probably because the centroid moves with each addition to the group 
thus causing it to be heavily influenced by outliers, as explained in section 7.3.2.3. – 
k-means Clustering.         
7.5.3.3 Results of K-Means Clustering of DSC Data 
K-means clustering of DSC data was initially performed with five groups requested 
based on the subjective comparison and then on the nine groups indicated by the 
AHC.  
The results of the five group analysis separated cases 4 and 14 but clustered cases 
5 and 25 together (Figure 7.10).  The result of the k-means cluster analysis based on 
the excipients analysed by DSC (Figure 7.10) is compared with subjective clusters in 
Figure 7.11.  As can be seen in the bar charts, ten of the twenty-six cases are 
clustered differently between the two techniques. It is also worth noting that where 
cases seem to cluster differently between these two methods, these differences 
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could also potentially identify further clusters. So, for example, Cases 13, 26, 31 and 
159, which formed part of Cluster 1 for the AHC of the DSC data and part of Cluster 
3 according to the subjective groupings, still form a cluster together.  In addition, they 
also formed part of a cluster together by AHC analysis of the physical data. 
 






Figure 7.11.  K-means clustering of DSC data using MA marked cases.  The case numbers 
have been listed according to groups determined by k-means clustering but have been 
coloured according to clusters indicated by the subjective groupings. 
In order to allow for discrepancies caused through the impact of outliers, as 
explained in section 7.3.2.2 ‘Sample Size Test’, k-means clustering was also run with 
9 clusters as suggested by the AHC dendrogram.   The results of this technique 
meant that the four cases which k-means had clustered with the pharmaceutical 
tablets but had been subjectively differentiated into Group 2, were again separated 
(the four cases listed in the pink section of column 1 in Figure 7.11).  The k-means 
analysis distinguishing nine clusters, separated these four cases (13.26.31 and 159) 
into Cluster 2 (Table 7.7). 
The remaining seven cases that had previously clustered with the known 
pharmaceutical cases were divided between clusters 1 and 5. The reason for this 
separation is unclear, however the larger the number of groups that are requested in 
the method, means the more the data will be teased out, to find differences (Table 





Table 7.7.  The results of K-Means Clustering and AHC of DSC data based on 9 clusters 
suggested by the AHC dendrogram at a distance of 5. 
 
K-Means Clustering Agglomerative Hierarchical Clustering 
Cluster 1 
2, 29, 30, MA 2, 16, 24, 29, 30 MA 
Cluster 2 13, 26, 31, 159 13, 26, 31, 159 
Cluster 3 73, 74, 76, 83, 86, 132, 135 73, 74, 76, 79, 82, 83, 86, 132, 135 
Cluster 4 75,  130 75 










The sample size is a limitation for the statistical analysis of this project and further 
work may be required to determine an optimum number of tablets to be analysed.  
Assessing a higher proportion of tablets in a case improves the reliability of the 
clustering model but many of the cases recovered by the police contain only small 
numbers of tablets.  This is an exploratory technique however, and there is no 
hypothesis test so although repeating and increasing the sample size would be 




7.5.4 Creation of Heat Map 
The results of the subjective, AHC and k-means clustering techniques were 
combined and compared using a heat map (Figure 7.12) which identified the number 
of times different cases clustered together.    The results were based on the tests 
using standardised data and included: 
1. Clustering by subjective comparison + drug identification (GC-MS) + 
quantification (HPLC) 
2. Clustering of cases using data from physical analysis (mean and standard 
deviation of weight) + diazepam (1) quantification by AHC 
3. Clustering of cases using DSC generated data by AHC  
4. Clustering of cases using data from physical analysis + diazepam (1) 
quantification by k-Means clustering 
5. Clustering of cases using DSC generated data by k-means 
 
Given the three independent data sets (subjective, physical and DSC chemical) and 
the three types of cluster analysis performed (subjective, AHC and k-means), there 
was a low chance of multiple grouping if there was no connection between the 
cases.  The probability of two cases clustering repeatedly is illustrated by calculating 
that if case x was in a given cluster, the probability of case y being in the same 
cluster would be 1/5 (given 5 clusters are produced, based on the subjective cluster 
analysis).    For every pair of cases, the clustering event will have one or other of two 
binary outcomes i.e. the cases cluster together (p) or they do not cluster together (1-
p) where p is the probability of the cases clustering together by chance alone.  The 
results of one trial do not influence the results of the remaining trials. There are still 
only two possible outcomes for each trial and the probability of these outcomes 
remain constant (The Open University, 2009).   This is comparable to the binomial 
calculation demonstrated by independent flips of a coin attaining the same result 
(Imrey, 2000). 
For 3 clustering events (1 with each independent data set) the probability would be 
calculated using the binomial model: 
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n = number of trials (3) 
k = number of successes 
p = probability of success in one trial (0.2) 
q = 1-p = probability of failure in one trial 
n-k = number of failures 
Therefore for two cases to cluster together in each of the three events, the 
probability would be:  
3 successes in 3 trials =  (3
3
)0.230.83−3 











3 𝑋 2 𝑋 1
3 𝑋 2 𝑋 1 𝑋 0!
 
 
As 0! = 1   and 3! / 3! = 1 
(1)0.230.80 
= 1 x 8x10-3x1 
= 8 x10-3 
Therefore the probability of 2 cases clustering together on 3 occasions is 8 x10-3. 
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For two cases to cluster together twice in the three trials, the probability would be: 













3 𝑋 2 𝑋 1




= 3 x 0.04 x 0.8 
= 9.6 x10-2 
Therefore the probability of two cases clustering together on two occasions is 9.6 
x10-2. 
For two cases to cluster together once in the three trials, the probability would be:
  













3 𝑋 2 𝑋 1








Therefore the probability of two cases clustering together once during the three trials 
is 0.384. 
These calculations are based on five clusters being produced by each set of data. 
However, as the AHC and k-means clustering of DSC data generated nine clusters, 
the probability would have been lower with p = 0.11 and q = 0.89 for those two 
results. 
The probability of the cases clustering together randomly with no connection is 
therefore small and suggests a potential link between them.  A connection between 
clustered cases could indicate that the cases were produced in the same laboratory 
or possibly manufactured by the same processes. 
The heat map (Figure 7.12) shows that five cases matched with the pharmaceutical 
tablets on a minimum of four out of five trials.  This would suggest that there is a 
strong connection and cases 2, 16, 24, 29 and 30 could be of pharmaceutical origin.  
However, the results are not entirely clear cut. Case 79, for example, clusters as 
many times with Cases 74, 83 and 86 and more times with Case 82 than with the 
known pharmaceutical tablets.  These are the remaining cases that had been 
subjectively clustered as potential pharmaceuticals.  Interestingly, these cases, along 
with Case 79 are also the cases which were given a reported level of 10 mg of 
diazepam (1) according to hplc analysis but were recognised as different to 
pharmaceutical tablets, based on DSC thermograms.  The origin of these tablets is 
therefore still uncertain.  It is possible that they may be well made counterfeits or 
degraded pharmaceuticals. 
The heat map also identifies potential links between other cases, such as Cases 73, 
76, 132, 135, which contain etizolam (7). There may also be a possible connection 
between Cases 13, 26, 31 and 159; and between 74, 83 and 86 all of which cluster 






Figure 7.12. Heat map showing a pairwise comparison of all cases.  Five different approaches to clustering were carried out and the numbers show 
the frequency that particular pair of cases were allocated to the same cluster out of a maximum of five clustering attempts.  The frequencies are 




The aim of the cluster analysis was to clarify the results of the physical and chemical 
tests on the seized cases, with the intention of distinguishing between the 
pharmaceutical and illicitly made tablets. In addition, it was hoped that potential links 
between illicit cases would emerge.  Despite the limitations posed by sample size, 
several groupings were found. For example cases 2, 16, 24, 29, and 30 were 
identified as potentially being of pharmaceutical origin.  In addition, links between 
illicit cases, such as Cases 13, 26, 31 and 159 were demonstrated by these cases 
matching in all five tests.  However, further background information would be 
required to support any connection but this information could prove useful to the 
police. 
Ideally a larger sample size would have been beneficial in terms of providing a more 
accurate mean or centroid on which to calculate the statistics.  It could also allow 
further information to be added to the heat map by performing further analytical tests.  
This would help to clarify any results.  However, the technique of combining all of the 
analytical and statistical results in a heat map has demonstrated great potential in 
identifying potential links. 
As some of the cases grouped together it indicates that there may be a link between 
them.  It is possible that tablets that grouped together were manufactured together.  
Some of the seized cases clustered with the pharmaceutical batches a number of 
times and therefore raises the possibility that they are pharmaceutically made.  
Pharmaceutical tablets enter the illicit market by a number of methods. A report into 
countering the problem posed by falsified and substandard drugs, commented that 
prescription medicines change hands many times between manufacturer and 
pharmacist, providing many opportunities to divert the tablets (Institute of Medicine, 
2014).  It was commented that tablets may be stolen at source, from a pharmacy, or 
by people selling their own, friends or relative’s prescription medication, with those 
stolen closer to source usually providing a much larger quantity for illicit sales. 
Therefore, illicit cases may be pharmaceutically manufactured but not directly 
prescribed.  It was also noted that many diverted pharmaceutical products 
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deteriorate over time due to incorrect storage and handling conditions (Institute of 
Medicine, 2014). 
Although the heat map can suggest that potential links exist, it cannot determine if 
the seized cases containing 10 mg of diazepam (1) are of pharmaceutical origin.  It 
could therefore be beneficial to further explore the potential pharmaceutical tablets in 
order to investigate differences and similarities between them and the genuine 
pharmaceutical tablets.  One method of performing this would be to use supervised 
statistical methods.  By using data produced by tablets known to be illicitly 
manufactured and known pharmaceutical tablets, a training model can be built.  This 






8.1 Chapter Summary 
In order to further examine the seized cases which contained approximately 10 mg 
of diazepam (1), a smaller test sample was chosen.  As the tablets could not be 
differentiated from the pharmaceutical tablets based on physical characteristics or 
type and quantity of active drug substance, the data from DSC was analysed by 
chemometric methods.  DSC was chosen because the thermograms generated were 
largely influenced by the excipient content of the tablets.  The data points were 
explored by principal component analysis and linear discriminant analysis to 
determine if any differences could be found between the pharmaceutically 
manufactured tablets and the seized cases.   
 
8.2 Introduction 
8.2.1 Tablet Classification 
Tablets may be classified based on their physical or chemical properties raising the 
possibility that legitimately produced tablets can be identified amongst illicit seizures 
of tablets.  Pharmaceutical tablets will possess certain properties such as correct 
markings and amount and type of active drug substance but well-made counterfeit 
tablets may also satisfy these requirements so additional aspects of the tablet’s 
contents such as the excipient may help to distinguish pharmaceutical tablets from 
illicitly made tablets. 
8.2.2 Rationale Behind the Statistical Methodology 
The aim of this part of the study was to compare the physical and chemical 
properties of a group of twenty-four illicit tablet batches with MA markings to ten 
known pharmaceutical tablets to see if there were any illicit tablets that could 
plausibly have been manufactured by a pharmaceutical company.  The first objective 
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was to separate out all tablets with MA markings then identify and quantify the active 
drug substance. This used the results of the gas chromatography mass spectrometry 
(GC-MS) analysis to isolate the cases that contained diazepam (1) and high 
performance liquid chromatography (HPLC) to identify those tablets that contained 
the pharmaceutical level of around 10 mg of diazepam (1).  
The second objective was to investigate further those cases that could not be 
distinguished from the pharmaceutical tablets based on markings and active drug 
substance alone.  The Differential Scanning Calorimeter (DSC) was used to 
investigate the excipient content of the tablets.  Excipients comprise of all the 
formulated components of a tablet excluding the active drug substance and can 
include fillers, glidants and binders for example.  Each tablet manufacturer chooses 
the excipients used in their manufacturing process, which means the excipient 
content of tablets with the same amount and type of active ingredient can differ 
between companies.  Information regarding excipients could therefore help to 
determine the authenticity of illicit cases because if there is a variation in excipient 
content between seized cases and pharmaceutical tablets bearing the same marking 
or logo, this discrepancy could support an argument for the illicit cases having been 
manufactured in a clandestine laboratory.  By analysing the tablets with DSC, a 
thermal profile is generated which is heavily influenced by the more abundant 
components within each tablet.  In the case of diazepam (1) tablets, this is largely 
the excipients.  The thermograms produced can then be compared both visually and 
by statistical and chemometric analysis. 
The third objective was therefore to compare DSC thermograms produced by the 
illicit and pharmaceutical tablets using multivariate statistical techniques and develop 
a simple model that could be used to distinguish between MA-marked cases that 
have been pharmaceutically or illicitly manufactured. 
8.2.3 Choice of model 
A thermogram is a plot of several thousand heat flow measurements taken at given 
temperature points between 100 and 250 oC, from a single observation or tablet.    In 
this study, the heat flow measurement at each temperature is considered an 
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independent variable and the dependent variable is the binary classification of known 
pharmaceutical or other manufacturer.  The DSC procedure produces a multi-
dimensional or multivariable dataset across the whole temperature range examined 
with each temperature point considered a variable.   The final dataset consisted of 
7211 variables for each of the 34 observations.  However, with such a data set, there 
is a high degree of correlation between the variables.  Correlation between the 
explanatory variables creates problems for statistical modelling techniques such as 
regression techniques and linear discriminant analysis, which constructs a 
discriminant value based on finding significant variables within the dataset that are 
related to the dependent variable or, in this case, classification group. Correlation 
can lead to important variables being ignored as insignificant, in favour of alternative, 
correlated variables.  The variables chosen could therefore be defective in 
representing the true importance of the data, thus creating an unstable and 
inaccurate model (Hosmer and Lemeshow, 1989). High-dimensionality and 
multicollinearity can be addressed by using Principal Component Analysis (PCA) to 
reduce the number of dimensions and produce a number of uncorrelated 
components. 
PCA is an unsupervised statistical method, whereby no information regarding 
potential groupings is included in the analysis.  PCA uses correlation in the 
independent variables to reduce the dimensionality of the dataset but retains most of 
the variation of the original dataset within a much smaller set of principal 
components (PC).  This is done by using the data on p variables for n observations 
so that the first PC (Z1) is then a linear combination on the variables X1, X2 …Xp, 
which maximizes the variation between the observation such that  
Equation 1 
Z1 = a11X1 +a12X2 ….+a1pXp    
 and  
Equation 2 
 (a11)2 + (a12)2 + …. (a1p)2  = 1 
 
244 
This is repeated for the remaining principal components so that Z1, Z2, Z3… Zn have 
zero correlation.  A worked example of Principal Component Analysis can be seen in 
Appendix III. 
Once the principal components have been calculated, the number of principal 
components that account for about 90% of the variation in the dataset (in the study 5 
principal components) were used as the variables in the discriminant analysis where 
they are combined according to equation 1 to calculate the discriminant value (D). 
Equation 3 
 D = ((b1PC1) + (b2PC2) + (b3PC3) + (b4PC4) + (b5PC5) + c) 
Where the discriminant function coefficients of the first five principal components of 
DSC data are represented by b1 to 5 and c is a constant associated to the Y-intercept 
of the regression line (Brown and Wicker,2000).  
The first component represents the largest percentage of the variation in the dataset 
and each subsequent component represents a smaller proportion.  Frequently 90% 
of the data variation resides in the first few components (The Open University, 2007).  
This means that most of the variation in the dataset can be visualised by plotting the 
values of the observations on a small number of PCs.  Each component, thus 
allowing visualisation of patterns within a compressed form of the original dataset.   
Principal Component Analysis is a widely used technique that is often favoured for 
exploring spectra because of its ability to compress large data sets by integrating 
correlated dimensions. Klara Dégardin used Raman Spectroscopy and PCA to firstly 
identify counterfeit tablets and then to investigate links between the illicit tablets and 
historical cases.  The PCA was particularly beneficial for finding clusters by plotting 
the principal components to visualise the data (Dégardin et al., 2011). The number of 
principal components required depends on the data and constituents involved. A 
recent study by Risoluti only required the first two principal components to be plotted 
in order to differentiate between two groups of New Psychoactive Substances (NPS) 
(Risoluti et al., 2016).  However, it has been noted that only a portion of the variation 
can usually be visualised with PCA alone (NicDaéid and Waddell, 2005).   Dégardin 
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used PCA to gain an initial insight into potential clusters of pharmaceutical and illicit 
tablets before following it up with supervised statistical methods (2016).   
Once the dataset has been compressed, the principal components can be used as 
surrogate explanatory variables in follow-on modelling procedures such as linear 
discriminant analysis (LDA). LDA is a method that uses low-dimensional data to 
highlight differences between subgroups. Information regarding the properties of the 
subgroups, whose classification is already known, is then used to create allocation 
rules which enable predictions to be made regarding the groupings of new 
observations (The Open University, 2007; Brown and Wicker,2000). 
The supervised technique of Linear Discriminant Analysis (LDA) was used by 
Johnston and King (1998), to detect links between heroin samples by analysing the 
levels of alkaloids and adulterants in the sample.  This ultimately led to some 
success in predicting their country of origin.   LDA was also applied to discrimination 
of young drug and fibre type cannabis plants according to chemical composition of 
their leaves as identified by GC-MS.  This technique classified observations correctly 
with 89% accuracy (Broséus, Vallat and Esseiva, 2011).  Similarly, LDA with leave 
one out cross validation was used to classify saffron into its geographical area of 
origin based on chemical constituents identified through HPLC analysis. Although it 
proved more difficult to distinguish between geographical areas that were closer 
together which, increased the misclassification rate (D’archivio et al., 2016).  Lesiak 
(2014) used LDA to distinguish between Mitragyna speciosa and other plant species 
based on the mass spectral data generated by Direct Analysis in Real Time - Mass 
Spectrometry (DART-MS), with 99% accuracy. 
In a study investigating counterfeit medicines, Dégardin used a variety of statistical 
techniques for distinguishing between samples.  This included PCA and Receiver 
Operating Characteristic (ROC) curves.  However, the most effective analysis 
resulted from studying a variety of information gained from all available resources, 
including police reports, in order to identify potential links (Dégardin et al., 2011). 
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In this chapter, I describe how data from DSC thermograms were used to develop an 
allocation rule to distinguish between pharmaceutical and non-pharmaceutical 
tablets using a combination of PCA and LDA. 
8.3 Aim of Statistical Model 
The aim of this section was to devise a model that could distinguish between illicit 
cases of MA tablets and known, pharmaceutically manufactured 10 mg diazepam 
tablets.  This first step was to examine the tablet type and quantity of diazepam (1) 
present, allowing classification of those tablets that did not contain 10 mg of 
diazepam (1) as non-pharmaceutical.  The second step used data from DSC 
thermograms and linear discriminant analysis to create a model that distinguishes 
pharmaceutical tablets with 10 mg of diazepam (1) from illicit, 10 mg diazepam (1) 
tablets.   
8.4 Analytical Procedure Employed 
8.4.1 The MA/D10 Test Group 
Visual examination of the tablets revealed that twenty-four of the sixty-eight illicit 
cases bore the markings MA/D10.  The number of cases of this design is illustrated 
in Figure 8.1.  These markings relate to a recognised pharmaceutical company, MA 
Pharmachem, which provided 10 mg diazepam (1) tablets for the United Kingdom.  
Although MA Pharmachem no longer produce diazepam (1) tablets, these tablets 
may have still been legitimately available at the time of seizure due to the length of 











Twenty-four illicit cases had the MA marking and relevant data regarding tablet 
weight and specifications was provided by the pharmaceutical company, along with 
two batches of pharmaceutically manufactured tablets for comparative purposes.  
The statistical analysis used physical and chemical data from all of the twenty-four 
illicit cases containing tablets marked MA and D/10, to assess whether these cases 
had the same properties as the pharmaceutically manufactured tablets. 
8.4.2 Pharmaceutical and Non Pharmaceutical Tablets 
The twenty-four illicit cases of MA tablets could have either been produced illicitly or 
pharmaceutically manufactured but then diverted into the illegal supply chain.  For 
the purposes of this project, ‘pharmaceutically manufactured’ refers to tablets that 
were produced legitimately for the UK market.   Illicit tablets may have been imported 
from other sources via the internet and could include either clandestine laboratories 
or pharmaceutical companies in other countries.  However, if the tablets did not meet 
the manufacturers’ specifications and therefore were not believed to be legitimately 
manufactured by pharmaceutical companies (MA Pharmachem in this instance) for 
UK consumption, the tablets were deemed as illicit.  
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8.4.3 Separation of Illicitly Manufactured Tablets 
8.4.3.1 Identification of the Active Drug Substance by GCMS 
Chemical analysis by Gas Chromatography-Mass Spectroscopy (GC-MS) showed 
that not all the twenty-four illicit cases marked MA/D10 contained diazepam (1).  Six 
cases contained phenazepam (16) or etizolam (7) and were automatically deemed 
illicitly manufactured tablets without consideration of properties since these active 
drug substances are not licenced within the UK. These cases were included in the 
remainder of the study as examples of illicit tablets.  The remaining 18 cases 
contained diazepam (1) and were then analysed by HPLC to ensure the quantity of 
active drug substance was consistent with the manufacturer’s specification (Figure 
8.2). 
8.4.3.2 Quantification of Diazepam by HPLC 
High Performance Liquid Chromatography (HPLC) was used to quantify the 
diazepam (1) content in the remaining 18 illicit cases.  Six of the illicit cases 
contained over 20 mg of diazepam (1) and two contained approximately 8 mg.  The 
tablets in these cases did not meet the manufacturer’s specification for quantity of 
diazepam (1) and were classified as non-pharmaceutical, leaving ten cases with the 
correct type and quantity of active drug substance and the potential to have been 





Figure 8.2.   Flow chart showing the separation of cases that had been illicitly manufactured. 
The latter group of illicit tablets were labelled the ‘unknown’ group because they 
were illicit seizures but their diazepam (1) content was indistinguishable from 
pharmaceutical tablets and based on this information alone, they could have been 
either illicitly manufactured or pharmaceutically manufactured but diverted into the 




8.4.3.3 Excipient Analysis using DSC 
The next step was to explore the excipients in the illicit cases to identify those that 
corresponded with the pharmaceutical tablets.  As each tablet weighed 
approximately 270 mg and contained around 10 mg of diazepam (1), the bulk of the 
tablets were comprised of excipients.  Excipients include all of the constituents 
added to a tablet apart from the active drug substance.  Pharmaceutically 
manufactured diazepam (1) tablets in the UK contain a large quantity of lactose that 
increases the tablet size and makes it easier to handle.  Although other excipients, 
such as lubricants and binders are also present, the large quantity of lactose is a 
strong influence on Differential Scanning Calorimetry. 
Results produced by the Differential Scanning Calorimeter (DSC) for this project, 
demonstrated that individual cases could be differentiated based on excipient 
content (Chapter 6 Differential Scanning Calorimetry).  DSC measures the difference 
in heat flow between a sample and a reference pan.  The heat flow is plotted against 
temperature to create a thermogram, as demonstrated in Figure 8.3 (also see 
Chapter 6).  A thermogram was produced for each of the twenty-four cases of illicit 
tablets marked MA and for 10 pharmaceutical MA tablets. 
The temperature on the thermograms ranged between 22 – 240 oC (Figure 8.3) but 
as the lower temperatures (<100 oC) reflect solvent and water loss from the tablet 
rather than the thermal characteristics of the substances present, this area of the 
thermogram was removed prior to the statistical analysis.   Likewise, degradation of 
the sample dominated higher temperatures so did not represent particular 
characteristics of the substances present and were not included in the analysis. 
Therefore, the statistical analysis used only the temperature range from 100 - 220 oC 
(Bibi et al., 2015).  Each thermogram comprised thermal flow measurements at 7211 





Figure 8.3.  DSC Thermogram indicating the temperature regions dominating each of the first 
five principal components.  
 
8.4.3.4 Reducing DSC dataset dimensionality with Principal Component 
Analysis (PCA) 
Examining the type and quantity of active drug substance had left ten illicit cases that 
were indistinguishable from pharmaceutical tablets so the next phase of the study 
was to develop a linear discriminant analysis (LDA) to distinguish between these two 
groups using DSC data that reflected the excipient content of the tablets.  DSC 
analysis produced a high dimensional, multivariate dataset however, having such a 
large number of variables leads to problems of multicollinearity and overfitting of 
statistical models.  Having correlated independent variables in an LDA model limits 
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the discriminatory power of the variables leading to an unstable model.  An ideal 
model is a parsimonious model with a small number of highly discriminating 
variables, therefore in order to achieve this, principal component analysis (PCA) was 
used to render the 7211 temperature variables in the DSC dataset to a small number 
of uncorrelated components (Garson, 2012).  Therefore, Principal Component 
Analysis (PCA) was performed on the thermal data produced by DSC, using the “R” 
statistical programming language (The R Foundation, 2017).  Thirty-four principal 
components were generated, with 79% of the variation contained in the first three 
components.  Ideally, the analytical variation should be higher but 90% variation was 
not reached until the fifth component.   Five components were therefore used as 
explanatory variables in the LDA model but since five dimensions are not easily 
visualised, only the first three dimensions (79%) of the variation are shown in the 
PCA plots (Figure 8.5).  The variances attributed to the first five principal 
components are shown in Table 8.1.  The principal components that dominated 
different regions of the DSC thermograms are shown in Figure 8.3. 
Table 8.1.  The variance in the first five principal components. 
Component % Variance Cumulative % 
1 57.09 57.09 
2 14.16 71.26 
3 7.55 78.81 
4 5.98 84.79 
5 5.79 90.58 
 
8.4.3.5 Visualisation of the Results of Principal Component Analysis  
Principal Component Analysis (PCA) was carried out on the DSC dataset that 
incorporated all illicit cases with MA markings and the ten known pharmaceutical 
tablets.  The results of the PCA on all cases were visualised using Miner 3D (Figure 
8.4).  This visualisation of the dataset shows the first two principal components of the 
DSC data and the quantity of the active drug substance diazepam (1), present in the 




Figure 8.4 Miner 3D image showing PCA results of the DSC data.  The first two principal 
components plotted against the level of diazepam (1).  Groupings can be identified according to 
the active drug substance (identified by GC-MS and colour-coded) and the amount of diazepam 
(1), where present (quantified by HPLC).   The tablets labelled as ‘Non-Pharma’ contain levels of 
diazepam (1) that do not meet pharmaceutical specification.  Tablets containing a different active 
drug substance are labelled ‘phenazepam’ (16) or ‘etizolam’ (7) according to the GC-MS results.  
Unknown tablets (illicit tablets with 10 mg of diazepam (1)) and genuine pharmaceutical tablets 




There are clear groupings in the illicit tablets (Figure 8.4) depending on the 
diazepam (1) content and the active drug substance.  The genuine pharmaceutical 
tablets are illustrated in red as a separate group.  However, these groups are not just 
distinguishable by their active drug content.  The tablets can also be separated by 
their values on PC1 and PC2 from the DSC data.   For example, the PC1 values 
range between 79 to 113 for tablets containing etizolam (7), -100 to -47 for tablets 
containing phenazepam (16) and between -110 to -25 for pharmaceutical tablets, 
while the PC2 values range between -4.5 to +5 for tablets containing etizolam (7), 65 
to 80 for tablets containing phenazepam (16) and between -30 to +2.5 for 
pharmaceutical tablets. This separation indicates variation in the excipient content as 
well.  
Two groups could not be distinguished using active ingredient content alone; these 
groups were named unknown tablets and genuine pharmaceutical tablets.  As the 
level of diazepam (1) present in the pharmaceutical tablets and unknown tablets was 
similar, the quantity of drug substance was no longer useful in discriminating 
between the groups of interest in this analysis but these two groups clustered 
separately on the PC1 and PC2 axes from DSC analysis which represented the 
excipient content.  Separation between these two groups was clearer if the DSC data 






Figure 8.5. Miner 3D image showing separation between the pharmaceutical (red) and 
unknown (green) cases based on the first three principal components of the DSC data.  
The subjective impression of the image illustrated in Figure 8.5, shows that there is 
separation between the two groups, based on the DSC data. Therefore, the 
hypothesis that the two groups of tablets could be distinguished based on their DSC 
thermogram alone, was investigated further using linear discriminant analysis. 
8.4.3.6 Application of Linear Discriminant Analysis 
The next step was to separate the pharmaceutical tablets from the unknown tablets.  
A variety of statistical techniques are available for classification purposes, including 
binary logistic regression.  However, Linear Discriminant Analysis (LDA) is generally 
simpler to use and does not undergo the level of iterations that slow down the 
calculations in the logistic regression.  LDA is also more precise in its results as long 
as the assumption of normality is met (Tufféry and Tuffery, 2011).   
The dataset is first split into two subsets; a training set and a test set.  To 
discriminate between groups of observations, an LDA model is produced using 
samples from the training set where the classification is known and a classification 
rule can be formulated.  The quality of this classification rule is assessed by applying 




The group used for testing the model was comprised of data from two randomly 
chosen cases containing illicit tablets and one tablet taken from each of the two 
batches provided by MA Pharmachem.  The remaining illicit cases and an equal 
number of pharmaceutical tablets comprised the training set.  The stratagem used to 
distinguish between illicit cases and those with the potential to have been 
pharmaceutically manufactured, is demonstrated in Figure 8.6. 
 
Figure 8.6.   The stratagem for discriminating between tablets which had been illicitly and 
pharmaceutically manufactured. The numbers of illicit tablets used to build and test the model 
were matched with pharmaceutical tablets. 
The independent variables used for the linear discriminant analysis were the first five 
components of the PCA carried out on the DSC data. Monfreda (2015) chose to use 
the first ten principal components for analysis into cocaine and gave equal weighting 
to the data generated by the alkaloid and residual solvent.  For this study, five 
components were used for Model 1 because this contained 90% of the variation from 
 
258 
the original dataset. A second model using only PCs 1, 2 and 5 was also tested as 
an alternative.  The second model was developed because two PCs were found to 
have no significant discriminatory power (Table 8:10) and were therefore removed to 
form a more parsimonious model (model 2).  This is discussed in Section 8.4.6 
‘Suitability of Data’. 
The analysis was performed with principal components that were both weighted and 
unweighted by the proportion of variance determined by the PCA.  This was to reflect 
the difference in discriminating power of each of the components.  However, 
although both methods were attempted with only slight differences in the figures, the 
results were the same and so only the results from the weighted data is shown 
below. The weighting was applied by multiplying the principal component values by 
their % variation prior to using them as independent variables for the LDA.  
8.5 The Statistical Model Applied 
8.5.1 Aim of the Analysis 
The aim of the linear discriminant analysis was to see if the DSC thermograms and 
hence the excipient content of the group of unknown tablets could be distinguished 
from pharmaceutically manufactured tablets.  If unknown tablets were 
indistinguishable from the pharmaceutical tablets, this could indicate that 
pharmaceutical tablets had been diverted into the illicit market.  If the groups were 
distinct, a number of possible explanations could exist:  
1. Unknowns were not pharmaceutically manufactured 
2. Unknowns were pharmaceutically manufactured with a slight difference in 
formulation 
3. Unknowns were pharmaceutically manufactured but the formulation had 




8.5.2 Results of Linear Discriminant Analysis 
Linear discriminant analysis creates a discriminant function (D), which is a weighted 
combination of the independent variables in the dataset, in this case, PC1 – PC5 of 
the DSC data variables.  A value (D) for each observation (tablet) on the discriminant 
function is determined and based on this value, an allocation rule was created to 
separate the tablets which share the characteristics of the pharmaceutical tablets 
and those which do not. The discriminant values for each observation in the training 
dataset were determined according to equation 1, where a1 to 5 are the discriminant 
function coefficients for the first five principal components of the DSC data and c is a 
constant related to the Y-intercept of the regression line (Brown and Wicker,2000).  
Equation 3 
 D = ((b1PC1) + (b2PC2) + (b3PC3) + (b4PC4) + (b5PC5) + c) 
In terms of the models used for this project, the equations translate as: 
Model 1 
D = ((PC1 x 0.031) + (PC2 x 0.089) + (PC3 x -0.17) + (PC4 x 0.107) + (PC5 x 0.035) 
+ 0.573). 
Model 2 
D = ((PC1 x 0.023) + (PC2 x 0.086) + (PC5 x 0.027) + 1.378). 
 
8.5.3 Allocation Rules 
The discriminant function values (D) were then used to establish an allocation rule.  
There are a number of ways this allocation rule can be calculated but three simple 
approaches were compared in this study. The first method used the average of the 
central D values for each group as a cut-off point. This is the default method used in 
SPSS and the independent variables are weighted such that the average for the 
centroid values of the two groups is zero.   
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Secondly, 95% confidence intervals for the mean D value for each group were 
calculated and a cut-off point for group allocation was determined as the midpoint 
between the lower 95% confidence limit of the mean D value for outcome = unknown 
and the upper 95% confidence limit of the mean D value for outcome = 
pharmaceutical (Figure 8.7).   
 
Figure 8.7.  Box plot of the D values.  The green dotted lines indicate the lower boundary of the 
95% confidence interval for the mean D value for the unknown group and the upper boundary of the 
95% confidence interval for the mean D value for the pharmaceutical group.  The blue line indicates 
the average value for these boundaries and the cut-off lines at 0.22 for model 1 and 0.23 for Model 
2.as blue lines. 
 
The final allocation technique involved the creation of a Receiver Operating 
Characteristic curve (ROC), which plots sensitivity vs 1-specificity from the predicted 
allocations for various values of D.  A cut-off value of D was selected that maximized 
the sensitivity and specificity of the predicted allocations.   
8.5.3.1 Investigation of Centroids 
Using discriminant analysis on SPSS, the default setting gives weight to the 
centroids creating a midpoint of “0”, which is used as the demarcation between the 
different types of tablets.   Cases that are evaluated with a discriminant function 
value above “0” are classified as being of unknown origin and those which are 
evaluated below “0” are classified as being of pharmaceutical origin.   
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Allocation rule 1:     




The discrimination value of “0” misclassified one of the known pharmaceutical tablets 
as being of unknown origin, thus resulting in a sensitivity value of 0.875 and a 
specificity of 1. The closer the sensitivity and specificity are to 1 reflects the closer 
the results are to the original classification. The results of models 1 and 2 are shown 
in Figure 8.8 and the corresponding data in Table 8.2. 
8.5.3.2 Investigation into Confidence Intervals 
The 95% confidence intervals were calculated for the unknown cases and the 
pharmaceutical tablets using SPSS. The midpoint between the lower confidence 
interval of the D value of the data for the unknown cases and the upper confidence 
interval for the pharmaceutical data was taken as the demarcation value.  
Allocation rule 2 (model 1): 




Allocation rule 2 (model 2): 




The use of the confidence intervals in determining a cut-off point resulted in one of 
the known pharmaceutical tablets being misclassified as unknown. This again 
resulted in a sensitivity value of 0.875 and a specificity of 1.  The results are shown 







Figure 8.8.   Histograms showing the separation of the unknown cases from the cases that were 
known to be pharmaceutically manufactured and their normal distribution curves.  The two blue 
lines identify the centroids for each type and the default discrimination line of 0, midway 
between the centroids, which was used in method 1 and is marked by the red dotted line.  The 
dotted green lines represent the 95% Confidence Interval boundaries used to determine the cut-
off point used to separate the two types of tablet in method 2. The cut-off point is shown as the 
black line at 0.22 for Model 1 (Figure 8.8a) and 0.23 for Model 2 (Figure 8.8b).   
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Table 8.2.  Results of allocation rules.  The original classifications indicate whether the tablet 
was taken from one of the seized cases (unknown origin) or provided by the pharmaceutical 
manufacturer.  Under each model description is the result of the statistical groupings and shows 
that one pharmaceutical tablet was misclassified using the first two methods but the ROC curve 
correctly identified all of the tablets.  Model classification uses the data in the dataset used to 
train the LDA model. 
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Unknown Origin 8 1 8 1 
Pharmaceutical 0 7 0 7 
 Sensitivity 0.875 0.875 
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Unknown Origin 8 1 8 1 
Pharmaceutical 0 7 0 7 
 Sensitivity 0.875 0.875 








































1.00 1.00 1.00 1.00 
Model 
Classification 
Unknown Origin 8 0 8 0 
Pharmaceutical 0 8 0 8 
 Sensitivity 1 1 
 Specificity 1 1 
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8.5.3.3 Receiver Operating Characteristic curve (ROC) Analysis 
The final allocation rule used a ROC curve, which operates a balance between 
sensitivity and specificity, to determine a cut-off point between the two groups and 
the discrimination value is chosen as the point that maximises both sensitivity and 
specificity.  According to the dataset used to train the LDA model, this value of D was 
D = 0.78 for Model 1 and D = 0.93 for Model 2. A lower cut-off value would reduce 
the specificity of the model and a higher cut-off value would decrease the sensitivity.  
In this case, the sensitivity is the true classification rate for pharmaceutical tablets 
and specificity is the true classification rate for illicit/unknown tablets.  Therefore,  
Sensitivity = 
𝑛𝑜 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 (𝑇𝑟𝑢𝑒)𝑎𝑠 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙 (𝑇𝑃)




𝑛𝑜 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 (𝑇𝑟𝑢𝑒) 𝑎𝑠 𝑢𝑛𝑘𝑁𝑜𝑤𝑛 (𝑇𝑁)
(𝑛𝑜 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 (𝑇𝑟𝑢𝑒) 𝑎𝑠 𝑢𝑛𝑘𝑁𝑜𝑤𝑛 (𝑇𝑁) + 𝑛𝑜 𝑜𝑓 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 (𝐹𝑎𝑙𝑠𝑒) 𝑎𝑠  𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙(𝐹𝑃)
 
A ROC curve plots sensitivity against 1-specificity to produce a curve.  The closer 
this is to the top left of the plot, the higher the proportion of true positive results and 
hence the more accurate the calculation.  If the curve lies close to the diagonal line 
(Figure 8.9), the classification is no better than random allocation of the tablets to the 
two groups (Altman and Bland, 1994).  This means that the closer the area under the 
curve is to 1, the closer the LDA model classification is to a perfect classification 
according to the original classification of pharmaceutical and unknown.  The ROC 
analysis was carried out in SPSS and the results for both models (1 and 2) indicated 
that this was a perfect classification, with no false positives being recorded.  The 




Figure 8.9.   The ROC curve produced by the analysis of the principal components of the DSC 
data. The result was the same for both models 1 and 2. 
 
Two validation methods were employed to assess the performance of the models. 
 
8.5.4 Validation of the Statistical Technique 
8.5.4.1 Validation by Leave-one-out analysis 
Validation was performed in order to ensure the model was fit for purpose by testing 
whether the model predictions were reliable. Validation of the model was performed 
using ‘Leave-one-out’ analysis.  This technique runs the application n times using n-
1 observations from the dataset each time and then the model is tested on the 
excluded observation as a form of cross-validation.  After all the n-1 iterations of the 
model, each observation has been used once to test the model and n-1 times to train 
the model. Each of the samples are therefore used for testing the classification 
capabilities of the model.   
The results of the validation show that although all the unknown cases were 
classified by the model in accordance with the original classification during the 
building process and one pharmaceutical was incorrectly classified as being of 
unknown origin, an additional unknown case was classified as being pharmaceutical 
during the cross-validation (Table 8.3).  The validation was performed using both 
models 1 and 2, producing identical results. The Leave-One-Out Cross Validation 
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(LOOCV) was performed by SPSS using the default mean centroid allocation rule 
which has the cut-off D>0 for unknown and D<0 for pharmaceutical. Options for 
changing the cut-off to test the other two allocation rules were not available in SPSS 
and this therefore made an impact on the results since the third allocation rule 
produced a more reliable classification on the data used. 
Table 8.3.   Classification and Cross-Validation Results using both models 1 and 2. 
  Predicted Group Membership  




Original Unknown Origin 8 0  
93.8 Pharmaceutical 1 7 
Cross-
Validated 
Unknown Origin 7 1  
87.5 Pharmaceutical 1 7 
 
8.5.4.2 Validation of models using test sample 
Prior to developing the LDA models, the dataset was split into a training dataset for 
training the model and a testing dataset to test the predictive quality of the model.  
The model for the LDA had been trained using all of the unknown cases except for 
two chosen at random (Cases 2 and 29) and two pharmaceutical tablets also taken 
at random (MA064 and MA061-30).  These reserved cases of unknown tablets and 
two pharmaceuticals, were used for testing the two models.  Ideally a larger number 
of samples would have been used for the test but this was not possible given the 
small number of tablets available for the dataset. 
 Centroids  
The SPSS default of 0 was used to analyse all of the four test cases, using both 
models 1 and 2.  All of the test samples were correctly identified using Model 1.  
However, one pharmaceutical tablet was misclassified as being of unknown origin by 
using Model 2.  In addition, all of the tablets that did originate from an unknown 
source were classified as being from the unknown group.   Since there were only 
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four samples in the test dataset, the number of observations is too small to calculate 
separate sensitivity and specificity.  The results are shown in Table 8.4.  
Table 8.4.   Results of the four test cases using discriminant analysis with centroids and the 
SPSS default discriminant value of 0. 










Classification 2 0 2 1 
Pharmaceutical Classification  0 2  0  1 
 
 Confidence Intervals 
Calculations of the midpoint between the upper 95% confidence interval of the 
pharmaceutical data and the lower 95% confidence interval of the unknown data, 
meant that the cut-off point moved only fractionally from the default point of 0 to 0.12 
for Model 1 and to 0.21 for Model 2.  This resulted in all of the test samples being 
correctly classified using Model 1, and one pharmaceutical tablet being misclassified 
as unknown, using Model 2.  However, all the tablets in the dataset that were known 




Table 8.5.  Results of Discriminant Analysis using 95% confidence interval boundaries using 
the data from the four test cases and the training samples. 
  Model 1 Model 2 


























Upper = 2.54 
Lower = 1.37 
Upper = -1.13 
Lower = -2.78 
Upper = 2.22 
Lower = 1.26 
Upper = -0.85 
Lower = -2.64 




















Classification Unknown Origin 2 0 2 1 
Pharmaceutical 0 2 0 1 
 
The results generated by the two models were slightly different.  Model 2 only used 
three of the five principal components, so it may be that although components 3 and 
4 did not contribute as much to the final result, it still made an impact on the final 
classification.  
 ROC Curve 
The allocation rule based on the ROC curve correctly classified all cases (Table 
8.6).  Both models 1 and 2 produced an area under the curve of 1, showing no 
discrepancies in the data and that a ‘perfect’ separation was achieved between the 
unknown cases and the pharmaceutically manufactured tablets using this allocation 
rule on the training dataset. This meant that both models produced a sensitivity and 
specificity of 1 using both the training samples and the four test cases.  The use of 
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the ROC Curve therefore produced the results that were closest to the original 
classification. 
Table 8.6.   Results of the ROC curve using data from the four test cases and the training 
samples. 
  Model 1 Model 2 


































Area Under Curve 1.00 1.00 1.00 1.00 
Classification Unknown Origin 2 0 2 0 
Pharmaceutical 0 2 0 2 
 
8.5.5 Test of Assumptions and Suitability of Data 
For the statistical technique to be successful, three assumptions are required for the 
use of LDA: 
1. Independence and non-multiple linearity of variables 
2. Multivariate normality 
3. Homogeneity of variance/covariance matrix 
Pearson correlation coefficient values greater than 0.3 increase the likelihood of 
false positives occurring, however, it has been argued that LDA can tolerate 
deviations from the assumption of multivariate normality and homogeneity of 
covariance (Brown and Wicker,2000). 
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8.5.5.1 Independence and non-multiple linearity. 
The assumption of independence and non-multiple linearity can be demonstrated by 
a lack of correlation between the variables, with an ideal Pearson’s correlation 
coefficient value of <0.3 between pairs on independent variables.  Tests of the 
assumption of independence and non-collinearity for both models (Table 8.7) show 
that the correlation coefficient was below the recommended 0.3 level for PC1, 2 and 
5 but the correlations to PC3 and 4 were slightly higher.  Therefore, the LDA 
assumption of independence and non-collinearity is acceptable for the three 
discriminating independent variables in the model. 
 
Table 8.7.  Correlation between variables. 
 
 
8.5.5.2 Multivariate normality 
The tests for multivariate normality are difficult to perform and are not generally 
included in most statistical packages but  Brown and Wicker (2000) suggest that if 
the discriminant function scores are normally distributed then multivariate normality 
is likely.  The Shapiro-Wilk test presents a null hypothesis that the population is 
normally distributed.    The results of the Shapiro-Wilk test are shown in Table 8.8 
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and demonstrate that the data used for the LDA are normally distributed so this 
assumption of the LDA method is satisfied.  
Table 8.8.  Results of Shapiro Wilk Test of normality on values of D for each tablet group, where: 
 W = the observed value of the Shapiro-Wilk statistic and p is the probability of the 
outcome. The number in brackets refers to the degrees of freedom.  H0: Data are normally 
distributed.  A p-value >0.05 indicates that the null hypothesis is true and the data are normally 
distributed. A p-value <0.05 results in the null hypothesis being rejected, indicating that the data 
are not normally distributed. 
Model 1 Shapiro-Wilk Null 
Hypothesis  
Distribution 
Unknown W(8) = 0.996; 
p=1.000    
Accepted Normal 
Pharmaceutical W(8) = 0.825; 
p=0.053   
Accepted Normal 
Model 2    
Unknown W(8) = 0.909; 
p=0.348    
Accepted Normal 
Pharmaceutical W(8) = 0.880; 
p=0.190   
Accepted Normal 
 
8.5.5.3 Homogeneity of variance/covariance matrix 
The variance/covariance matrices should demonstrate similarity across groups and 
the assumption is examined by the Box’s M test.  The null hypothesis states that the 
covariance matrices do not differ and the significance level is set at p=0.01.  
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However, this is a very sensitive test and Garson (2012) suggested that the results 
of the Box’s M test could be disregarded if the log determinants are similar.  Some 
variation is expected but too much could denote the presence of outliers and 
inaccuracy of significance tests.   
The population variation matrices were not equal, according to Box’s M (Table 8.9).  
The log determinants are similar but not equal.  Brown and Wicker suggest that 
violations of this assumption are permitted if the nPHARMACEUTICAL /nUNKNOWN <1.5 
(Brown and Wicker,2000), which is true in this case. 
Table 8.9.  Results of Box’s M Test and the log determinants, where: F = the ratio of  two variants 




Box’s M  Equation 
Unknown 21.492 52.619 








   
Unknown 
16.144 19.689 












8.5.6 Suitability of Data 
An important step of the LDA was to ensure the data was suitable for this type of 
analysis.    A discriminant procedure such as LDA requires variance between the 
independent variables in order to distinguish between groups.   The Wilks’ Lambda 
test evaluates the discriminating power of each of the independent variables. The 
test generates a Wilks’ Lambda value which is the ratio between the within group 
variance and the total variance.  Wilks’ Lambda uses a scale of 0 – 1, where results 
of 0 indicate there is significant variation in the means of the groups, giving it total 
discriminatory power.  Results of 1 signify that there is no difference in the groups’ 
means and therefore no discriminatory potential.  However, even if only one group 
variable is significant, then the whole model is regarded as significant (Garson, 
2012).   
The F test explores the ratio of variance and determines the level of significance. It 
stipulates that when p<0.05, the independent variable has a significant impact on 
discrimination.  An F test with p>0.05 indicates that discrimination simply occurs by 
chance (Garson, 2012).  In this study PC1, PC2 and PC5 have significant 
discriminatory power whereas, PC3 and PC4 have little discriminatory potential 
(Table 8.10).  Wilks’ Lambda can be used to refine a model by removal of the less 
discriminating functions (Garson, 2012).  For this reason, two models were created 
for this project.  Model 1 incorporated the statistical results produced by all five 
principal components and Model 2 was based on the results of only principal 




 Table 8.10.  Wilks’ Lambda test for significance of independent variables. 
 Wilks’ Lambda Discriminatory Significance 
PC1 0.332 F(1,14) = 28.15; p<0.00 
PC2 0.401 F(1,14) = 20.88; p<0.00 
PC3 0.943 F(1,14) = 0.85; p<0.373 
PC4 0.767 F(1,14) = 4.25; p<0.058 
PC5 0.678 F(1,14) = 6.66; p<0.022 
 
The aim of the discriminant analysis was to use the DSC data which represents the 
tablets’ excipient content to separate the illicit cases into groups which originate from 
a pharmaceutical manufacturing process to those where the origin is unknown.  
Therefore, only one discriminant function, or allocation rule, was required to 
distinguish between the two groups. Wilks’ Lambda was used to determine the 
effectiveness of the discriminant function.  The null hypothesis stated that the group 
means are equal and therefore do not discriminate but a significant Wilks’ Lambda 
score, as determined by both models in this project, indicates that the null hypothesis 
can be rejected (Garson, 2012). This means that both models were found to be 




Table 8.11.  Wilks’ Lambda test of discriminant function significance and Eigenvalue results. 
Model Wilks’ Lambda Eigenvalue % Variance Canonical 
Correlation 
Model 1 0.139   (p<0.00) 6.176 100 0.928 
Model 2 0.154   (p<0.00) 5.491 100 0.920 
 
Eigenvalues demonstrate the relative importance of each of the discriminant 
functions.  For this project, only one discriminant function was required to classify the 
cases into two groups.  Therefore, the eigenvalue should reflect 100% 
discrimination, as seen in Table 8.11. 
The canonical correlation indicates that correlation was present between the group 
values and the values related to the discriminant function.  As there was only one 
discriminant function, this value illustrates that most of the difference between the 
groups is determined by the one function and is therefore close to a value of 1 (Table 
8.11) (Garson, 2012). 
The standardized discriminant function coefficients (Table 8.12) reflect the relative 
importance of each of the independent variables (i.e. PCs 1 to 5) to the discriminant 
function and the classification results.  When variables flagged as non-significant by 
the Wilks’ Lambda test (Table 8.11) are removed (i.e. PC3 and PC4), the level of 
importance assigned to each of the remaining variables is affected (Model 2).  The 
results of both models indicated that the greatest contribution was provided by PC1 
(Table 8.12).  This is expected since the first PC represents the largest portion of the 
variance in the original DSC dataset. 
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Table 8.12.  Standardized discriminant function coefficients showing the relative importance of 
each principal component to the discriminant function.  The results identify that the largest 
contribution for both models was given by PC1.   
Model 1 PC1 PC2 PC3 PC4 PC5 
Coefficients 1.073 0.817 -0.205 0.484 0.411 
Model 2      
Coefficients 0.815 0.792   0.320 
 
8.6 Conclusion 
Illicit tablets can be distinguished from pharmaceutical tablets using a variety of 
analytical methods which examined either the nature and amount of active drug 
substance or the properties of the excipient.  Two groups of illicit tablets contained 
an active drug substance other than diazepam (1) and another group contained 
quantities of diazepam (1) that were outside the specified level for a pharmaceutical 
tablet.  This left a group of illicit tablets with the correct type and amount of active 
drug substance (10 mg diazepam 1) but DSC analysis discriminated between these 
tablets and pharmaceutical tablets based on the tablets’ excipient content.  Linear 
discriminant analysis of the DSC data indicated that the excipient content of the 
unknown tablets was distinct from pharmaceutical diazepam (1) tablets licenced in 
the UK.  However, this result does not rule out the possibility that the unknown 
tablets were pharmaceutically manufactured outside the UK and diverted for illicit 
use or that they had been pharmaceutically manufactured for the UK market and 
diverted but were older than the pharmaceutical tablets used in this study and had 
degraded over time.  Degradation of the excipient could generate a DSC 
thermogram that was distinct from the newer tablets obtained directly from the 
pharmaceutical company.  This possibility merits further investigation. 
The LDA model had good predictive power as indicated by the LOOCV but one 
pharmaceutical and one unknown tablet in the training dataset were misclassified.  
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However, analysis of the four test cases and the training data using the centroid and 
confidence interval methods only misclassified one pharmaceutical tablet using the 
first model and two using the second.  One possible reason for two of the 
pharmaceutical tablets being misclassified is that not all of the pharmaceutical 
tablets were run on the DSC on the same day.  The first two cases (MA061 and 
MA064) were analysed along with the illicit cases.  The remaining eight cases of 
pharmaceutical tablets were run later. It was these two pharmaceutical tablets 
(MA061 and MA064) which were misclassified, as they did not group with the 
remaining pharmaceutical tablets. The DSC instrument underwent maintenance 
during the interval between analyses and this may have had an effect on the 
outcome and explain why these two pharmaceutical tablets were misclassified by the 
model.  Potentially, if the tablets had all been run together, it may have been more 
difficult to separate the pharmaceutical tablets from the unknown.  This would be 
worth further investigation in the future and could help to produce a more effective 
model.  
Despite this, the unknown tablets were correctly classified using the majority of 
methods.  However, the LOOCV result achieved 87.5% accuracy, while the use of 
centroids and confidence intervals gave a result of over 90%.   In addition the ROC 
Curve correctly identified all of the tablets.  The limitation of this analysis was the 






9.1 Chapter Summary 
The conclusion describes the context in which this study is set and provides a brief 
summary of the work performed and the results obtained.   
This section also suggests ideas for future work to build upon the analysis performed 
during this project.  Some investigations could have been performed in different 
ways and a variety of avenues could have been taken. Initial tests were also made 
into alternative methods of analysis such as DSC.  Therefore, the work performed in 
this project has provided an important step on which to base future work and 
suggestions are described with a view to obtaining further information that would 
help in the characterisation of illicit tablets.  
9.2 Conclusions 
The results of this project have proved that differentiation can be made between 
tablets in the illegal supply chain by using information gained from their physical and 
chemical analysis. By characterising the illicit blue tablets and comparing the 
resulting data to results generated by similar analysis of known pharmaceutical 
tablets, differences emerged which enabled some distinction to be made between 
illicitly produced and pharmaceutically manufactured tablets.  Comparison of the illicit 
tablets also revealed an array of different active drug substances in varying 
quantities in the illegal drug tablets.  However, some similarities were also 
discovered between the illicit tablets, indicating possible connections between the 
seized cases, which may provide important intelligence to police forces. 
Differences in tablet markings showed that many of the tablets in the illegal supply 
chain had not been pharmaceutically manufactured for the UK market, including 
tablets containing the letters EZ or NTZ. Some of the markings, such as MA / D10 
were consistent with pharmaceutical logos that were no longer in production in the 
UK.  However, due to shelf life, they may have been legally available at the time of 
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manufacture and then diverted for illegal use. Other cases contained tablets marked 
CP | D10, which correspond with the imprints used by Wockhardt and which are still 
being manufactured in the UK, indicating that they may also have been diverted into 
the illegal supply chain. 
Weight analysis of the illicit tablets highlighted differences in the consistency of illicit 
cases.  The weight range of pharmaceutical tablets was very small because of the 
requirement to comply with pharmaceutical regulations. Variation in tablet weight 
could ultimately affect the dosage level of the drug and is therefore carefully 
monitored within the pharmaceutical industry.   However, greater variation of tablet 
weight existed within illicit cases.  This provides an insight into illicit manufacturing 
procedures and can provide a quick and simple basis for initial screening of seized 
cases.   
Similarly, tablets manufactured by for example, the pharmaceutical company MA 
Pharmachem, consistently weighed between 165 – 175 mg, however, twelve of the 
illicit cases with a corresponding MA | D/10 marking were found to have a mean 
weight above this level, therefore suggesting that these cases had been illicitly 
manufactured, or were possibly a failed pharmaceutical batch, which had not been 
destroyed.  Another twelve illicit cases contained tablets that did correspond to the 
pharmaceutical range indicating they may have been pharmaceutically 
manufactured, but diverted tablets. 
Greater variation was also found in tablet depth, within illicit cases compared to 
pharmaceutical batches and was emphasised through relative standard deviation. 
The data was analysed in conjunction with box plots and graphical representations 
which enabled differences to be clearly visualised.  
Measurements of diameter, depth and weight allowed 14 cases of seized tablets to 
be identified as matching known pharmaceutical tablets.  These 14 cases were 
comprised of ten cases marked MA and one case consistent with tablets produced 
by each of Tensium, Teva and Wockhardt.  These companies have all been licensed 
to produce diazepam (1) tablets.  The final case which matched the pharmaceutical 
tablets was marked Roche which is a legitimate manufacturer of diazepam (1) 
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tablets in other countries but has no license for the UK.  Significantly, these 14 
identified cases remained consistent with pharmaceutical tablets in all of the 
following chemical tests performed thus giving a viable indication that these cases 
had been pharmaceutically manufactured (albeit Roche was manufactured outside 
the UK) and had been diverted into the illegal supply chain. 
The results of the physical analysis therefore demonstrated that difference in weight 
and depths of tablets can identify some cases which have been illicitly manufactured.  
Further analysis, such as through standard deviation and boxplots to explore the 
range of variation may also help to distinguish some cases which are of illicit origin.  
This new research into illicit street drugs seized in Scotland, has therefore identified 
a valuable initial step for future work in tablet discrimination. 
Analysis by GC-MS revealed that only 38 of the 62 seized cases tested contained 
any diazepam (1). Instead, a variety of active ingredients were present in the illicit 
tablets, including some such as etizolam (7) and phenazepam (16), which are not 
licensed for use in the UK.  This important technique was therefore able to identify 
many tablets which had not been pharmaceutically manufactured for the UK market.  
As no work has previously investigated the active ingredient present in the illicit blue 
tablets seized in Scotland, GC-MS revealed how vital this is, in order to provide up to 
date information for both police and medical services. 
Work performed on the GC-MS also highlighted the growing sophistication of illicit 
manufacturing processes, with lubricants being detected in illicit tablets.  This 
indicates an increase in knowledge and availability of equipment. 
Although not a confirmatory technique, comparison of analyte retention times by 
HPLC was able to support the GC-MS identifications while also providing information 
regarding the quantity of diazepam (1) present in the tablets.  HPLC revealed there 
was a variation from around 8 – 48 mg in the amount of active drug substance 
present in the diazepam (1) tablets.  Only 20 of the 38 cases identified with any 
diazepam (1) by GC-MS, were found to contain the correct amount of diazepam (1) 
(around 9 - 11 mg). Two of the cases were discovered to contain a slightly lower 
amount (around 8 mg) and 17 cases contained substantially higher than the 
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expected quantity (approximately 19 – 48 mg).  The remaining tablets contained 
other active drug substances.  HPLC analysis therefore revealed that many of the 
tablets containing diazepam (1) on the illicit market, had not been pharmaceutically 
manufactured and reflects a potential change away from diverting pharmaceutical 
tablets to illicit manufacture. 
This vital investigation was therefore able to distinguish between cases containing 
different levels of active drug substance and revealed the true nature of diazepam 
(1) being sold on the streets of Tayside.   This again may provide useful information 
to both police and medical staff. 
Use of DSC proved very informative and provided a thermal profile which was largely 
based on the excipients present in the analysed tablets, due to the small amount of 
active drug substance present in diazepam (1) tablets.  DSC thermograms clearly 
showed differences and similarities between the illicit cases and in comparison to the 
pharmaceutical tablets.  This therefore proved valuable for distinguishing between 
the various cases and for revealing potential links which may have otherwise been 
missed.  Although unable to identify excipients, the technique gave an indication of 
substances present, such as lactose, which gives a distinctive trace and is often a 
major component of both pharmaceutical and some illicit tablets.  The use of DSC 
proved invaluable for this project and has demonstrated great potential for future 
projects. 
The DSC thermograms also provided data influenced by the excipients, which was 
subjected to statistical cluster analysis using k-means clustering. Data reduction 
using principal component analysis was also performed on the data and allowed 
linear discriminant analysis to be performed on the seized cases which were most 
similar to the pharmaceutical tablets.  By using three different allocation rules, the 
results indicated that illicit tablets were able to be distinguished from the 
pharmaceutical tablets.  This novel investigation into illicit tablets using a 
combination of DSC and statistical analysis has demonstrated how powerful the 
technique can be, by exploring finer detail of the main constituents of the tablets and 
distinguishing all cases from the pharmaceutical tablets.  This new and innovative 
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technique, developed from well-established methodologies could provide vital 
insights in future work. 
Statistical cluster analysis using AHC, k-means clustering and a subjective approach 
based on visual comparison, was performed using three sets of independent data 
generated by each of the analytical techniques.  The results of the analyses were 
combined in a heat map which, highlighted how similar different illicit cases were to 
each other and to analysed pharmaceutical tablets based on statistical analysis of 
their physical and chemical properties.  The heat map identified seized cases which 
clustered with the pharmaceutical batches a varying number of times, which could 
suggest that they had been pharmaceutically manufactured and diverted into the 
illegal supply chain.  In addition, a number of the illicit cases were found to cluster 
together on multiple occasions, implying there may be a link between the seized 
cases.  The heat map proved to be a useful and informative way of combining results 
from multiple tests and an effective method of visualising cases which shared certain 
characteristics. 
Study into illicit diazepam (1) tablets had not previously been performed and this 
work has successfully provided a greater understanding of “blue tablets” (allegedly 
diazepam 1) in the Scottish illicit market.  In addition, an investigation into the 
forensic use of DSC has demonstrated the potential value that thermal analysis 
could provide in future investigations.  The study has also shown how physical and 
chemical characterisation and statistical analysis can successfully be combined to 
both differentiate between tablets and to highlight potential links. The results have 
indicated that of the twenty-four MA / D10 marked tablets (which were used as the 
sample set) obtained from the Scottish Police Authority there is a high probability 
that five are diverted pharmaceutical tablets, with another five potential diverted 
tablets. The remaining fourteen are illicit.  
9.3 Recommendations for Future Work 
Based on the work performed a number of recommendations for future work can be 
suggested to build on the knowledge already gained.  Firstly, the great potential 
offered by DSC would require a substantial amount of further investigation.  Reruns 
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of tablets suggest that changes take place over time and investigation into effects of 
time and storage conditions would provide greater understanding of the limitations of 
the technique.  This could reveal that direct comparison of different cases is difficult 
as resulting thermograms may show variation despite tablets originating from the 
same source.  However, it may also provide an understanding of how each excipient 
would behave over time thus helping to identify links been illicit seizures.  
Consequently, the forensic analysis of tablets using DSC would benefit from further 
research in this area.  
Some differences between samples may also be due to inconsistent blending of the 
tablet and the small sample size.  Therefore, it may be advisable to analyse more 
samples from each tablet and case.  It should be noted however, that samples that 
were used in this project were those obtained by Police Scotland so the sample size 
was dependent on the seizures. 
The sensitivity of DSC had shown that tablets could be separated according to visual 
comparison of the thermograms produced.  The tablets marked MA / D10 for 
example, could be separated into groups similar to those distinguished by visual 
comparison (Chapter 7 – Statistical Cluster Analysis).  The difference being the 
amalgamation of groups 1 and 2 through comparison of thermograms.  However, 
this was not due to the inability of DSC but due to the subjective nature of deciding a 
cut-off point by which to distinguish between levels of diazepam (1) detected.  
Interestingly, analysis of spectra produced testing the use of near infrared 
spectroscopy (NIR) for this project, had only been able to separate the cases into 
three groups.  Groups 1 and 2 with varying amounts of diazepam (1) again looked 
similar but the cases containing etizolam (7) also appeared comparable making it 
difficult to distinguish between the spectra produced by cases containing diazepam 
(1) and etizolam (7).  This would suggest that DSC may be a more sensitive 
technique for visual comparison of traces produced.  This would be supported by the 
study by Matos et al. (2017) whose compatibility studies using both DSC and 
infrared spectroscopy found that interaction between diazepam (1) and colloidal 
silicon dioxide produce a lower enthalpy value, which was not detected by infrared 
spectroscopy alone, suggesting that DSC is a more sensitive technique.  However, a 
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more detailed investigation into the benefits and comparison of each technique may 
be required to assess whether the two methods could complement each other.  
DSC thermograms show initial moisture loss from tablets through the presence of a 
gentle endothermic slope from the start of the trace.  It is possible that this may hide 
events affecting the lower level constituents and could also affect data used for 
statistical analysis depending on the amount present.  Therefore, for this project, the 
temperature range up to 100 oC was disregarded in the statistical analysis.  Future 
work could benefit from pre-drying tablets for DSC analysis to assess whether further 
information could be revealed. 
Inclusion of Thermal Gravimetric Analysis would also be interesting to compare to 
DSC analysis, as it would help to clarify thermal events taking place in the sample.  
In tests performed as part of this research, TGA was able to clarify instances of 
dehydration or melting because of differences in weight loss.  This could be valuable 
particularly if endotherms from melting were obscured by a broader endotherm 
produced by dehydration.  
Other work that could prove useful would be colour analysis and granularity of 
tablets.  Identifying a means of describing colour that is not subjective and allows for 
mottled tablets, would help with the classification.  Uneven colour could be to do with 
an uneven blend but variance in the level of dye added between different batches, 
may also change perception of the colour.  However, analysis of dyes may indicate 
that the same food dyes are used, which would not help to distinguish between 
cases.  The use of photography may be a more realist approach and may also be 
combined with assessing granularity.  The granularity of tablets gives an indication of 
the methods of production used and could provide useful intelligence for the police.   
Identification of sugars could determine whether the same excipients were used by 
the pharmaceutical companies and those produced illegally and could highlight 
differences or similarities between different illicit seizures.  Similarly, although 
investigations into tablet markings and damage analysis could prove problematic, 
largely due to tableting machines with multiple stations, overlaying photographs of 
similarly marked cases may again help to identify links between seizures.  
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By including information related to where each seizure was made could also prove 
interesting because when combined with information relating to potential links 
between cases, this could indicate how widespread the market is for a particular illicit 
manufacturer. 
This work has a number of avenues which could be pursued and a potential first step 
would be to approach the procurator fiscal to increase the number of tablets 
analysed, thus giving a greater understanding of the illicit “blue tablet” market.  Over 
the time this project has been performed, differences have been witnessed in the 
types of tablets received.  Many of the first batch of seizures received from the police 
contained tablets with 10 mg of diazepam (1) and only two cases which contained 
another active drug substance (phenazepam 16).  By the time the last batch was 
received, six of the twenty-two cases contained diazepam (1) and, of those, only two 
contained the pharmaceutical amount of between 9 – 11 mg.  This would indicate 
that more illegally manufactured tablets were entering the illicit market than 
pharmaceutically diverted tablets.  The market is constantly changing, possibly due 
to using whichever active drug substance is the most easily accessible and the 
availability of tableting equipment.  This highlights the importance of the work started 
in this project and the need to continue with the work in order to provide police and 
medical staff with up to date information on what is being bought and sold on the 
streets of Scotland.  
The final overall aim of this and later projects would be to develop a rapid robust 
system for determining the active ingredients in seized drug tablets and, along with 
some of the techniques described herein, be able to provide highly useful drug 
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 Appendix I - Statistical Techniques Applied 
1. Euclidean Distance 
2. Agglomerative Hierarchical Clustering 
3. K-Means Clustering 
4. Principal Component Analysis 
5. Linear Discriminant Analysis 
6. ‘R’ Scripts used for PCA Analysis 
 
Each technique is demonstrated using the data produced by chemical and physical 






         (𝓍2 -  1)2  +  (y2 -  y1)2 
 
It is the distance of a straight line between two points.  
 
 
The source of this formula is the Pythagorean theorem,  
ie.  The (hypotenuse)2 = 32 + 42 = 9 + 16 = 25 
               25      = 5 
Therefore Euclidean Distance between points (2,-1) and (-2,2) = 
Dist ((2,-1), (-2,2)) =         (2- (-2))2 + ((-1) -2)2 
                                 =      (2+2)2 + (-1-2)2 
                                 =      (4)2 + (-3)2 
                                 =      16 + 9 
                                 =     25 
                                 =    5 
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Therefore using data relating to cases 26, 31, 13, 83, 16, 74, indicating their 
diazepam (1) levels and relative standard deviation of weight of four tablets taken 
from each case, a distance matrix showing the distance between each of the points 
is required. 
In order to determine the matrix, the distance between each of the points needs to 
be calculated. 
Cases 26 – 31 
Points (25, 3.06) and (22, 1.99) =  
Dist  ((25, 3.06), (22, 1.99)) =  (25 -22)2 + (3.06 – 1.99)2 
                                 =      (25 - 22)2 + (3.06 – 1.99)2 
                                 =      (3)2 + (-1.07)2 
                                 =      9 + 1.1449 
                                 =     10.1449 
                                 =    3.185 
Cases 26 – 13 
Points (25, 3.06) and (22, 1.99) = 
Dist  ((25, 3.06), (22, 1.27)) =  (25 -22)2 + (3.06 – 1.27)2 
                                 =      (25 - 22)2 + (3.06 – 1.27)2 
                                 =      (3)2 + (-1.79)2 
                                 =      9 + 3.204 
                                 =     12.204 
                                 = 3.493 
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Cases 26 – 83 
Points (25, 3.06) and (9, 0.92) =  
Dist  ((25, 3.06), (9, 0.92)) =  (25 - 9)2 + (3.06 – 0.92)2 
                                 =      (25 - 9)2 + (3.06 – 0.92)2 
                                 =      (16)2 + (3.98)2 
                                 =      256 + 15.8404 
                                 =     271.8404 
                                 =    16.488 
 
Cases 26 – 16 
Points (25, 3.06) and (10, 0.82) =  
Dist  ((25, 3.06), (10, 0.82)) =  (25 -10)2 + (3.06 – 0.82)2 
                                 =      (25 - 10)2 + (3.06 – 0.82)2 
                                 =      (15)2 + (2.24)2 
                                 =      225 + 5.0176 
                                 =     230.0176 




Cases 26 – 74 
Points (25, 3.06) and (9, 1.32) =  
Dist  ((25, 3.06), (9, 1.32))  
                                 =      (25 – 9)2 + (3.06 – 1.32)2 
                                 =      (16)2 + (1.74)2 
                                 =      256 + 3.0276 
                                 =     259.0276 
                                 =     16.094 
 
Cases 31 – 13 
Points (22, 1.99) and (22, 1.27) =  
Dist  ((22, 1.99), (22, 1.27)) =     
                                 =      (22 - 22)2 + (1.99 – 1.27)2 
                                 =      (0)2 + (0.72)2 
                                 =      0 + 0.5184 




Cases 31 – 83 
Points (22, 1.99) and (9, 0.92) =  
Dist  ((22, 1.99), (9, 0.92)) =     
                                 =      (22 - 9)2 + (1.99 – 0.92)2 
                                 =      (13)2 + (2.91)2 
                                 =      169 + 8.4681 
                                 =     177.4681 
                                 =    13.222 
 
Cases 31 – 16 
Points (22, 1.99) and (10, 0.82) =  
Dist  ((22, 1.99), (10, 0.82)) =     
                                 =      (22 - 10)2 + (1.99 – 0.82)2 
                                 =      (12)2 + (1.17)2 
                                 =      144 + 1.3689 
                                 =     145.3689 




Cases 31 – 74 
Points (22, 1.99) and (9, 1.32) =  
Dist  ((22, 1.99), (9, 1.32)) =     
                                 =      (22 - 9)2 + (1.99 – 1.32)2 
                                 =      (13)2 + (0.67)2 
                                 =      169 + 0.4489 
                                 =     169.4489 
                                 =    13.017 
 
Cases 13 – 83 
Points (22, 1.27) and (9, 0.92) =  
Dist  ((22, 1.27), (9, 0.92)) =     
                                 =      (22 - 9)2 + (1.27 – 0.92)2 
                                 =      (13)2 + (0.35)2 
                                 =      169 + 0.1225 
                                 =     169.1225 




Cases 13 – 16 
Points (22, 1.27) and (10, 0.82) =  
Dist  ((22, 1.27), (10, 0.82)) =     
                                 =      (22 - 10)2 + (1.27 – 0.82)2 
                                 =      (12)2 + (0.45)2 
                                 =      144 + 0.2025 
                                 =     144.2025 
                                 =    12.008 
 
Cases 13 – 74 
Points (22, 1.27) and (9, 1.32) =  
Dist  ((22, 1.27), (9, 1.32)) =     
                                 =      (22 - 9)2 + (1.27 – 1.32)2 
                                 =      (13)2 + (-0.05)2 
                                 =      169 + 0.0025 
                                 =     169.0025 




Cases 83 – 16 
Points (10, 0.82) and (9, 0.92) =  
Dist  ((10, 0.82), (9, 0.92)) =     
                                 =      (10 - 9)2 + (0.82 – 0.92)2 
                                 =      (1)2 + (-0.1)2 
                                 =      1 + 0.01 
                                 =     1.01 
                                 =    1.005 
 
Cases 83 - 74 
Points (9, 1.32) and (9, 0.92) =  
Dist  ((9, 1.32), (9, 0.92)) =     
                                 =      (9 - 9)2 + (1.32 – 0.92)2 
                                 =      (0)2 + (0.4)2 
                                 =      0 + 0.16 
                                 =     0.16 
                                 =    0.4 
Cases 16 – 74 
Points (10, 0.82) and (9, 1.32) =  
Dist  ((10, 0.82), (9, 1.32)) =     
                                 =      (10 - 9)2 + (0.82– 1.32)2 
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                                 =      (1)2 + (-0.5)2 
                                 =      1 + 0.25 
                                 =     1.25 
                                 =    1.118 
 
Distance Matrix 
Table 10.3.1 Distance matrix produced using data from six seized cases. 
Distance  Case 13 Case 16 Case 26 Case 31 Case 74 Case 83 
Case 13 - 12.008 3.493 0.72 13.00 13.005 
Case 16 12.008 - 15.166 12.057 1.118 1.005 
Case 26 3.493 15.166 - 3.185 16.094 16.488 
Case 31 0.72 12.057 3.185 - 13.017 13.222 
Case 74 13.00 1.118 16.094 13.017 - 0.400 




Agglomerative Hierarchical Clustering 
Agglomerative Hierarchical Clustering (AHC) uses the Euclidean distances 
demonstrated in section 10.3.1 -  Euclidean Distance above. 
Table 10.3.2 Distance matrix showing Euclidean distance between 6 seized cases. 
Distance  Case 13 Case 16 Case 26 Case 31 Case 74 Case 83 
Case 13 - 12.008 3.493 0.72 13.00 13.005 
Case 16 12.008 - 15.166 12.057 1.118 1.005 
Case 26 3.493 15.166 - 3.185 16.094 16.488 
Case 31 0.72 12.057 3.185 - 13.017 13.222 
Case 74 13.00 1.118 16.094 13.017 - 0.400 
Case 83 13.005 1.005 16.488 13.222 0.400 - 
In each iteration, the closest pairs in the distance matrix (Table 10.3.2) are grouped 
into one cluster. 
Step 1. 
Using the distances calculated for the cases and shown in the tablet, the closest 
pairs in the distance matrix are cases 74 and 83 at a distance of 0.4. 
The distance matrix is then recalculated (Table 10.3.3), using the single linkage rule, 
where the minimum distance is specified so that: 
d (74,83) -> 13 = min (d74-13, d83-13)  = min (13.00, 13.005) = 13.00   
d (74,83) -> 16 = min (d74-16, d83-16)  = min (1.118, 1.005) = 1.005 
d (74,83) -> 26 = min (d74-26, d83-26)  = min (16.094, 16.488) = 16.094 




Table 10.3.3 Recalculated distance matrix where cases 74 and 83 are combined. 
Distance  Case 13 Case 16 Case 26 Case 31 (Cases 
74,83) 
Case 13 - 12.008 3.493 0.72 13.00 
Case 16 12.008 - 15.166 12.057 1.005 
Case 26 3.493 15.166 - 3.185 16.094 
Case 31 0.72 12.057 3.185 - 13.017 
Cases 
(74,83) 
13.00 1.005 16.094 13.017 - 
 
Step 2. 
The step is repeated with the next closest clusters.  In this example, the next closest 
are cases 13 and 31 at a distance of 0.72. 
The distance matrix is recalculated as follows: 
d (13,31) -> 16 = min (d13-16, d31-16)  = min (12.008, 12.057) = 12.008  
d (13,31) -> 26 = min (d13-26, d31-26)  = min (3.493, 3.185) = 3.185 
d (13,31) -> (74,83) = min (d13-74, d13-83m d31-74, d31-83), using original distance 
matrix. 
Therefore = min (13.00, 13.005, 13.017, 13.222) = 13.00 
 
Table 10.3.4 Recalculated distance matrix where cases 74 and 83; and cases 
13 and 31 are combined. 
Distance  Cases 
(13,31) 
Case 16 Case 26 Cases (74,83) 
Cases 
(13,31) 
- 12.008 3.185 13.00 
Case 16 12.008 - 15.166 1.005 
Case 26 3.185 15.166 - 16.094 
Cases 
(74,83) 




The step is repeated with the next closest clusters.  In this example, the next closest 
are clusters (64, 83) and case 16 at a distance of 1.005. 
The distance matrix is recalculated as follows: 
d ((74,83),16) -> (13,31) = min (d74-13, d74-31, d83-13, d83-31, d16-13, d16-31 )  
     = min (13.00, 13.017, 13.005, 13.222, 12.008, 12.057) = 12.008  
d ((74,83),16) -> 26 = min (d74-26, d83-26, d16-26)   
     = min (16.094, 16.488, 15.166) = 15.166  
Table 10.3.5 Recalculated distance matrix where cases 16, 74 and 83; and cases 13 and 31 are 
combined. 
Distance  Cases  (13,31) Case 26 Cases  
((74,83)16) 
Cases (13,31) - 3.185 12.008 
Case 26 3.185 - 15.166 
Cases 
((74,83)16) 
12.008 15.166 - 
 
Step 4. 
The next closest are clusters (13, 31) and case 26 at a distance of 3.185. 
The distance matrix is recalculated as follows: 
d ((13,31),26) -> ((74,83),16)  
     = min (d13-74, d13-83, d13-16, d31-74, d31-83, d31-16, d26-74, d26-83, d26-16)  
     = min (13.00, 13.005, 12.008, 13.017, 13.222, 12.057, 16.094, 16.488, 15.166)  




Table 10.3.6 Recalculated distance matrix where cases 16, 74 and 83; and cases 13, 26 and 31 
are combined. 












The remaining two clusters are merged. 
Results 
1. Six original clusters 
2. Merge 74 and 83 at 0.4 
3. Merge 13 and 31 at 0.72 
4. Merge (74, 83) and 16 at 1.005 
5. Merge (13, 31) and 26 at 3.185 
6. Merge ((74, 83),16) and ((13, 31), 26 at 12.008 




Figure 10.3.1 Dendrogram of the Agglomerative Hierarchical Clustering Results. 
 
By returning to the original data points produced by analysis of diazepam (1) content 
and relative standard deviation of weight, a scatter graph can be plotted in 𝓍, y 






















Data related to the diazepam (1) concentration and relative standard deviation of 
weight produced from four tablets taken from each of the seized cases 26, 31, 13, 
83, 16, 74 is used to demonstrate k-means clustering.  The data is shown in table 
10.3.7. 
Table 10.3.7 Diazepam (1) concentration and relative standard deviation recorded for six 
seized cases. 
Case Number Diazepam Concentration 
(mg) 
Relative Standard 
Deviation of Weight 
13 22 1.27 
16 10 0.82 
26 25 3.06 
31 22 1.99 
74 9 1.32 
83 9 0.92 
 
K-Means clustering uses two points which are furthest away from each other 
according to Euclidean distance, to become central vectors for two clusters. 
 
Step 1. 
The two furthest away points in the demonstration data are cases 26 and 83, using 
Euclidean Distance.  These become the mean vectors for two clusters. 
Table 10.3.8 Initial centroids created using Euclidean distance based on data produced by six 
seized cases. 
Cluster Case Centroid (Mean Vector) 
1 26 25, 3.06 




Working through each of the remaining cases, each are assigned to the nearest 
centroid and the mean is recalculated.  So: 
Case 13: 
 Cluster Case Centroid (Mean 
Vector) 
 1 26, 13 23.5, 2.165 
Unchanged 2 83 9, 0.92 
 
Case 16: 
 Cluster Case Centroid (Mean 
Vector) 
Unchanged 1 26, 13 23.5, 2.165 
 2 83, 16 9.5, 0.87 
 
Case 31: 
 Cluster Case Centroid (Mean 
Vector) 
 1 26, 13, 31 23, 2.107 
Unchanged 2 83, 16 9.5, 0.87 
 
Case 74: 
 Cluster Case Centroid (Mean 
Vector) 
Unchanged 1 26, 13, 31 23, 2.107 




To ensure correct clustering, each subject is compared to both cluster means. 
Case 13 -> Centroid of group 1 
Points (23, 2.107) and (22, 1.27) =  
Dist  ((23, 2.107)  (22, 1.27)) =     
                                 =      (23 - 22)2 + (2.107 – 1.27)2 
                                 =      (1)2 + (0.837)2 
                                 =      1 + 0.7006 
                                 =     1.706 
                                 =     1.306 
Case 13 -> Centroid of group 2 
Points (22, 1.27) and (9.333, 1.02) =  
Dist  ((22, 1.27) (9.333, 1.02)) =     
                                 =      (22-9.333)2 + (1.27-1.02)2 
                                 =      (12.667)2 + (0.25)2 
                                 =      160.453 + 0.0625 
                                 =     160.5155 




Case 16 -> Centroid of group 1 
Points (10, 0.82)  and (23, 2.107) =  
Dist  ((10, 0.82)  (23, 2.107)) =     
                                 =      (10-23)2 + (0.82-2.107)2 
                                 =      (-13)2 + (1.287)2 
                                 =      169 + 1.656 
                                 =     170.656 
                                 =     13.064 
Case 16 -> Centroid of group 2 
Points (10, 0.82) and (9.333, 1.02) =  
Dist. ((10, 0.82) (9.333, 1.02)) =     
                                 =      (10-9.333)2 + (0.82-1.02)2 
                                 =      (0.667)2 + (-0.20)2 
                                 =      0.445 + 0.04 
                                 =     0.485 
                                 =  0.696 
Case 26 -> Centroid of group 1 
Points (25, 3.06) (23, 2.107) =  
Dist.  ((25, 3.06) (23, 2.107)) =     
                                 =      (25 - 23)2 + (3.06 – 2.107)2 
                                 =      (2)2 + (0.953)2 
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                                 =      4 + 0.908 
                                 =     4.908 
                                 =    2.215 
Case 26-> Centroid of group 2 
Points (25, 3.06) and (9.333, 1.02) =  
Dist.  ((25, 3.06) (9.333, 1.02)) =     
                                 =      (25 - 9.333)2 + (3.06 - 1.02)2 
                                 =      (15.667)2 + (2.04)2 
                                 =      245.455 + 4.162 
                                 =     249.617 
                                 =     15.799 
Case 31 -> Centroid of group 1 
Points (22, 1.99) and (23, 2.107) =  
Dist.  ((22, 1.99) (23, 2.107)) =     
                                 =      (22 - 23)2 + (1.99 - 2.107)2 
                                 =      (1)2 + (0.117)2 
                                 =      1 + 0.0137 
                                 =     1.014 





Case 31 -> Centroid of group 2 
Points (22, 1.99) and (9.333, 1.02) =  
Dist.  ((22, 1.99) (9.333, 1.02)) =     
                                 =      (22 - 9.333)2 + (1.99 - 1.02)2 
                                 =      (12.667)2 + (0.97)2 
                                 =      160.453 + 0.941 
                                 =     161.394 
                                 =    12.704 
Case 74 -> Centroid of group 1 
Points (9, 1.32) and (23, 2.107) =  
Dist.  ((9, 1.32) (23, 2.107)) =     
                                 =      (9 - 23)2 + (1.32 - 2.107)2 
                                 =      (-14)2 + (-0.787)2 
                                 =      196 + 0.619 
                                 =     196.619 
                                 =    14.022 
Case 74 -> Centroid of group 2 
Points (9, 1.32) and (9.333, 1.02) =  
Dist.  ((9, 1.32) (9.333, 1.02)) =     
                                 =      (9 - 9.333)2 + (1.32 - 1.02)2 
                                 =      (-0.333)2 + (0.3)2 
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                                 =      0.111 + 0.09 
                                 =     0.201 
                                 =    0.448 
Case 83 -> Centroid of group 1 
Points (9, 0.92) and (23, 2.107) =  
Dist.  ((9, 0.92) (23, 2.107)) =     
                                 =      (9 - 23)2 + (0.92 - 2.107)2 
                                 =      (-14)2 + (-1.187)2 
                                 =      196 + 1.409 
                                 =     197.409 
                                 =    14.050 
Case 83 -> Centroid of group 2 
Points (9, 0.92) and (9.333, 1.02) =  
Dist.  ((9, 0.92) (9.333, 1.02)) =     
                                 =      (9 - 9.333)2 + (0.92 - 1.02)2 
                                 =      (-0.333)2 + (-0.1)2 
                                 =      0.111 + 0.01 
                                 =     0.121 







The results of the k-means clustering are shown in Table 10.3.3. 
Table 10.3.3 Results of k-means clustering of six seized cases. 
Case Distance to centroid of 
Cluster 1 
Distance to centroid of 
Cluster 2 
13 1.306 12.670 
16 13.064 0.696 
26 2.215 15.799 
31 1.007 12.704 
74 14.022 0.448 
83 14.050 0.348 
  
The results of the k-means clustering indicates that all cases remain in the same 
clusters and no further iterations are required.  The final clusters created are shown 
in Table 10.3.4. 
Table 10.3.9 Final clustering results determined by k-means clustering of six seized cases. 
Cluster Case Centroid (Mean 
Vector) 
1 26, 13, 31 23, 2.107 
2 83, 16, 74 9.333, 1.02 
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Principal Component Analysis 
To work out PCA on data, the first step is to zero the mean of the variables.  In order to do 
this, the mean has to be calculated for each row of variables, then it needs to be subtracted 




 (𝓍1 +…..+ 𝓍n)  
Where µ is the mean in vector form, n is the number of samples 𝓍 and represents the 
samples in vector form. 
Therefore matrix A becomes:   
  
 a1-µ1       b1-µ1      c1-µ1   
                      a2-µ2       b2-µ2      c1-µ2 
                                 a3-µ3       b3-µ3      c3-µ3                                                 
                      an-µn       bn-µn      cn-µn 
 
Using data produced by Cases 2, 3 and 4, using the differential scanning calorimeter for the 
first three blocks of temperature, with data rounded to two decimal places: 
Temperature Case 2 Case 3 Case 4 
100 – 105 oC -1082.37 -1111.79 -882.15 
105 – 110 oC -1107.89 -1176.85 -902.51 
110 – 115 oC -1133.25 -1250.24 -927.76 
 
The mean of each row was calculated as:  100 – 105 oC   =   1025.44 
        105 – 110 oC   =   1062.42 







So matrix A is: 
                           
                        -1082.37 – (-1025.44)      -1111.79 – (-1025.44)      -882.15 – (-1025.44)       
                        -1107.89 – (-1062.42)      -1176.85 – (-1062.42)      -902.51 – (-1062.42)  
                        -1133.25 – (-1103.75)      -1250.24 – (-1103.75)      -927.76 – (-1103.75)                                        
  
                                      
          =             -56.93       -86.35        143.29       
                         -45.47      -114.43       159.91 
                         -29.50      -146.49       176.00                                          
 
A covariance matrix (S) is then created to provide for relationship between variables.  It is 
determined by using the equation: 




Where A T is the transpose of matrix A. 
For our example, n=3 therefore  
1
𝑛−1









        =      B       -56.93       -86.35        143.29              BT        -56.93        -45.47        -29.50        
                         -45.47      -114.43       159.91          x              -86.35      -114.43       -146.49 








          =             31229.37       35383.14        39547.89                                                           




                         39547.89       46248.38        53305.57 
 
 
S =                    15614.69       17691.57        19773.95                                                           
                         17691.57       20366.48        23124.19          
                         19773.95       23124.19        26652.79 
 
The next step is to find the eigenvalues and eigenvectors for this matrix. 
As this data proved complicated to factorise by hand, an alternate matrix has been included 
below, to demonstrate the technique. 
For this example: 
 
Matrix A    =             3       1      -1       
                                   1       3      -1 








To find the Eigenvalues: 
The first step is to find the determinant  (A - 𝜆 I) : 
So                3 - 𝜆        1           -1 
                       1         3 - 𝜆        -1                                                                                            
                      -1          -1        5 - 𝜆           
 
= (3- 𝜆)  |
3 −  𝜆 −1
−1 5 −  𝜆
| -1 |
1 −1
−1  5 −  𝜆
| -1 |




= (3- 𝜆)  ((3- 𝜆) (5 - 𝜆) – (-1) (-1)) -1 (1(5 - 𝜆) – (-1) (-1)) – (1 (-1) - (-1) (3 - 𝜆)) 
 
Simplify: 
=  (3- 𝜆)  (15 - 3𝜆 - 5𝜆 + 𝜆2 – 1) -1 ( 5 – 𝜆 -1) -1 ( -1 + 3 – 𝜆) 
=  (3- 𝜆)  ( 𝜆2 - 8𝜆 + 14) - ( – 𝜆 + 4) - ( – 𝜆 + 2) 
Multiply: 
=  3𝜆2 - 24𝜆 + 42 –𝜆3 + 8𝜆2 - 14𝜆 + 𝜆 – 4 + 𝜆 – 2 
Rearrange: 
=  –𝜆3 + 11𝜆2 - 36𝜆 + 36 
 
 Factorise:      and   a x b = c 










 - λ2 +  9λ  -  18 
λ-2  - λ3 + 11λ2 – 36λ + 36  
      - - λ3 +  2λ2 
          0   +  9λ2  - 36λ + 36 
                   9λ2  – 18λ            
0  -  18λ + 36 
 -  -  18λ + 36 
                0 
 
So,  
    - λ3 + 11λ2 – 36λ + 36 
=  (λ-2) (- λ2 + 9λ - 18) 
= (λ-2) (- λ + 3) (λ - 6)  = 0   
 
As each bracket = 0; 
λ-2 = 0       Therefore λ = 2  
-λ+3 = 0     Therefore λ = 3           These are the eigenvalues.   






The eigenvectors are calculated for each of the eigenvalues. 
a.  For λ = 2 
(A – λ1 I) v1  = 0  
 
v1 =      v1,1  
            v1,2 
            v1,3 
  
   3 - 𝜆        1           -1                     3-2     1     -1                     1     1    -1                                                                                              
      1         3 - 𝜆        -1         =           1     3-2   -1           =        1     1    -1                                                                                                                                                                            
     -1          -1        5 - 𝜆                    -1      -1   5-2                   -1   -1     3          
                                                                                   
 
   1    1    -1                      v1,1                        
   1    1    -1          x          v1,2           =   0 
  -1   -1     3                      v1,3         
 
 
  v1,1    + v1,2    -v1,3      
  v1,1    + v1,2    -v1,3             =  0        So, each row = 0                                                   
  -v1,1    -v1,2   +3v1,3      
       
v1,1    + v1,2    -v1,3     =  0 
-v1,1    -v1,2   +3v1,3    =  0 
Rearrange to find V1,3:  
v1,3 = v1,1    + v1,2  ⇒  3v1,3    =  3v1,1  +   3v1,2        
Replace this value of 3V1,3   into the second equation: 
-v1,1    -v1,2   + 3v1,1  +   3v1,2     =  0 
2v1,1   +  2v1,2   =  0 
v1,1   =  - v1,2    
So,    v1,1  =       1               
         v1,2  =      -1 
         v1,3  =       0          (Because there is no v1,3  in the final equation. 
 






This is the eigenvector for λ = 2. 
 
b. For λ = 3 
(A – λ2 I) v2  = 0  
 
V2 =      v2,1  
            v2,2 
            v2,3 
  
   3 - 𝜆        1           -1                     3-3     1     -1                     0     1    -1                                                                                              
      1         3 - 𝜆        -1         =           1     3-3   -1           =        1     0    -1                                                                                                                                                                            
     -1          -1        5 - 𝜆                    -1      -1   5-3                   -1   -1     2             
                                                                                
 
   0    1    -1                      v2,1                        
   1    0    -1          x          v2,2           =   0 
  -1   -1     2                      v2,3         
 
 
             v2,2    - v2,3      
  v2,1                      - v2,3               =  0        So, each row = 0                                                   
  -v2,1    -v2,2   + 2v2,3      
       
v2,2    - v2,3     =  0                    So,  v2,2   =   v2,3      
v2,1    - v2,3     =  0                     So,  v2,1   =   v2,3      
- v2,1   - v2,2   + 2v2,3    = 0        So,  v2,1 , v2,2   and v2,3    are equal. 
 
So,    v2,1  =       1               
         V2,2  =       1 
         V2,3  =       1           
 
This is the eigenvector for λ = 3. 
c. For λ = 6 
 






(A – λ3 I) v3  = 0  
 
v3 =      v3,1  
            v3,2 
            v3,3 
 
   3 - 𝜆        1           -1                     3-6     1     -1                    -3     1    -1                                                                                              
      1         3 - 𝜆        -1         =           1     3-6   -1           =        1    -3    -1                                                                                                                                                                            
     -1          -1        5 - 𝜆                    -1      -1   5-6                   -1   -1    -1                                                                                            
 
 
   -3    1    -1                      v3,1                        
   1    -3    -1          x          v3,2           =   0 
  -1   -1     -1                      v3,3         
 
 
  -3v3,1     + v3,2     - v3,3      
     v3,1      -3v3,2     - v3,3             =  0        So, each row = 0                                                   
    -v3,1      -v3,2      + v3,3      
       
- 3v3,1    + v3,2   - v3,3     =  0   (equation 1) 
   v3,1    - 3v3,2   - v3,3    =  0    (equation 2) 
-  v3,1     - v3,2    - v3,3     =  0    (equation 3) 
 
To remove v3, subtract equation 2 from equation 1. 
- 3v3,1    + v3,2    - v3,3   -  v3,1    + 3v3,2   + v3,3    =  0     
 - 4v3,1   + 4v3,2    =  0    
v3,1   =  v3,2        
Then, 
-  v3,1     - v3,2    - v3,3     =  0   
And   -  v3,1     - v3,1    - v3,3     =  0   
And   -  2v3,1     =   v3,3  
 






  So,    v3,1  =       1               
           V3,2  =       1 
           V3,3  =      -2           
 
This is the eigenvector for λ = 6. 
 
An eigenvector gives the position on a multidimensional graph, where each one represents 
a position of a different axis.  The more values present represents a greater number of 
dimensions. 
Once the eigenvalues and corresponding eigenvectors have been calculated, they are lined 
up from highest to lowest in order to interpret the results.  Eigenvector 1 is the first 
principal component because it has the highest eigenvalue. 
The eigenvalues for the small sample of my data was calculated using data points originating 
from DSC thermograms, which plot heat flow against temperature.    The results were as 
follows: 
λ1  ≈  62016.6       This is the first principal component because it is the highest value. 
λ2  ≈  617.344       This is the second principal component. 





Corresponding eigenvectors:                                                                       
v1  ≈      - 0.496372                         
               - 0.57294      
               - 0.652192    The vector is closest to this axis, therefore this is the most 
                                       important for influencing the results.       
                                                         
v2  ≈      - 0.736324 
               - 0.120077     
                 0.665889     
 
v3  ≈        0.459828 
               - 0.810754     




To find the variation in the data: 
In this case    
𝜆
𝜆1+𝜆2+𝜆3

















Linear Discriminant Analysis 
The data used for this analysis was based on the unweighted data and used the first 
five principal components.  The first five were used as they encompassed 90.6% of 
the variance between the cases. The same technique would be applied for the 
weighted data. 
 
Type PC1 PC2 PC3 PC4 PC5 
Case16 Unknown 1.611569 9.979493 22.02392 10.77099 10.96247 
Case24 Unknown 9.30618 -1.17388 37.34808 16.02456 18.13521 
Case30 Unknown -27.4899 6.732931 8.849905 8.032669 4.403203 
Case74 Unknown 59.61188 -0.21113 2.560188 1.207882 10.65152 
Case79 Unknown 33.58785 -8.32657 -7.91726 3.51313 11.31877 
Case82 Unknown 17.74199 5.162663 -9.31653 12.09781 -29.5744 
Case83 Unknown 73.66236 -15.6356 5.012886 3.532008 11.71255 
Case86 Unknown 101.3126 -9.69608 15.58579 4.896815 11.58848 
MA061 Pharma -40.7589 -0.80465 -4.56029 9.020978 2.772301 
MA061-19 Pharma -107.293 -29.9489 -10.5968 16.95552 0.373502 
MA061-21 Pharma -47.6988 -20.8416 3.189416 13.45571 -14.651 
MA061-23 Pharma -39.6191 -21.3693 8.729064 6.896403 -17.7891 
MA064-11 Pharma -47.0201 -26.1642 7.907796 8.528296 -8.45288 
MA064-14 Pharma -89.5017 -26.451 4.618471 13.21014 -9.03729 
MA064-17 Pharma -48.8645 -29.6766 10.07736 17.58832 -9.7547 
MA064-20 Pharma -47.8942 -25.7434 9.80379 11.88389 -15.5551 
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The first step was to calculate the average of the 8 principal component values for 
each type of case (Sayad, 2017). 
The results of the calculation are presented in the Principal Component Analysis 
Data Table below. 
Type Count 
(N) 
Statistics PC1 PC2 PC3 PC4 PC5 
Pharmaceutical 8 Mean 
(µ1) 
-58.58 -22.63 3.65 12.19 -9.01 
Unknown 8 Mean 
(µ2) 
33.67 -1.65 9.27 7.51 6.15 
 
The calculation for the covariant matrices results in a 5x5 matrix for each type.  The 
layout shows the variance on the diagonal and covariance to complete the remaining 
entries.  This layout is demonstrated in the matrix layout below (Berman, 2017). 
Variance Covariance Covariance Covariance Covariance 
Covariance Variance Covariance Covariance Covariance 
Covariance Covariance Variance Covariance Covariance 
Covariance Covariance Covariance Variance Covariance 






In order to visualise the positions of the entries described below, the positions of the 
entries are demonstrated in the following table.   
1 2 3 4 5 
6 7 8 9 10 
11 12 13 14 15 
16 17 18 19 20 
21 22 23 24 25 
 
As the table is reflective on the diagonal, only half the table needs to be calculated 
and copied over. 
Each variance calculation is the same but the value of x varies according to its 
position in the matrix. Each covariance calculation varies in the same way. For 
example, to find the value of position 9 in row 2 and column 4, the values used would 
be x2 and x4 (Berman, 2017). 
The calculation for entries 1 and 2 would be slightly different as one is for variance 
and the other covariance. The equations for each are shown below (Columbia 
Business School, 2003). 
 
Entry 1 (variance) would be calculated using the equation: 
  ∑ (𝑥1 − 𝑥1̅̅̅)
2/(𝑁 − 1) 𝑐𝑎𝑠𝑒𝑠  
 







= (Case MA061 PC1 value – average of PC1)2 /(N-1)    
+ (Case MA061-19 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA061-21 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA061-23 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA064-11 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA064-14 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA064-17 PC1 value – average of PC1)2 /(N-1) 
+ (Case MA064-20 PC1 value – average of PC1)2 /(N-1) 
 
= (-40.76 - (-58.58))2 / 7  +  (-107.29 - (-58.58))2 / 7  + (-47.70 - (58.58))2 / 7 
+  (-39.63 - (-58.58))2 / 7  +  (-47.02 - (-58.58))2 / 7  + (-89.50 - (58.58))2 / 7 
+  (-48.86 - (-58.58))2 / 7  + (-47.89 - (58.58))2 / 7 
 
= 45.38 + 338.98 + 16.92 + 51.37 + 19.09 + 136.58 + 13.49 + 16.32 
=  638.12 
 
The Calculation for entry 2 (row 1 column 2) is for covariance and uses the equation: 
 










= (Case MA061 PC1 value – average of PC1)  x  (Case MA061 PC2 – average of 
PC2)  /(N-1)   
+ (Case MA061-19 PC1 value – average of PC1)  x  (Case MA061-19 PC2 – 
average of PC2)  /(N-1)   
+ (Case MA061-21 PC1 value – average of PC1)  x  (Case MA061-21 PC2 – 
average of PC2)  /(N-1)  
+ (Case MA061-23 PC1 value – average of PC1)  x  (Case MA061-23 PC2 – 
average of PC2)  /(N-1)   
+ (Case MA064-11 PC1 value – average of PC1)  x  (Case MA064-11 PC2 – 
average of PC2)  /(N-1)   
+ (Case MA064-14 PC1 value – average of PC1)  x  (Case MA064-14 PC2 – 
average of PC2)  /(N-1)   
+ (Case MA064-17 PC1 value – average of PC1)  x  (Case MA064-17 PC2 – 
average of PC2)  /(N-1)  
+ (Case MA064-20 PC1 value – average of PC1)  x  (Case MA064-20 PC2 – 
average of PC2)  /(N-1)  
 
= 
(-40.76 – (-58.58)) x (-0.80 – (22.63)) / 7  +  (-107.293 – (-58.58)) x (-29.95 –  
(-22.63)) / 7 
+ (-47.70 – (-58.58)) x (-20.84 – (22.63)) / 7  +  (-39.62 – (-58.58)) x (-21.37 –  
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(-22.63)) / 7 
+ (-47.02 – (-58.58)) x (-26.16 – (22.63)) / 7  +  (-89.50 – (-58.58)) x (-26.45 – 
 (-22.63)) / 7 
+ (-48.86 – (-58.58)) x (-29.68 – (22.63)) / 7  +  (-47.89 – (-58.58)) x (-25.74 –  
(-22.63)) / 7 
=  109.20 
 





638.12 109.20 112.35 −57.13 −77.84
109.20 88.73 −21.79 −19.50 27.30
112.35 −21.79 56.38 −7.30 −45.02
−57.13 −19.50 −7.30 15.15 6.09










1780.50 −295.91 −98.13 −130.86 133.75
−295.91 79.88 20.77 24.56 −49.42
−98.13 20.77 242.16 43.80 136.32
−130.86 24.56 43.80 26.11 −18.92



























1209.31 −93.35 7.11 −94.00 27.96
−93.35 84.31 −0.51 2.53 −11.06
7.11 −0.51 149.27 18.25 45.65
−94.00 2.53 18.25 20.63 −6.41





This pooled covariance matrix then needs to be inverted. 






Elementary row operations are conducted to turn this into a 3x3 identity matrix.  
Every operation used to create this is also performed on a separate 3x3 identity 

















                                                     R2        R2  - R1                               




                                                             (
1    4     4
0 −2     0
0 −1 −2
)               (





                                                         R2          - R2/2    
 
        (
1    4    4
0    1    0
0 −1 −2
)           (




                                                           R1        R1  - 4R2    
            R3        R3  + R2 
 
                                                            (
1 0    4
0 1    0
0 0 −2
)          (
−1 2 0












)        (
−1    2 0
0.5 −0.5 0
  0.25      0.25 −0.5
) 
 








)       (
−2    1 2
0.5 −0.5 0
  0.25      0.25 −0.5
) 
 
 Returning to the unweighted data, the information was inserted into: 
http://matrix.reshish.com/inverCalculation.php (Reshish.com, 2017).   





0.001597 0.001589 −0.00129 0.08415 0.000621
0.001589 0.013599 −0.0014 0.007302 0.00157
−0.00129 −0.0014 0.009832 −0.01559 −0.00383
0.08415 0.007302 −0.01559 0.102441 0.00879





The coefficients can then be calculated. (Sayad, 2017). 
 












































= [0.143413 0.413628 −0.07807 0.495355 0.167] 
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‘R’ Scripts used for PCA Analysis 
 
options(max.print=999999) #(This increases the number of print lines in R because 
the file is big)  
 
MAset<-read.table("MA tablets_22Feb17.txt", header =TRUE) #(Read the table in 
from the file and store as object ‘MAset’)  
 
comp=prcomp(MAset, scale = TRUE) # (Run the pca on the dataset MAset using a 
built in function called prcomp and assign outcome to a variable ‘comp’. TRUE 
means that the data are standardised so that each variable has a mean=0 and a 
standard deviation =1)  
 
summary(comp) # (Get a summary of the outcome of the PCA - output of 34 
components).  
 
compvalue<-comp$x # (To view the component value for each observation in 
comp. Assign this output to ‘compvalue’).  
 
compvalue # (Print out compvalue. This gives you all the principal components  
usually far more than needed).  
(output of observation values across 34 components).  
  
To Plot A Bi-Plot, there are 3 separate steps most of the code relates to axes labels 
and choice of dot.  
 
plot(compvalue[ ,1], compvalue[ ,2], pch=19, xlab = "PCA1 - 57%", ylab ="PC2 - 
14%") # (plotting the observations on the first two principal components)  
 
abline(h=0, v=0, lty =2) # (put in the horizontal and vertical dotted lines)  








out=comp$rotation (To obtain the weightings of the individual variables to each 
component) 
 
write.csv(out, file="loadings2.txt", col.names=TRUE, row.names=TRUE)  (To 
write the loadings to text file, there are too many for the screen) 
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